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Abstract 
 
3’,5’-cyclic adenosine monophosphate (cAMP) is the best studied intracellular 
second messenger. Adenylyl cyclase (AC) catalyses the synthesis of cAMP from 
ATP following the stimulation of a G protein coupled receptor (GPCR), and its 
degradation is catalysed by cAMP phosphodiesterases (PDEs)  to allow cessation 
of signal. cAMP can act to bring about a multitude  of varying and often opposing 
cellular responses, which depend on the stimulus received by the GPCR, the cell 
type, the cell cycle stage, and the complement of downstream effector 
molecules within that cell. The cAMP PDE subfamilies express multiple splice 
variants, which possess unique N-termini and non-redundant functional roles. By 
virtue of this, they are targeted to specific and discrete subcellular locations, 
where they may form highly specific interactions with scaffold proteins and 
other enzymes. Here, in these discrete locales, PDEs act to hydrolyse local 
cAMP, thereby underpinning the spatial and temporal compartmentalisation of 
cAMP gradients. This fine-tuned balance of synthesis and degradation is 
paramount for the dynamic cellular responses to extracellular stimuli, allowing 
differing signal transduction cascades to occur simultaneously in the crowded 
macromolecular environment of the cell. The compartmentalisation of cAMP 
signalling is, thus, essential for maintaining cellular homeostasis, and is subject 
to perturbation in various diseases, including prostate cancer (PC).   
 
Despite the wealth of literature implicating cAMP signalling in the progression of 
PC, little work has been done on the expression or function of PDE splice variant 
in this disease. Our group, in collaboration with Philips Research and the 
Prostate Cancer and Molecular Medicine (PCMM) group in the Netherlands, set 
out to investigate the changes in cAMP signalling during PC progression by 
studying the expression of cAMP PDE isoforms, with the aim of identifying a 
novel PC biomarker, as the current standard biomarker (PSA) is not disease-
specific and leads to much over-diagnosis and over-treatment of otherwise non-
life threatening prostate tumours. Interestingly, we found PDE4D7 to be 
dramatically downregulated as PC progresses from an androgen sensitive (AS) to 
an androgen insensitive (AI) state, and, indeed, this enzyme is showing promise 
as a novel, disease-specific PC biomarker.  
ii 
 
In this thesis, I report my efforts to characterise a function of PDE4D7 within 
prostate cancer. Firstly, I report the raising of a novel highly specific PDE4D7 
antibody and describe the differential expression of this isoform, at the protein 
level, between AS and AI PC cell models. I present evidence to suggest that 
PDE4D7 mediates PC cell growth and migration, and that its loss may play a role 
in PC progression. I propose that an altered epigenome plays a role in the 
downregulation of PDE4D7 expression.  I then report on the raising of a novel 
phospho-specific antibody and present evidence to show that PDE4D7 is 
regulated by PKA phosphorylation within its unique N-terminal region, and that 
this event confers negative regulation on enzyme activity. Finally, I describe my 
endeavours to elucidate a PDE4D7 protein-protein interaction that may help 
transduce PDE4D7-specific signals and maintain the enzymes cellular location.  
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1 cAMP Signalling, Phosphodiesterases and 
Prostate Cancer  
Signal transduction is essential for the survival of multi-cellular organisms as it 
enables them to adapt to their environment, and cells to adapt to 
microenvironment changes. Signal transduction may involve simple diffusion of 
molecules across the plasma membrane, such as class 1 steroid hormones, which 
bind intracellular receptors to bring about transcriptional regulation. However, 
the majority of signalling molecules cannot diffuse across the plasma membrane, 
and instead must bind cell surface receptors to have their effect. As a result, 
such molecules are called “first messengers”.  Once activated, these cell surface 
receptors elicit a downstream response to bring about the desired physiological 
effect on the cell. Eliciting specific cellular responses is an amazing feat given 
the abundance of first messengers that may bombard the cell at once, and the 
abundance of receptors expressed on a cell at any one time.  This specificity 
relies on the ability of receptors to employ distinct mechanisms of ligand 
recognition and compartmentalised second messenger activation.  
 
Cyclic adenosine monophosphate (cAMP) was the first second messenger to be 
identified, and has remained the best studied. It was discovered by Earl Wilbur 
Sutherland and colleagues while working on glycogen metabolism in rat liver 
homogenates (Robison, Butcher et al. 1968). Since then, cAMP has been found to 
mediate a vast array of cellular activities, which depend on the cell type 
studied, the receptor activated, adenylyl cyclases expressed and cAMP effector 
proteins available in the specific cell type. cAMP regulates many cellular events 
such as cell differentiation, proliferation, apoptosis and learning and memory  
(Shaulsky, Fuller et al. 1998; Richards 2001; Hochbaum, Hong et al. 2008; 
Rutten, Wallace et al. 2011; Insel, Zhang et al. 2012). The other related second 
messenger cyclic guanine monophosphate (cGMP), was later discovered and was 
initially believed to antagonise the cAMP pathway, but it is now known there is 
much cross talk between both networks and their relationship is complex 
(Weissmann, Goldstein et al. 1975; Zaccolo and Movsesian 2007; Levy 2013). The 
levels of intracellular cAMP and cGMP are tightly regulated by their synthesis by 
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adenylyl and guanylyl cyclases respectively, and their degradation by 
phosphodiesterases (PDEs). The balance of synthesis and degradation of the 
second messengers is stringently controlled. cAMP PDEs are targeted to discrete 
subcellular localisations by their unique N-termini, where they interact with 
various proteins such as cAMP effector molecules. Within their location, PDEs 
mould cAMP gradients and allow differential activation of subsets of cAMP 
effectors. This compartmentalisation of cAMP signalling is essential for eliciting 
pleiotropic cellular effects, and is paramount to the homeostasis of the tissue 
(Houslay 2010; Francis, Blount et al. 2011).  Compartmentalisation of cyclic 
nucleotide gradients allows multiple signalling transduction events to occur 
simultaneously, and crucially underpins the specificity of receptor action (as 
many receptors use cAMP to trigger intracellular responses). Another point worth 
noting is that cell signalling is not linear, but transduction pathways often cross 
talk with each other in various directions to bring about the desired cellular 
effect (Bhalla and Iyengar 1999). A Schematic showing an example of cAMP 
signalling is shown in figure 1.1. 
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Figure 1.1. An example cAMP signalling pathway.  
Upregulation of target gene transcription by phospho-CREB is an example of 
classical Gs-coupled GPCR activation of cAMP signalling, which is described in 
more detail below. Briefly; ligand binding to a GPCR brings about synthesis of 
cAMP from ATP and adenylyl cyclases (AC). cAMP then activates local 
downstream effector proteins, such as PKA, which phosphorylates target 
substrates such as CREB, and long form cAMP PDEs. Activated cAMP PDEs then 
hydrolyse cAMP to 5’AMP to attenuate the signal, thereby sculpting and 
compartmentalising the cAMP pool.  
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Extracellular signals modulate intracellular cAMP via at least three components; 
a heptahelical G protein coupled receptor (GPCR), a heterotrimeric G protein, 
and adenylyl cyclase. 
 
 
1.1 G protein Coupled Receptors and Heterotrimeric G 
proteins.   
The G protein Coupled Receptor (GPCR) superfamily and heterotrimeric guanine 
nucleotide exchange proteins (G proteins) play pivotal roles in signal 
transduction. They are activated by various external stimuli such as hormones, 
peptides, nucleotides, Ca2+, ions, lipids, amines, photons and organic odourants 
(Bockaert and Pin 1999; Fredriksson and Schiöth 2005). GPCR activation allows 
the receptor to couple to heterotrimeric G proteins which then act on effectors 
in a cyclical activation-inactivation mechanism. Via ligand binding or 
constitutive activation, GPCRs can undergo a conformational change that alters 
their  affinity for the G protein, which in turn results in signal transduction to 
downstream effectors such as adenylyl cyclases (ACs) (Kleuss, Raw et al. 1994).  
G proteins are composed of 3 subunits, α, β and γ. At the unbound GPCR, Gα is 
GDP bound and associated with the β/γ subunits. Once the GPCR is activated, it 
more efficiently binds the G protein, and, acting as a guanine exchange factor 
(GEF), causes Gα to swap GDP for GTP, resulting in its activation and 
dissociation from the β/γ subunits. The free Gα-GTP and/or the β/γ complex 
can then interact with effector molecules. The β and γ subunits function only as 
a tightly bound complex in which the β subunit binds the effector protein, 
thereby directly modulating the downstream effect (Downes and Gautam 1999; 
Milligan and Kostenis 2006; Oldham and Hamm 2008). However, one study shows 
that the γ subunit may also be involved in effector binding (Bell, Xing et al. 
1999). Following effector stimulation, Gα acts as an intrinsic GTPase and 
initiates its own inactivation through nucelophilic attack on GTP, reverting to 
the GDP bound G protein, a reaction which in some cases is accelerated by 
GTPase activating proteins such as the regulators of G protein signalling (RGS) 
proteins. The GDP bound Gα then re-associates with the β/γ dimer bringing 
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about cessation of signal from the GPCR (Kleuss, Raw et al. 1994; Milligan and 
Kostenis 2006). Agonist stimulation of the GPCR is diminished also by receptor 
desensitisation due to phosphorylation by kinases such as PKA (Ferguson, Zhang 
et al. 1998; Kohout and Lefkowitz 2003). The mechanism of Gα dissociating from 
the β/γ complex is well described, but doubt has been cast as to whether it 
occurs in vivo as FRET studies have suggested that the subunits actually  undergo 
a rearrangement and remain associated (Bunemann, Frank et al. 2003). The 
crystal structure of activated Gα was used to elucidate the arginine that is 
essential for mechanism of action, mutation of which leads to a constitutively 
active protein (Noel, Hamm et al. 1993). Although rare, such a mutation has 
been documented to be involved in pituitary adenomas, where constitutive cAMP 
synthesis is pro-proliferative (Landis, Masters et al. 1989).  
 
 Humans express 21 Gα, 16 Gβ and 12 Gγ subunits from 16, 5, and 12 genes 
respectively (Downes and Gautam 1999). If each Gβ subunit could dimerise with 
each Gγ subunit, there would be over 60 different possible dimers  (Cabrera-
Vera, Vanhauwe et al. 2003). However, it is more likely that only certain β/γ 
dimers function within tissues, for example Gβ1γ11 is the predominant dimer 
found in the retina (Fawzi, Fay et al. 1991). The Gα subunit confers the basic 
properties of a G protein, and can be one of four families based on sequence 
similarity; Gαs, Gαi/ Gαo, Gαq/ Gα11 and Gα12/ Gα 13.  Each family contains a 
number of isoforms and may be ubiquitously or specifically expressed. G proteins 
containing Gαs couple many GPCRs to ACs to bring about increases in 
intracellular cAMP (Wettschureck and Offermanns 2005).  
 
G proteins are subject to post-translational modifications that affect their 
association with various GPCRs and effectors, and the G protein subunits 
themselves (Chen and Manning 2001).  GPCRS are the most common membrane 
bound protein receptor families, accounting for >1% of the vertebrate genome, 
and represent one the largest and most diverse protein superfamilies in 
mammals. They are encoded by ~800 different genes in humans (Bockaert and 
Pin 1999). Human GPCRs can be grouped into 5 different families based on 
phylogenetic analysis, called; glutamate, rhodopsin, adhesion, frizzled and 
secretin (Fredriksson, Lagerstrom et al. 2003). The rhodopsin family is the 
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largest, and much structural information on this GPCR family has been gained 
from the 2D crystal structures of frog and bovine rhodopsin (Unger, Hargrave et 
al. 1997). Common to all GPCRs are 7-transmembrane spanning α-helices (TMI-
VII), connected by 3 intracellular and 3 extracellular loops that anchor the 
receptor within the plasma membrane. The end of the extracellular loop forms 
the N-termini, which contain functional and/or ligand binding domains, whereas 
the intracellular loops end with the C-termini. The N- and C-termini differ in 
sequence and length between different GPCRs (Fredriksson and Schiöth 2005). 
There has been much interest in GPCRs due to their implication in disease, e.g. 
germline loss of function mutations in rhodopsin cause retinitis pigmentosa, and 
most notably, cholera (Spiegel 1996). Endotoxins produced by Vibrio cholerea 
and other bacteria that target the Gα subunit have been widely used in the 
characterisation of the function of G proteins (Milligan and Kostenis 2006).  
 
GPCRs are some of the most pharmaceutically targeted proteins. From the ~ 800 
genes encoding GPCRs, ~400 are considered to be potential drug targets. The 
cognate ligands are known for over 200 GPCRs, with many other receptors 
deemed ‘orphan’; with no known function. Currently, ~30 GPCRs are drug 
targets, being targets of ~30% of all current marketed drugs. Targeted GPCRs 
include opioid receptors for pain, 2-adrenoreceptors for asthma and 
angiotensin receptors for hypertension (Hopkins and Groom 2002; Wise, Gearing 
et al. 2002). Alfred Gilmand and Martin Rodbell were awarded the 1994 Nobel 
Prize for Physiology or Medicine for their work on the structure and function of 
heterotrimeric G proteins (Gilman 1995; Rodbell 1995). In 2012, the Nobel Prize 
for Chemistry was awarded jointly to Robert J. Lefkowitz and Brian K. Kobilka 
for their work on the structure and function of GPCRs over the past few decades.  
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1.2 Adenylyl Cyclases 
Adenylyl cyclases (ACs) catalyse the synthesis of cAMP from ATP following 
hormonal activation. They were first described in the 1970s (Neer 1974; Ishikawa 
and Homcy 1997), with the first AC isoform cloned from brain (Krupinski, 
Coussen et al. 1989; Tang, Krupinski et al. 1991). Originally all ACs were thought 
to be transmembrane bound (tmAC), and activated only following GPCR 
stimulation (Geng, Wang et al. 2005). To date, nine such mammalian tmAC 
isoforms have been described (ACI-ACIX), which share a membrane bound 
topological structure, but differ in expression pattern and mode of regulation by 
G protein subunits, forskolin, Ca2+ influx and phosphorylation by protein kinases 
(Iwami, Kawabe et al. 1995; Zimmermann and Taussig 1996; Dessauer, Scully et 
al. 1997; Tesmer, Sunahara et al. 1997; Willoughby and Cooper 2007). A class of 
soluble AC (sAC) enzymes were subsequently identified in rat testes (Buck, 
Sinclair et al. 1999), which is regulated by bicarbonate ions and pH (Chen, Cann 
et al. 2000).  
 
ACs I, III and VIII are activated by Ca2+  influx via calmodulin binding, inhibited by 
Gβγ, and insensitive to PKC regulation (Tang and Gilman 1991; Levin and Reed 
1995; Willoughby and Cooper 2007). They are expressed in brain (I and III) and 
olfactory cells (VIII) (Ishikawa and Homcy 1997).   
 
ACs II, IV and VII are Gαs, Gβγ and PKC activated, Gαi inhibited, and Ca
2+ 
insensitive. They are expressed in lung (II) and ubiquitously (IV and VII) (Levin 
and Reed 1995; Ishikawa and Homcy 1997; Cooper 2003). 
 
ACs V and VI are Gαs activated and inhibited by Ca
2+, PKC and PKA. They are 
expressed mostly in heart and brain tissues (Ishikawa and Homcy 1997; Cooper 
2003). 
 
ACIX is the most inactive of the known isoforms. It is inactivated by Ca2+ 
signalling via the phosphatase calcineurin.  It is notably expressed in the 
pituitary gland (Cooper 2003).  
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ACX, or sAC, is activated by bicarbonate ions under strict pH conditions. It was 
first identified in the testes and found to be involved in sperm activation 
following ejaculation, and was considered a target for male contraceptives. It 
was later found to be expressed in many other tissues including the brain and 
kidneys (Buck, Sinclair et al. 1999; Chen, Cann et al. 2000; Geng, Wang et al. 
2005; Wang, Lin et al. 2009). 
 
All mammalian ACs except IX are activated by the naturally occurring labdane 
diterpene, forskolin, produced by the plant Coleus forskohlli. Forskolin is widely 
used to study cAMP signalling. It directly activates ACs, without the need for 
GPCR stimulation, thereby increasing intracellular cAMP and thus PKA activity 
(Seamon, Vaillancourt et al. 1984; Hurley 1999; Onda, Hashimoto et al. 2001). 
Forskolin has been widely used in studying the structure and function of ACs 
(Tang and Hurley 1998). It has been suggested that there are endogenous 
forskolin-like small molecules that regulate ACs.  
 
Regulation of the tmACs adds further layers to the complexity of cAMP 
signalling. Not only is their activity modulated by GPCR and calcium signalling, 
but they may be subject to post-translational modifications by protein kinases 
and phosphatases in signalling feedback loops. Their isoform-specific regulation, 
tissue expression and/or specific subcellular localisation also lend to cAMP 
signalling control. Given the various G protein families, the 9 tmACs with the 
regulation of each G protein and AC, the potential plethora of G protein/AC 
interactions further makes for convoluted multifaceted cAMP signalling. sACs 
suggest cAMP can be synthesised closer to intracellular downstream effectors, 
and not necessarily at the plasma membrane, thereby adding a spatial 
component to the regulation of cAMP signalling. It may be that tmACs and sACs 
cooperate in the same signalling pathway. ACs are targeted to and act in 
microdomains of the cell, in association with other signalling proteins such as 
PKA, AKAPs and PDEs. Specific AC interactions within microdomains facilitate 
compartmentalisation of cAMP signalling and underpin receptor specificity 
(Willoughby and Cooper 2007; Wang, Lin et al. 2009).  
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1.3 Guanylyl Cyclases 
Guanylyl cyclases (GCs) catalyse the synthesis of cGMP from GTP in response to 
nitric oxide (NO), peptide hormones, free radicals, bacterial toxins and Ca2+ 
among other stimuli. The GC family also contains membrane bound and soluble 
isoforms that are widely expressed (Lucas, Pitari et al. 2000). 
 
 
1.4 Phosphodiesterases 
Phosphodiesterases (PDEs) are a large divergent superfamily of enzymes that act 
as the sole route for hydrolysis of the cyclic nucleotides, cAMP and cGMP, both 
of which function as major intracellular second messengers. They cleave the 
phosphodiester bond of the cyclic nucleotide to generate inactive 5’-nucelotide 
metabolites. Along with ACs, PDEs determine the intracellular concentrations of 
cyclic nucleotides and thus are pivotal in maintaining cAMP and cGMP 
homeostasis. PDEs are central to the preservation of compartmentalised cyclic 
nucleotide signalling. It is suggested that they may also alter protein-protein 
interactions by conformational change induced through allosteric binding to 
cyclic nucleotides (Bender and Beavo 2006). PDEs are themselves subject to 
post-translational modifications such as phosphorylation, SUMOylation and 
ubiquitination.   PDEs were first described in early studies by Sutherland and 
colleagues who noted the formation of 5’AMP in tissue fractions, in a manner 
that was potentiated in the presence of divalent cations and inhibited by 
methylxanthines, such as caffeine. This activity was subsequently identified as 
that of a PDE (Rall and Sutherland 1958; Francis, Turko et al. 2001). PDEs have 
been studied for more than 50 years but still a great deal is unknown due to the 
complexity of the this superfamily. However, in recent years a lot of knowledge 
has been gained on the structure, physiological functions and regulation of 
mammalian PDEs.   
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1.4.1 Overview of PDE Families  
PDEs have long been divided into two main classes based on their primary 
structure; PDEI and PDEII. Identification of the low affinity cAMP PDEI and the 
high-affinity cAMP PDEII in  S. cerevisiae showed how PDEs had diverged 
throughout evolution (Sass, Field et al. 1986; Nikawa, Sass et al. 1987). 
Subsequently, isolation of the dual specificity Candida albicans PDEI (Hoyer, 
Cieslinski et al. 1994) was found to share homology to the S. cerevisiae PDEI 
(Nikawa, Sass et al. 1987). Originally, Escherichia coli (E. coli) cAMP was 
believed to be under the control of only its synthesis, but in the 1960s a PDE was 
described from lysed bacterial cells (Brana and Chytil 1966). Subsequently this E. 
coli PDE was characterised, cpdA, but showed no homology to class I or II PDEs 
and so represented a third class of PDE (Imamura, Yamanaka et al. 1996; Richter 
2002).  It seems, so far, that class I PDEs include those of higher eukaryotes 
(vertebrates, Drosophila melanogaster, Caenorhabditis elegans, and a few 
fungal PDEs), class II is comprised of mostly fungal enzymes and Vibrio fischeri, 
and class III is made up of PDEs from prokaryote enzymes (Richter 2002).  
Most human PDEs belong to class I PDEs. 21 PDEI genes have to date been 
identified in humans, rat and mouse, which give rise to eleven families of PDEs 
(PDE1-11). PDEI enzymes are grouped based on 270 conserved amino acids in the 
C-terminal catalytic domain, and around 35-50% sequence identity is found 
between the 11 different families (Richter 2002; Omori and Kotera 2007). The 
PDE1 families are grouped according to sequence homology, presence of certain 
regulatory domains, sensitivity to specific inhibitors and whether they hydrolyse 
cAMP, cGMP or both (figure 1.2). Most families are composed of 2-4 subfamily 
genes, each of which may give rise to splice variants. The subfamilies show >70% 
sequence identity and have identical regulatory domains that lie to the N-
terminal side of  the catalytic domain (Omori and Kotera 2007). Distinct genes, 
alternative splicing and use of alternative promoters give rise to the various 
isozymes, of which there may be 100 (Francis, Houslay et al. 2011). The PDE 
splice variants are unique in terms of tissue expression, subcellular localisation, 
regulation by phosphorylation or Ca2+/ calmodulin and their interactome. 
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Figure 1.2. Phosphodiesterase regulatory domains and substrate specificity.  
A; Unique N-terminal regulatory domains that affect PDE activity are expressed 
in a family specific fashion. Calcium/calmodulin binding domains (Ca2+/Cal.) in 
PDE1, GAF domains in PDEs 2,5,6,10,11, membrane associated domains (MEM) in 
PDE3, upstream conserved regions (UCR) in PDE4, Rec and Pas domains in PDE8, 
and no known regulatory domains in PDE9. B; the substrate specificities of the 
PDE families. 
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1.4.2 Nomenclature 
A nomenclature classification system devised by Beavo and colleagues in 1994 is 
widely used.  The acronym PDE is preceded by letters representing the species 
(e.g. Hs for Homo sapiens), it is then followed by the Arabic number designating 
the family (1-11), which is followed by a capital letter indicating the subfamily 
gene (A-D), this is further followed by a number to assign the splice variant of 
that subfamily; example HsPDE4D7 (Beavo, Conti et al. 1994). The splice variant 
number is simply its order of appearance in GenBank. Inconsistencies exist due 
to different researchers working on the same variant in different species and 
entering their findings.  Based on the mouse genome a new, slightly modified 
system has been logged; 
http://www.informatics.jax.org/mgihome/nomen/gene.shtml. Both 
classifications are very similar and acceptable; indeed both are used depending 
on the journal. 
 
 Further classification can be based on the presence or absence of GAF domains 
which are involved in cyclic nucleotide allosteric regulation and dimerisation of 
the PDEs. There are five GAF-PDE families; PDE2, PDE5, PDE6, PDE10 and PDE11, 
each of which contains two GAF domains, and the others are non-GAF-PDE 
families (Martinez, Wu et al. 2002; Omori and Kotera 2007). The acronym GAF 
comes from the first three protein families found to contain this domain; GMP 
binding PDE, Anabaena adenylyl cyclase and E. coli FhlA domain, (Aravind and 
Ponting 1997). GAF domains are actually very rare in human proteins but are 
widespread in other species and well conserved (Heikaus, Pandit et al. 2009). They 
were first recognised to play a regulatory role in PDE5, following the discovery that 
one of the GAF domains allosterically binds cGMP along with the catalytic site 
(Turko, Francis et al. 1998). This binding brings about conformational change and 
potentiates activity of the enzyme and also regulates its activity via phosphorylation 
by cGMP dependant kinase (PKG) (Francis, Bessay et al. 2002; Martinez, Wu et al. 
2002; Rybalkin, Rybalkina et al. 2003; Heikaus, Pandit et al. 2009). GAF domains 
present quite a kinetic puzzle; as cGMP acts as both a substrate and an allosteric 
modulator of GAF-PDEs. 
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Based on the amino acid sequences of the mammalian PDEs 1-7, the S. cerevisiae 
PDEII, the two nematode PDEs 1 and 4, and the four Ephydatia fluviatilis (freshwater 
sponge) PDEs 1-4, a phylogenetic tree was constructed. This arrangement clearly 
shows how vertebrate PDEs diverged from a common ancestral gene by gene 
duplication and domain shuffling before the parazoan-eumetazoan split 
(Koyanagi, Suga et al. 1998).  
 
The PDE superfamily is a major pharmacological target for a variety of human 
illnesses (Xu, Hassell et al. 2000; Francis, Turko et al. 2001). Immediately after 
Sutherland and colleagues discovered PDE activity, it was found that they could 
be inhibited by caffeine. Indeed, a caffeine analogue, theophylline, has been 
used as a non-selective PDE inhibitor in a therapeutic setting for many years. 
Most early PDE inhibitors acted on every PDE in every tissue due to lack of 
specificity and thus had a low therapeutic index (Bender and Beavo 2006). The 
presence of multiple PDEs, expression of various splice variants, specific tissue 
distribution and intracellular localisation and different conformations of PDE 
enzymes have been challenging to the development of anti-PDE drugs, but these 
attributes are also promising in the development of more specific compounds. 
The crystal structures of the catalytic domain and active site have been solved, 
and this has facilitated the rational design of more specific and efficacious PDE 
inhibitors.  
 
 
1.4.3 PDE Structure  
1.4.3.1 The Catalytic Site 
Within recent years, the crystal structures for the catalytic domains of a number 
of PDE families have been solved (Bender and Beavo 2006). This is also true for 
the structure of the GAF domains of PDE2A (Martinez, Wu et al. 2002). Much 
information was gained from the first crystal structure of the PDE4B catalytic 
domain (Xu, Hassell et al. 2000) and the later structure of the PDE4D2 catalytic 
domain in complex with AMP (Huai, Colicelli et al. 2003). The models of cyclic 
nucleotide-bound PDEs are based on the co-crystal structures of the isolated 
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catalytic domains of the PDE bound to its 5’ metabolite product or a substrate 
analog inhibitor. Co-crystals of PDEs bound to substrates are not available, nor 
are crystal structures of a PDE holoenzyme.  
 
Around 300 amino acids in the region of the active site are conserved across all 
11 PDE families and these give rise to similar 3D catalytic structures (Richter 
2002; Ke 2004; Omori and Kotera 2007). The catalytic site is composed of 15-17 
α-helices and an extended β-hairpin loop, which folds into a compact structure 
of 3 subdomains. For PDE4 (based on PDE4B2), there are of 17 α-helices (figure 
1.3) (Xu, Hassell et al. 2000). The junction of the helices forms a hydrophobic 
pocket large enough to accommodate cyclic nucleotide or 5’ nucleotide 
metabolite. This represents the cyclic nucleotide-binding pocket. Several amino 
acids found within the catalytic domain are conserved across all PDEs. Two 
metal ions are bound to the PDE catalytic domain; tightly bound Zn2+ and more 
loosely bound Mn2+ or Mg2+, which are essential for stabilisation of the active site 
structure and catalysis of cyclic nucleotide (Xu, Hassell et al. 2000; Huai, Wang 
et al. 2003; Zhang, Card et al. 2004). This can be termed the metal binding 
pocket, and is highly conserved and histidine rich. The metal cations also bind a 
solvent water molecule that likely acts as a nucleophile in the hydrolysis 
reaction.  
 
Zn2+ has been identified in most PDE catalytic domains; however, preference for 
the second metal cation varies and may add another layer of PDE regulation. 
Phosphorylation of long form PDE4 isozymes leads to an increased affinity for 
Mg2+ (Sette and Conti 1996), whereas PDE9 activity has a preference for  Mn2+ 
(Wang, Wu et al. 2003). The concentrations of these cations differ between 
tissues and this would influence the metal cation complement and therefore PDE 
activity. Studies with PDE inhibitors show the metal cation pair influence the 
PDE-inhibitor interaction, for example, PDE4D in complex with the PDE4 
inhibitor rolipram (Huai, Wang et al. 2003).  
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Figure 1.3. Ribbon diagram of the PDE4B2 catalytic site secondary structure.  
The 17 α helices H0-H16 form 3 subdomains; the N-terminal domain (cyan), the 
middle domain (green) and the C terminal domain (yellow). The metal binding 
pocket is found in the catalytic domain behind helix 13. 
 
1.4.3.2 cAMP or cGMP or Both? 
Selectivity of PDEs for the two different cyclic nucleotides (cAMP/cGMP) is 
complex and the mechanism is not fully understood.  
 
It has been suggested that a glutamine residue conserved in all PDE families 
underscores the mechanism of cyclic nucleotide specificity (Xu, Hassell et al. 
2000; Xu, Rocque et al. 2004). This mechanism was later coined the ‘Glutamine 
Switch’ (Zhang, Card et al. 2004). From high resolution co-crystal structures of 
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the cAMP PDEs 4B and 4D with AMP, the cGMP PDE5A with GMP, and the apo-
structure of dual specificity PDE1B, Zhang and colleagues described how the 
invariant glutamine determines the specificity of each PDE, by recognising the 
purine moiety in the cyclic nucleotide. The hydrogen bond arrangement 
surrounding the conserved glutamine ‘lock’ it in a specific orientation so as only 
cAMP or cGMP is recognised. In dual specificity enzymes, a neighbouring 
histidine residue enables flexibility of the hydrogen-bond network and allows 
free ‘rotation’ of the glutamine and so either cyclic nucleotide may be bound. A 
hydrophobic ‘clamp’ also holds the purine base tightly within the active site. 
The crystal structure analysis uncovered four key interactions that affect cyclic 
nucleotide selectivity and catalysis; 1) metal binding; 2) coordination to the 
phosphate group; 3) a hydrophobic ‘clamp’; and 4) a hydrogen-bonding 
arrangement that determines cyclic nucleotide specificity. These elements may 
also determine inhibitor selectivity (Huai, Wang et al. 2003). However, there are 
many critics of this proposal, stating it is too simple a mechanism as evidenced 
by studies on PDE 9 and PDE10 (Ke, Wang et al. 2011). PDE9A2 has specificity for 
cGMP, but the ‘glutamine switch’ is flexible, and its catalytic domain more 
closely resembles that of cAMP specific PDE4D2 and not PDE5A1, another cGMP 
PDE (Huai, Wang et al. 2004). In this case, the authors stated that PDE9A2 only 
weakly binds the non selective inhibitor 3-isobuty-1-methylxanthine (IBMX) due 
to this flexibility.  Another argument against this mechanism involves the locked 
glutamine switches in PDE10A2 (Wang, Liu et al. 2007) and PDE2A3 (Iffland, 
Kohls et al. 2005), both dual specificity PDEs. It is proposed that substrate 
specificity is more complex and is due not to a single glutamine residue, but the 
complement of many residues within the binding pockets of a specific PDE 
(Wang, Liu et al. 2005; Wang, Liu et al. 2007).  
 
 
1.4.4 PDE Oligomerisation 
Observations from the crystal structure studies on the PDE catalytic sites suggest 
that oligomeristaion is not necessary for PDE function in cell free systems.  
There is, however, much evidence to suggest that PDEs can oligomerise under 
physiological conditions. The GAF domains of PDEs 2, 5 and 10 mediate their 
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homo-dimerisation via intermolecular interactions, and this dimerisation 
regulates enzyme activity (Martinez, Wu et al. 2002; Zoraghi, Bessay et al. 2005; 
Handa, Mizohata et al. 2008). PDE1 and PDE6 exist as heterotetramers with their 
cognate regulatory proteins, two calmodulin molecules and two γ subunits 
respectively (Sonnenburg, Seger et al. 1995; Barren, Gakhar et al. 2009).  
 
 
1.4.4.1 PDE4 Dimerisation 
Long form PDE4 isozymes act as dimers via intermolecular interactions of their 
UCR1 and UCR2 regions, whereas as short form PDE4s that lack UCR1 exist only 
as monomers (Richter and Conti 2002). It has also been demonstrated that long 
form PDE4D dimerisation is a structural requirement for activation of the 
enzyme by PKA phosphorylation or PA binding, and that it acts to stabilise the 
enzymes in a high affinity rolipram binding site (HARBS) conformation. It is also 
suggested that both oligomers must be phosphorylated by PKA for enzyme 
activation (Richter and Conti 2004).  
 
 
1.4.5 PDEI family  
1.4.5.1 Regulation Overview 
PDEs are firstly regulated at the level of their transcription and differential 
expression patterns in cells/tissue. Another level of regulation is afforded by 
protein domains specific to each family, such as GAF domains, described above. 
These domains; GAF, PAS, Ca2+/ Cam, UCR are responsible for receiving 
stimulatory or inhibitory signals from the signalling pathway within which a 
specific PDE acts. Fine tuning of PDE activity and function is achieved via an 
array of biochemical alterations of the PDE, such as 
phosphorylation/dephosphorylation, binding of Ca2+/ calmodulin and protein-
protein interactions.  
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1.4.5.2 Overview of Families 1-3, and 5-11 
1.4.5.2.1 PDE1 
PDE1 enzymes are part of the Ca2+/ calmodulin-dependant group of PDEs (CaM-
PDEs), which have been well studied and characterised. Three subfamily genes, 
PDE1A-C, give rise to a number of splice variants with dual specificity, that 
contain Ca2+/calmodulin regulatory domains towards their N-terminus. The 
isozymes share similar kinetics, displaying the same Vmax values for both cGMP 
and cAMP, but sensitivity to CaM varies between them (Yan, Zhao et al. 1996). 
All CaM PDEs are activated by calmodulin binding in the presence of calcium, 
with a 10-fold increase in Vmax and are negatively regulated by phosphorylation, 
which acts to decrease their affinity for Ca2+/ calmodulin (Huang, Chau et al. 
1981; Sharma and Wang 1985; Hashimoto, Sharma et al. 1989; Beavo 1995; 
Kakkar, Raju et al. 1999). Due to its regulation by Ca2+/calmodulin, PDE1, along 
with the Ca2+/calmodulin regulated ACs I III and VIII, provide a link between the 
cAMP and Ca2+ second messenger signalling systems (Beavo 1995; Kakkar, Raju et 
al. 1999).  
 
1.4.5.2.2 PDE2  
One gene, PDE2A, is expressed as three splice variants, PDE2A1-3, all of which 
show dual specificity for cGMP and cAMP. Isozymes are notably expressed in 
cardiac myocytes with different subcellular locations due to their N-termini, 
which may impact on cyclic nucleotide preference (Stephenson, Coskran et al. 
2009; Lee and Kass 2012). GAF domains regulate PDE2s; GAF A and B, and they 
exist as homodimers. The C-terminal end of GAF A is linked to the N-terminal 
end of GAF B by a linker helix (LH1), with GAF A-GAF A and GAF B-GAF B 
associations between the dimers. Binding of cyclic nucleotide to GAF B initiates 
enzyme activation (Martinez, Wu et al. 2002; Pandit, Forman et al. 2009). It has 
been suggested that activation occurs with different conformational changes in 
the catalytic domain depending on which cyclic nucleotide binds (Wu, Tang et 
al. 2004). Evidence also suggests that cyclic nucleotide hydrolysis depends on co-
activation by the other cyclic nucleotide, placing PDE2 as a regulator of cyclic 
nucleotide crosstalk (Lee and Kass 2012).  
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1.4.5.2.3 PDE3 
Two PDE3 subfamily genes are known currently, PDE3A and PDE3B.  Both 
hydrolyse cGMP and cAMP. PDE3A is more highly expressed in oocytes and cells 
of the cardiovascular system, whereas PDE3B is more highly expressed in cells 
involved in energy homeostasis such as pancreatic β-cells, adipocytes and 
hepatocytes (Beavo 1995; Ahmad, Degerman et al. 2012). Although PDE3s show 
dual selectivity, the Vmax for cGMP is quite low, conferring higher specificity for 
cAMP. However cGMP binds with high affinity and low hydrolysis, and it is 
suggested that cGMP acts to inhibit cAMP hydrolysis by these PDE isozymes. PDE3 
is activated by insulin via Akt phosphorylation (Loten and Sneyd 1970; Kitamura, 
Kitamura et al. 1999) and by leptin via PI3K (Zhao, Shinohara et al. 2000). Many 
studies show that PDE3 is pivotal in maintaining insulin homeostasis and 
modulation of insulin in erythrocytes. It also may be involved in vascular disease 
in prediabetes patients (Hanson, Stephenson et al. 2010). PDE3, particularly 
PDE3A, is of major importance in the heart. It has long been a target of 
inhibition by inotropics, such as milrinone, for chronic heart failure. This drug 
provides short term reprieve, but is associated with long term increases patient 
mortality (Packer, Carver et al. 1991). PDE3 has been shown to be 
downregulated in heart failure, which may be a causative factor, and the reason 
for treatment failure (Ding, Abe et al. 2005).  
 
1.4.5.2.4 PDE5 
PDE5A encodes three isoforms; PDE5A1-3, from two alternative promoter regions 
(Lin, Chow et al. 2002), and was the first cGMP PDE identified. PDE5 was first 
described in lung (Francis, Lincoln et al. 1980) and heart (Lugnier, Schoeffter et 
al. 1986) tissue. PDE5 is a GAF-PDE. It contains a GAF tandem domain towards its 
N-terminus that modulates its activity. PDE5 can be phosphorylated and 
activated by PKA following cGMP binding, another link between cAMP and cGMP 
signalling networks (Thomas, Francis et al. 1990). However, PKG seems to be the 
preferred kinase, which upon cGMP directly binding the catalytic site (and 
allosterically to a GAF domain), phosphorylates and activates PDE5 (Corbin, 
Turko et al. 2000). It has also been shown that high-affinity binding of cGMP to 
GAF A can directly activate PDE5 without phosphorylation and that GAF B may 
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confer regulatory properties on this interaction and thus enzyme activation 
(Rybalkin, Rybalkina et al. 2003; Zoraghi, Bessay et al. 2005).  
 
 PDE5 expression is normally low and is increased in disease states leading to 
vasoconstriction. It is involved in NO/cGMP signalling pathways. PDE5 inhibitors 
were originally developed to treat cardiac disease and hypertension via NO 
mediated vasodilation, but had little efficacy in trials. However due to their 
famous side effects, such inhibitors are now used to treat erectile dysfunction 
(Schwartz, Levine et al. 2012). Recently, the inhibitor sildenafil, was approved 
for treating pulmonary hypertension, and research on the inhibition of PDE5 in 
heart disease is ongoing (Nagendran, Archer et al. 2007; Kanwar, Agarwal et al. 
2013). PDE inhibition is also showing promise as a therapeutic strategy to reduce 
the symptoms of Huntington’s disease, in which NO-cGMP signalling is 
downregulated (Saavedra, Giralt et al. 2013). PDE5 inhibitors are also showing 
promise in treating the lower urinary tract symptoms (LUTS) associated with 
benign prostatic hyperplasia (Giuliano, Ückert et al. 2013). 
 
1.4.5.2.5 PDE6 
PDE6 is a cGMP specific, GAF-PDE. PDE6 is highly expressed in the rods (PDE6R) 
and cones (PDE6C) of photoreceptors. PDE6 exists as a heterotetramer composed 
of α, β and γ subunits. The PDE6R arrangement is αβγγ, whereas PDE6C is ααγγ 
(Deterre, Bigay et al. 1988; Cote 2004). The αβ or αα dimers constitute the 
catalytic site and the γγ (Pγ) dimer acts as an inhibitory element. Under dark 
conditions, cGMP is bound to the GAF A domain, which increases the affinity of 
Pγ for the catalytic dimer, thereby inhibiting PDE6 (D'Amours and Cote 1999). 
Once a photon of light is received by rhodopsin, it activates the retinal G protein 
transducin, which brings about dissociation of Pγ from the catalytic site and 
PDE6 is activated. cGMP then dissociates from GAF A and is hydrolysed by PDE6, 
leading to reassociation of the αβ/ αα and Pγ, closure of a cyclic nucleotide 
gated channel, and generation of a photoresponse (Artemyev, Arshavsky et al. 
1998; Guo, Grant et al. 2005). Mutations in PDE6R cause simplex and familial 
retinitis pigmentosa (RP) (Daiger, Bowne et al. 2007). Currently there is no cure, 
but gene therapy is a promising treatment for RP (Wert, Davis et al. 2013).  
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1.4.5.2.6 PDE7 
The PDE7 family is cAMP specific and is encoded by two genes; PDE7A and 
PDE7B. The family is notably involved in inflammation (Safavi, Maliheh, et al. 
2013). PDE7A is highly expressed in cells of the immune system and PDE7B is 
highly expressed in pancreas (Hetman, Soderling et al. 2000; Dong, Zitt et al. 
2010). Early studies recognised rolipram insensitive PDE activity in T cells, later 
identified as PDE7, which was subsequently shown to be required for T cell 
activation due to inhibition of PKA. Inhibition of PDE7 decreased T cell 
proliferation and showed promise as a therapeutic target for T cell-mediated 
immune diseases (Ichimura and Kase 1993; Bloom and Beavo 1996; Li, Yee et al. 
1999). However, subsequent investigations demonstrated that PDE7 knockout 
mice maintained fully functioning T cells (Yang, McIntyre et al. 2003), and 
selective PDE7 inhibition did not affect naive T cell function (Nueda, Garcia-
Roger et al. 2006). PDE7 over expression is implicated in leukaemia and has been 
shown to be a promising therapeutic target, especially with co-inhibition of PDE3 
and PDE4 (Zhang, Murray et al. 2008; Dong, Zitt et al. 2010). More recent 
investigations place PDE7, along with PDE4, as an important mediator of the 
inflammatory response following spinal cord injury (SCI). Two PDE7 inhibitors 
were successful in reducing the degree of neuroinflammation and tissue damage 
in SCI mice (Paterniti, Mazzon et al. 2011). PDE4 inhibition by rolipram was 
previously shown to promote axon regeneration following SPI (Nikulina, Tidwell 
et al. 2004) and dual inhibition of PDE7 and PDE4 may be a promising 
therapeutic intervention in the treatment of SPI. A recent study also shows PDE7 
inhibition is efficacious in reducing the Alzheimer’s disease phenotype(Perez-
Gonzalez, Pascual et al. 2013)    
 
1.4.5.2.7 PDE8 
PDE8 encodes PDE8A and PDE8B subfamilies, which are cAMP-specific and 
sensitive to the PDE inhibitor dipyridimole. PDE8A gives rise to five isoforms 
through alternative splicing (Wang, Wu et al. 2001), and PDE8B to two; PDE8B1 
and PDE8B2 (Hayashi, Shimada et al. 2002). PDE8A is expressed in many tissues 
with highest expression in testes, ovary, small intestine and colon. PDE8B is 
mostly expressed in the thyroid gland (Fisher, Smith et al. 1998; Hayashi, 
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Matsushima et al. 1998). Not much is known on the function of PDE8 enzymes 
due to the lack of specific inhibitors, however PDE8A knockout mice have shown 
that PDE8 mediates androgenic steroidogenesis in the testes and adrenal gland 
(Tsai and Beavo 2011). PDE8A plays a crucial role in luteinising hormone (LH)- 
mediated testosterone production in the testis, which is mediated by an increase 
in cAMP. PDE8A KO mice displayed increases in testosterone levels (Vasta, 
Shimizu-Albergine et al. 2006). A testosterone deficit is responsible for many 
conditions, such as idiopathic male infertility. Current treatments for such 
ailments are unfavourable and inhibiting PDE8 may be a novel approach. 
Similarly, PDE8 activating agents could be considered as male contraceptives. As 
a result, PDE8B has been identified as a mediator of glucocorticoid 
steroidogenesis in the adrenal gland fasiculata cells using knockout mice, which 
exhibited an increase in urinary corticosterone levels (Tsai, Shimizu-Albergine et 
al. 2011). These findings place PDE8 as a mediator of the endocrinal regulation 
of the prostate and thus the dysregulation involved in prostate cancer (PC). 
PDE8A is also suggested to mediate Raf-1 and ERK signalling (Brown, Day et al. 
2013). Some of the PDE8 isozymes posses N-terminal regulatory domains called 
PAS, and acronym of the proteins in which they were first indentified; Per, 
ARNT, and Sim. These domains have been Identified in several proteins in 
archea, eubacteria and lower eukaryotes and seem to be involved in binding of 
small molecules and protein-protein interactions (Soderling, Bayuga et al. 1998; 
Wang, Wu et al. 2001).  
 
Some PDE8 isozymes contain a REC (receiver) domain in addition to the PAS 
domain. REC domains play a crucial role in bacterial signalling systems. They 
may also be involved in protein-protein interactions (Galperin 2010). 
Phosphorylation of the REC domain may be involved in enzyme activation 
(Thomason, Traynor et al. 1999). Indeed our group found PDE8 to be activated 
by PKA (Brown, Lee et al. 2012). However, little is known about the function of 
these domains in mammals, and PDE8 is the only PDE family that contains such 
motifs.  
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1.4.5.2.8 PDE9 
The PDE9 family hydrolyses cGMP specifically, with the highest affinity of all the 
cGMP PDEs (Soderling, Bayuga et al. 1998). The PDE9A gene gives rise to over 21 
isoforms through alternative splicing.  It was characterised as part of a study 
looking at Down syndrome and other genes on chromosome 21 and was suggested 
to be involved in the Downs phenotype (Guipponi, Scott et al. 1998). It is 
sensitive to the PDE5 inhibitor zaprinast and like PDE5 is implicated in NO/cGMP 
signalling. But unlike cGMP PDEs 2, 5 and 6, PDE9 does not possess GAF, or any 
N-terminal protein domains (Fisher, Smith et al. 1998). As a result, its regulation 
is ill understood. PDE9 seems to be expressed in all tissues except blood. It 
shows wide distribution in the brain, having the same expression pattern of as 
soluble guanylyl cyclase (sGC) and nitric oxide synthase (NOS) in rat brain. High 
relative PDE9 expression was identified in areas of the brain in which the nitric 
oxide (NO)-sGC-cGMP signalling pathway operates, suggesting this PDE is 
involved in processes such as learning and behavioural state regulation 
(Andreeva, Dikkes et al. 2001). Indeed, alteration of NO-cGMP signalling via 
PDE9 inhibition improves cognition and LTP. This is a promising therapeutic 
strategy for AD and other diseases involving cognitive impairment, indeed the 
selective PDE9 inhibitor; PF-04447943, has just completed phase II clinical trials 
as an AD drug (Wunder, Tersteegen et al. 2005; Zhihui 2013). PDE9 has also been 
shown to be regulated by testosterone via  NO-cGMP signalling in the Leydig cells 
of rats (Andric, Janjic et al. 2010) and recent evidence suggests that PDE9 
inhibition could also be efficacious in the treatment of erectile dysfunction (da 
Silva, Pereira et al. 2013), and that it is expressed in LUTS (Nagasaki, Nakano et 
al. 2012). Other  recent studies implicate PDE9, along with PDE5, in breast 
cancer cell proliferation, and inhibition of PDE9 has been shown to bring about 
apoptosis via caspase 3 induction  (Saravani, Karami-Tehrani et al. 2012). 
 
1.4.5.2.9 PDE10 
PDE10(A) is a dual specificity PDE. In this case, cAMP inhibits cGMP hydrolysis 
and cGMP inhibits cAMP hydrolysis, so one cyclic nucleotide may somehow act to 
regulate the other in PDE10 localised regions. The cyclic nucleotides bind the 
active site with different orientations and interactions (Wang, Liu et al. 2007). 
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Two human variants are known; PDE10A1 and PDE10A2, which sensitive to the 
inhibitor dipyridimole. PDE10 does not contain PKA or PKG phosphorylation sites, 
but instead is regulated by PKC (Fujishige, Kotera et al. 1999). PDE10 shows an 
interesting brain expression pattern, being in the same locations as dopamine 
receptors, where it may serve to regulate cAMP and cGMP during neuronal signal 
transduction (Fujishige, Kotera et al. 1999; Fujishige, Kotera et al. 1999). Many 
studies suggest its involvement in neurological disorders such as Huntington’s 
disease (HD) and recent findings show PDE10 inhibition improves  motor skills 
and cognition  in HD mice (Giampa, Laurenti et al. 2010; Giralt, Saavedra et al. 
2013). It is also expressed in rat testes and may mediate spermatogenesis along 
with PDE4 (Fujishige, Kotera et al. 1999). PDE10 is a GAF-PDE, but unlike all the 
others (PDEs 2, 5 and 6), the GAF domain is allosterically bound by cAMP rather 
than cGMP (Gross-Langenhoff, Hofbauer et al. 2006). The effect on PDE activity 
of cAMP binding GAF B of PDE10 is unclear. Some studies show no effect 
(Matthiesen and Nielsen 2009), while others report that the interaction  
activates PDE10, like for PDE2 and PDE5 (Jager, Russwurm et al. 2012). It may 
be that interactions at the GAF tandem bring about a conformational change and 
affect enzyme activity indirectly. The crystal structure of PDE10 GAF domain 
implies it is involved in dimerisation like in PDE2, but in an asymmetric manner 
(Handa, Mizohata et al. 2008). 
 
1.4.5.2.10 PDE11 
PDE11 is the latest addition to the PDE superfamily (Fawcett, Baxendale et al. 
2000). It is a dual specificity, GAF-PDE and shows sensitivity to IBMX and 
dipyridimole. PDE11A is expressed as four transcripts, PDE11A1-4, with 
differential tissue expression in skeletal muscle, prostate, testis, kidney, liver, 
pituitary, brain and salivary glands. PDE11A1 and PDE11A2 contain only a single 
GAF domain, PDE11A3 contains one full GAF and a truncated GAF, and PDE11A4 
contains the GAF tandem seen in all other GAF-PDEs (Hetman, Robas et al. 2000; 
Yuasa, Kotera et al. 2000). The differences in the N-termini suggest diverse 
regulation between the isozymes. It would seem that cGMP regulates PDE11A via 
these domains, as it does in other GAF-PDEs, but studies are conflicting (Gross-
Langenhoff, Hofbauer et al. 2006; Matthiesen and Nielsen 2009; Jager, Russwurm 
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et al. 2012). A recent study found PDE11A functions in the CNS, and 
polymorphisms in this gene are implicated in major depressive disorder (MDD) 
(Wong, Whelan et al. 2006). This is unsurprising, as many studies implicate cGMP 
hydrolysing PDEs in neurological disorders. A PDE11A deficit has also been 
connected to spermatogenesis and fertility (Wayman, Phillips et al. 2005). 
 
 
1.4.6 The Phosphodiesterase 4 Family 
The PDE4 family is cAMP specific, and comprises 4 subgenes, PDE4A-D. PDE4 has 
been the subject of much research due to the fact that its inhibition leads to 
potent anti-inflammatory effects. Rolipram is the archetypal PDE4 inhibitor, and 
rolipram-sensitive PDE activity had been documented for some time, finally to 
be classified as the PDEIV family (Reeves, Leigh et al. 1987). A mutant dunce 
gene which caused Drosophila to exhibit learning defects (Dudai, Jan et al. 
1976), was also found to cause abnormal cAMP metabolism, and so, the dunce 
gene was characterised as a cAMP PDE (Byers, Davis et al. 1981; Davis and Kiger 
1981). Dunce cDNA was then used to search for homologs in mammals, leading to 
the first molecular cloning of a PDE4, indeed of any PDE, from rat (Davis, 
Takayasu et al. 1989). This PDE shared >70% sequence identity with dunce in the 
conserved region, underscoring the conservation of PDEs throughout evolution 
and highlighting their importance. Subsequent cloning experiments isolated four 
groups of rat cDNA clones that showed homology to dunce and corresponded to 
four different genes (Swinnen, Joseph et al. 1989). These were later found to 
have human homologs (Bolger, Michaeli et al. 1993) encoding four subfamilies; 
PDE4A, PDE4B, PDE4C and PDE4D, which gave rise to splice variants. The PDE4 
family was found to express distinct N-terminal motifs sharing no homology to 
each other, but with homologous regions on rat PDEs. These class specific motifs 
were termed upstream conserved regions 1 and 2 (UCR1 and UCR2) (Bolger, 
Michaeli et al. 1993).  
 
Human PDE4A and C genes map to chromosome 19 (19p13.2 and 19p13.1 
respectively), PDE4B to chromosome 1 (1p31.3) and PDE4D is located on 
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chromosome 5 (5q12.1) (Milatovich, Bolger et al. 1994; Horton, Sullivan et al. 
1995; Szpirer, Szpirer et al. 1995; Sullivan, Olsen et al. 1999) 
The PDE4 subfamily genes encode over 25 slice variants. It is likely that no two 
isozymes will exhibit redundancy due to the unique extreme N-terminal 
domains. The unique N-termini of most isozymes are encoded by a single exon; 
however multiple exons are employed for PDEs 4B1, 4C1 and 4D7. One exception 
to this is the identical N-terminal regions expressed on the super short isoforms 
PDE4D6 and PDE4B5 (Cheung, Kan et al. 2007).  
 
 
1.4.6.1 PDE4A 
There are 11 recorded PDE4A splice variants, but some are rodent specific and 
the human PDE4As are PDE4A1, PDE4A4, PDE4A7, PDE4A10 and PDE4A11. 
 
PDE4A1 is a super-short, exclusively membrane-associated isozyme (Shakur, 
Wilson et al. 1995). It is regulated by Ca2+ and binds phosphatidic acid (PA) via a 
TAPAS domain in its unique N-terminal region. An increase in intracellular CA2+ 
brings about binding of PDE4A1 to PA and insertion into lipid bilayers in an 
irreversible manner (Baillie, Huston et al. 2002). Deletion of the PDE4A1 N-
terminus prevented its membrane insertion and created a soluble enzyme, giving 
evidence for the hypothesis that PDEs are targeted to distinct subcellular 
locations via their unique N-termini (Shakur, Pryde et al. 1993).  
 
PDE4A4 is a long form isozyme, homologous to rat PDE4A5, and is the most 
studied PDE4A isozyme. It is associated with neural signalling and the isozymes 
have been shown to be differentially expressed across the brain and CNS (D'Sa, 
Eisch et al. 2005). Expression in the hippocampus suggests PDE4A4 is involved in 
learning/memory processes and cAMP dependant neurogenesis. Anti-depressive 
treatment with various PDE4 inhibitors led to region-specific upregulation of 
some PDE4A isoforms (Ye, Jackson et al. 2000; D'Sa, Eisch et al. 2005). This 
compensatory mechanism likely affects the efficacy of antidepressants and 
isoform-selective inhibitors would serve as more efficacious antidepressant 
drugs. PDE4A has also been shown to be involved in impaired LTP and memory 
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due to sleep deprivation. Mice showed an upregulation of PDE4A5 (human 
PDE4A4) when cAMP/PKA dependant LTP was impaired, and PDE4 rolipram 
inhibition rescued this phenotype (Vecsey, Baillie et al. 2009).  
 
It has been shown that PDE4A4 undergoes a conformational change following 
rolipram challenge, and this induces reversible association with p62, a protein 
involved in protein aggregation disorders. It is proposed that this event would 
sequester PDE4A4 in a p62 aggregate, away from its functional sites within the 
cell, and thereby be an additive affect to therapeutic inhibition. It may also be a 
means of sequestering PDE4A4 and therefore adapting cAMP signalling during 
time of cellular stress (Christian, Anthony et al. 2010). It was later found that 
this rolipram-induced conformational change is mediated by activation of the 
p38 MAPK pathway and consequent phosphorylation of PDE4A5 by MAPKAPK2 
(MK2) (MacKenzie, Wallace et al. 2011). This study also found that such MK2 
phosphorylation of long form PDE4s somewhat inhibits their phosphorylation by 
PKA, thereby lessening the desensitisation response to cAMP activation mediated 
by long form PDE4s.  
 
PDE4A5 was found to undergo apoptosis-induced caspase 3 cleavage of its N-
terminus, and is the only know PDE isoform which encodes a caspase 3 cleavage 
site (Huston, Beard et al. 2000). The location of this isozyme changed following 
cleavage, again showing how the N-termini of PDEs are involved in their 
subcellular targeting. PDE4A5 can interact with the SH3 domains of SRC family 
kinases (O'Connell, McCallum et al. 1996; Beard, Huston et al. 2002), an action 
which is inhibited following cleavage by caspase 3. Binding of PDE4A5 to SH3 
domains may be to alter the local cAMP environment as required by these 
kinases. 
 
A study on groups of smokers (with and without COPD) tested for changes in 
PDE4 isoform expression and found that PDE4A4 was uniquely upregulated in the 
macrophages of COPD patients (Barber, Baillie et al. 2004). This underscored the 
importance of the isozyme in inflammatory related diseases. PDE4A5 was found 
to bind the immunophilin XAP2/AIP/ARA9 via its N-terminus and probably also its 
UCR2 domain (Bolger, Peden et al. 2003). This interaction causes reversible 
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inhibition of PDE4A5, potentiates inhibition caused by rolipram, and it inhibits 
phosphorylation of PDE4A5 by PKA; effects which are likely mediated by 
conformational changes in this isozyme. The consequence of the XAP2/ 
PDE4A4/5 interaction is unknown but it may be to sequester the PDE to a certain 
locale/complex. XAP2 also binds and stabilises the aryl hydrocarbon receptor 
(AHR) which is the receptor for carcinogens found in cigarette smoke (Meyer and 
Perdew 1999; de Oliveira and Smolenski 2009). This is another link between 
PDE4A4/5 and inflammation, as cigarette smoke is main cause of COPD. A more 
recent study showed a rolipram-sensitive upregulation of PDE4A5 in SCI, again 
placing PDE4A4/5 in an inflammatory setting (Schaal, Garg et al. 2012).  
 
An unusual splice variant; the short form PDE4A7, has a unique C-terminus as 
well as a unique N-terminus, with a conserved core region. Atypically, PDE4A7 is 
also catalytically inactive (Horton, Sullivan et al. 1995; Sullivan, Rena et al. 
1998). It is widely expressed and its function is unclear. It may oligomerise with 
other PDE isoforms to modulate their activity or intracellular targeting 
(Johnston, Erdogan et al. 2004), or may indeed be a scaffold protein.  
 
The long forms PDE4A10 and PDE4A11 are the most recently identified PDE4As. 
They show different localisation and sensitivity to PDE4 inhibitors when 
compared with PDE4A4/5, again, suggesting different targeting and catalytic site 
conformations due to their unique N-termini (Rena, Begg et al. 2001; Wallace, 
Johnston et al. 2005). PDE4A10 is widely expressed in rat tissues, but is 
concentrated in the heart, with high basal expression. Unusually, this isoform is 
downregulated following an increase in cAMP levels, a process that is observed 
in neonatal rat hearts.  The significance of this is unknown, but it may be to 
remodel  the signalling in a distinct, as yet unknown, cAMP pool (McCahill, 
Campbell et al. 2008).  The converse of this can be seen during monocyte to 
macrophage differentiation which involves a complex remodelling of the PDE4 
profile, including upregulation of the normally absent PDE410 (Shepherd, Baillie 
et al. 2004). These isozymes are only beginning to be studied so other facets of 
their function should be discovered soon. Recent evidence shows PDE10A is 
upregulated during the inflammatory response following traumatic brain injury 
(TMI) (Oliva, Kang et al. 2012) 
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1.4.6.2 PDE4B 
PDE4B encodes 5 isozymes; the long PDE4B1, PDE4B3 and PDE4B3; the short 
PDE4B2 and the supershort PDE4B5. 
 
Many studies have linked the long arm of chromosome 1 and mutated disrupted 
in schizophrenia 1 (DISC1) gene to schizophrenia and related mental disorders 
(Blackwood, Fordyce et al. 2001; Waterwort, Bassett et al. 2002; Hennah, Varilo 
et al. 2003; Ozeki, Tomoda et al. 2003; Kamiya, Kubo et al. 2005; Millar, Pickard 
et al. 2005).  A study of a Scottish family found the schizophrenic phenotype to 
be caused by a balanced (1;11)(q42;q14.3) chromosomal translocation resulting 
in disruption of the DISC1 gene by the breakpoint on chromosome 1 (Blackwood, 
Fordyce et al. 2001). A subsequent study found another balanced 
t(1;16)(p31.2;q21) translocation associated with schizophrenia (Millar, Pickard et 
al. 2005). The translocation breakpoint on chromosome 16 lies within an intron 
of cadherin 8, and the 1p31.2 breakpoint lies within a PDE4B1 intron, placing 
PDE4B as a susceptibility gene for schizophrenia and related mental maladies. 
The t(1;16) translocation event caused a 50% reduction in PDE4B1 protein 
expression. It has also been found that wild type DISC1 binds a number of PDE4 
isoforms via sites in the UCR2 and catalytic domain, indeed isolated UCR2 region 
is sufficient to bind DISC1, (Millar, Pickard et al. 2005; Murdoch, Mackie et al. 
2007). It has been suggested that DISC1 binds to the low activity form of PDE4B 
and activation of the enzyme by PKA leads to dissociation of its interaction with 
DISC1 and an increase in PDE4B activity (Millar, Pickard et al. 2005). However, a 
study using a full length DISC1 isoform suggests that an increase in cAMP does 
not cause such dissociation from PDE4B1 (Murdoch, Mackie et al. 2007). The 
differences may be due to different isoforms of PDE4B and DISC1 being used in 
each study. In fact, the latter report found that DISC1 interactions with various 
PDE4 isoforms are differentially regulated by cAMP/PKA, suggesting these 
interactions are very complex. Two point mutations in mouse DISC1 located 
within the PDE4B binding region inhibited the DISC1/PDE4B interaction and 
conferred psychiatric phenotypes (Clapcote, Lipina et al. 2007; Murdoch, Mackie 
et al. 2007). Single nucleotide polymorphisms (SNPSs) within the PDE4B gene, 
particularly within PDE4B2 introns, have been shown to positively correlate with 
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the incidence of schizophrenia  (Fatemi, King et al. 2008). PDE4B1, PDE4B2, 
PDE4B3 and PDE4B4 protein levels were found to be decreased in post-mortem 
samples from schizophrenic patients, and PDE4B3 was decreased in bi-polar 
samples. These findings suggest that PDE4B plays a role in the etiology of 
schizophrenia and related psychoses. Truncated DISC1 and/or PDE4B1 due to the 
translocation events, mutations within DISC1 and PDE4B genes, or SNPs, may 
affect the DISC1/PDE4B interaction thereby affecting cAMP signalling in specific 
brain regions and may lead to the schizophrenic phenotype. 
 
As previously discussed, PDE4 is involved in memory and cognition. Using 
hippocampal slices from rat, it was found that PDE4B3 expressed in neurons is 
regulated by NMDA-receptors and LTP, suggesting that cAMP modulation is 
important for synaptic plasticity and  LTP(Ahmed and Frey 2003), and a number 
of studies suggest a role for glutamatergic signalling in schizophrenia. 
Interestingly, altered PDE4A and PDE4B profiles were observed in the brains of 
autism patients’ post-mortem (Braun, Reutiman et al. 2007).  
 
A number of studies have used PDE4B knockout mice to study its role in cognition 
and psychiatric illnesses. These mice displayed; the antipsychotic ability of 
rolipram PDE4 inhibition (Siuciak, Chapin et al. 2007); abnormal information 
processing and attention deficits (PPI) due to altered dopaminergic signalling 
(Siuciak, McCarthy et al. 2008); an increase in anxiety associated behaviour and 
corticosterone production (Zhang, Huang et al. 2008); and augmented long term 
depression (LTD) and reversal learning phenotype (Rutten, Wallace et al. 2011). 
Also, nicotine can exert antidepressant effects, and rats which underwent 
chronic nicotine treatment displayed a downregulation in PDE4B mRNA in 
selective brain regions (Polesskaya, Smith et al. 2007). 
 
Lipopolysaccharide (LPS) is a potent inflammatory agent, which can cause tissue 
damage and even death via tumour necrosis factor (TNF) α, which is produced by 
monocytes and macrophages, cells that play an important role in alcohol-
induced liver disease and hepatitis due to dysregulated cytokine signalling. 
PDE4B has been associated with this disease, where LPS induces its upregulation 
in monocytes and macrophages following chronic ethanol exposure. The 
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resultant decrease in cAMP causes an LPS-induced increase in TNF.  (Jin and 
Conti 2002; Gobejishvili, Barve et al. 2008). Further work showed that the anti-
inflammatory S-adenosylmethionine (SAM), a biological methyl donor, inhibits 
the LPS-induced upregulation of PDE4B2 due to hypermethylation of the PDE4B2 
promoter region. This leads to an increase in cAMP and PKA, inhibition of TNF 
induction, and anti-inflammatory effects (Gobejishvili, Avila et al. 2011). A 
recent study shows that PDE4B inhibits transcription of the bacterial induced 
anti-inflammatory mediator, cylindromatosis (CYLD). Inhibition of PDE4B with 
rolipram led to upregulation of CYLD and an anti-inflammatory response 
(Komatsu, Lee et al. 2013). These studies, once again, display the importance of 
PDE4 in inflammation and support the notion that PDE4 inhibition has huge 
therapeutic potential. They suggest a role for PDE4B2 in bacterial infection 
mediated inflammation. Using SAM to inhibit LPS/PDE4B2/TNF-mediated 
inflammation is a promising treatment for liver disease, especially due to the 
safe tolerability profile of SAM.  
 
The supershort PDE4B5 is the most recently identified isoform (Cheung, Kan et 
al. 2007). It is highly conserved across species and is brain specific. It is highly 
unusual, with a ‘unique’ N-terminus identical to that of supershort PDE4D6, 
which is also brain specific. However, PDE4B5 and PDE4D6 do not share any 
upstream transcription factor binding sites, suggesting they are indeed 
independent PDE4 isoforms. Interestingly PDE4B5 also binds DISC1, suggesting 
the binding site for DISC1 resides in the part of UCR2 left in this supershort 
isozyme.  
 
 
1.4.6.3 PDE4C 
The PDE4C subfamily comprises the long forms PDE4C1, PDE4C2 and PDE4C3. It is 
the least studied and characterised PDE4 subfamily due to its limited expression. 
Initial clones of PDE4C isoforms turned out to be mRNA artefacts (Engels, 
Sullivan et al. 1995; Obernolte, Ratzliff et al. 1997; Sullivan, Olsen et al. 1999). 
A number of screens carried out to look at differential PDE4 expression within 
various tissues have shed some light on PDE4C expression. 
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 In a screen of rat retina samples, various PDE4 proteins were detected except 
PDE4C. However, a small amount of mRNA was detected, suggesting a possible 
low level of PDE4C protein may exist in this tissue. It is worth noting that, 
abundant PDE4C protein was seen in a lung sample, which was used as a positive 
control. (Whitaker and Cooper 2009). In a study looking at the PDE4 profile of 
inflammatory cells (monocytes, macrophages, T-cells and neutrophils) from 
COPD patients, PDE4C was found to be expressed in the macrophages, 
monocytes and neutrophils of COPD, non-COPD smokers and non-smokers. It was 
poorly expressed in blood monocytes but was upregulated following their 
differentiation to macrophages in the lung, in all samples (Barber, Baillie et al. 
2004). This study suggests PDE4C is involved in inflammatory cell signalling, but 
not perhaps in the disease phenotype of COPD. However, in contrast to these 
findings, PDE4C expression was detected in monocyte to macrophage 
differentiation in U937 monocytic cells (Shepherd, Baillie et al. 2004) and it 
showed very low expression, with no activity in lung fibroblasts compared to 
PDE4B and PDED4D isoforms (Selige, Hatzelmann et al. 2011). PDE4C is suggested 
to be upregulated in the autoimmune disease Wegener’s, which is associated 
with neutrophil activation. Healthy donor granulocytes that were TNFα-primed 
were stimulated with the antibody responsible for this disease, resulting in 
upregulation of a number of genes, including PDE4C (Surmiak, Kaczor et al. 
2012). Neutrophils play an important role in the inflammatory response to 
bacterial infection and so this study again places PDE4 as an inflammatory 
mediator, and particularly PDE4C, as a mediator of bacterial toxin mediated 
inflammation, underscoring the importance of cAMP signalling in these 
responses.  
 
PDE4C also showed no expression in the heart (Richter, Day et al. 2008), but was 
found to be the major PDE4 isozyme in pancreatic islet cells (Heimann, Jones et 
al. 2010). This may suggest a role in homeostasis, like PDE3, and a recent study 
identified PDE4C mRNA in rat penile smooth muscle cells (RPSMCs) (Chung, Jung 
et al. 2012). PDE4C has also recently been identified as a novel p53 target gene 
(Garritano, Inga et al. 2013).  
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1.4.6.4 PDE4D 
The PDE4D subfamily is the largest to date, comprising 9 human isoforms; 
PDE4D1-9. PDE4D10 and PDE4D11 have been identified in rodents 
(Chandrasekaran, Toh et al. 2008; Lynex, Li et al. 2008), with possible PDE4D11 
sequence in the human genome, but no evidence for any protein expression. 
PDE4D3, PDE4D4, PDE4D5, PDE4D7, PDE4D8 and PDE4D9 are long form variants, 
PDE4D1 and PDE4D6 are short and PDE4D2 is a super-short form. The PDE4D 
subfamily represents the highest PDE4 expression in many tissues including the 
prostate and adenocarcinoma of the prostate (Henderson D., thesis 2011).  
 
1.4.6.4.1 PDE4D1 and PDE4D2 
cAMP and follicle stimulating hormone (FSH) induce transcription of PDE4D1 and 
PDE4D2 from an intronic PDE4D promoter, within Sertoli cells (Vicini and Conti 
1997). The promoter contains a cAMP response element binding protein (CREB) 
and cAMP response elements (CRE).  mRNA of both enzymes was increased, but 
only PDE4D2 was translated. cAMP-inducible transcription of PDE4D1/2 
constitutes a feedback loop involved in desensitisation of chronic cAMP signalling  
and  is paramount to homeostasis in these cells. These isoforms are also 
upregulated in response to cAMP elevation in Jurkat T cells, with higher 
transcription of PDE4D1 (Erdogan and Houslay 1997). Healthy (quiescent) and 
diseased (activated) vascular smooth muscle cells (VSMCs) were found to have 
different PDE4D profiles, with an increase in the expression of short form 
variants following cAMP elevation in only diseased VSMCs (Tilley and Maurice 
2005). This represents phenotype-dependent differential PDE4 expression, 
similar to that during monocyte-macrophage differentiation (Shepherd, Baillie et 
al. 2004). These findings suggest short form-specific PDE4D inhibitors would be 
of therapeutic value to augment cAMP signalling in activated VSMCs, without 
affecting normal VSMCs in the same artery.  
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1.4.6.4.2 PDE4D3 
A number of signalling pathways and binding partners have been elucidated for 
PDE4D3. 
 
In overexpressing cells, PDE4D3 was shown to directly bind phosphatidic acid 
(PA) (Grange, Sette et al. 2000) which caused an increase in PDE activity. No 
such increase for PDE4D1 was observed; suggesting PA binding regulates long 
form PDE4D isoforms. PDE4D3 also binds relaxin family peptide receptor 1 
(RXFP1) via B arrestin2 and AKAP79, and acts to negatively regulate signalling by 
the hormone relaxin. The signalosome involved here also includes PKA and a 
constitutively active GPCR and the complex acts to mediate low level basal 
relaxin signalling (Halls and Cooper 2010).  
 
cAMP enhances skin pigmentation following signals from melanocyte-stimulating 
hormone (MSH), which, in turn, stimulates the transcription factor MITF, a 
signalling pathway that plays a crucial role in the proliferation of skin pigment 
cells. PDE4D3 was specifically found to be upregulated in melanocytes following 
forskolin treatment. This increase was ablated when MITF was knocked down by 
siRNA, suggesting MITF regulates PDE4D3 expression in melanocytes. This is 
another example of a feedback loop, whereby MSH activates a cAMP “pool” that 
stimulates MITF, which in turn induces PDE4D3 expression which dampens the 
cAMP signal. Targeting this MITF-PDE4D3 loop may be of therapeutic value for 
skin cancer (Khaled, Levy et al. 2010; Ohanna, Bertolotto et al. 2011).  
 
Various PDE4 isoforms have been found to interact with the neuronal scaffolding 
protein Ndel1, but it uniquely interacts with PDE4D3 in a dynamic manner.  PKA 
phosphorylation on Ser13 within the N-terminus of PDE4D3 causes dissociation 
from Ndel1 (Collins, Murdoch et al. 2008). This event mirrors the differential 
PDE4 isoform release from N-terminally truncated or full length DISC1 (Millar, 
Pickard et al. 2005; Murdoch, Mackie et al. 2007) 
 
Interestingly, Ser13 falls within the region on which mAKAP binds PDE4D3 and It 
has been suggested that PKA phosphorylation acts to increase the affinity of this 
PDE for mAKAP (Carlisle Michel, Dodge et al. 2004), suggesting a ‘switching of 
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partners’ mechanism. Later, it was shown that within this mAKAP/PKA/PDE4D3 
complex is also EPAC1, members of the ERK5 MAPK pathway and protein 
phosphatase PP2A (Dodge-Kafka, Soughayer et al. 2005; Dodge-Kafka and 
Kapiloff 2006; Dodge-Kafka, Bauman et al. 2010). This complex serves to tightly 
regulate localised cAMP signalling in cardiac cells in an extremely elegant and 
efficient manner (figure 1.5). Interestingly, Collins et al. had independently 
found EPAC to interact with Ndel1. This multifaceted signalosome displays 
interweaving negative and positive cAMP regulatory loops to fine tune the cAMP 
signalling response, further exemplifying the complexity of cAMP signalling, and 
how tightly regulated complexes are paramount to modulating the 
compartmentalisation of this signalling to allow pleiotropic responses to occur.  
 
 PDE4D3 is also part of the cardiac ryanodine receptor (RyR2)/ calcium-release-
channel complex (Lehnart, Wehrens et al. 2005). This macromolecular complex 
is crucial to excitation-contraction (EC) coupling in the heart. Lehnart and 
colleagues observed a reduction in PDE4D3 levels within the RyR2 complex, 
which resulted in PKA hyperphosphorylation and ‘leakiness’ of the complex in 
failing hearts. This suggests PDE4D3 deficiency may play a role in the 
pathogenesis of heart failure (HF). This work also underscores how important it 
may be to find isoform-specific inhibitors when treating heart disease.   
 
PDE4D3 has been found to also bind LIS1 (Murdoch, Vadrevu et al. 2011), a 
protein essential for neuronal migration where loss of function mutations are the 
causative factor of the neurodevelopmental disorder lissencephaly (Cardoso, 
Leventer et al. 2000). LIS1 is a microtubule-associated protein, maintaining the 
cell’s microtubule network integrity. It interacts with dynein, and perturbation 
of this interaction likely plays a role in lissencephaly. Murdoch et al. found that 
PDE4D3 and other long form PDE4 isozymes bind LIS1 following PKA 
phosphorylation, and in fact, compete with dynein for binding. This interaction 
would act to sequester LIS1, inhibit its association with dynein and thus 
downregulate dynein activity. This study suggests that PDEs can modulate 
signalling by acting as scaffold proteins, and not just by cAMP regulation. This 
may explain the expression of the catalytically inactive PDE4A7 isoform (Horton, 
Sullivan et al. 1995; Sullivan, Rena et al. 1998).  
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To date, PDE4D3 is the only documented case of PKA phosphorylation within the 
unique N-terminus of any long form PDE4 (Sette and Conti 1996). However, 
results presented in this thesis suggest that the long form PDE4D7 is also PKA 
phosphorylated within its N-terminus, and that this affects its activity.  
 
1.4.6.4.3 PDE4D4 
PDE4D4 is a long form isozyme with the ability to bind the SH3 domain of src, lyn 
and fyn kinases (Beard, O’Connell et al. 1999). A perturbed PDE4D4 epigenome 
has been implicated in PC. Gestational low-dose exposure to environmental 
oestrogens, such as bisphenol A, causes susceptibility to later hormonal hits and 
the development of PC in adult life. Rat neonatal prostate glands represent 
those of human foetal prostates. Following various oestrogenic exposures of rat 
neonates, PDE4D4 was found to be hypomethylated in the prostate. Normally 
PDE4D4 expression is decreased in the aging prostate due to gradual 
hypermethylation. However brief neonatal exposure to oestrogens led to 
continued hypomethylation of PDE4D4 throughout the life of the rats. These 
changes in methylation status and gene expression were identified prior to any 
histopathologic changes, suggesting such events are a driving force of prostate 
carcinogenesis (Ho, Tang et al. 2006; Prins, Tang et al. 2008).  
 
PDE4D4 interacts with spectrin to maintain integrity of the lung microvascular 
endothelial cell barrier (Creighton, Zhu et al. 2008). It has also been implicated 
in depression, where knockdown of this isoform along with PDE4D5 produced 
antidepressant effects (Wang, Zhang et al. 2013) 
 
1.4.6.4.4 PDE4D5 
Historically, PDE4D5 was the first example of a PDE4 isoform having a specific 
function within the cell. PDE4D5 acts in complex with PKA, AKAP79 and the 
scaffold protein β-arrestin to regulate the switch from β2-adrenoreceptor (β2-
AR) coupling to Gi mediated ERK activation, thereby helping to compartmentalise 
cAMP signalling at the β2-AR in cardiac cells (Perry, Baillie et al. 2002; Lynch, 
Baillie et al. 2005). PDE4D5 also binds the scaffold protein receptor for activated 
c-kinase (RACK1) (Yarwood, Steele et al. 1999). In fact, β-arrestin and RACK1 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     51 
 
interact with overlapping sites within the PDE4D5 N-terminus and therefore 
compete for binding to regulate PDE4D5 signalling (Bolger, Baillie et al. 2006). 
RACK1 sequestration of PDE4D5 ultimately limits the amount of PDE4D5 available 
for recruitment to the β2-AR. This is an example of yet another layer of 
regulation within the cAMP/PDE signalling network. Recent work has also 
demonstrated that, following β2AR activation, PDE4D5 competes with EPAC1 for 
binding to β-arrestin2.  β-arrestin2 recruits EPAC1 to β1AR, resulting in H-ras 
activation (Berthouze-Duquesnes, Lucas et al. 2013). Therefore PDE4D5 may also 
exert its function by acting as a scaffold, to sequester EPAC1 thereby modulating 
and offering specificity to βAR signalling. This is another example of how a 
PDE4D may regulate signalling aside from cAMP hydrolysis. It also exemplifies the 
intricate and complex nature of compartmentalised cyclic nucleotide signalling. 
This signalling axis is involved in cardiac cell remodelling, and perturbation of 
this βAR regulation may be involved in HF.  
 
PDE4D5 has also been placed in a signalling system with RACK1 and focal 
adhesion kinase (FAK) whereby the PDE4D5/RACK1/FAK complex regulates cell 
polarity (Serrels, Sandilands et al. 2010). Knockdown of PDE4D5 pinpointed its 
role in cell spreading and signal-induced polarisation, and the 
PDE4D5/RACK1/FAK complex localises to nascent adhesion structures and the 
leading edge of polarising cells. A follow on study found this signalling pathway 
to employ EPAC and its downstream effector Rap1 (Serrels, Sandilands et al. 
2011). Perturbation of this ‘direction sensing’ signalling complex to cause 
constitutive EPAC/Rap1 activation resulted in lack of nascent adhesion 
stabilisation and impaired cell spreading and responses to polarisation signals. 
Indeed FAK and PDE4D5 are upregulated in mouse squamous cell carcinomas 
(SCCs), suggesting that perturbation of this direction sensing complex is involved 
in cancer cell migration and invasiveness. One study employed the Sleeping 
Beauty (SB) transposon system to identify novel oncogenes involved in PC 
(Rahrmann, Collier et al. 2009). Transposon based mutagenesis caused altered 
prostate histology and an increase in proliferation of the epithelium, features 
associated with PC precursor lesions. Within these lesions, candidate cancer 
genes were identified, among them PDE4D. This study also found PDE4D to be 
upregulated in prostate adenocarcinoma patient samples compared to those 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     52 
 
with BPH. Additionally, shRNA PDE4D knockdown decreased cell proliferation. 
The report went on to suggest that PDE4D5 is the main player in cAMP 
dysregulation in PC. PDE4D overexpression may occur in the aging prostate and 
lead to increased risk for PC. This is in contrast to a number of PC expression 
profiling studies that are listed in the Oncomine Database. Within these, no 
change of PDE4D mRNA expression, or a decrease in expression with increasing 
tumour grade, were observed. It may be that an mRNA decrease does not 
represent post transcriptional regulation of PDE4D. Indeed, poor correlation 
between the mRNA and protein levels of many PDE4D isoforms has been noted in 
rats due to post transcriptional modifications (Rhodes, Yu et al. 2004; Richter, 
Jin et al. 2005; Rahrmann, Collier et al. 2009). However, the protein level of 
PDE4D7 matches that of its mRNA, as shown in this thesis. 
 
1.4.6.4.5 PDE4D6 
PDE4D6 is a supershort isozyme, sharing its unique N-terminal region with the 
super short PDE4B5. Both are exclusively expressed in brain, and no specific 
function has been assigned to either (Wang, Deng et al. 2003; Cheung, Kan et al. 
2007).   
 
1.4.6.4.6 PDE4D7 
This long form isozyme was first described alongside PDE4D6 (Wang, Deng et al. 
2003). PDE4D7 has been implicated in carotid (common) stroke. The PDE4D gene 
was linked to ischemic stroke in Northern European populations via its role in 
atherosclerosis, which involves proliferation and migration of VSMCs. A 
genomewide search for stroke susceptibility genes within an Icelandic cohort 
identified the susceptibility locus to be located at 5q12 (Gretarsdottir, 
Sveinbjornsdottir et al. 2002) which was in fact pinpointed to the PDE4D locus 
(Gretarsdottir, Thorleifsson et al. 2003). They further pinpointed the stroke-
associated haplotype/SNPs to extend over the 5’ exon and promoter regions of 
PDE4D7, and found a significant correlation between the stroke-associated 
haplotype and PDE4D7 mRNA levels. Since the disease haplotype is located at 
the 5’ end of PDE4D7, it may affect transcription of this isoform. Surprisingly, no 
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further studies on PDE4D7 have been carried out to look at the behaviour of its 
promoter region or the function of the PDE4D7 protein. 
 
1.4.6.4.7 PDE4D8 
PDE4D8 is a long form PDE4. In mice it shows restricted expression that is highest 
in lung, heart and liver (Richter, Jin et al. 2005). Studies using cardiomyocytes 
have found β1-adrenoreceptor (β1AR) to associate preferentially with PDE4D8, 
which dissociates from the receptor following agonist activation (De Arcangelis, 
Liu et al. 2009; De Arcangelis, Liu et al. 2010). PDE4D8 also associates with β2AR 
by β arrestin recruitment, much like PDE4D5. However, while PDE4D5 mediates 
β2AR signalling following receptor activation, it seems PDE4D8 (along with 
PDE4D9) acts to regulate basal cAMP signalling around the β2AR (De Arcangelis, 
Liu et al. 2009). So, following receptor stimulation PDE4D8 is released from 
β1AR, but recruited to β2AR. Perhaps simultaneous activation of both βARs 
causes PDE4D8 to move from β1AR to β2AR via arrestins, which would allow a 
local increase in cAMP at the β1ARs, so as to elicit downstream signalling and 
bring about contractility of cardiac cells. This is yet another example of the 
complexity and elegance that underpins tightly regulated, compartmentalised 
cAMP signalling.  
 
1.4.6.4.8 PDE4D9 
Very little is known about this long form PDE. It is widely expressed in rat tissue 
(Richter, Jin et al. 2005). Akin to PDE4D8, it is involved in β adrenergic signalling 
in cardiomyocytes. It has been shown to bind β2AR, but in contrast to PDE4D8, 
they are associated in the resting state and receptor stimulation causes 
dissociation of PDE4D9 (De Arcangelis, Liu et al. 2009). Recent work places 
PDE4D9 within the dopaminergic signalling network. ATF4 (CREB2) and DISC1 
associate to act as a transcriptional repressor complex on the PDE4D locus, and 
suppress  PDE4D9 promoter activity (Soda, Frank et al. 2013). It seems PDE4D9 
transcription is regulated via dopamine receptor signalling. PKA phosphorylation 
of DISC1 inhibits its nuclear localisation and association with ATF4, thereby 
leading to an upregulation of PDE4D9. PDE4D9 can also interact with DISC1, but 
this interaction decreases with dopamine treatment. These results add to the 
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growing amount of evidence that PDE4 isoform functionality is regulated by 
DISC1. Again, this represents an example of feedback signalling where activated 
dopamine receptor leads to an increase in cAMP, activating PKA which 
phosphorylates DISC1 thereby relieving the transcriptional constraint on the 
PDE4D9 promoter, leading to an increase in PDE4D9 expression and attenuation 
of the cAMP signal. Mutations in DISC1, such as those described by Clapcote et 
al., would then inhibit formation of the repressor complex resulting in PDE4D9 
overexpression (Clapcote, Lipina et al. 2007). Indeed, perturbation of this 
signalling axis within the dopaminergic system may play a role in psychiatric 
pathophysiology.  
 
 
1.4.7 PDE4 Regulation 
1.4.7.1 UCRs and PKA Phosphorylation 
The UCR1 and UCR2 domains confer important regulation on PDE4 isozymes. 
UCR2 underpins an auto-inhibitory mechanism. Deletion of short form PDE4D1 
sequences encompassing the UCR2 region, led to increases in Vmax of 2-3 fold 
(Jin, Swinnen et al. 1992), and 6 fold (Kovala, Sanwal et al. 1997), with little 
change in Km. Deletion of PDE4A5 N-terminal region up to the and including 
UCR2, also caused a 3-fold increase in activity (Beard, Huston et al. 2002). All 
long form PDE4 isoforms are activated by PKA phosphorylation within the 
conserved RRESF motif in the UCR1 region (Sette, Iona et al. 1994; Sette and 
Conti 1996; MacKenzie, Baillie et al. 2002). Long form PDE4D3 is activated upon 
cleavage of its UCR2 domain, and also by antibody binding to the UCR2, which 
acted to ablate its inhibitory constraint (Lim, Pahlke et al. 1999). This activation 
had the same characteristics as that produced following PDE4D3 
phosphorylation, giving credence to the idea that enzyme activation involves 
release of an auto-inhibitory mechanism and a conformational change around 
the catalytic site. This idea was confirmed with the elucidation of the crystal 
structure of the PDE4 UCR2 domain (Burgin, Magnusson et al. 2010). PDE4D UCR2 
and catalytic domains were co-crystallised, with and without the presence of 
inhibitor molecules. The UCR2 domain displayed shape complementarity with 
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the catalytic site. The Inhibitors acted to close the UCR2 around the active site, 
precluding cAMP from the binding pocket (figure 1.4 A). This investigation 
clearly supported the UCR1-UCR2 model for activation of long form PDE4s. In the 
absence of UCR1 phosphorylation by PKA, UCR2 straddles the active site, 
keeping the enzyme in a ‘closed’ conformation. PKA phosphorylation of UCR1 
then causes release of the UCR2 constraint, and the active site is available for 
cAMP to bind (figure 1.4 B). Since PDE4 isoforms dimerise, inhibition by UCR2 
may be intra- or intermolecular. Intermolecular regulation is likely to occur, 
highlighting the functional importance of PDE4 dimerisation (Gurney, Burgin et 
al. 2011). 
 
Another regulatory mechanism stems from the fact that UCR1 and UCR2 are 
capable of forming independent protein folds and interacting with each other 
and with other regions of the PDE4s to regulate enzyme activity (Beard, Olsen et 
al. 2000). The carboxyl end of UCR1 interacts with the amino end of UCR2 via 
electrostatic interactions. PKA phosphorylation of UCR1 inhibits this interaction, 
leading to conformational change and enzyme activation (figure 1.4 B).  
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Figure 1.4. Long form PDE4 regulation by the UCR2 domain.  
A; a surface representation of the PDE4D catalytic domain (grey) bound by 
inhibitor interacting with UCR2 (green). B; UCR2 and UCR1 interact via 
electrostatic interactions to form an inhibitory module. UCR2 straddles the 
active site, precluding cAMP from entering the catalytic pocket. PKA 
phosphorylation of UCR1 relieves this constraint, leading to enzyme activation.  
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1.4.7.2 PDE4 Conformers 
Although the catalytic site is highly conserved across all PDEs, PDE4 is suggested 
to exist in one of two different conformers, adding another layer of enzyme 
regulation. These are the high affinity rolipram-binding state (HARBS) and the 
low affinity rolipram-binding state (LARBS) (Souness and Rao 1997). The 
significance of these different conformations is unclear. PDE4 isoforms may exist 
in one or the other, depending on tissue/cell expression, as different affinities 
for rolipram have been seen in different tissues for the same isoform. UCR2 is 
involved in HARBS, as it binds both the active site and inhibitor via a Phe residue 
(Burgin, Magnusson et al. 2010). The two conformers are a consideration when 
designing PDE4 inhibitors.  
 
 
1.4.7.3 ERK Phosphorylation 
ERK is a member of the MAPK superfamily signalling pathway. This mitogen-
activated protein kinase pathway consists of sequential phosphorylation events 
from MAPKKK to MAPKK to MAPK, each activating the next kinase. ERK is a MAPK. 
The pathway is conserved from yeast to mammals (Widmann, Gibson et al. 
1999). It is both activated by, and acts on a diverse range of signalling 
molecules, including androgens (Nguyen, Yao et al. 2005).   
 
ERK phosphorylates long form PDE4B/C and D isozymes on a PQSP consensus site, 
C terminal to the catalytic domain. EGF-stimulated phosphorylation of PDE4D3 
and PDE4D5 by ERK2 was shown to markedly decrease their activity, with a 75% 
reduction in Vmax for PDE4D3 and no change in Km (Hoffmann, Baillie et al. 
1999). This inhibition was ablated by a MEK inhibitor. Here we see an another 
example of a signalling feedback loop where ERK inactivation of the PDEs 
permits a local increase in cAMP, followed by activation of PKA which 
phosphorylates and activates the PDE to override ERK phosphorylation-mediated 
inhibition.  
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 The catalytic region of all PDE4 isoforms contains two ERK docking sites 
necessary for ERK association with PDE4s. This is a prerequisite for 
phosphorylation. The docking sites are made up of an FQF site, C-terminal to the 
substrate serine, and a KIM domain situated N-terminal to the serine 
(MacKenzie, Baillie et al. 2000). ERK phosphorylation also inhibits super short 
isoforms, albeit weakly, but intriguingly activates short PDE4 isoforms, as 
demonstrated with PDE4D2  (MacKenzie, Baillie et al. 2000), and PDE4D1 and 
PDE4B2 (Baillie, MacKenzie et al. 2000; MacKenzie, Baillie et al. 2000). 
Interestingly, ERK cannot phosphorylate PDE4A isoforms due to the presence of 
arginine instead of a proline in the ERK consensus site; RQSP instead of PQSP. 
Thus the PDE4 profile of a tissue/cell will dictate the outcomes from ERK 
signalling. ERK therefore provides cross-talk between cAMP and MAPK signalling. 
 
 
1.4.7.4 Phospholipids and Phosphatidic Acid 
Long PDE4 isoforms may be activated by phosphatidic acid (PA). For example, 
PDE4D3 shows a PA-induced 2-3 fold increase in Vmax and no change in Km, 
similar to PKA activation. However, little effect is seen on short form PDE4s, 
such as PDE4D1 (DiSanto, Glaser et al. 1995; Némoz, Sette et al. 1997). This 
suggests UCR1 is involved in phospholipid binding. Phosphatidic Acid (PA) also 
altered the sensitivity of PDE4D3 to Mg2+ in a manner akin to PKA 
phosphorylation. PKA and PA do not activate long form PDE4s simultaneously, as 
they do not have an additive effect (Némoz, Sette et al. 1997). This suggests a 
distinct mode of regulation by PA. PA binding sites are not well characterised. 
However, the N-terminus of super short PDE4A1 was found to contain a novel 
tryptophan anchoring phosphatidic acid selective binding domain 1 (TAPAS1) PA 
binding site which mediates its membrane insertion (Baillie, Huston et al. 2002). 
An insertion helix of LWWF lies opposite to the Ca2+ binding helix DKR. 
Submicromolar Ca2+ is required to gate the insertion process, likely through 
conformational change of the second helix. TAPAS1 is not expressed on long 
form PDE4s, and PA binding to the UCR1 is via an unknown mechanism.  
A.M. Byrne  |  PhD Thesis 2014                                                                                                     59 
 
1.4.7.5 PDE4 Intracellular Targeting 
The unique N-termini of PDE4 isoforms are paramount to their intracellular 
targeting. Evidence also suggests that the UCR2 domain contributes to targeting, 
except in cases of super-short isoforms such as PDE4A1, which is targeted to the 
membrane solely by its N-terminus (Houslay and Adams 2003). Protein-protein 
interactions involving the N-termini (and UCR2) determine the subcellular 
localisation of most PDE4s. Targeting of PDE4 isoforms to specific intracellular 
locales and their functional coupling to specific receptors and scaffold proteins 
underpins the spatial dynamics of cAMP gradients. The importance of PDE 
locations was demonstrated by Mongillo et al. in neonatal rat cardiomyoctyes. 
Using FRET-based cAMP reporter constructs to measure cAMP concentrations, 
they found that PDE4 and PDE3 showed distinct responses to βAR agonists due to 
their location (Mongillo, McSorley et al. 2004).  
 
 
1.4.7.6 AKAPs 
A kinase anchoring proteins (AKAPs) also play an important role in signal 
compartmentalisation. They act to sequester and target PKA to discrete cAMP 
pools, and keep PKA close to substrate proteins such as PDE4s. AKAPs act as 
scaffold proteins that ensure strict organisation of cAMP signalling proteins. They 
allow the broad spectrum kinase that is PKA to exert distinct cellular responses.  
AKAPs are well conserved across species and more than 50 have been identified 
based on their ability to co-purify with PKA. They are structurally diverse but 
functionally similar as all possess a PKA anchoring domain, unique targeting 
regions and all have the ability to form multiprotein complexes (Carnegie and 
Scott 2003; Wong and Scott 2004; McConnachie, Langeberg et al. 2006). 
Microtubule associated protein 2 (MAP2) was the first identified AKAP, having co-
purified with PKA RII subunit from brain extract (Lohmann, DeCamilli et al. 
1984). Most AKAPS bind the RII subunit of PKA, but RI-binding AKAPs have been 
identified (Angelo and Rubin 1998). AKAPs with dual specificity have also been 
described (Huang, Durick et al. 1997; Huang, Durick et al. 1997; Ruppelt, 
Mosenden et al. 2007).  
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PDE4D3 interacts and co-localises with muscle specific mAKAP at the nuclear 
membrane in cardiomyoctyes (Dodge, Khouangsathiene et al. 2001). mAKAP 
directly binds to the N-terminus of PDE4D3 lending specificity to this interaction, 
as PDE4D5 was not seen to associate with mAKAP. mAKAP associated PDE4D3 
maintains basal cAMP levels, and upon stimulation of GPCRs, increased cAMP 
production overcomes this inhibition and brings about release of PKA C subunits 
from the complex, followed by PDE activation and cessation of the signal. Later, 
it was shown that this mAKAP/PKA/PDE4D3 complex also contained EPAC1, 
members of the ERK5 MAPK pathway, ryanodine receptor (RyR) and protein 
phosphatase 2A (PP2A) (Kapiloff, Jackson et al. 2001; Dodge-Kafka, Soughayer et 
al. 2005; Dodge-Kafka and Kapiloff 2006; Dodge-Kafka, Bauman et al. 2010). It 
also seems that phosphorylation of PDE4D3 by PKA increases its affinity for 
mAKAP (Carlisle Michel, Dodge et al. 2004). This macromolecular complex 
orchestrates concomitant cAMP regulatory loops. For example, cAMP increases 
result in activated PKA, which, by being bound to mAKAP, phosphorylates and 
activates PDE4D3, which in turn hydrolyses cAMP. Another loop involves mAKAP 
binding and activating PP2A, which in turn dephosphorylates PDE4D3, inactivating 
the PDE, thereby regulating PKA phosphorylation of the RyR Ca2+ sensitive channel. 
Such an intricate signalosome highlights the complexity of compartmentalised 
signalling, and provides cross-talk between the cAMP and Ca2+ networks (figure 
1.5).  
 
A study on the effect of naturally occurring mAKAP coding polymorphisms 
revealed perturbations in the mAKAP/PKA/PDE4D3 complex (Rababa'h, Craft Jr 
et al. 2013). The mutations either affected the AKAP binding to PKA or PDE4D3 
with consequent alterations in PKA activity and Ca2+ signalling. There was also an 
increase in calcineurin expression and CREB phosphorylation, suggesting such 
mutations may induce pro-hypertrophic gene expression. Indeed, such mAKAP 
polymorphisms may be involved in hypertrophy, an element of HF.  
 
The mAKAP/PKA/PDE4D3 complex has been extensively studied in the 
perinuclear region of cardiomyocytes but PKA/AKAP/PDE4 complexes are 
involved in many processes within various tissues and cell types.  PDE4 has been 
shown to associate with the AKAP gravin, where it is in complex with PKA at the 
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sub-plasma membrane region (Willoughby, Wong et al. 2006). PDE4D3 also 
associates with AKAP450, PKA and other proteins at the centrosomes, implying a 
role in cell division (Taskén, Collas et al. 2001). PDE4A1 can associate with three 
different AKAPs in T cells; AKAP149, AKAP95 and MTG (Asirvatham, Galligan et 
al. 2004). This demonstrates that a certain PDE4 can act in different regions 
within the cell with distinct functional outcomes by being anchored to different 
AKAPs complexes.  
 
AKAPS are a key component of T cell signalling. PKA plays an unusual role in T 
cell activation as it acts in lipid rafts to negatively regulate T cell receptor (TCR) 
immune responses. PKA phosphorylates C-terminal Src kinase (Csk), which 
subsequently phosphorylates and inhibits lymphocyte specific protein tyrosine 
kinase (Lck). Lck is required for T cell signalling by phosphorylating the TCR-CD3 
complex, thus, PKA brings about inhibition of TCR responses (Halle, Haus-
Seuffert et al. 1997; Ramstad, Sundvold et al. 2000; Ruppelt, Mosenden et al. 
2007). PDE4 recruitment to lipid rafts via β arrestin plays an important role in 
this signalling axis (Abrahamsen, Baillie et al. 2004) and the dual specificity 
AKAP EZRIN has been found to target PKA to the lipid rafts where it will be close 
to its substrate, Csk (Ruppelt, Mosenden et al. 2007). It is therefore likely that 
PKA, EZRIN and PDE4 act in a signalling complex to mediate T cell activation. 
Indeed PDE4A has been shown to bind three different AKAPS in distinct 
subcellular regions within T cells (Asirvatham, Galligan et al. 2004).  
 
Some AKAP genes express splice variants that locate to different subcellular 
locations (McSorley, Stefan et al. 2006), and AKAPs can also bind ACs (Kritzer, Li 
et al. 2012), presumably different AC isoforms may bind different AKAPs, maybe 
different AKAP isoforms. This multifariousness adds yet another level of 
complexity to cAMP compartmentalised signalling.  
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Figure 1.5. The mAKAP/PDE4D3/PPP2A/PKA/EPAC/MAPK/RyR multienzyme signalosome in 
the heart.  
Β-adrenergic stimulation brings about synthesis of cAMP which activates 
anchored PKA. This in turn activates PDE4D3 in a negative feedback loop, and 
increases the affinity of PDE4D3 for mAKAP. PKA also activates RyR2 and PP2A, 
the latter dephosphorylates and thereby inactivates PDE4D3. EPAC1 activates 
Rap1 which inhibits the hypertrophic ERK5 MAPK pathway. The latter 
dephosphorylates and thereby inactivates PDE4D3. EPAC1 activates Rap1 which 
inhibits the hypertrophic ERK5 MAPK pathway.  
 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     63 
 
1.4.7.7 β-arrestins 
β-arrestins are scaffold proteins that modulate the activity of Gs at GPCRs, as 
already discussed. There are two types of β-arrestins, the visual arrestins found 
in the retina involved in photoreceptor signalling, and the non-visual β-arrestins 
1,2 and 3 which are ubiquitous and regulate the function of a variety GPCRs and 
the internalisation of GPCRs in clathrin-coated pits (Attramadal, Arriza et al. 
1992; Gurevich and Benovic 1992; Krupnick, Goodman et al. 1997; Laporte, 
Oakley et al. 1999).  
 
β-arrestin recruitment of PDEs to GPCRs is necessary to bring about receptor 
desensitisation and regulate cAMP signalling that emanates from activated Gs-
coupled GPCRs. β-arrestins can potentially bind to all PDE4 isoforms via their 
conserved catalytic domains (Perry, Baillie et al. 2002). However not all PDE4s 
seem to be recruited by β-arrestins. Upon isoproterenol challenge of 
cardiomyocytes and other cell types, PDE4D5 is preferentially recruited to β2AR 
compared to PDE4D3, the other major isoform in the cells studied (Bolger, 
McCahill et al. 2003). The C-terminus of β-arrestin binds the N-terminus of 
PDE4D5, and the N-terminus of β-arrestin interacts with the conserved motifs 
FXFELXL and FQFELTLEED in the PDE4D5 catalytic region (Baillie, Adams et al. 
2007). The affinity of this interaction is increased by PDE4D5 ubiquitination (Li, 
Baillie et al. 2009). Thus, it may be that only certain PDE4 isoforms have the 
ability to bind these scaffold proteins via their N-termini, and this is influenced 
by the post-translational modification status of the isozyme.  
 
Signalling via 2AR, cAMP and PKA has long been implicated in environmental 
chronic stress responses (Thaker, Lutgendorf et al. 2007). β-arrestin2 has been 
implicated in PC. It was found to negatively regulate AR dependant gene 
expression. It binds the AR in complex with the E3 ligase MDM2, thereby bringing 
about AR ubiquitination and degradation (Lakshmikanthan, Zou et al. 2009). The 
authors proposed that upregulation of β-arrestin2 would lead to downregulation 
of AR. This may play a role in the switch to ‘non-classical’ AR signalling, an 
event observed in advanced PC. Indeed, activation of β-arrestin2 has been 
shown to increase the proliferation and migration rate of PC cells (Zhang, He et 
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al. 2011). β-arrestin2 interacts with c-Src to bring about an increase in ERK 
activation and cAMP concentration. This would suggest that a long form PDE4 is 
involved, and is hyperphosphorylated by ERK, leading to its inhibition and an 
increase in cAMP.   
 
 
1.4.7.8 RACK1  
RACK1 was first identified as a PKC binding protein (Mochly-Rosen, Khaner et al. 
1991). It is a ubiquitously expressed WD repeat scaffold protein, with homology 
to the G protein β subunit (McCahill, Warwicker et al. 2002). RACK1 acts as a 
scaffold for many proteins involved in a variety of signalling pathways, many of 
which are involved in G protein signalling (Dell, Connor et al. 2002; Chen, 
Spiegelberg et al. 2004). It is also involved in cell cycle progression via 
sequestration of Src (Mamidipudi, Zhang et al. 2004), and is implicated in cancer 
cell migration via its role in cell polarity (Serrels, Sandilands et al. 2010). RACK1 
is an important scaffold in the brain, and has been linked to neurological 
disorders (Sklan, Podoly et al. 2006). RACK1 also binds the androgen receptor 
(AR). In a PKC dependent manner it allows the AR to shuttle to the nucleus in 
absence of ligand, thereby repressing androgen activation of the AR and thus 
expression of androgen responsive genes, such as PSA (Rigas, Ozanne et al. 
2003). As discussed, RACK1 interacts with PDE4D5. Interaction is via the WD 
repeat propeller structure in a highly specific manner. PDE4D5 does not bind 
other WD repeat proteins, nor does RACK1 bind any other PDE isoforms 
(Yarwood, Steele et al. 1999). The interaction is via the PDE4D5 N-terminus, but 
also via a conserved motif in the catalytic region, with RACK1 essentially 
straddling PDE4D5. This binding mode provides steric hindrance, which aids the 
sequestration of PDE4D5, and may prevent it binding other proteins at that time 
(Bolger, Baillie et al. 2006). The N-terminal binding region actually overlaps with 
the β-arrestin binding site ensuring that binding of these scaffolds to PDE4D5 is 
mutually exclusive. 
 
RACK1 is pivotal to many signalling pathways, helping to keep them linear and 
coordinated, and may allow different networks to cross talk. Aberrations in any 
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of these pathways due to RACK1 are likely involved in various pathologies and 
RACK1 is a potential therapeutic target (Ron, Adams et al. 2013). 
 
 
1.4.7.9 SH3 Domains 
Protein-protein interaction via SH3 domains is a well conserved mechanism 
throughout eukaryotes.  Src, Lyn and Fyn are tyrosine kinases that are involved 
in a variety of cellular events, and bind target proteins via their SH3 domains 
(Houslay and Adams 2003). These SH3 domain proteins play important roles in 
intracellular targeting of other proteins. PDE4D4 and PDE4A5 can bind SH3 
domains via a proline rich region in their N-termini. PDE4D4 can bind the SH3 
domains of many proteins, whereas PDE4A5 selectively interacts with the tyrosyl 
kinases Src, Lyn and Fyn. (Beard, O’Connell et al. 1999). This is due to the 
difference in their N-terminal proline rich SH3 binding motifs where PDE4D4 
contains a polyproline motif, whereas that of PDE4A5 is PxxPxxP. These 
differences may affect the targeting of the PDEs, and their functional outcome. 
Indeed, the binding of PDE4A5 to SH3 brings about its membrane and perinuclear 
localisation, which is ablated when the proline rich region in its N-terminus is 
cleaved. Along with the N-terminal SH3 binding motif, PDE4A isoforms also 
contain such a motif in their LR2 domain (McPhee, Yarwood et al. 1999). Binding 
at this site to the SH3 domain of Lyn increases PDE4A5 sensitivity to rolipram 
putting it into the HARBs state by causing a conformational change (McPhee, 
Yarwood et al. 1999). PDE4A5 actually possess three proline rich SH3 consensus 
motifs within its N-terminal region, only one of which binds Lyn. PDE4A5 actually 
localises to two subcellular regions; membrane ruffles at the cell margin and the 
perinuclear region (Huston, Beard et al. 2000). It seems the N-terminal SH3 
binding motif determines targeting to the membrane ruffles, and SH3 binding at 
UCR2 targets PDE4A5 to the perinuclear region (Beard, Huston et al. 2002). 
PDE4A5 localisation is clearly a complex issue, and may vary between tissues and 
cell cycle stage. It may depend on synergism between SH3 binding of the N-
terminal region and the UCR2 domain.  
A.M. Byrne  |  PhD Thesis 2014                                                                                                     66 
 
1.5 cAMP Effector Proteins 
Second messengers require effector proteins in order to elicit their desired 
downstream effects. Any proteins that directly bind a second messenger are 
termed second effector proteins. cAMP and cGMP each have specific effectors.  
 
 
1.5.1 PKA 
Protein kinase A (PKA) is one of the highly conserved eukaryotic protein kinases 
(EPKs) which function as  molecular switches to activate downstream signalling 
cascades (Taylor, Zhang et al. 2013). The notion that proteins could be 
regulated by phosphorylation was first observed by Krebs and co-workers, who 
saw that glycogen phosphorylase could be reversibly activated by addition of a 
phosphate moiety (Krebs and Fischer 1956). This paved the way for the discovery 
of EPKs, which comprise 2% of the human genome, translating to more than 500 
proteins (Manning, Whyte et al. 2002). The EPKs all share a common kinase core 
and together are known as the kinome (Taylor, Keshwani et al. 2012).  
 
PKA is assembled as an inactive tetrameric holo-enzyme composed of two 
catalytic (C) and two regulatory (R) subunits, C2R2; where upon cAMP binding, 
active C2 dissociates from R2 (figure 1.6) (Døskeland, Maronde et al. 1993; Kim, 
Xuong et al. 2005; Kim, Cheng et al. 2007). Different genes give rise to four 
different R subunits (RIα, RIIα, RIβ and RIIβ) and 3 different C subunits (Cα, Cβ 
and Cγ), resulting in different PKA holo-enzymes, which lend specificity to the 
signalling system. The holoenzyme is named according to the R subunits present. 
The two major forms of PKA; PKAI and PKAII, are made of RI and RII, 
respectively, interacting with identical subunits (Merkle and Hoffmann 2011). 
PKAI and PKAII show significant differential tissue expression. The R subunits 
share a common domain organisation but differ in biochemical characteristics 
(Døskeland, Maronde et al. 1993; Heller, Vigil et al. 2004; Vigil, Blumenthal et 
al. 2004). The R subunits posses dimerisation/docking (D/D) domains in their N-
terminus via which they bind the relevant AKAP, allowing PKA to be in the 
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vicinity of its substrate. This D/D domain is connected to two tandem C-terminal 
cAMP binding domains A and B (CBD A/B) by a flexible linker region. The linker 
region contains an autoinhibitory pseudosubstrate motif that sits on and inhibits 
the active sites of the C subunits in the absence of cAMP. Four molecules of 
cAMP bind the R homodimers to cause release of the auto-inhibition of the C 
subunits (Heller, Vigil et al. 2004; Wong and Scott 2004; Taylor, Kim et al. 2005; 
Taylor, Zhang et al. 2013). The activated C subunits are then free to 
phosphorylate target proteins by phosphoryl transfer of the ATP γ-phosphate. 
The optimal PKA consensus site is RRxS/T(h), where h is any hydrophobic residue  
(Songyang, Blechner et al. 1994). Differences in the length and amino acid 
composition of the linker regions seem to be the determinant for conferring 
different quaternary structure between the R isoforms (Vigil, Blumenthal et al. 
2004). Such differences may grant steric specificity for associating with 
signalling complexes.  
 
 
 
 
 
 
 
Figure 1.6. PKA.  
In the inactive state PKA exists as a holoenzyme composed of two regulatory (R) 
and two catalytic (C) subunits. Following GPCR activation, two molecules of 
cAMP bind each R subunit, liberating the C subunits which are then free to 
phosphorylate downstream targets.    
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PKA possess the conserved hydrophobic, bi-lobal EPK core. It comprises a small 
N-lobe and large C-lobe, between which, is a deep cleft that houses the active 
site of the C domain (Bossemeyer 1995). This cleft accommodates ATP and 
substrate. The N-terminal (N-) lobe comprises a 5 stranded antiparallel β sheet 
and 2 helices. The C-terminal (C-) lobe comprises 7 helices and 4 short β 
strands. Several residues in the C lobe interact with the ATP triphosphate group. 
The β strands form the base of the cleft, the catalytic loop and a metal binding 
loop. The C lobe also possesses an activation loop, phosphorylation of which is 
essential for catalysis and binding to the RIα subunit (Adams, McGlone et al. 
1995; Taylor, Zhang et al. 2013). This phosphorylation brings about the assembly 
of a hydrophobic spine that connects the lobes; it comprises 2 residues from 
each of the lobes. This spine is termed the regulatory (R-) spine as it seems to 
‘break’ while acting as a switch during PKA activation (Knighton, Zheng et al. 
1991; Kornev and Taylor 2010; Taylor, Keshwani et al. 2012). There is also a 
catalytic (C-) spine that runs parallel to the R-spine, formation of which is 
induced upon cAMP binding the CBDs. This brings about conformational change 
and priming of PKA for catalysis. 
 
 The core itself is not sufficient for catalysis, and requires a short N-tail and C-
tail that extend from the C subunit and wrap around the core. These tails may 
be post-translationally modified themselves, and act as cis-regulatory elements, 
providing both stability to the holoenzyme and allosteric regulation (Taylor, Kim 
et al. 2008; Taylor, Keshwani et al. 2012). They are also essential for protein-
protein interactions (Taylor, Kim et al. 2005).  
 
Many studies on the crystal structure of PKA have been carried out. Catalysis 
involves dynamic conformational changes, not just at the active site, but 
throughout the whole enzyme, notably within the linker region of the R subunits 
(Heller, Vigil et al. 2004). cAMP binding to the CBD induces a small local 
conformational change, followed by a large conformational change in R and 
release of C (Vigil, Blumenthal et al. 2004). This larger change occurs more 
slowly, allowing attenuation of upstream cAMP prior to reformation of the 
holoenzyme. To date, the data suggest an opening-closing mechanism for PKA 
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catalysis. ATP and cAMP bind PKA leading to an orchestrated movement of 
residues in the PKA backbone, resulting in a closed conformation which is poised 
for catalysis. (Masterson, Cheng et al. 2010; Masterson, Shi et al. 2011). Thus, 
the process of PKA activation and subunit disassociation is highly dynamic.  
 
The C subunit also acts as a scaffold to mediate protein-protein interactions, 
particularly the large C-lobe (Taylor, Kim et al. 2008). NMR studies showed that 
the D/D domain of RIIα provides a hydrophobic groove for AKAP binding (Newlon, 
Roy et al. 2001). Although the D/D domain is conserved, this groove can 
discriminate between the different R dimers, contributing to specificity of PKA 
signalling. RIα can accept bulky side chains into its groove, RIIα cannot but has a 
more flexible groove  (Kinderman, Kim et al. 2006).  
 
Mg2+ ions have been shown to affect PKA activity, and due to their differential 
concentration throughout the cell cycle and in different subcellular locations 
these ions may represent another level of regulation of PKA signalling specificity 
(Masterson, Shi et al. 2011). 
 
Binding of cAMP to the CBDs occurs in a sequential manner, whereby cAMP firstly 
binds CBD-B, priming CBD-A to accept another cAMP molecule, with consequent 
release of the active C subunit (Kim, Cheng et al. 2007; McNicholl, Das et al. 
2010).  
 
The differences in R subunit function have been demonstrated in knockout (KO) 
mice. RIα KO is embryologically lethal, whereas RIβ KO led to a compensatory 
mechanism by RIα and a deficit in neural plasticity (Hensch, Gordon et al. 1998). 
Protein kinases are involved in all signalling pathways, and they are desirable 
drug targets due to their implied roles in disease. Such compounds could inhibit 
activity, activation or localisation  of PKA (Taylor, Kim et al. 2008). 
Dysregulation of PKA holoenzyme construction may play a role in PC progression. 
C and R splice variant switching has been observed with a downregulation of 
Cβ2; upregulation of CβI Cβ3 and Cβ4; and upregulation of RIIβ during 
neuroendocrine differentiation (NED) (Kvissel, Ramberg et al. 2007). Differential 
expression of the C isoforms was also observed between non-tumour and tumour 
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samples and between AS and AI PC cell lines. Interestingly, Cβ2 is upregulated in 
tumour compared to normal tissue, and so is involved in aberrant proliferation. 
Changes in the PKAI and PKAII ratio is an important part of cellular 
differentiation but is also implicated in cancer progression (Merkle and Hoffmann 
2011). PKAI is normally transiently expressed in response to stimuli but is often 
constitutively expressed in malignancies. PKI upregulation in PC brings about the 
excretion of a cAMP independent extracellular PKA (ECPKA), which may act as a 
growth factor to promote tumourgeneisis. Upon overexpression of exogenous 
PKAII, PKAI and ECPKA are downregulated and the cancer phenotype is reversed 
(Cho, Lee et al. 2000). 
 
 
1.5.2 Exchange Proteins Directly Activated by cAMP (EPAC)  
EPAC1 and EPAC2 are guanine nucleotide exchange factors (GEFs) for the 
ubiquitous GTPases Rap1 and Rap2 (de Rooij, Zwartkruis et al. 1998; de Rooij, 
Rehmann et al. 2000). The cAMP activation of Rap1 in a PKA-independent 
manner led to notion that not all effects of cAMP are mediated by PKA or cyclic 
nucleotide gated ion channels (de Rooij, Zwartkruis et al. 1998). 
 
EPACs possess N-terminal regulatory, and C-terminal catalytic domains. The 
regulatory domain contains a cAMP binding site, which shares sequence 
homology to those found in PKA and acts as an autoinhibitory element on the 
GEF domain. Such autoinhibition is alleviated upon cAMP binding. Also found 
here is a Dishevelled, Egl-10, Pleckstrin (DEP) domain. This is not involved in 
cAMP binding, but is required for localisation to membrane structures (EPACs are 
most often localised to membranes). The catalytic domain comprises the GEF 
domain and a Ras exchange motif (REM), which lends stability to the GEF 
domain. It also possesses a CDC25-homolgy domain (CDC25HD) and in EPAC2, a 
Ras-association domain (RA) is present (de Rooij, Zwartkruis et al. 1998; de 
Rooij, Rehmann et al. 2000; Rehmann, Das et al. 2006; Niimura, Miki et al. 
2009). EPAC2 has an additional, lower affinity, cAMP binding domain that lies N-
terminal to the DEP motif (de Rooij, Rehmann et al. 2000). The functional 
consequence of cAMP binding here is unknown.   
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Similar to the case with PKA, the binding of cAMP to EPAC involves small local 
conformational changes followed by huge conformational change throughout the 
rest of the enzyme in order to lift the stable autoinhibitory element and allow 
Rap1/2 access to the catalytic GEF site (Harper, Wienk et al. 2008; Rehmann, 
Arias-Palomo et al. 2008).  
 
EPAC2 is also involved in oncogenic Ras signalling (Li, Asuri et al. 2006). Growth 
factor activation of Ras can recruit EPAC2 to the plasma membrane in a bid to 
activate local Rap1; however, EPAC2 must be cAMP bound and activated in order 
for transport to the plasma membrane. Thus, EPAC2 provides cross talk between 
growth factor signalling and cAMP signalling. 
 
PKA- and cAMP-gated ion channels are understood to underpin cAMP and Ca2+ 
signalling in the heart (Fink, Zakhary et al. 2001). However, EPAC1 associates 
with the mAKAP/PKA/PDE4D3/RyR macromolecular complex in cardiomyocytes 
(Dodge-Kafka, Soughayer et al. 2005). Different studies have shown EPAC to be 
both pro- and anti- hypertrophic, but evidence leans towards the former (Morel, 
Marcantoni et al. 2005; Schmidt, Sand et al. 2007). EPAC can regulate Ca2+ 
oscillations in cardiomyocytes and ventricular myocytes as part of a signalling 
pathway involving PKC, CaMKII and RyR (Pereira, Metrich et al. 2007; Oestreich, 
Malik et al. 2009). EPAC/Rap1 mediates the formation of gap junctions in 
neonatal rat cardiac myocytes by enhancing accumulation of connexion 43 at 
cell-cell boundaries, thus coordinating with PKA signalling to regulate gap 
junction function and contractility (Somekawa, Fukuhara et al. 2005).  
 
EPACs locate to various subcellular regions and so have been suggested to play 
roles in several biological functions, notably in integrin-mediated cell adhesion 
and cell-junction formation (Bos, de Rooij et al. 2001; Bos 2006). Activation of 
EPAC with cAMP analogs can potentiate the therapeutic efficacy of human 
endothelial progenitor cells (EPCs), which are administered to treat ischemic 
tissue, via increased integrin-dependent migration to sites of ischemia 
(Carmona, Chavakis et al. 2008). EPAC localisation changes throughout the cell 
cycle in a manner which suggests an important role in the coordination of 
microtubule transport and organelle partition during division into daughter cells 
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during mitosis (Qiao, Mei et al. 2002). A small nuclear pool of EPAC appears to 
be involved in DNA repair (Huston, Lynch et al. 2008). EPAC/Rap2 initiates the 
nuclear exit of DNA-dependent protein kinase (DNA-PK) in a PDE4B-regulated 
manner. Interestingly, PKA mediates the re-entry of this enzyme, giving us an 
example of an antagonistic interlacing cAMP signalling network.  
 
EPAC also plays an important role in the immune system. EPAC1/Rap1 
potentiates cell adhesion, polarisation and chemotaxis of, and regulates 
apoptosis of leukocytes (Shimonaka, Katagiri et al. 2003; Lorenowicz, van Gils et 
al. 2006; Gerard, Mertens et al. 2007; Grandoch, Bujok et al. 2009). Along with 
PKA, EPAC modulates the activity of macrophages by inhibiting phagocytosis 
(Aronoff, Canetti et al. 2005). In monocytes cAMP signals exclusively through 
PKA, but upon differentiation to macrophages, EPAC1 is upregulated and works 
with PKA to mediate signalling in these cells (Bryn, Mahic et al. 2006). However, 
EPAC1 inhibition of macrophage phagocytosis may be Rap1 independent (Brock, 
Serezani et al. 2008).  
 
EPAC has also been implicated in PC. It has been found that EPAC1/Rap1 action 
increases PC cell proliferation and survival by activation of B-Raf/ERK, PI3K/AKT 
and mTOR signalling, all of which cross talk to bring about an upregulation in 
pro-proliferative genes (Misra and Pizzo 2009). However, another study suggests 
EPAC inhibits PC proliferation and migration (Grandoch, Rose et al. 2009). This 
involves an inhibition of MAPK and RhoA signalling and collapse of the F-actin 
cytoskeleton. The former study employed early stage, androgen sensitive (AS) 
cells, whereas the latter employed later stage, androgen insensitive (AI) PC 
cells. This suggests a possible differential role of EPAC depending on PC stage. 
As PKA signalling is perturbed during PC progression, compensatory cAMP 
signalling may come into play, via EPAC. A recent follow on study by Misra et al. 
found that activation of EPAC also brings about an upregulation of pro-
inflammatory markers in both AS and AI PC cells, and acts via MAPK-COX2-PGE2-
mTOR signalling to bring about proliferation (Misra and Pizzo 2013).  
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1.5.3 Cyclic Nucleotide gated Ion Channels 
Cyclic Nucleotide-gated (CNG) Ion Channels were first identified in retinal rod 
and cone cells and olfactory sensory neurons (OSNs) (Fesenko, Kolesnikov et al. 
1985; Haynes and Yau 1985; Nakamura and Gold 1987). CNG channels have since 
been described in many sensory organs, neuronal function and in spermatozoa, 
although their function is not fully understood  (Kaupp and Seifert 2002). Rod 
and cone CNG channels show cyclic nucleotide selectivity, but OSN CNG channels 
are activated by both cAMP and cGMP. CNG ion channels belong to an ion 
channel superfamily, based on a shared transmembrane topology, pore structure 
and C-terminal cyclic nucleotide binding domain (Kaupp and Seifert 2002). cAMP 
or cGMP binding to the intracellular cyclic nucleotide binding domain results in 
opening of the channel and the passage of both alkali and divalent ions, 
particularly Ca2+, and consequent electrical and chemical response (Kaupp and 
Seifert 2002). Six genes encode human CNG ion channels, which fall into two 
gene subfamilies. The genes show differential tissue expression and some give 
rise to splice variants.  One subfamily comprises of CNGα1-α4, whereas the 
second is made up of CNGβ1 and CNGβ3. These proteins can associate to form 
hetero- or homo-trimeric channels. There is no desensitisation of signal at the 
channels, but they are regulated by CaM binding and Ca2+and post-translational 
modifications. Pseudechetoxin from snake venom is a potent CNG channel 
antagonist. Mutations in CNG channel are linked to sight defects and KO mice 
suggest they are involved in LTP in the hippocampus (Parent, Schrader et al. 
1998; Kaupp and Seifert 2002).  
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1.6 The Human Male Prostate Gland-a Brief Synopsis of 
Biology and Structure 
1.6.1  Function of the Male Human Prostate 
The male prostate gland is about the size and shape of a walnut, it surrounds the 
urethra at the neck of the bladder, weighing in at about 20g in the young adult 
(Kumar and Majumder 1995). The prostate is a secretory endocrine gland that 
contributes 0.5ml to the total 3ml of ejaculated seminal fluid (Steers 2011). 
These secretions are antibacterial and alkaline in order to protect the 
reproductive glands from infection, and protect sperm in the acidic environment 
of the vagina. Prostatic secretions are high in electrolytes, especially citrate, 
zinc, calcium, magnesium and potassium; which are important for metabolism 
and DNA stability of spermatozoa (Kavanagh 1985; Canale, Bartelloni et al. 
1986). The electrolyte composition of prostatic fluid changes during early in PC, 
with a marked decrease in the levels of citrate and zinc (Costello and Franklin 
2009). The serine protease prostate specific antigen (PSA) is also a constituent 
of prostatic secretions; it presumably acts to liquefy semen prior to ejaculation 
(Malm, Hellman et al. 2000).  
 
 
1.6.2 Structure of the Male Human Prostate 
The anatomy of the prostate gland is divided into four main zones fused together 
within a capsule (McNeal 1988; Cornud and Papanicolaou 2011) (figure 1.6). 
Three zones consist of glandular tissue, and each zone constitutes a certain 
proportion of the gland. These are; the peripheral (70%), central (25%), 
transitional (5%) and the fibromuscular anterior zone, named according to the 
anatomical relationship of the zone to the urethra. 60-65% of adenocarcinomas 
arise in the peripheral zone, <5% in the central zone, 25-30% in the transitional 
zone, and no pathology is found in the fibromuscular anterior zone as it is non 
glandular. Benign prostatic hyperplasia (BPH) arises in the transitional zone. The 
fibromuscular anterior zone forms a connective tissue and smooth muscle layer 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     75 
 
that makes up the entire anterior surface of the gland (Cornud and Papanicolaou 
2011). Whether prognosis can be inferred from the zone in which the carcinoma 
arises is unclear, but certainly, cancers arising in the transitional zone have a 
more favourable outcome than those from the peripheral zone, and express a 
number of different markers (Sakai, Harada et al. 2005).  
 
 
 
 
 
 
 
 
 
 
Figure 1.7. The male human prostate gland.  
The gland is anatomically divided into four zones; the central, peripheral, 
transitional and anterior fibromuscular zones.  
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The prostate gland possesses two main cell types. Firstly, epithelium; which 
forms glands composed of secretory luminal cells, basal stem cells and 
neuroendocrine (NE) cells, and secondly stroma; which consists of smooth 
muscle and fibroblast cells and surrounds the glands (Liu and True 2002). The 
androgen receptor (AR) and PSA are expressed in the luminal secretory cells of 
all zones. The epithelium is separated from the basement membrane and stroma 
by the basal cells. Other cells include nerves, blood vessels and infiltrating 
immune cells. These cells are highly organised within the normal prostate, and 
this organisation becomes perturbed during normal aging and in PC (McNeal 
1988; Liu and True 2002). Throughout the life of a man, the cellular make up of 
the prostate changes, for example, during development there is an abundance of 
stem cells (Schalken and van Leenders 2003). The balance of cells and histology 
of the prostate is paramount to the health of the gland, and is perturbed in 
adenocarcinoma.  
 
 
1.7 Signalling in the Prostate 
1.7.1 Androgens and the AR 
1.7.1.1 Androgens  
Testosterone has been of scientific interest for over 160 years, but was called 
testosterone only 77 years ago. It is mainly synthesised in the Leydig cells of the 
testes, but also the adrenal gland (Freeman, Bloom et al. 2001). Along with 
oestrogen, testosterone and its derivatives are paramount to the growth, 
differentiation and homeostasis of the prostate gland, and of male secondary 
sexual characteristics, and its importance has been demonstrated in AR knockout 
(ARKO) mice (Hess, Bunick et al. 1997; Kurita, Wang et al. 2001; Matsumoto, 
Shiina et al. 2008; Walters, Simanainen et al. 2010). Testosterone and its 
androgen metabolite 5α-dihydrotestosterone (DHT) are members of the steroid 
hormone superfamily, and are both ligands for the AR, which acts to bring about 
transcription of target genes (Matsumoto, Shiina et al. 2008).  
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Synthesis of testosterone and DHT occurs in testes following Luteinising hormone 
stimulation of its cognate GPCR (Payne and Hales 2004). Figure 1.8 outlines the 
synthesis pathway, and how testosterone ties into the ‘female’ oestrogen 
signalling network.  DHT possess far more potency for the AR than testosterone, 
with >2-5 fold increased affinity for, and >2-10 fold slower dissociation from the 
receptor (Toth and Zakar 1982; Kemppainen, Lane et al. 1992; Bruchovsky and 
Wilson 1999; Jarow, Wright et al. 2005). Testosterone and DHT activation of the 
AR occurs in different tissues and serves different functions (Deslypere, Young et 
al. 1992; George 1997; Hsiao, Thin et al. 2000). Testosterone is more important 
for Wolffian duct development during embryogenesis, whereas DHT mediates the 
development of the prostate gland and external genitalia, and virilising events 
during puberty (Deslypere, Young et al. 1992). Thus, two hormones activate the 
same receptor with quite different outcomes.  
 
Testosterone is found in the blood stream in one of three states; bound to 
albumin, bound to sex hormone-binding globulin (SHBG), or unbound. To enter 
target cells and be metabolised to DHT or other derivatives, or access the AR, it 
must dissociate from any protein-binding partner; thus there is cycling between 
free and bound testosterone (Rosnera, Hryb et al. 1999; Vermeulen, Verdonck et 
al. 1999). Studies done on rats demonstrated that within cells, 90% of 
testosterone is rapidly metabolised to it derivatives, mostly DHT (Bruchovsky and 
Wilson 1968; Foley and Kirby 2003).  
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Figure 1.8. Synthesis of androgens.  
The androgens; testosterone and DHT, are synthesised in the Leydig cells of the 
testes from cholesterol, following luteinising hormone stimulation of a cognate 
GPCR. DHT is synthesised from testosterone by 5α reductase. Androgens and 
oestrogens are essential for homeostasis of the prostate gland.  
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1.7.1.2 The AR 
The androgen receptor is a 110kDa protein that belongs to the steroid receptor 
(SR) superfamily. SRs are bound in the cytosol by heat shock proteins (HSPs). 
Upon binding of cognate steroid hormone, the HSPs are released, exposing the 
nuclear localisation signal on the SR, which then translocates to the nucleus. 
Here, the AR binds to androgen response elements (AREs) within target genes to 
bring about their transcription (Bain, Heneghan et al. 2007; Dehm and Tindall 
2007). Genomic signalling following DHT or testosterone binding is the major 
function of the AR, but it has been shown to participate in other pathways such 
as that of ERK (Dehm and Tindall 2007). The AR gene is found on the long arm of 
the X chromosome (Xq11-X12) (Brown, Goss et al. 1989). Two isoforms of the AR, 
AR-A and AR-B, have been reported, with differing functions in mesenchymal 
tissue (Liegibel, Sommer et al. 2003). The existence of AR-B has been disputed, 
and is possibly an artefact of caspase-3 cleavage (Gregory, He et al. 2001), but a 
lot of evidence does point towards its existence (Hirawat, Budman et al. 2003). 
The AR structure includes a C-terminal ligand (androgen)-binding domain (LBD), 
followed by a hinge region which houses the nuclear translocation signal (NTS), a 
DNA-binding domain (DBD) and an N-terminal domain (NTD). Within the NTD and 
LBD are activation function 1 and 2 (AF1/AF2), respectively. AF1 and AF2 don’t 
share sequence homology, and recruit exclusive co-activators to facilitate 
specific gene transcription when the AR is bound to AREs. Mutations within AR 
domains are linked to disease, such as PC (Glass and Rosenfeld 2000; Rosenfeld 
and Glass 2001; Hirawat, Budman et al. 2003; Pemberton and Paschal 2005; 
Wilson 2009).  
 
When unbound, the AR exists as a monomer in the cytoplasm bound by 
immunophilins and many HSPs, such as HSP90. HSP90 stabilises the unbound AR, 
and facilitates activation following ligand binding (Georget, Térouanne et al. 
2002). Androgen binding initiates release of these binding partners, major 
conformational change in the LBD, and the formation of homodimers via inter-
molecular interactions between the LBDs and NTDs of two AR monomers (Chang 
and McDonnell 2005; Wilson 2009). 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     80 
 
All classical SRs, such as the AR, can bind identical DNA response elements 
(DREs). However, the AR has a selective preference for AREs. The AR DBD 
contains two zinc finger motifs in which Zn2+ is coordinated by 4 cysteine 
residues, and these contribute to ARE selectivity (Shaffer, Jivan et al. 2004; 
Helsen, Kerkhofs et al. 2012). The presence of a serine in the AR DBD, head-to-
head binding to the DNA rather than the usual head-to-tail, hydrogen bonding, 
and Van der Walls forces also contribute to AR-ARE specificity (Shaffer, Jivan et 
al. 2004).  
 
Post-translational modifications of the AR are also paramount to its activation. It 
is subject to phosphorylation, methylation, acetylation, SUMOylation, and 
ubiquitination. This suggests that the SR provides a point of cross talk between 
androgen signalling and other signalling cascades (Gioeli and Paschal 2012). 
There are a number of phosphosites on the AR, mostly within the NTD. They are 
differentially phosphorylated depending on whether the AR is in the cytosol or 
the nucleus. Phosphorylation is potentiated upon androgen binding of the AR, 
and dephosphorylation, which can be stimulated by PKA signalling, may impair 
androgen binding (Blok, de Ruiter et al. 1998). Perturbation of PKA signalling 
crosstalk with the AR is implicated in PC, and is the subject of many 
investigations.  
 
1.7.1.2.1 AR Nuclear Transport and Transcription Regulation 
Ligand binding is necessary for nuclear translocation of the AR. The LBD 
modulates the unbound receptor; and LBD deletion mutants are constitutively 
nuclear with decreased transcriptional activity (Simental, Sar et al. 1991). 
Androgen binding causes rapid nuclear translocation. The NTS within the hinge 
region of the AR contains two clusters of basic residues that are essential for 
translocation, which is common amongst steroid hormone receptors (Jenster, 
Trapman et al. 1993). AR nuclear entry employs the classical β-karyopherin 
pathway of other SRs where the NTS binds the importin-α/β heterodimer and the 
AR is facilitated through nuclear pore complexes (NPCs) (Stewart 2007; Cutress, 
Whitaker et al. 2008). Mutations in this region are implicated in diseases, such as 
PC. Following transcriptional modulation, the AR exits the nucleus to re-enter 
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the cytosol, completing the cycle. The double strand break repair enzyme DNA 
dependant protein kinase (DNA-PK) directly binds the AR and acts both as a 
transcriptional coactivator, and to recycle the transcription machinery, thus 
bringing about disassembly of the AR /transcription factor complex (Mayeur, 
Kung et al. 2005). This stimulates AR nuclear export and may involve 
phosphorylation of the AR by DNA-PK, and the exportin pathway (Shank, Kelley 
et al. 2008). cAMP has been shown to mediate DNA-PK nuclear translocation as 
PKA signalling promotes its entry and retention, while EPAC/Rap2 signalling 
brings about its nuclear export (Huston, Lynch et al. 2008). This suggests a 
possible role for cAMP signalling in the nuclear/cytosol shuttling of SRs.  
 
Once imported into the nucleus, the AR binds to AREs that contain the consensus 
nucleotide sequence 5’-GGA/TACNNNTGTTCT-3’, where N is any base (Roche, 
Hoare et al. 1992). This initiates the recruitment of various transcription 
coactivators and basal transcription factors which form a stable transcription 
complex (Hirawat, Budman et al. 2003). The coactivators p160 and CBP/p300 are 
preferentially recruited to the PSA enhancer region, along with RNA polymerase 
II (RNA Pol II) (Louie, Yang et al. 2003). These coactivators possess histone 
acetylation activity and can recruit histone acetyl transferase (HAT), thus 
‘loosening’ the chromatin which is necessary for transcription (Fu, Rao et al. 
2004). Acetylation of the AR itself within the hinge region also modulates its 
activity at ARE loci (Fu, Rao et al. 2004; Lavery and Bevan 2011). Aberrant AR 
acetylation is implicated in PC.  
 
1.7.1.2.2 AR Signalling Cross-Talk with Other Pathways 
Phosphorylation of the AR is essential for its transcriptional activity (Wang, Liu 
et al. 1999). It can occur with or without the presence of steroid hormone, 
suggesting that AR activity is modulated by non-steroidal signalling as well as 
androgens (Gioeli and Paschal 2012). Such pathways may directly activate the AR 
or increase its affinity for low levels of androgens. MAPK, PKA, PKC, Akt and CDK 
pathways have been shown mediate phosphorylation of the AR (Nazareth and 
Weigel 1996; Guo, Dai et al. 2006; Gioeli and Paschal 2012). A number of 
phosphorylation sites have been identified, including serines 16, 81, 256, 308, 
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424, 650 and 94 (Zhu, Becklin et al. 2001; Gioeli, Ficarro et al. 2002). Steroidal 
and non-steroidal pathways differentially modulate the AR phospho-status. 
Perturbation of AR phosphorylation is associated with PC. Non-steroidal 
phosphorylation provides an AR activation mechanism in the absence of 
androgen, which occurs in androgen ablation resistance and late stage androgen 
insensitive prostate cancer (AI PC) (Nazareth and Weigel 1996; Gioeli, Ficarro et 
al. 2002; Guo, Dai et al. 2006) (figure 1.9). 
 
 
 
 
 
 
 
Figure 1.9 AR signalling.  
The AR can be classically activated by ligand (testosterone/DHT) or non-
classically by crosstalk with other signalling pathways, such as cAMP/PKA. 
Ligand-independent activation via crosstalk with these pathways is proposed to 
play a major role in the development and progression of AI PC. (adapted from 
(Lonergan and Tindall 2011)). 
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1.8 Prostate Pathogenesis- Benign Disease and Prostate 
Cancer 
1.8.1 Benign Prostatic Hyperplasia (BPH) 
Of all mammals, only humans and dogs develop BPH and PC (De Marzo, Coffey et 
al. 1999). A high fat diet plays a huge role in these pathologies, and humans 
quickly took on a diet high in animal fat following our descent from the trees.  
Population studies show that similar endocrine and dietary factors are associated 
with BPH and PC (Guess 2001). Risk factors also include other lifestyle choices 
such as smoking, race, ethnicity, familial history and especially age (Ziada, 
Rosenblum et al. 1999). BPH presents with LUTS and is the commonest benign 
tumour in men over 60 (Ziada, Rosenblum et al. 1999). While PC is uncontrolled 
proliferation of genetically-abnormal cells, BPH involves hyperplasia of ‘normal’ 
epithelial and stromal cells within the transitional zone of the prostate gland, 
leading to enlargement of the prostate (De Marzo, Coffey et al. 1999). Whether 
or not BPH leads to PC has been a topic of controversy, but most evidence 
suggests it rarely, if ever, is a causative factor. Indeed, there is significantly 
different gene expression between the two pathologies (Luo, Duggan et al. 
2001), but it must be remembered that BPH and PC occur in different regions of 
the prostate gland that would normally display differential gene expression (Lee 
and Peehl 2004).  
 
Infection and Inflammation also play a role in BPH (Penna, Fibbi et al. 2009). 
Prostatitis is the original name for prostate complaints, and is also an 
inflammation of the gland. BPH and prostatic inflammation (prostatitis) both 
cause an increase in PSA, which leads to problems when trying to detect cancer 
(Nadler, Humphrey et al. 1995). The molecular mechanisms underlying BPH are 
ill understood due to the heterogeneity of the disorder, and it is not always 
distinguishable from prostatitis (Nickel 2008). Many molecular events seem to 
underpin the development of BPH, but due to the variety of factors that this 
umbrella term describes, much work has to be done to better understand BPH 
(Lee and Peehl 2004). 
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1.8.2 Prostate Stem Cells and Senescence  
The prostatic epithelium contains the basal and luminal layers, which are 
composed of basal, secretory and neuroendocrine cells and differ in their gene 
expression and morphology (Miki and Rhim 2008). The AR and PSA are expressed 
in the luminal secretory cells (Liu, True et al. 1997). All epithelial tissues 
undergo continual cell replacement due to damage or cell death. They are able 
to do this due to adult stem cells that have the ability to self-renew and 
differentiate into cells of their tissue of origin, thereby maintaining tissue 
homeostasis (Blanpain, Horsley et al. 2007). The wnt, Sonic and Notch signalling 
pathways are important in this process and perturbations of these pathways in 
prostatic stem cells (PSCs) have been linked to prostate tumourigenesis (Lawson, 
Xin et al. 2005). With age, less regeneration occurs, and epithelial cells become 
replicatively senescent. This may be a mechanism to decrease transcription of 
proto-oncogenes, and indeed many cells become cancerous because they bypass 
senescence. However, an amassing of senescent PSCs may be a causative factor 
in BPH. These cells display an upregulation of cytokines, which are secreted and 
act as paracrine factors on non-senescent, neighbouring cells, driving their 
proliferation and increasing the prostate mass (Castro, Giri et al. 2003; Castro, 
Xia et al. 2004). Senescent aging cells also show resistance to apoptosis and in 
this way may directly increase the prostate mass. A number of reasons for this 
have been suggested, such as constitutive expression of the proto-oncogene Bcl2 
(Wang 1995), aberrant cell cycle regulation (Schwarze, Shi et al. 2001), and 
downregulation of pro-apoptotic Bad (Untergasser, Koch et al. 2002).  
 
 
1.8.3 The Intra-prostatic Immune System; Prostatitis and 
Inflammation 
There is much evidence to suggest that inflammation is a major causative factor 
of BPH and PC, and the development of metastases (Drake 2010). Prostatitis is 
chronic inflammation of the prostate. It presents with LUTS and pelvic pain and 
often overlaps with BPH, where men may have both. Additionally, men with a 
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history of BPH are more likely to later develop prostatitis. Unlike BPH, 
prostatitis can affect men of all ages. Factors such as stress, vasectomy, a 
previous STD and other bacterial infections are associated with prostatitis. 
However, it can be difficult to distinguish between BPH and prostatitis due to 
symptom overlap and lack of gold standard diagnostics (Collins, Meigs et al. 
2002; St. Sauver, Jacobson et al. 2008).  
 
The prostate seems to possess an intra-immune system, much like the lungs and 
gut. Normally it is composed of small numbers of mainly CD4+ and CD8+ T cells, 
macrophages and B lymphocytes. With age, the immune cell complement ratio 
changes, with an increase in T cell infiltrates, and this is particularly seen in 
BPH. The changing testosterone to oestrogen ratio that occurs with age may also 
upset the immune infiltrate of the prostate. There is also an increase in 
interferon and cytokine production, which causes increased proliferation of BPH 
cells, essentially chronic ‘wound healing’. The cause of chronic inflammation 
and BPH is unclear, and may or may not be due to infection, or indeed an 
autoimmune mechanism (Kramer, Mitteregger et al. 2007; Fibbi, Penna et al. 
2010).  
 
Perturbations in the intraprostatic immune cell infiltrate are also associated 
with PC, and can be caused by androgen deprivation therapy (ADT). An increase 
in the level of T cells, particularly CD4+, and macrophages is observed within 
primary tumours following ADT (Mercader, Bodner et al. 2001; Gannon, Poisson 
et al. 2009). Post-ADT inflammation is common but the cause is unclear. It 
seems that circulating androgens play an immunosuppressive role in the normal 
prostate. TLR4 is a main player in innate immune responses. Its expression has 
been observed to be increased in prostatic epithelial and stromal cells following 
castration (Quintar, Roth et al. 2006), and TLR4 signalling in the prostate has 
been shown to be pro-inflammatory (Gatti, Quintar et al. 2009). A SNP in the 
3’UTR of the TLR4 gene has also been suggested to be a susceptibility factor for 
PC (Zheng, Augustsson-Balter et al. 2004). TLR4 and NFκB signalling following 
viral or bacterial infection of the prostate, results in an increase in epithelial 
proliferation (Kundu, Lee et al. 2008) 
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Aberrant cytokine and cognate receptor expression is associated with the 
pathophysiology of PC. The pro-inflammatory cytokines IL-1α, IL-6 and its 
receptors, and TNFα have been shown to be upregulated in BPH and PC, and 
their expression correlates with that of PSA and tumour progression (Bouraoui, 
Ricote et al. 2008). These cytokines, along with IL-8, are also involved in PC 
associated cachexia, an ill understood wasting disease associated with many 
cancers. The cytokine profile of PC changes as the cancer progresses and 
between patients (with and without cachexia) in a manner that can distinguish 
PC stage (Tazaki, Shimizu et al. 2011). IL-8 has also been shown to be 
constitutively and abundantly expressed in AI PC, correlating with cancer 
progression, angiogenesis and metastasis. It acts via AKT and NFκB to bring 
about downregulation of pro-apoptotic proteins and upregulation of anti-
apoptotic proteins, and it also renders AI PC cells resistant to ADT (Ma, Ren et 
al. 2009; Singh and Lokeshwar 2009). 
The intra-prostatic immune system thus plays a huge role in the risk and 
development of PC, and may be a target for pharmacological intervention (Drake 
2010). 
 
 
1.9 Prostate Cancer  
Second to lung cancer, PC is the commonest cancer in men, and the second 
leading cause of all cancer related deaths in the US. 238,590 new cases and 
29,720 deaths due to PC are predicted for 2013 in the US. Throughout a man’s 
life, the chance of getting PC is 1 in 6. The disease is more prevalent in African 
American men than any other race (Siegel, Naishadham et al. 2013). In the UK, 
over 10,000 men died due to PC in 2010 (Cancer Research UK). With our aging 
societies there is a great need to better understand the underlying mechanisms 
of PC, to identify more specific biomarkers, and to develop tailored anti-cancer 
therapies.  
 
PC shares many features with BPH and they often go hand in hand, but whether 
or not BPH is causative is unclear. Despite the biochemical similarities, such as 
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dependence on the AR (Berry, Maitland et al. 2008), differing histology and 
anatomy suggest BPH is not linked to PC. BPH arises in the transitional zone 
stroma, whereas PC most commonly originates in the epithelium of the 
peripheral and central zones (Schenk, Kristal et al. 2011). There is no obvious 
staged progression of PC because tumours display very high heterogeneity, 
within the same patient and between patients (Liu, Roudier et al. 2004; Lamont 
and Tindall 2011). This of course, makes detection and treatment difficult. 
However, chronic inflammation does play a role in the progression of both BPH 
and PC (De Nunzio, Kramer et al. 2011).  
 
 
1.9.1 Steroid Signalling in PC and BPH 
AR signalling is essential for development of the prostate and sex organs, bone 
and male secondary sexual characteristics (Matsumoto, Shiina et al. 2008). 
However, during prostatic pathologies, AR signalling becomes perturbed, 
upsetting the balance between proliferation and apoptosis (Merkle and Hoffmann 
2011). AR signalling is necessary for early  stage PC (AS PC) and the progression 
into AI PC, even after ADT (Kaarbo, Klokk et al. 2007). As discussed, the AR 
crosstalks with a number of other signalling pathways such as PKA and PI3K. 
During PC progression, these networks become perturbed leading to aberrant 
gene expression (Kaarbo, Klokk et al. 2007; Desiniotis, Schafer et al. 2010; 
Merkle and Hoffmann 2011). Studies have shown differential gene expression 
between AS PC, AI PC, and during ADT, including those involved in androgen 
metabolism and upregulation of the AR (Holzbeierlein, Lal et al. 2004; Chandran, 
Ma et al. 2007). As well as upregulation of the AR and an increase in its activity, 
there is significant change in the expression of AR pathway genes as the disease 
evolves from AS to AI PC. A number of genes involved in adhesion, 
differentiation and apoptosis are downregulated from AS to AI PC (Hendriksen, 
Dits et al. 2006). PKA has been shown to be involved in the AR regulation of gene 
expression in androgen derived cells, suggesting it’s a key player in AR 
reactivation following ADT (Wang, Jones et al. 2006).  
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Oestrogenic signalling is also necessary for the development of the prostate (El-
Shafei, Mostafa et al. 2011) but can be perturbed in BPH and PC (Ellem and 
Risbridger 2010). The androgen: oestrogen balance is essential for prostatic 
homeostasis, but this changes with age, leading to a decreased testosterone to 
oestrogen ratio (Schatzl, Brössner et al. 2000). There are many studies on the 
affects of oestrogens in BPH and PC but with varied results.  
 
Estrogen receptor-related receptor α (ERRα) is an orphan receptor whose 
endogenous ligands are unknown. It is activated by environmental chemicals 
with oestrogen-like activity. It is expressed in the prostate and is important 
during embryogenesis, but overexpression of EERα has been observed in PC 
(Miao, Shi et al. 2010). PGE2 has been shown to cause an upregulation of EERα 
and subsequent increase in aromatase expression, leading to high oestrogen 
levels in the prostate (Miao, Shi et al. 2010). Indeed, a synergism between 
overexpressed androgens and oestrogens may be involved in both BPH and PC 
progression (Roberts, Jacobson et al. 2004; Ricke, McPherson et al. 2008). 
Perhaps changes in the levels of one hormone leads to compensatory expression 
of the other, disturbing the steroid hormone equilibrium and homeostasis. 
Melatonin has also been shown to regulate the oestrogen-androgen balance, and 
this is perturbed in BPH (Gilad, Matzkin et al. 1997). Further evidence for 
oestrogens playing a role in PC is seen by the oestrogen-induced upregulation of 
PSA in PC cells in the absence of androgens (Nakhla, Romas et al. 1997). Some 
studies suggest a high level of estradiol is anti-proliferative, while other studies 
suggest the opposite. This may be due to expression of two oestrogen receptors, 
ERα and ERβ, which mediate different cellular responses (Yao, Till et al. 2011). 
It seems likely that the balance of signalling via these receptors is perturbed 
during PC. Yao et al. found no correlation between oestrogen and a risk of PC in 
normal prostates, but did find an upregulation of oestrogens in men who have 
taken the BPH drug finasteride, and they suggest this creates a low-moderate 
risk of PC. The breast cancer drug toremifene which inhibits oestrogen receptors 
has been shown to prevent the progression of PC (Raghow, Hooshdaran et al. 
2002; Price, Stein et al. 2006). Clearly the role of oestrogens in the prostate and 
prostatic pathologies is complex and highly ambiguous.  
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Stromal-epithelial cell interaction is also very important in prostatic 
homeostasis. It involves ERα and ERβ, which are exclusively expressed in the 
stroma and epithelium, respectively (Risbridger, Wang et al. 2001). BPH and PC 
tissues exhibit an increase in these receptors compared to normal prostate, and 
there is expression of ERβ in the stroma in PC only, again suggesting oestrogens 
are involved in hyperplasia and cancer progression (Royuela, de Miguel et al. 
2001). Many studies suggest ERβ mediates anti-proliferative signals, while ERα 
mediates pro-proliferative signals. Indeed ERβ KO mice display prostatic 
hyperplasia (Krege, Hodgin et al. 1998). ERβ has also been shown to be 
downregulated in PC due to hypermethylation, and its re-expression induces 
apoptosis (Walton, Li et al. 2008). Differential expression of these receptors 
between normal and diseased prostate tissue, and perturbation of the ratio of 
these receptors in prostatic stroma and epithelia, would clearly upset the 
prostatic oestrogen balance, and likely plays in role in the progression of both 
BPH and PC.  This makes these receptors and indeed oestrogen a promising 
therapeutic target. 
 
Despite the involvement of oestrogens, the AR and androgens still underpin 
prostatic pathologies, and the AR is the still the main therapeutic target in PC 
(Massie, Lynch et al. 2011). Within PC cells, AR signalling brings about a 
coordinated system of transcriptional alterations. The AR is essential for 
tumourigenesis and progression into AIPC (Taplin and Balk 2004).  
 
Androgen deprivation therapy (ADT) and AR antagonists have long been used in 
the treatment of BPH and PC to inhibit cell proliferation and LUTS. However, a 
lot of drugs block testosterone, which produces undesirable side effects such as 
impotence. The advent of 5α-reductase inhibitors (5-αRIs), such as finasteride, 
showed promise due to their more specific mode of action (Stoner 1990). 
Finasteride inhibits testosterone catabolism to DHT, therefore reducing levels of 
the more potent androgen and thus AR stimulation, while not affecting 
testosterone levels. 5-αRIs have since been very successful in treating LUTS and 
BPH (Robinson, Garmo et al. 2013). 
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There are two isoforms of 5α-reductase, 5αR1 and 5αR2. Finasteride inhibits 
5αR2, as it was originally thought to be the main player in testosterone 
metabolism. However, there is an upregulation of 5αR1 and a downregulation of 
5αR2 along with decreased activity, in early PC. And both isozymes are 
upregulated in localised high-grade compared to low-grade PC and BPH (Thomas, 
Douglas et al. 2008; Thomas, Douglas et al. 2008). This is another example of a 
balance being perturbed and adds to the complexity of BPH and PC. It also 
explains why finasteride loses potency, and suggests that a dual inhibitor 
strategy may be the way forward.  
 
High serum testosterone/estradiol levels and a high testosterone:17β-diol-
glucuronide ratio have been associated with a decreased risk of BPH (Kristal, 
Schenk et al. 2008). This suggests a reduction in 5α-reductase correlates to 
reduced BPH risk. Indeed, population studies done on pre-BPH healthy men, with 
follow-up, found a correlation between BPH risk and high DHT serum levels 
(Parsons, Palazzi-Churas et al. 2010; Liao, Li et al. 2012). The DHT/testosterone 
ratio remains constant or changes with age, suggesting an increase in 5α-
reductase activity as men age.  
 
Genetic abnormalities of 5α-reductase type 2 have also been linked to BPH and 
PC. Although rare, polymorphisms in the type 2 gene have been associated with 
an enlarged prostate gland and a predisposition to both BPH and PC (Roberts, 
Bergstralh et al. 2005; Salam, Ursin et al. 2005). Hypermethylation of the 5α-
reductase type 2 gene promoter region has been suggested to account for the 
lack of expression of this enzyme in 25-30% of prostate cancers (Niu, Ge et al. 
2011). This may explain the decrease in type 2 in early PC seen by Thomas et 
al., and a compensatory upregulation of type 1. It would also explain the 
resistance to finasteride seen in a number of BPH and PC patients. Continuous 
finasteride treatment for BPH has been linked to neuroendocrine differentiation 
(NED), which is associated with aggressive PC and poor prognosis (Tarle, Spajic 
et al. 2009). NED plays a major role in PC progression. These cells release 
neuropeptides that act in an autocrine fashion via GPCRs to promote growth and 
aggressiveness.  The neuropeptides can activate tyrosine kinases such as Src, Lyn 
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and FAK which cause activation of the AR, supporting androgen independence 
(Yang, Ok et al. 2009).  
 
 
1.9.2 Other Genetic Abnormalities in Prostate Cancer 
A number of chromosomal deletions and rearrangements are associated with PC. 
Deletions at 5q are common and become more frequent as tumours advance 
(Dong 2001). Rearrangements and deletions in chromosome 5 are present in AI 
PC cell lines, but not in the AS LNCaP cell line. 5q11 is the most common break 
point (Ozen, Navone et al. 1998). It has been suggested that tumour suppressor 
genes reside on 5q. This is interesting given that PDE4D is also located on 5q12.  
 
 
1.9.2.1 TMPRSS2:ERG  
One of the commonest genetic abnormalities in PC is the TMPRSS2 and Ets 
fusion.  TMPRSS2 is an androgen responsive transmembrane serine protease that 
is highly expressed in normal prostatic epithelium, and Ets genes are a family of 
oncogenic transcription factors (Lin, Ferguson et al. 1999; Kumar-Sinha, Tomlins 
et al. 2008). The fusion causes overexpression of the Ets isogene; ERG, ETV1 or 
ETV4 (Tomlins, Rhodes et al. 2005; Macaluso and Giordano 2007). TMPRSS2-ERG 
is the commonest fusion event, observed in 70% of clinically localised cancers 
(Mehra, Tomlins et al. 2007). It has shown promise as a biomarker for PC, 
detectable in urine and far more specific than PSA (Nguyen, Violette et al. 2011; 
Tomlins, Aubin et al. 2011). The TMPRSS2-ERG gene contains AREs, and the 
protein product is upregulated via AR signalling, and this also brings about an 
upregulation of wild-type (wt) ERG (Mani, Iyer et al. 2011). 
 
TMPRSS2 and ERG are both located on chromosome 21q, and the chimera is most 
commonly caused by deletion of the region in between them, and less commonly 
due to reciprocal translocation. There are a possible 14 fusion variants, with 
T1/E4 being the most common (Tu, Rohan et al. 2007). The fusion is composed 
of the 5’ promoter region of TMPRSS2 and the coding region of ERG, thus a 
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fusion protein is not translated, but most commonly a truncated ERG (T1/E4) 
(Fernandez-Serra, Rubio-Briones et al. 2011). The truncated ERG brings about 
aberrant upregulation of its target genes, such as histone modifying enzymes. 
Prostate tumours that contain the TMPRSS2-ERG chimera are considered to be in 
a different group to those without. They display very different altered 
proteomes, with an upregulation of genes involved in oestrogen receptor 
signalling in those containing the fusion event (Setlur, Mertz et al. 2008). Studies 
looking at the correlation between the TMPRSS2-ERG and patient outcome have 
been discordant, but most suggest that tumours harbouring high copy numbers of 
the chimera are associated with poor clinical outcome compared to those not 
expressing the fusion, and its presence may be used as a prognostic tool when 
combined with PSA value and Gleason score (Attard, Clark et al. 2008; Fine, 
Gopalan et al. 2010). The TMPRSS2-ERG fusion may occur in some tumour foci, 
but not in other foci, within the same patient, giving credence to the idea of 
independent origin of separate tumours, which can have different Gleason scores 
(Furusato, Gao et al. 2008). The fusion is more prevalent in early stage PC 
compared to high grade aggressive disease, and has been identified in benign 
lesions and prostatic intraepithelial neoplasia (PIN-widely believed to be a pre-
cursor of PC), thus it is likely involved in the onset and/or progression of PC 
(Perner, Mosquera et al. 2007; Furusato, Gao et al. 2008).  
 
 
1.9.2.2  TMPRSS2:ERG and PTEN 
Despite the above observations by Perner et al. and Furusato et al., 
TMPRSS2:ERG chimeras have been less commonly found in PIN lesions than in PC 
(Carver, Tran et al. 2009; Carver, Tran et al. 2009; King, Xu et al. 2009). This 
suggests the fusion event is not a driving force for PC progression. King et al. 
interestingly found that TMPRSS2:ERG fusion occurs alongside loss of PTEN, the 
other commonest event in PC. They propose that cooperation of ERG 
overexpression and PI3K pathway activation in PIN lesions contribute to 
progression to adenocarcinoma.  TMPRSS2:ERG and PTEN loss have been shown 
to be additive, possibly due to a coordinated increase in epithelium to 
mesenchymal transition (EMT), which confers motility, and the occurrence of 
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both events correlates with a reduced time to biochemical recurrence of PC 
following treatment (Yoshimoto, Joshua et al. 2008; Carver, Tran et al. 2009).  
 
 
1.9.2.3 AR Mutations 
Although rare in untreated PC, a number of AR genetic and epigenetic 
abnormalities are found in castration resistant PC (CRPC) (AI PC; following ADT). 
These events mainly fall into 3 categories; (1) AR gene amplification and AR 
overexpression, which sensitises cells to low levels of androgen and occurs in a 
third of CRPC cases; (2) point mutations that render the receptor promiscuous, 
and (3) AR splice variants and truncations that lead to androgen-independent 
receptor activation (Waltering, Urbanucci et al. 2012). The best studied point 
mutation is T877A, originally identified in LNCaP cells (Veldscholte, Ris-Stalpers 
et al. 1990). It mutates the binding pocket, conferring promiscuity on the AR, 
where even anti-androgen drugs become agonistic, leading to androgen 
withdrawal syndrome (AWS) (Hara, Miyazaki et al. 2003; Sun, Shi et al. 2006; 
Waltering, Urbanucci et al. 2012). AWS makes targeting the AR in CR/AI PC 
extremely complex and difficult. Downstream signalling molecules which may 
provide better therapeutic targets are becoming the focus of much research 
(Waltering, Urbanucci et al. 2012). 
 
 
1.9.3 Androgen-Independent Prostate Cancer 
ADT is successful when initially administered, with a reduction in tumour size 
due to induced apoptosis of cancer cells. However, following treatment the PC 
invariably reappears, and this constitutes the aggressive androgen-
independent/castration resistant-prostate cancer (AI PC/CRPC). AI PC comes 
about because the PC cells adapt to the androgen-deprived microenvironment 
and in fact thrive in such conditions (Dutt and Gao 2009). It is suggested that 
androgen-independence comes about in two stages, called clonal evolution. 
Stage one involves a transition of a subset of tumour cells, where they remain 
androgen-responsive but not dependent on androgens. These cells may originally 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     94 
 
require androgen for growth, but not survival. Stage two involves clonal 
selection of such cells and outgrowth of an androgen-independent tumour (Craft, 
Chhor et al. 1999). PC tumours are highly heterogeneous, even in the same 
patient. Metastatic tumours from different sites within the same patient can 
possess different transcriptomes, suggesting that late stage PC represents a 
heterogeneous group of diseases. AR negative and AR positive tumours can exist 
in the different sites. Despite being termed androgen-independent cancer, the 
belief is that progression into AI disease is still reliant on the AR (Shah, Mehra et 
al. 2004). 
 
 
1.9.4 Suggested Mechanisms for Progression into Androgen 
Insensitive Prostate Cancer 
 Although the development of AI disease is ill understood, several mechanisms 
have been suggested.  
 
 
1.9.4.1 Selection for Androgen-Independence - Stem Cells  
As discussed earlier, epithelial stem cells are an important part of the basal 
layer of the prostate (Lawson, Xin et al. 2005). Unlike neighbouring epithelial 
cells, they do not express the AR and thus are out-with the normal androgen 
signalling axis. They are quiescent and can self renew, making them valid 
escapees of ADT (Nikitin, Nafus et al. 2009). These cells are found in primary 
and metastatic prostate tumours. They undergo extensive proliferation and have 
the ability to differentiate into the tumour cells from which they were derived, 
thereby carrying mutations (Collins, Berry et al. 2005). The idea that these 
androgen-independent cells are selected during ADT is supported by the 
overexpression of stem and basal cell genes in AI PC, such as Bcl2 (Lawson, Xin 
et al. 2005). Indeed upregulation of Bcl2 seems to be a main player in the 
transition to AI disease. Bcl2 overexpression occurs as a result of ADT and 
subsequent selection of stem cells, and its overexpression then allows cells to 
rapidly proliferate in the absence of androgens (Catz and Johnson 2003). Recent 
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evidence suggests that selection of stem cells may be a very early event 
following ADT, and these may be cancer initiating cells (CICs) (Finones, Yeargin 
et al. 2013). The AR is expressed in most AI tumours, and is lost only in very late 
stage metastatic disease (Balk 2002), therefore prostate tumours are not solely 
composed of aberrant stem cells, and as stated earlier, are highly 
heterogeneous.  
 
 
1.9.4.2 AR Amplification 
Amplification of the AR gene, resulting in overexpression of the AR is a common 
feature of prostate tumours following ADT. It sensitises the cells to low levels of 
androgens enabling them to maintain AR signalling in an androgen deprived 
environment (Visakorpi, Hyytinen et al. 1995). 
 
 
1.9.4.3 Non-steroidal AR Signalling 
The early stages of ADT are successful in repressing AR signalling. However, a 
host of other signalling pathways have been suggested to cross-talk with the AR, 
and may act to stabilise the receptor and its transcriptional activity, and 
compensate for AR signalling during ADT (Shafi, Yen et al. 2013). Indeed, some 
signalling pathways have been found to be upregulated in AI PC, suggesting the 
cells try to compensate for lack of AR signalling, or they may enable AR 
activation by residual levels of androgens.  
 
Both PKA and NFκB/p52 can activate the AR in the absence of androgens by 
interacting directly with NTD of the AR, enhancing its translocation and 
recruiting coactivators, thereby bringing about transcription of genes such as 
PSA (Nazareth and Weigel 1996; Sadar, Hussain et al. 1999; Nadiminty, Lou et al. 
2010). 
 
As discussed earlier, inflammation and cytokine signalling are important factors 
in PC progression. Upregulation of the atypical protein kinase C (aPKC), which is 
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involved in epithelial signalling, brings about an concomitant upregulation and 
secretion of IL-6, thereby contributing to AI PC progression via autocrine and 
paracrine signalling (Ishiguro, Akimoto et al. 2009; Malinowska, Neuwirt et al. 
2009). IL-6 overexpression can activate the AR and is also associated with distant 
metastases, particularly bone, and poor patient outcome (Hobisch, Eder et al. 
1998; Shariat, Andrews et al. 2001). Studies on the mechanism  of IL-6 action 
have been confusing as it has been shown to activate the AR NTD in a PKA 
independent, MAPK-mediated process (Ueda, Bruchovsky et al. 2002), and to 
mediate NED in a PKA- and MAPK-dependent manner (Deeble, Murphy et al. 
2001).  
 
As discussed earlier, IL-8 is also an important cytokine in PC pathogenesis. It has 
been shown to increase AR expression and activation in an androgen free 
environment, possibly mediated by NFκB (Seaton, Scullin et al. 2008). Interferon 
(IFN) has also been shown to increase protein levels of the AR by stabilising it, 
with consequent nuclear accumulation and upregulation of AR-responsive genes 
(Chen and Sawyers 2002; Basrawala, Alimirah et al. 2006). Down-regulation and 
polymorphisms of the anti-inflammatory IL-10 are positively associated with PC 
(Faupel-Badger, Kidd et al. 2008). 
 
These are just some examples of how cytokine signalling loops can act on the AR 
signalling pathway and mediate transcription of androgen-regulated genes. 
Growth factor (GF) signalling is also important in PC progression. Stromal 
fibroblasts secrete GFs which bring about autocrine and paracrine pro-
proliferative loops, an important process in many cancers (Bhowmick, Neilson et 
al. 2004). Epidermal, insulin-like, transforming, fibroblast, and vascular 
endothelial growth factors (EGF, IGF, TGFβ, FGF and VEGF, respectively) and 
their cognate receptors all crosstalk with the AR signalling axis (Zhu and 
Kyprianou 2008). The AR has been shown to participate in a signalosome 
involving EGF kinase members, in which there is bidirectional regulation of their 
transduction pathways (Migliaccio, Castoria et al. 2010). Additionally, the EGF 
receptor (EGFR) is overexpressed in AI PC (Di Lorenzo, Tortora et al. 2002; Gan, 
Shi et al. 2010). Upregulation of EGFR can lead to increased secretion of 
cytokines, such as IL-6, forming positive autocrine and paracrine feedback loops, 
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thereby promoting PC progression (Sauer, Gitenay et al. 2010). Indeed, 
treatment of PC cells with either EGF or IL-6 resulted in Src and Ack1 kinase-
mediated phosphorylation of the AR, its consequent activation and cell 
proliferation (Liu, Karaca et al. 2010). EGF/EGFR signalling is suggested to be 
involved in the transition from AS to AI PC, to be correlated to poor patient 
outcome, and to be a potential therapeutic target (Di Lorenzo, Tortora et al. 
2002; Schlomm, Kirstein et al. 2007). Transactivation of the AR by EGF shows 
how this steroid receptor acts as a signalling hub, allowing crosstalk between 
different cascades, which promote PC progression if perturbed.    
 
Nerve growth factor (NGF) signalling via one of its cognate receptors; p75NGFR, is 
anti-proliferative and important in prostate homeostasis. Expression of NGF and 
its p75 receptor is lost as PC progresses, and this also contributes to the AI 
phenotype (Sigala, Bodei et al. 2008). 
 
 
1.9.5 Prostate Cancer Diagnosis and Treatment 
The risk factors for PC are not well understood, but increasing age, ethnicity and 
heredity are three well known factors (Heidenreich, Bellmunt et al. 2011). 
The clinical symptoms of PC often do not show until the disease is advanced and 
metastatic, therefore, early detection is important and much research is focused 
on finding specific PC biomarkers for early disease. Prostate specific antigen 
(PSA) has been used as a biomarker since the 1980s, and has greatly contributed 
to the early detection of PC. However, although highly tissue specific, it is not 
disease-specific and the level of circulating PSA can be raised in benign prostatic 
disease. Therefore, using PSA as a diagnostic tool is controversial, and has led to 
over diagnosis and over treatment of what would otherwise have been harmless 
cancers. Despite this, the discovery of PSA as an indicator of disease paved the 
way for much research into our understanding of PC and treatment regimes. 
(Stamey, Yang et al. 1987; Lilja, Ulmert et al. 2008).  
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1.9.5.1 Diagnosis  
In the pre-PSA years, PC detection was based on a trans-rectal ultrasound (TRUS) 
along with an invasive biopsy, at which stage the cancer had most likely spread 
and was incurable (Jacobsen, Katusic et al. 1995). Following PSA testing, there 
was a huge increase in the incidence of PC (Potosky, Miller et al. 1995). PSA 
screening has proved successful in decreasing PC mortality, however only 
modestly so, and whether or not this outweighs the problem of over 
detection/treatment is of constant debate (Hugosson, Carlsson et al. 2010). The 
threshold level of PSA is also being debated. A study using a lower threshold, 
found lower PC mortality, but higher over diagnosis, and the exact cut off of 
normal PSA level is unclear (Heidenreich, Bellmunt et al. 2011). 
 
The latest European Association of Urology (EAU) guidelines for PC cancer 
detection state that PSA screening and digital rectal exam be the first port of 
call. Following this, TRUS-guided repeated biopsies should be carried out to 
obtain histological information.  PSA level should also be continually monitored 
(Heidenreich, Bellmunt et al. 2011). If a tumour is confirmed, it is then given a 
Gleason score (Shah 2009). This score enables the clinician to predict the 
outcome of the cancer and to determine what treatment, if any, is most 
suitable. The tumour is assigned a score of 1-5, where 5, represents the most 
advanced tumour with complex morphology. The tumour is not assigned one 
grade, but the sum of the most prevalent and the second most prevalent 
morphological pattern within that tumour. The resulting number (2-10) is the 
Gleason score for that tumour, and is a strong indicator of survival of men aged 
65-75 (Albertsen, Fryback et al. 1995). However, multifocal prostate tumours 
may have different Gleason scores in different foci, which makes assigning a 
grade problematic, and consequently, scores may differ between clinicians (Shah 
2009). 
 
Over the years, PC care has evolved immensely, with earlier and more effective 
detection and improved treatments regimes resulting in decreased PC-specific 
mortality (Heidenreich, Bellmunt et al. 2011) 
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1.9.5.1.1 Prostate Specific Antigen 
PSA is member of the kallikrein family of proteases, it acts to liquefy the semen 
in order to facilitate ejaculation (Malm, Hellman et al. 2000). PSA is highly tissue 
specific, with little or no expression elsewhere. It is androgen-regulated and is 
therefore increased in PC due to increased AR activity (Cleutjens, van Eekelen et 
al. 1996). This increase, along with a compromised prostate architecture allows 
extra PSA into the circulation (Barry 2001). As discussed, blood PSA is also raised 
during benign prostatic diseases, and so this method of detection is very 
controversial. Also, the threshold level that should prompt a biopsy is unclear, 
but >4ng/ml blood is the general consensus for a raised PSA level (Barry 2001). 
However, PC can be present with PSA values below 4ng/ml, and levels above this 
do not mean a cancer is definitely present, especially in older men.  
 
Although not perfect, PSA testing is widely used as it is simple and non-invasive. 
Consequently, this has revolutionised patient care. It has allowed for early 
diagnosis of cancers that otherwise would have presented at an incurable stage, 
and allows monitoring of indolent cancers. Lead time of a disease is the time 
gained by screening, the amount of time between the screen and when the 
disease would otherwise have presented, i.e. with symptoms. The lead time of 
PC due to PSA screening with a cut off of 4ng/ml has been shown to be between 
4-8 years (Finne, Fallah et al. 2010). This provides a vast window of opportunity 
to implement treatment that otherwise may not be effective and this aspect has 
resulted in >30% reduction in PC-specific mortality (Roobol, Kerkhof et al. 2009; 
van Leeuwen, Connolly et al. 2010). The diagnosis of PC, while still organ 
confined, has also improved biochemical recurrence-free survival, i.e. it has 
reduced re-emergence of the cancer, again due to improved therapeutic 
outcome due to the lead time (Han, Partin et al. 2001). 
 
 Despite the favourable outcome for many patients, overdiagnosis is a huge 
problem. It constitutes a large percentage of the lead time through diagnosis of 
cancers that otherwise would never have presented due to being clinically 
insignificant and non-life threatening (Draisma, Etzioni et al. 2009). Such 
overdiagnosis results in men having inappropriate treatment with severe 
consequences such as impotence, and puts extreme financial pressure on health 
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care systems. This is why population-based PSA screening is rare, and is not 
carried out in the UK (van Leeuwen, Connolly et al. 2010). 
 
One study suggests that underdiagnosis more commonly occurs than 
overdiagnosis (Graif, Loeb et al. 2007). Lowering the PSA threshold for 
recommending biopsy to 2.5ng/ml decreased underdiagnosis and increased the 
number of men with 5 year progression-free survival (PFS). However, using this 
PSA cut off increased the rate of overdiagnosis.  
 
Currently, 15 novel biomarkers are undergoing evaluation as predictors of AI 
disease (Klotz 2013). Of these PCA3 is becoming widely used.  Prostate cancer 
gene 3 (PCA3) is a non-coding mRNA that is specifically overexpressed in PC and 
can be detected in urine following prostate massage. Its usefulness as a 
standalone biomarker has been debated, but it has been successful when tested 
alongside or following PSA and/or digital rectum exam (DRE) to determine which 
patients should undergo a second biopsy, following a negative first biopsy 
(Filella, Foj et al. 2013). It has been suggested that using a low cut-off PCA3 
score, following an abnormal PSA test/DRE may prevent unnecessary first 
biopsies (Crawford, Rove et al. 2012). Currently a PCA3 test is not available on 
the NHS but can be carried out for £300-£400 (Cancer Research UK).  
 
The search for new biomarkers continues. A highly sensitive disease-specific 
biomarker that can be detected in urine would be desired. The ideal scenario is 
to be able to detect patient specific biomarkers based on personalised genome 
sequencing. This would enable tailored patient care. The field of proteomics 
research is showing much promise in finding such methods and novel biomarkers 
(Goo and Goodlett 2010; Pin, Fredolini et al. 2013). 
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1.9.5.2 Prostate Cancer Treatment 
1.9.5.2.1 Watchful Waiting and Active Surveillance  
Prostate tumours have often been identified during autopsy on elderly men that 
died of unrelated causes. Most PCs are in fact indolent, and given the problems 
associated with treatment, such as impotence and incontinence, treatment is 
not always the preferred first port of call (Dall'Era and Kane 2008). 
 
 Watchful waiting, or deferred treatment,  has been in place since pre-PSA times 
(Adolfsson 2008), where treatment was employed only when the cancer had 
advanced locally or metastasised (Klotz 2013). It is now used mainly with elderly 
men, or men who do not expect to live longer than 10 years, and who present 
with low risk PC. The use of watchful waiting varies worldwide (Adolfsson 2008). 
If the cancer progresses, palliative hormone therapy is offered (Dall'Era and Kane 
2008).  
 
Active surveillance is an evolution of watchful waiting and the technique was 
developed in response to the problem of overdiagnosis and overtreatment. It is 
also applied to patients with low risk PC, but usually younger men. The patient 
is continually monitored and treatment is undertaken if the cancer progresses 
according to predefined thresholds that define progression (Adolfsson 2008). The 
criteria for active surveillance are, a low tumour grade (Gleason score <6), a 
locally confined tumour, a PSA level <10ng/ml, and a history of 3 or less 
biopsies. Progression is generally defined as a PSA doubling time of <2-4 years, a 
PSA level of >10ng/ml, and a higher Gleason score on subsequent biopsy 
(Heidenreich, Bellmunt et al. 2011). In contrast to watchful waiting, treatment 
following active surveillance is intended to cure the patient (Adolfsson 2008).  
 
The fact that PC with a Gleason score of 6 or lower has a long natural history 
makes active surveillance a viable option for patients. Although follow up studies 
are still quite young, (10-15 years), PC-specific mortality is very low in active 
surveillance cohorts (Klotz 2013). However, the psychological effects of active 
surveillance need to be better addressed. Often men opt for treatment due to 
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anxiety caused by the knowledge of having an untreated tumour, despite no 
evidence of disease progression (Dall'Era and Kane 2008). 
 
1.9.5.2.2 Hormone Therapy 
Androgen ablation therapy (ADT) has been the ‘gold standard’ treatment for 
advanced, recurrent and high risk PCs since 1941 (Chodak, Sharifi et al. 1995; 
Gleave, Klotz et al. 2009). It may be the primary treatment or is administered 
alongside other treatments in patients where locally-advanced cancer has re-
emerged following radiotherapy or prostatectomy (Ahmadi and Daneshmand 
2013). The European Association of Urology (EAU) recommends ADT for 
metastatic PC, and as adjuvant treatment for locally advanced PC with 
radiotherapy, or when the patient is unfit for radical local treatment. 
 
Combined androgen blockade (CAB)/maximal androgen blockade (MAB) is the use 
of an antiandrogen following surgical or medical castration (McLeod 1997). 
Antiandrogens compete with steroid androgens for AR binding, leading to 
apoptosis (Thomas and Neal 2013). The first antiandrogens used were steroidal 
and produced cardiovascular side effects. Later, non-steroidal agents were 
developed which were much better tolerated. These include flutamide and 
bicalutamide (McLeod 1997). Combined therapy is far more effective than 
castration alone for metastatic disease (Chen, Huang et al. 2010). Chemical 
castration causes an initial surge/flare in androgens, and so the antiandrogens 
combat this.  
 
Luteinising hormone-releasing hormone (LHRH) mediates LH production of 
testosterone. Both LHRH agonists and antagonists are used as chemical 
castration agents in the treatment of PC. Agonists are the primary ADT agents 
and cause an initial ‘flare’ of testosterone, which desensitises the receptor 
leading to an overall decrease in testosterone production. Antagonists are more 
recently on the market, and they inhibit the receptor, thereby blocking release 
of LH and testosterone synthesis. Thus, these agents induce castrate-levels of 
testosterone (Huirne and Lambalk 2001; Thompson 2001; Thomas and Neal 
2013).  
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ADT prevents progression of PC and associated consequences, but does not cure 
it nor prolong survival of patients with advanced disease.  Despite castrate levels 
of testosterone, the cancer invariably re-grows and is insensitive to ADT.  New 
drugs that inhibit androgen biosynthesis and AR nuclear translocation are used 
during this phase (Thomas and Neal 2013). Also, long term ADT has high 
morbidity with side effects such as impotence, incontinence, hot flushes, 
gynecomastia, osteoporosis, depression and metabolic complications (Gleave, 
Klotz et al. 2009; Ahmadi and Daneshmand 2013).  
 
1.9.5.2.3 Radiotherapy 
Radiotherapy is used in the management of low-high risk localised PC. 
Treatment can be either external beam radiotherapy (EBRT) or brachytherapy. 
The former is external radiation that is targeted to the outside of the body, in 
the region of the prostate. The latter involves the implantation of radioactive 
isotopes into the prostate that emit radiation over 60 days (Pieters, de Back et 
al. 2009; Chen and Zhao 2013). Brachytherapy uses a much lower dose of 
radiation, is non-invasive, and is commonly used in the treatment of low risk 
prostate tumours.  
 
External radiotherapy is the preferred option for higher risk PC, although it can 
be used for low risk cancer also. Different amounts of radiation are used 
depending on whether the PC is low, intermediate or high-risk (Heidenreich, 
Bellmunt et al. 2011). Indeed, both radiotherapies may be used together if a 
clinically occult extraprostatic tumour is suspected, which radiation from the 
prostatic implants would not reach (Davis, Pisansky et al. 1999). 
 
External beam radiotherapy with long term ADT (3 years) for advanced localised 
PC has been shown to delay PC-specific mortality longer than radiotherapy alone 
(Bolla, de Reijke et al. 2009), and is the current standard for radiotherapeutic 
management of high risk PC (Heidenreich, Bellmunt et al. 2011). Side effects of 
EBRT were common, due to irradiation of nearby tissue, such as the bladder. 
However methods such as MRI reconstruction of the prostate and better beam 
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targeting have greatly reduced damage to peripheral tissue (Dowling, Lambert et 
al. 2010).  
 
1.9.5.2.4 Prostatectomy  
Prostatectomy is the partial or complete (radical-RP) removal of the prostate 
gland in the treatment of BPH, LUPS and PC. There are a number of different 
techniques that fall under three main types. 
 
1) Laparoscopic prostatectomy is the least invasive method to remove the whole 
prostate. It may or may not be robot-assisted and involves only small incisions 
and little blood loss (Trabulsi and Guillonneau 2005). 
 
2) Open prostatectomy is open surgical removal of the whole gland via a large 
incisions in the abdomen or perineum (Serretta, Morgia et al. 2002). It is 
preferred in some countries, such as Italy. 
 
3) Transurethral resection of the prostate (TURP) is carried out to relieve 
moderate to severe symptoms of LUTS associated with BPH or PC. The surgical 
instrument is a resectoscope, which also has a camera on the end to guide it to 
the prostate. Morbidity after TURP used to be high but has improved greatly 
since the introduction of the modern instrument (Rassweiler, Teber et al. 2006). 
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1.10 cAMP Signalling in the Prostate and Prostate Cancer 
 
As discussed, cAMP is strongly associated with PC progression via proproliferative 
and proinflammatory signalling. Dysregulation of cAMP signalling in PC was first 
noted by Shima et al. who identified differential expression of AC in normal and 
tumour tissue (Shima, Kawashima et al. 1976). Since then, cAMP PDEs and 
effector proteins have been implicated in prostate carcinogenesis.  
 
Androgen-independent activation of the AR has been reported in response to 
several signalling pathways such as Rho-GTPase and NFκB/p52 signalling (Lyons, 
Rao et al. 2008; Nadiminty, Lou et al. 2010). Such androgen-independent AR 
transactivation is a matter of debate, but cAMP signalling is implicated in many 
of the observations. Cross talk between cAMP signalling and the AR was first 
observed when activated PKA resulted in an androgen-independent rise in PSA 
expression in PC cells (Sadar 1999). It was later found that PKA can mediate 
recruitment of the coactivators CREB and CBP/p300, and HAT to the PSA locus 
(Kim, Jia et al. 2005). Vasoactive intestinal peptide (VIP) which is associated 
with PC progression has been shown to mediate androgen-independent AR 
transactivation via a PKA/ERK pathway (Xie, Wolff et al. 2007). PKA-mediated 
enhancement of AR activity in an androgen-free environment places cAMP as a 
main player in the progression of AI PC. Also,  PKA isoform switching occurs as 
PC progresses into an AI phenotype (Merkle and Hoffmann 2011). 
 
 
1.10.1 cAMP PDEs in Prostate Cancer 
Given the vast amount of evidence suggesting a role for cAMP in the progression 
of PC and the transition to AI PC, there is surprisingly little in the literature on 
the role of cAMP PDEs in this disease.  
 
In order to gain knowledge of the role of PDEs in the prostate, Uckert et al. 
sought to characterise the expression of PDE isoforms in the various prostatic 
zones (Uckert, Kuthe et al. 2001). mRNA was detected for PDEs 1, 2, 4, 5, 7, 8, 9 
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and 10. Later they confirmed the presence of PDE4, PDE5 and PDE11 protein in 
the transitional zone of the human prostate (Uckert, Oelke et al. 2006). PDE4 
was later found to be abundant in the fibromuscular stroma and to regulate 
prostate smooth muscle tone in complex with PKA and actin (Waldkirch, Uckert 
et al. 2010). These studies highlight the need for more research into the 
implications of dysregulated cAMP compartmentalisation in PC. 
 
PDE4B has been shown to be downregulated in AIPC due to oxidative stress, 
which results in an increase in PKA and phospho-CREB and consequent 
transactivation of the AR and development of an AI phenotype (Kashiwagi, Shiota 
et al. 2012).  
 
As discussed earlier, the Sleeping Beauty transposon study by Rahrmann et al. 
identified PDE4D as a candidate PC gene (Rahrmann, Collier et al. 2009). They 
claimed that knockdown of PDE4D via shRNA decreased the proliferation of AI 
DU145 cells. A more recent study showed that inhibition of all PDE4 subfamily 
isoforms led to an increase in the expression of the AR and upregulation of PSA 
in AS LNCaP cells (Sarwar, Sandberg et al. 2013). 
 
 
1.10.2 Protein Kinase A and Prostate Cancer 
As discussed, several studies show that the cAMP/PKA pathway crosstalks with 
the AR in androgen-deprived conditions (Merkle and Hoffmann 2011).  
 
The regulatory subunits of PKA undergo differential expression during PC 
progression. PKA-II is the main isoform expressed in normal tissue, but during 
prostate carcinogenesis there is an increase in the expression of RIα, shifting the 
main PKA isoform to PKA-I (Cho, Lee et al. 2000). An increase in RIα expression 
has also been demonstrated in many other cancers (Kvissel, Ramberg et al. 
2007), and it has been shown that overexpression of RIα  negatively correlates 
with PC disease outcome (Merkle and Hoffmann 2011). It has also been 
postulated that overexpression of RIIα can reverse the tumour phenotype (Cho, 
Lee et al. 2000; Neary, Nesterova et al. 2004). In contrast, a recent study found 
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that RIα was downregulated in tumour tissue compared to normal prostatic 
tissue, and in AI cells compared to AS cells (Sarwar, Sandberg et al. 2013). 
Sarwar et al. also found that a forskolin-induced increase in cAMP led to the 
upregulation of RIα in AS LNCaP cells, whereas it abolished expression of R1α in 
AI PC3 cells. These findings are confusing given the results of the 
aforementioned studies. However, the cAMP-induced increase in R1α expression 
in AS cells suggests that an increase in cAMP due to downregulation of PDE4, 
(Kashiwagi, Shiota et al. 2012) and consequent upregulation of RIα is involved in 
the AS to AI transition of PC. Indeed, Kvissel et al. found an upregulation of RIα 
in PC cells but not in primary tumour samples, and they suggest it may be a late 
event in disease progression (Kvissel, Ramberg et al. 2007). Another study which 
also found an upregulation of RIα to be neoplastic speculated that cancer 
associated RIα may function independently of PKA (Bossis and Stratakis 2004). 
 
As discussed, it is the R subunit that confers binding interactions of PKA, and 
thus switching of this subunit may perturb the signalosome in which PKA is 
involved, even possible placing PKA in a different complex at a different 
subcellular location. 
 
Although PKA is an intracellular enzyme for the most part, a catalytically active, 
extracellular PKA (ECPKA) isoform that is cAMP-independent has been found to 
be secreted from malignant cells (Cho, Lee et al. 2000; Cvijic, Kita et al. 2000). 
ECPKA expression is correlated with that of RIα and it may be involved in 
adherence and invasion of cancer cells.  
 
The catalytic subunits of PKA are also differentially expressed during PC 
progression (Kvissel, Ramberg et al. 2007). An increase in Cβ2 is associated with 
increased proliferation, and an increase in Cβ3 and Cβ4 is associated with NED. 
Cβ2 was increased in specimens from localised untreated tumours of Gleason 
score 6-7.  
 
Thus, these studies suggest that an aberration in the PKA-I:PKA-II ratio is 
indicative of tumour formation, and may be a driving force for PC progression.   
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As discussed, the cAMP-responsive transcription factor, CREB, is phosphorylated 
and activated by PKA and provides a point of crosstalk between PKA and AR 
signalling cascades. It has been found that oestrogens and androgens can 
activate IGF-1R via CREB phosphorylation in PC cells, and this may mediate cell 
survival (Genua, Pandini et al. 2009). This, and the work described above, show 
that PKA can mediate steroid-independent transactivation of the AR; highlighting 
the importance of cAMP-mediated autocrine and paracrine signalling loops 
within the prostate and PC progression.  
 
 
1.10.3 EPAC and Prostate Cancer 
As discussed above, there have been some conflicting results on the role of EPAC 
in PC. Chronic inflammation leads to activation of the COX2-PGE2-cAMP signalling 
pathway which promotes tumourigenesis and metastasis in various cancers (Misra 
and Pizzo 2013). Misra et al. have found that EPAC1 is involved in PC progression 
via upregulation of inflammatory pathways. They found that EPAC1/Rap1 
activates the B-Raf/ERK, PI3K/AKT and mTOR signalling networks, all of which 
cross talk to bring about an upregulation of pro-proliferative genes (Misra and 
Pizzo 2009). A recent follow up study by the same group found that EPAC 
activation also brings about an upregulation of pro-inflammatory markers in PC 
cells, and acts via MAPK-COX2-PGE2-mTOR signalling to bring about an autocrine 
proliferation loop (Misra and Pizzo 2013). However, another study suggested that 
EPAC inhibits PC proliferation and migration (Grandoch, Rose et al. 2009). This 
involves an inhibition of MAPK and RhoA signalling and collapse of the F-actin 
cytoskeleton. Both studies employed AI PC3 and DU145 cells; however, in the 
study by Grandoch et al., the cells were serum starved prior to EPAC activation. 
This meant that the cell medium contained no hormones such as androgens. 
Perhaps, in the presence of androgens EPAC elicits a pro-inflammatory, pro-
proliferative effect, but in the absence of androgens the opposite is true. This 
suggests a mechanism whereby residual androgens, following ADT, potentiate PC 
progression during the later stages of the disease. 
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There is little else in the literature on the direct role of EPAC, but studies 
looking at the activity of Rap proteins in PC give an indication of the role of 
EPAC.  
 
As discussed earlier, EPAC1/Rap1 signalling plays an important role in cell 
adhesion and chemotaxis. Constitutive Rap1 activation has been shown to 
promote angiogenesis via VEGF (Menon, Doebele et al. 2012). The authors show 
that PKA antagonises this pro-angiogenic effect of Rap1, suggesting interplay 
between PKA and EPAC signalling loops in PC. They propose that PKA activation 
may explain the anti-proliferative effects of EPAC1 reported by Grandoch and 
colleagues.   
 
It has also been demonstrated that an increase in cAMP in AS PC cells leads to 
Rap1/PKA/EGF-dependent activation of MAPK (Chen, Cho et al. 1999). Again this 
represents an example of EPAC/PKA synergism in PC. Increased Rap1 activity in 
AI PC cells promotes migration and invasion via a process that involves integrins 
(Bailey, Kelly et al. 2009). This likely involves EPAC, which is known to play a 
key role in integrin-mediated cell adhesion (Bos 2006).  
 
Rap2 has also been shown to mediate androgen-dependent PC cell growth 
(Bigler, Gioeli et al. 2007) Its expression is decreased in AI PC, suggesting loss of 
Rap2 may be involved in AI PC progression. When overexpressed in AS cells, Rap2 
inhibited MAPK activation and PSA expression.  This suggests a possible 
antagonistic relationship between Rap1 and Rap2, and would explain why 
activating EPAC can induce either pro- or anti-proliferative cellular effects. 
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1.10.4 Neuroendocrine Differentiation in Prostate Cancer 
Neuroendocrine (NE) cells are found dispersed around the stromal and luminal 
epithelium cells in the normal prostate gland, the amount of which can vary 
between individuals (Sun, Niu et al. 2009; Li, Chen et al. 2013). They are non-
mitotic and do not express the AR or PSA, are distinct from stem cells, and are 
most closely related to the secretory cells (Huang, Yao et al. 2006). Little is 
known of their function, but they are presumed to play paracrine and secretory 
roles in the development and function of the gland (Cox, Deeble et al. 1999). NE 
cells make up only 1% of untreated prostate tumours, but become abundant in AI 
PC, following ADT (Li, Chen et al. 2013). This is likely because they do not 
express the AR so are resistant to ADT, and there may be selection for NE cells 
during PC progression, like with stem cells. The higher the density of NE cells, 
the more poorly differentiated the tumour is (Sun, Niu et al. 2009). 
 
It has long been known that an increase in cAMP can trigger neuroendocrine 
differentiation (NED) characteristics in AS cells, likely through PKA signalling 
(Bang, Pirnia et al. 1994; Cox, Deeble et al. 2000). NE cells secrete 
neuropeptides and cytokines that act via autocrine and paracrine signalling to 
facilitate NED and increase the proliferation of neighbouring non-NE cells 
(Gkonos, Krongrad et al. 1995; Juarranz, Bolanos et al. 2001; Li, Chen et al. 
2013). An increasing NE cell population and thus level of secreted neuropeptides 
is believed to be involved in the transition to AI PC (Jongsma, Oomen et al. 
2000). It has also been suggested that neuropeptides may be involved in atypical 
androgen signalling in the transition to AI PC (Gkonos, Krongrad et al. 1995). NE 
cells also highly express the potent angiogenic peptide VEGF, with higher levels 
in AI cells compared to AS cells (Harper, Glynne-Jones et al. 1996). This likely 
facilitates metastasis and neovascularisation, giving NE cells another driver for 
the progression of PC. The neuropeptide vasocactive intestinal peptide (VIP) has 
been highly implicated in NED-mediated PC progression, as it potentiates 
angiogenesis through upregulation of VEGF in AS cells (Collado, Gutierrez-Canas 
et al. 2004; Collado, Sanchez et al. 2005). This pathway may involve PKA, ERK 
and PI3K signalling cascades (Gutiérrez-Cañas, Juarranz et al. 2005). VIP has also 
been shown to increase PSA secretion (Gkonos, Ashby et al. 1996). Thus 
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increasing levels of VIP during NED and PC progression may be involved in the 
increase in serum PSA levels.  
 
Interestingly NED is reversible (Cox, Deeble et al. 1999). Exposure to 
neuropeptides brings about conversion to a NE morphology. When differentiating 
agents are withdrawn or decreased, the cells can re-enter the cell cycle and 
proliferate. This mechanism may provide PC with a double-edged sword. Under 
the right conditions, with increasing cAMP, cells may become NE, secreting 
growth stimulating agents to neighbouring cells, and eventually these agents 
may act in an autocrine manner to reverse the NED, returning the cells to a 
proliferative state. If this occurs in vivo, it may occur in a cyclical manner, 
increasing tumour mass and potentiating androgen-independence.  
 
A recent study has linked inflammation to NED, where differentiated AS LNCaP 
cells displayed increased secretion of the pro-inflammatory cytokine MIF 
(Tawadros, Alonso et al. 2013).  
 
A small subset of men develops small cell neuroendocrine carcinoma (SCNC) 
following ADT (Sun, Niu et al. 2009; Li, Chen et al. 2013). SCNC cells are all NE-
like cells, but they are highly proliferative and metastasise rapidly with very 
poor prognosis. An SCNC can exist alone or alongside a conventional PC tumour 
which is more common, and may develop following tumour suppressor gene 
mutation in normal NE cells.  
 
Despite the apparent importance of NED in PC progression and transition into 
androgen independence, little is known on the cAMP-dependent mechanisms 
involved.  
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Aims of Research 
 
In summary, there is much evidence implicating cAMP signalling in the 
progression of PC. Despite this, the roles of individual cAMP PDE isoforms in PC 
have not been investigated. Given their highly specific and non-redundant roles, 
this seems pertinent in order to understand the effects of changes in cAMP 
signalling during the progression of this disease. Due to the current lack of a 
disease-specific biomarker, our group undertook such an investigation; in the 
hope that changes in cAMP signalling would present a novel biomarker. Indeed, 
we identified a significant change in the expression of PDE4D7 mRNA between AS 
and AI disease, such that it successfully discriminates between normal and 
tumour prostate tissue, and as such is a promising novel PC biomarker. This 
thesis focuses on characterising a function of PDE4D7, as none have yet been 
assigned to this enzyme. 
 
This study is divided into three parts; 
 
1) Investigations into the expression of PDE4D7 protein in AS versus AI PC cell 
lines, and the effect of PDE4D7-mediated cAMP hydrolysis on PC cell 
proliferation and migration. 
 
2) Identification of a novel mode of PDE4D7 isoform-specific regulation. 
 
3) Investigations into the PDE4D7 interactome.  
 
 
It is expected that the findings presented here may enhance our current 
knowledge about cAMP and in the progression of PC, and that PDE4D7 may 
provide a novel node for therapeutic manipulation in the treatment of PC.  
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2 Materials and Methods 
2.1 Molecular Biology 
2.1.1 Cloning and PCR  
2.1.1.1 Primer Design 
Primers of 15-20 nucleotides in length were designed for optimal annealing 
between 55oC and 65oC using the formula; 
 
Tm (oC) = 2 (NA+NT) + 4 (NG+NC)  
 
Where N= number of the corresponding bases (A,T,G and C).  
 
They were designed with complementarity to the sense and 3’ antisense end of 
the target DNA, with or without the introduction of mutations. Primers were 
tested in silico using Geneious bioinformatics software (Biomatters).  Following 
this they were made and purified by Thermo-Fischer Scientific.   
 
 
2.1.1.2 Site Directed Mutagenesis (SDM) 
The following primers were used in this study for SDM, to create PDE4D7 Ser42 
mutants using VSV-PDE4D7 as template DNA; 
 
PDE4D7 S42A forward:   
5' CGG AGA CTT GCA TGT CGC AAT ATT CAG CTT CCC CCT CTC 3' 
 
PDE4D7 S42A reverse:    
5' ATT GCG ACA TGC AAG TCT CCG GAC AAG ATA GGG TTC CAT TCC 3' 
 
PDE4D7 S42D forward:   
5' CGGAGACTTGACTGTCGCAATATTCAGCTTCCCCCTCTC 3' 
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PDE4D7 S42D reverse:   
5' GGGATAGAACAGGCCTCTGAACTGACAGCGTTATAAGTCG 3' 
 
 
2.1.2 PCR Product Clean-up 
All PCR products were purified using Qiaquick PCR Purification Kit (Qiagen) 
according to manufacturer’s protocol. Briefly, high salt buffers are used to bind 
DNA to a silica membrane in a spin column. Contaminants are washed away-they 
pass through the membrane. DNA was then eluted in nuclease free water.  
 
 
2.1.3 Restriction Endonuclease Digestion of DNA  
All restriction endonucleases and corresponding buffers were sourced from 
Roche. Sub-cloning of all cloned human genes used within this study was 
performed using two differing restriction sites so as to ensure correct orientation 
of insertion into vector plasmids.  
 
Digestion of purified PCR products were performed in 100μl volumes with the 
following composition:  
 
Enzyme 1:  1.5ul                                                                                                                                           
Enzyme2:  1.5ul                                                                                                                                                     
10x buffer: 10ul                                                                                                                                                                
Eluted PCR product: 87ul 
 
Plasmid vector was digested using the following reaction composition: 
Enzyme 1:  1.5ul                                                                                                                                           
Enzyme2:  1.5ul                                                                                                                                                     
10x buffer: 2ul                                                                                                                                                                
Plasmid vector:100ng                                                                                                                                         
dH2O: up to 20ul               
 
                                                                                                                                                                
The digestion reactions were allowed to proceed for 1h at 37oC. 
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2.1.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to analyse 5ul of PCR reaction mixtures. 1% 
agarose (w/v) was dissolved in TAE (Tris-acetate-EDTA) buffer (40mM Tris-Cl; pH 
8.5, 0.114% (v/v) glacial acetic acid and 2mM EDTA). 0.001% Ethidium Bromide 
was added to visualise the separated DNA fragments under UV light. The DNA 
was added to loading buffer containing (final concentration 5% [v/v] glycerol 
solution, 0.06% [w/v] bromophenol blue, 0.06% [w/v] xylene cyanol). A 1kb DNA 
ladder (Promega) was used as a marker. The gel was run for ~45 minutes at 100 
V. The gel was removed from the tank and analysed using the Gel Doc XR+ 
System (Bio-Rad) using the ultra-violet light setting. If the cloning was 
successful; i.e. DNA bands at the correct molecular weight, the remainder of the 
PCR reaction product was purified as described in section 2.1.2. 
 
 
2.1.5 Ligation  
Ligation of PCR fragments and digested plasmids was conducted using the Rapid 
DNA Ligation Kit from Roche as per the manufacturer’s instruction. All buffers 
were supplied with the kit. Briefly; vector and insert DNA fragments were 
combined in a 1:4 molar ratio (of vector/insert) in 10μl of 1x DNA dilution 
buffer. 10μl of ligation buffer was then added to the mixture. Ligations were 
incubated at room temperature for 20 minutes before transformation into 
competent DH5α E.coli cells from Invitrogen. Competent cells were then 
transformed with 2ul of ligation reaction as described in section 2.1.6. Plasmid 
DNA was extracted, purified and sequenced (GATC Biotech). 
 
 
2.1.6 Transformation of Competent Cells 
Transformations were carried out using One Shot TOP10 or DH5α E. coli 
competent cells (Invitrogen) for protein expression or plasmid amplification 
respectively. 2ul of a plasmid DNA or ligation mixture was gently added to 50ul 
of cells and incubated on ice for 30mins. Cells were then subjected to heat-
shock at 42oC for 30 seconds, and placed back on ice for 1-2 minutes. 250ul of LB 
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medium was then added and the cells were placed in a 37oC shaking incubator 
for 45mins-1 hour to recover. The cell suspension was then plated onto LB-agar 
plates containing 100ug/ml of the appropriate antibiotic. The plates were left to 
dry and incubated at 37oC overnight.  
 
 
2.1.7 Sequencing  
The day following transformation of E. coli, a number of colonies were picked 
with a sterile pipette tip and placed in to 50ml Falcon tubes containing LB and 
100ug/ml of the appropriate antibiotic and inoculated overnight at 37oC. 
Following this the plasmid DNA was isolated using a Qiaprep Spin Miniprep Kit 
(Qiagen) according to manufacturer’s instructions. Plasmid samples were then 
sent to GATC sequencing services, where they sequence 30-100ng/ul of plasmid 
DNA in 20ul samples. The sequencing results for each colony were analysed in 
silico using Geneious bioinformatics package (Biomatters), to determine the 
sequence was correct and void of any unwanted mutations.  
 
Sequencing was performed using single GATC universal primers; 
 
For pcDNA3.1: 5’CAAACAACAGATGGCTGGC3’ 
For pGEX: 5’CTGGCAAGCCACGTTTGG3’ 
 
 
2.1.8 Storage of Plasmid DNA 
For plasmid storage, sterile glycerol was added to an overnight culture of cells 
to make a final concentration of 20% glycerol. The glycerol stock was then snap-
frozen on dry ice and stored at -80oC until required.  
 
Glycerol stocks could then be used to inoculate culture media by scraping the 
frozen stock with a sterile pipette tip and then transferred into 5 ml LB media 
containing the appropriate antibiotic. Plasmid isolation was then performed as 
described in Section 2.1.9. 
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2.1.9 Isolation of plasmid DNA 
Plasmid DNA was harvested subsequent to the overnight incubation of glycerol 
stock sample. For small scale harvesting (5ml), DNA was isolated using QIAprep 
Spin Miniprep Kit (Qiagen) according to manufacturer’s instructions. For large 
scale harvesting, the bacterial cell culture was centrifuged at 6000xg for 15 
minutes and plasmid DNA was subsequently purified by QIAGEN Plasmid Maxi Kit 
(Qiagen) according to manufacturer’s instructions. Both kits work on the 
principles of alkaline lysis of the bacterial cells followed by anion exchange on a 
column and precipitation of DNA under low salt and pH conditions. RNA, proteins 
and other low molecular weight contaminants are washed away using medium 
slat buffers and high purity DNA is then eluted in high salt buffer. Isopropanol 
precipitation is used to desalt and concentrate the DNA.  
 
 
2.1.10 Bioinformatic Analysis 
All bioinformatic analysis conducted within this study was performed using the 
Geneious® bioinformatics package (v5.3) from Biomatters. All sequence and 
accession files were sourced from the NCBI database. 
 
 
2.1.11 RNA Extraction and Purification 
RNase Zap (Invitrogen) was used on the bench, pipettes and all other items used 
when extracting tRNA. Filter tips (Rannin) were used to also prevent 
contamination and degradation of RNA samples. tRNA isolation was carried out 
using an RNeasy Kit midi from Qiagen. Prior to harvesting the RNA, cells were 
grown in the appropriate cell culture dish, all medium was removed, and they 
were directly harvested using RLT buffer. RLT contains highly denaturing 
guanidine-thiocyanate and immediately inhibits any RNases. The amount of RLT 
buffer added was based on cell density, as outlined in the manufacturer’s 
protocol. For example, 200ul was used for one well of a 6 well plate and if 3 
wells were used this was pooled to make 600ul final volume. Samples were then 
added to Eppendorf tubes and homogenised by vortexing for 1 min and being 
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passed through a 19 gauge needle a number of times (5-7). Following this, all 
steps listed in the manufacturer’s protocol were carried out. Briefly, tRNA was 
ethanol-precipitated and applied to an RNeasy spin column. High salt buffers 
bind tRNA longer than 200bps to the silica column membrane, thereby enriching 
mRNA isolation. On-column DNase digestion was then performed using DNase1 
(Qiagen) for 30mins at RT, in order to remove any genomic DNA contamination. 
Bound tRNA was then washed to remove other contaminants. RNA was then 
eluted in nuclease-free water.  
 
 
2.1.12 Nucleic acid Quantification 
Isolated DNA and RNA samples were assessed for quantity and purity using a 
Nanodrop spectrophotometer (Thermo-Scientific) Nucleic Acid concentration was 
quantified by absorbance at A260nm and purity (protein contamination) was 
assessed by the A260/A280 nm ratio, with 1.7-1.8 being optimal values for 
protein/nucleic acid ratio for DNA, and 1.8-2 being optimal for RNA.   
 
 
2.1.13 cDNA Synthesis 
1ug of RNA was reverse transcribed into cDNA using Affinty Script Multiple 
Temperature cDNA synthesis Kit (Agilent) according to manufacturer’s 
instructions. Briefly, random primer amplification synthesises cDNA from tRNA.  
RNA is incubated with the random primers at 65oC for 5 minutes followed by 
cooling to RT at which point the primers anneal to the RNA. When cooled, dNTP 
mix and the reverse transcriptase are added, along with buffer and an RNase 
inhibitor.  cDNA was then synthesised at 42oC for 60minutes followed by 
termination of the reaction at by heat inactivation at 85oC for 5 minutes. The 
reverse transcriptase enzyme provided in this kit is a genetically modified 
version of MMLV RT, which is highly thermostable. The cDNA was quantified 
using the Nanodrop. 
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2.1.14 Quantitative Real Time PCR 
2.1.14.1 Primer Design 
Primers with melting temperatures of 55-60oC were designed to amplify an 80-
120bp segment of target cDNA within the gene of interest (GOI). The primers 
contained 3’ TAMRA and 5’ FAM labels. All primers were BLAST-searched against 
the NCBI mRNA database to ensure specificity. If any displayed affinity for a 
possible off-target region of the cDNA it was ensured that the cognate 
oligonucleotides used in the probe-set showed no such affinity or homology to 
that off-target transcript. These primers were then designed and HPLC purified 
by Eurofins MWG Operon.  Taqman Probe sets were used to increase specificity 
of the qPCR reaction for the desired cDNA target transcripts and reduce post 
assay analysis time (table 2.2).  
 
 
Accession Gene Forward Reverse Probe 
 panPDE4D ACCATTACCAT
GCTGATGTGGC
CT  
 
ACACAGCCTCCAAAGC
AGGTG  
 
TCCATGCTGCAGATGTTGTCC
AGT  
 
AF53696.1 PDE4D7 TGCCTCTGAGG
AAACACTAC  
 
GCTGAATATTGCGACA
TGAAAG  
 
CCAGTAATGAAGAGGAAGAC
CCTTTCCGC  
 
AF012073 PDE4D5 AACGAAGACCT
TGTGAAATCC  
 
GCTGCTGAGAAGCATT
CTG 
ATCTCTCCGAGAAATTCCCCCA
GGCT  
 
 
Table 2.1. List of Primers and Probes used in this Study 
 
 
2.1.14.2 qPCR Protocol 
qPCR was carried out using a Prism 7300 qPCR cycler from Applied Biosystems. 
The qPCR buffer used was PerfeCTa qPCR FastMix Reaction Mix (Quanta 
Biosciences). Reactions were carried out in MicroAmp Fast Optical 96-well 
Reaction Plates (Applied Biosystems).  
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15ul reaction mixes were added to each well:  
 
 
REAGENT 
FINAL 
CONCENTRATION/VOLUME IN 
15uL MIX 
qPCR FastMix buffer 7.5ul 
Forward Primer 500nM (0.1ul) 
Reverse Primer 500nM (0.1ul) 
Dual Labelled Probe 500nM (0.1ul) 
Nuclease free water 2.2ul 
Diluted cDNA (10ng/ul) 5ul 
 
 
The qPCR reaction was carried out in 2 segments:  
 
 
 
 
 
 
Cycle Threshold (Ct) values were obtained for each GOI and GAPDH and used to 
calculated the fold expression of a GOI and as a percentage of GAPDH control.  
 
 
2.1.14.3 qPCR data analysis 
Relative changes in gene expression were quantified using the comparative Ct 
(∆∆Ct) method as described by Livak and Schmittgen (2001). Here the PCR signal 
of the transcript of interest in a treated sample is compared to that of a control 
sample, after both are normalised to an endogenous housekeeping gene such as 
GAPDH. The objective of this method is to compare the PCR signal of a target 
gene in a treatment group to the untreated control after normalising to an 
endogenous reference gene. Firstly, the point at which the PCR was detected 
above a set threshold in exponential phase, termed threshold cycle (Ct), was 
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obtained from the real-time PCR instrumentation. Ct is determined from a log-
linear curve where PCR signal is plotted against the cycle number. The Ct values 
of each sample were then imported into Microsoft Excel and the average Ct of 
triplicate samples was calculated. The amount detected at a certain cycle 
number is directly related to the initial amount of target in the sample. Hence, 
to determine the quantity of gene-specific transcripts present in cDNA, Ct values 
for each treatment had to be normalised first to obtain ΔCt. This was 
accomplished by subtracting the mean Ct value of endogenous reference gene 
GAPDH of each group from the corresponding mean Ct value of gene of interest 
(GOI) accordingly (ΔCt = CtGOI - ΔCtGAPDH). The concentration of gene-specific 
mRNA in treated cells relative to control cells was then normalized through 
subtraction again to obtain ΔΔCt values (ΔΔCt = ΔCt of treated cells - ΔCt of 
control treated cells). Finally, the relative expression which is often termed as 
RQ value was determined by raising 2 to the power of the negative value of ΔΔCt 
(2-ΔΔCt) for each sample (Amount of target = 2-ΔΔCt). Alteration in mRNA 
expression of target genes was defined as fold difference in the expression level 
in cells after the treatment relative to that of the control treatment. Samples 
with poor technical replicate values were excluded from analysis. 
 
 
2.2 Protein Chemistry 
2.2.1 Peptide Array Technology 
PDE4D7 peptide arrays were produced by automatic SPOT synthesis employing 
the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments) (figure 2.1 A) and 
Fmoc (9-fluorenylmethoxycarbonyl) chemistry (Frank 2002). The fundamental 
principle of this technique is the dispensation of a solvent droplet onto the 
planar surface of a porous membrane which is absorbed and forms a circular 
spot; this spot then acts as a reaction vessel. The peptide array can then be 
overlaid with purified proteins or antibodies to verify PPIs and identify 
functional binding motifs and antigen epitopes. PDE4D7 peptide arrays were 
created with overlapping 25mer peptides, each shifted along by 5 amino acids so 
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each overlaps the next by 20 amino acids, until the full protein was spotted onto 
the nitrocellulose support (figure 2.1 B).  
 
 
 
 
 
 
Figure 2.1. SPOT synthesis.  
A; the AutoSpot-Robot ASS 222 spotting robot (the peptide sewing machine) 
(Frank 2002). B; 25mer peptides encompassing PDE4D7 were spotted onto a 
nitrocellulose support, which is on a glass slide.  
 
 
2.2.1.1 Peptide Array Validation of Novel PDE4D7 Antibody  
PDE4D7 arrays were blocked in 5% non-fat milk (Marvel) in TBST for 1h at RT 
with gentle shaking. Arrays were then incubated with the antibody at 1:1000 in 
1% milk overnight with gentle shaking at 4oC. Following 3 TBST washes, arrays 
were incubated with HRP-conjugated anti-goat at 1:5000 in 1% milk for 1h at RT. 
The arrays were again washed several times with TBST before subjected to 
enhanced chemiluminescence (ECL) Western immunoblotting kit for 
autoradiography as described previously. The dark spots detected were 
indicative of a positive interaction of the antibody with the peptide array. 
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2.2.2 Phosphorylation Assays 
2.2.2.1 In vitro Phosphorylation of PDE4D7 Peptide Arrays  
Peptide arrays were blocked in 5% PhosphoBLOCKER (Cell Biolabs) containing 0.5 
mM DTT and 1mM ATP, in TBST for 1h at RT with gentle shaking. They were then 
incubated in phospho-buffer (20 mM Tris-HCl; pH 7.5, 10 mM MgCl2, 0.5 mM 
CaCl2, 1 mM DTT, 0.2 mg/ml BSA, 1 mM ATP) with or without 100 units of active 
bovine PKA catalytic subunit (Sigma) for 1h at 30oC with gentle agitation. 
Following the phosphorylation assay, the arrays were washed thrice in TBST. 
Phosphorylated peptides were detected using either RXXpS antibody or the 
custom made PDE4D7-pSer42 antibody.  
 
 
2.2.2.2 In vitro Phosphorylation of purified PDE4D7 
N-terminal only GST-PDE4D7 wt, and GST-PDE4D7 S42A mutant proteins were 
purified as described. 2ug of each and 2ug of purified GST were incubated with 
phospho-buffer (20 mM Tris-HCl; pH 7.5, 10 mM MgCl2, 0.5 mM CaCl2, 1 mM DTT, 
0.2 mg/ml BSA, 1 mM ATP) with or without 25 units of active bovine PKA 
catalytic subunit (Sigma) for 1h at 30oC with gentle agitation. The proteins were 
then analysed by SDS-PAGE followed by immunoblotting with either RXXpS 
antibody or the custom made PDE4D7-pSer42 antibody.  
 
 
2.2.3 PDE4 Activity Assay 
The PDE4 assays carried out were based on that described by Marchmont and 
Houslay (Marchmont and Houslay 1980). It comprises a two-step radioassay 
whereby samples are firstly incubated with 8-[3H]-labelled cAMP substrate and 
the cAMP is hydrolysed to 8-[3H] labelled 5’AMP by PDE4 enzymes in the samples. 
Secondly, the labelled 5’AMP is dephosphorylated to adenosine by addition of 
snake venom which contains 5’ nucleosidase. Dowex ion exchange resin is then 
added to separate negatively charged un-hydrolysed cAMP from the uncharged 
adenosine. The amount of 8-[3H] bound adenosine in the samples is then 
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determined by scintillation counting which calculates the rate of cAMP 
hydrolysis.  
 
The following buffers were used; 
 
Buffer A (20Mm TRIS-HCL, pH7.4)                                                                                                                   
Substrate Buffer (20Mm TRIS-HCL/10mM MgCl2, pH7.4)                                                                            
Dowex (Sigma/Fluka); in a 1:1:1 ratio of Dowex:dH2O:EtOH      
 
                                                                                                                       
2.2.3.1 Preparation of Dowex Ion-exchange Resin 
Dowex was prepared and activated by dissolving 400g of Dowex resin in 4 litres 
of 1M NaOH. The solution was stirred for 15 minutes at room temperature and 
the resin was allowed to settle. The supernatant was removed and the Dowex 
resin was repeatedly washed with dH2O and allowed to settle after each wash 
(~30 washes, 4L of dH2O). After washing with dH2O the resin was stirred with 4 
litres of 1M HCl for 15 minutes at room temperature and allowed to settle. The 
resin was then washed a further 5 times with dH2O and stored at 4oC as 1:1 
slurry with distilled water. This Dowex slurry was utilised in the PDE assay as a 
2:1 solution of slurry to 100% ethanol. 
 
 
2.2.3.2 Preparation of Cell Lysates 
Cells to be assayed were harvested in KHEM buffer (50mM HEPES pH7.4, 50mM 
KCL, 1.92mM MgCl2) containing Complete, EDTA-free Protease Inhibitor Cocktail 
Tablets (Roche) and PhosStop Phosphatase Inhibitor Cocktail Tablets (Roche). 
Lysates were diluted to 1ug/ul total protein.  
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2.2.3.3 PDE Assay Protocol 
Lysate samples were prepared in triplicate in 1.5ml Eppendorf tubes on ice. 
Samples were made to 50ul final volume with Buffer A. Three blank control 
samples were prepared which contained 50ul of Buffer A only. 50ul of cAMP 
substrate mix (2uM 8-[3H]-cAMP (Amersham Biosciences) + 2ul 1mM cAMP (sodium 
salt, Sigma) per ml of Substrate Buffer) was added to each sample, including 
blanks, giving 2uM unlabelled cAMP and 3uCi/ml 8-[3H] cAMP final. The samples 
were incubated for exactly 10 minutes at 30oC to start the PDE reaction, and 
then boiled for 1-2 minutes to terminate the reaction. The samples were placed 
back on ice and allowed to cool for at least 15 minutes. Following this, 25ul of 
1mg/ml snake venom (Sigma, made in Buffer A) was added to all samples 
(0.2mg/ml final). Again samples were incubated for 10 minutes at 30 oC. 400ul of 
the Dowex solution was then added and samples were vortexed, followed by 
cooling on ice for at least 15 minutes. Samples were then centrifuged at 
13000rpm for 3 minutes at 4oC. 150ul of supernatant was added to new, labelled 
eppindorf tubes. To this, 1ml of Opti-flow SAFE 1 scintillant (Fischer Scientific) 
was added. Standards were made with 1ml of scintillant and 50ul of the cAMP 
substrate mix. All tubes were vortexed and placed in the scintillation counter 
(Wallac 1409 Liquid Scintillation Counter).  
 
 
2.2.3.4 Calculation of PDE Activity 
To calculate the specific cAMP hydrolysing activity the following equation was 
used to give PDE activity in ρmoles/min/mg protein: 
 
 
 
 
Where: 
 
A = Specific PDE activity (pmol cAMP/mg/min)  
C = Sample value (CPM)  
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B = Blank value (CPM)  
S = Standard value (CPM)  
N = Amount of cAMP in substrate (moles)  
P = Amount of protein added (ug)  
t = Time (min) 
 
 
2.2.4 Protein-Protein Interactions 
2.2.4.1 Pull-Down Assay (IP) and Mass Spectrometry 
Hek293 cells were transfected with VSV-tagged PDE4D7 or control vector 
(pcDNA3.1). Following an appropriate expression time (~30 h), cells were 
harvested in 3T3 lysis buffer. Cell suspension was gently agitated on an end-
over-end wheel at 4oC.  The lysate was then centrifuged and the supernatant 
was assayed for protein concentration by means of a Bradford assay. 500ug of 
total protein was used for each IP; untransfected and transfected lysates were 
immunoprecipitated with 20ul FLAG (Invitrogen) or VSV (Sigma) tagged agarose 
beads. The IP samples were incubated at 4oC on an end-over-end wheel 
overnight. The input samples were boiled in sample buffer and frozen at -20oC.  
The following morning the beads were pelleted by centrifugation and washed 
thrice with lysis buffer. 20ul 2x SDS-PAGE sample buffer was added and the 
beads were boiled for 5 min. Input and IP samples were then loaded onto a pre-
cast polyacrylamide gel which was run for 1h40min at 100V. Following this the 
gel was Coomassie stained. The gel bands representing proteins pulling down 
with PDE4D7 were excised, along with the corresponding gel band areas in the 
control lanes.  
These bands were shipped to Mr. Eberhard Krausse of the FMP - Leibniz-Institut 
für Molekulare Pharmakologie Berlin who kindly performed the mass 
spectroscopic anaylses.  
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2.2.4.2 Yeast Two Hybrid (Y2H) Screen 
The Y2H screen was outsourced to Mr. Bangze Jin of Shanghai Genomics Inc. It is 
described in Chapter 5.  
 
 
2.2.4.3 ProtoArray  
ProtoArray Human Protein Microarray slides V5.0 (Invitrogen) were used for this 
study. Each array contains over 9,000 human proteins printed in duplicate on 
nitrocellulose on a 1x3 inch slide. Proteins on the slides are produced from 
clones in the Invitrogen Ultimate™ ORF Collection. The proteins are expressed as 
GST fusions using a baculovirus system, after which they are purified under non-
denaturing conditions and printed onto the slide. Briefly, a slide is incubated 
with a purified protein of interest, followed by fluorescent antibody detection. 
Any proteins on the slide to which the protein of interest has bound are seen as 
fluorescent dots. Three ProtoArray slides were used in this study. The slides 
were stored at -80oC. Before beginning the experiment they were removed from 
the freezer and allowed to equilibrate on ice for at least 15 minutes. All 
incubations are performed in a 4-chamber incubation tray (Griener).  
Following equilibration, the slides were incubated with blocking buffer (50mM 
HEPES pH7.5, 200mM NaCl, 0.08% Triton X-100, 25% glycerol, 20mM reduced 
glutathione, 1mM DTT, 1X Synthetic Block) on a rocker at 4oC. The slides were 
then probed with 1) purified GST tagged PDE4D7, 2) purified GST alone, 3) 
washing buffer alone (1X PBS, 1X Synthetic Block, 0.1% Tween). 120ul of 
buffer/probe mix was dropped onto the slide and covered with a LifterSlip 
(Thermo Scientific) to prevent evaporation. Following a number of washes, slides 
were incubated with primary antibody (anti-PDE4D7, Millipore). Again slides 
were washed, followed by probing with fluorescent secondary antibody (Alexa 
Fluor 647-Goat anti- Rabbit). All antibody incubations were carried out at 4oC for 
90 minutes at a dilution of 1 in 1000 in washing buffer.  
The slides were allowed to dry at room temperature (RT) overnight before being 
scanned on a ScanArray Express Microarray Analysis System (PerkinElmer Life 
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Sciences). Bluefuse software (BlueGnome) was used to organise the data 
generated by the scanner. It employs object-oriented perl programming to 
manage microarray files and map data fields in a ‘Bluefuse’ output. It generates 
a list of the protein pairs on the microarray along with a confidence score of A-
E, representing the confidence that that protein binds the protein of interest, 
with A being highest confidence score. Protein pairs that scored A or B on the 
slide probed with PDE4D7, and D or E on both control slides were shortlisted. 
They were then compared to the image output, and if indeed full fluorescent 
red dots are present on both of the duplicate proteins, they were considered for 
further research.  
 
 
2.2.4.4 Co-Immunoprecipitation (Co-IP) 
Co-IP is an ex vivo method for the verification of PPIs. For overexpressed 
PDE4D7, ~500ug of total protein was used for IPs with VSV-tagged agarose beads. 
For endogenous PDE4D7, 1mg of total protein was used for IPs with 0.65ug of the 
novel PDE4D7 antibody or 0.65ug of isotype-matched IgG (Jackson 
ImmunoResearch Laboratories, Inc.) from the same species, with protein G-
agarose beads. The cell lysates were precleared with 20ul of the appropriate 
beads for 30min on an end-over-end wheel at 4oC. The beads were then 
pelleted, and the supernatant added to fresh Eppendorf tubes. For VSV IPs, 20ul 
fresh beads were added and the lysates were incubated overnight at 4oC on the 
wheel.  For PDE4D7 IPs, antibody or IgG was added and the lysates were 
incubated overnight at 4oC on the wheel. The following morning 20ul protein G-
agarose beads were added for 2h. Prior to analysis by SDS-PAGE, the beads were 
washed thrice with 3T3 lysis buffer and boiled in 20ul 2x sample buffer. Test and 
control IPs, along with input samples, were loaded onto pre-cast polyacrylamide 
gels followed by western immunoblotting for the PPI hits.  
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2.2.5 Expression and Purification of Recombinant Proteins 
Full length PDE4D7, N-terminal PDE4D7 and the N-terminal PDE4D7-S42A mutant 
were expressed as N-terminal GST fusion proteins using pGEX-6P1 (Invitrogen). 
10mls of Luria-Bertani (LB) medium supplemented with 100 μg/ml ampicillin was 
inoculated with BL21 E. coli cells (Invitrogen) containing the plasmids and grown 
overnight in an orbital shaker at 37oC. The following morning this was added to 
500ml of LB + ampicillin, and grown for a further 2-4 hours, until the cell density 
reached OD600 ~0.6-0.7, at which point cell growth was in the logarithmic phase. 
At this point, 1mM of isopropyl-β-D-thiogalactopyranoside (IPTG) was added to 
the cultures to induce protein expression. Cells were grown for a further 3-4 
hours at 30oC and subsequently pelleted by centrifugation at 6000 x g for 10 min 
at 4oC. The cell pellets were resuspended in 10ml of ice cold GST lysis buffer (20 
mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.05% NP-40) 
supplemented with protease cocktail inhibitor tablet (Roche). Cells were lysed 
by sonication; 3 x 30 sec, with 30 sec rest in between. Following lysis, cell 
lysates were centrifuged at 13000 rpm for 15 min at 4oC to collect the soluble 
fractions and remove cell debris.  
 
Glutathione-sepharose beads (Amersham) were washed thrice with GST lysis 
buffer and 200ul of slurry was added to 15ml conical tubes. 10ml of the lysed 
cell supernatant was then added to each 15ml tube and incubated end-over-end 
overnight at 4oC. Subsequently the beads were pelleted by centrifugation, the 
supernatant was removed and the beads were washed with GST lysis buffer. The 
beads were again pelleted and washed with elution buffer (EB) (50mM Tris-HCl 
pH 8.0). Again the beads were spun down, and most of the supernatant was 
removed. The beads were resuspended in the remaining supernatant and 
transferred to a 1.5ml tube on ice; beads from different tubes were combined if 
they were the same sample. The volume was brought up with more elution 
buffer, the beads were pelleted and the supernatant was removed. The beads 
were then resuspended in 500ul EB + glutathione (6.8mg of reduced glutathione 
(Sigma) per 1ml of EB) and gently mixed by hand. The beads were spun down 
and the supernatant (eluate) was collected. This was repeated a number of 
times and the eluate was pooled.  Overnight dialysis of the collected eluate was 
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carried out in dialysis buffer (100mM NaCl, 50mM Tris-HCl; pH 8.0, 5% glycerol, 
5mM DTT) in slide-a-lyzer cassettes (Piercenet) at 4oC to remove any detergents 
or glutathione. Following recovery of the eluates from the cassettes, the protein 
concentration was determined by a Bradford assay.  
 
 
2.2.6 Protein Concentration Assay 
Bradford assays were carried out to determine the total protein concentration in 
all lysate samples. BSA was used to make standards, i.e. protein samples of 
known concentration. A titre of BSA concentrations was used; 0-5ug in dH2O up 
to 50ul. The unknown lysate samples were assayed in triplicate at 1/50 dilutions. 
The Bradford assay is a colourimetric assay whereby addition of Coomassie 
Brilliant Blue Dye (Bio-Rad) is added to the samples and changes from brown/red 
to blue upon binding to protein (Bradford 1976). Here the absorbance spectra of 
the dye shift from 490 to 590, and absorbance at A590 is measured for each 
standard and unknown sample. A standard curve is generated from the 
absorbance values of the BSA standards, and from this the unknown total protein 
concentrations are determined.  
 
 
2.3 Protein Analysis 
2.3.1 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gel electrophoresis was 
carried out to separate proteins according to their molecular weight. Briefly, 
equal concentration of protein samples were denatured and reduced in 5x SDS-
PAGE sample buffer (10% SDS, 300 mM Tris-Cl; pH 6.8, 0.05% bromophenol blue, 
50% glycerol, 10% β-mercaptoethanol) followed by boiling for 2 min. Protein 
samples were then resolved on precast polyacrylamide gels (4-12% NuPAGE 
Novex Bis-Tris gel, Invitrogen) immersed in MOPS SDS running buffer (50mM 
MOPS, 50mM Tris, 0.1% SDS, 1mM EDTA pH 7.7) (NuPage, Invitrogen). Pre-stained 
protein marker (Bio-Rad) was loaded to the first well of the gel while the protein 
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samples were loaded to the subsequent wells. The gel was then run for 1 h 40 
min at 200 V. 
 
For IP samples, ~20ul 2x SDS-PAGE sample buffer was added to the washed 
beads. The beads were boiled for 5 min, followed by brief centrifugation. The 
supernatant was then loaded onto the gel. 
 
 
2.3.2 Coomassie staining  
For direct protein visualisation, gels were removed from the pre-cast gel 
cassette and stained with Coomassie blue (1.25 g Coomassie Brilliant Blue, 44% 
methanol [v/v], 6 % acetic acid [v/v]) and incubated for 20 min at room 
temperature with gentle agitation. Residual Coomassie background stain was 
then removed using destain solution (10% methanol [v/v], 10% acetic acid [v/v]) 
and incubated for 5-6 h at room temperature with gentle agitation to give 
clearly visible bands. The gel was washed in sterile water and the molecular 
weight of proteins was estimated by referring to the protein marker. 
 
 
2.3.3 Western Immunoblotting 
For Western blotting, resolved proteins were electrotransferred onto 
nitrocellulose membranes (0.45 μm pore, Protran, Whatman GmbH) using X-Cell 
II blotting module (Invitrogen) in transfer buffer (NuPage) containing 20% 
methanol for 2 h at 30V. Successful transfer was indicated by full transfer of the 
pre-stained molecular weight markers onto the nitrocellulose membrane. The 
membrane was then blocked in 5% (w/v) non-fat dry milk (Marvel) or 
PhosphoBLOCKER blocking reagent (Cell Biolabs, Inc.) in TBST (20 mM Tris-Cl; pH 
7.6, 150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature with gentle 
agitation. Membranes were then probed with specific primary antibodies (Table 
2.1) diluted in 1% milk/TBST solution and incubated overnight at 4oC. The 
membranes were washed thrice for 10 min each in TBST before adding 
appropriate horseradish peroxidise (HRP)-conjugated anti-immunoglobulin G 
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(IgG) secondary antibodies diluted 1:5000, or Alexa Fluor fluorescent secondary 
antibodies diluted 1:10,000, in 1% milk/TBST solution. After secondary antibody 
incubation, membranes were washed and detected by enhance 
chemiluminescence (ECL) Western Blotting Substrate (Thermo Scientific) and 
autoradiography. Chemiluminescent images of immunodetected bands were 
recorded on blue-light sensitive autoradiography X-ray films (Kodak BioMax MS, 
Carestream Health, Inc.) which were then developed using the Kodak® X-Omat 
Model 2000 processor. Immunoblot intensities were quantitatively analysed using 
Quantity One software (Bio-Rad) and averaged from at least three independent 
experiments. Alternatively, blots were scanned using the Odyssey Infrared 
Imaging System (LI-COR Biosciences, UK) for fluorescence detection of the 
secondary antibodies. Fluorescence signal intensity was quantified using the 
Odyssey application software (LI-COR Biosciences, UK). 
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Antibody Supplier Catalogue # Host Dilution 
PDE4D7 In house-
Altabioscience 
n/a Sheep 1/1000 
PDE4D7 In house-Millipore n/a Rabbit 1/1000 
panPDE4D In house-Millipore n/a Sheep 1/5000 
RXXpS (PKA substrate 
antibody) 
Cell Signaling 9621 Rabbit 1/1000 
pSer42 In house-AMSBIO n/a Rabbit 1/1000 
VSV Sigma V5507 Mouse 1/5000 
FLAG Sigma F7425 Mouse 1/5000 
ERRFI1 Cell Signaling 2440 Rabbit 1/1000 
ENKURIN Novus Biologicals   
 
H00219670-
B01P 
Mouse 1/1000 
NUAK1 Cell Signaling 4458 Rabbit 1/1000  
CXCL5 Sigma  SAB1401356 Mouse 1/1000 
MAP3K9 Cell Signaling 5029 Rabbit 1/1000 
IRAK4 Cell Signaling 4363 Rabbit 1/1000 
CSNK1ε Sigma SAB2500278 Goat 1/1000 
PPP3CB Abcam Ab96573 Rabbit 1/1000 
NONO Millipore  05-950 Mouse 1/5000 
NIKRAS2 Sigma WH0028511M2 Mouse 1/1000 
SNAPIN Sigma  SAB1407227 Mouse 1/1000 
ATF3 Millipore DR1086 Mouse 1/1000 
BCAR3 Sigma WH0008412M1 Mouse 1/1000 
NLK Abcam AB97642  Rabbit 1/1000 
RXRβ Abcam AB2815 Mouse 1/1000 
CT45A3 Abcam AB111360 
 
Rabbit 1/1000 
GTF3A Abnova H00002971-A01 Mouse 1/1000 
panPDE4A In house-Millipore n/a Sheep 1/5000 
GLYR1 Abcam AB69277 Mouse 1/1000 
ZNF302 Abcam AB67794 Mouse 1/1000 
MCRS1 Abcam AB67393 Mouse 1/1000 
NLK Abcam AB97642 Rabbit 1/1000 
HSPA8 Abnova MAB6636 Mouse 1/5000 
DHX9 Abcam AB26271  Rabbit 1/1000 
GAPDH Millipore MAB374 Mouse  1/10k 
V5 Sigma V8137 Rabbit 1/2000 
 
Table 2.2. List of primary antibodies used.   
 
For ECL and film detection, the secondary HRP-conjugated mouse (Amersham), 
rabbit (Sigma) and goat (Thermo) antibodies were used. For detection using the 
Odyssey Infrared Imaging System (LI-COR Biosciences, UK) Alexa Fluor antibodies 
were employed.  
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2.4 Mammalian Cell Culture  
2.4.1 Culture of Human Cell Lines 
All cell culture procedures were performed in class II hoods using aseptic 
technique with sterile plastics and instruments. Media and all other culture 
reagents were purchased from Sigma. All plastics were purchased from Corning. 
The health of the cells and cell density were regularly observed using a phase 
contrast inverted microscope (Leitz Diavert, Germany). 
 
Cells were maintained at 37°C with 5% CO2 and 95% air. All cell lines were 
except DuCaps were purchased from the ATCC, the DuCaP cell line was a gift 
from the PCMM group at Philips, Eindhoven.  
 
All cell lines were cultured in DMEM medium supplemented with 10% foetal 
bovine serum (FBS) and 100  units/ml penicillin and streptomycin and 2mM 
glutamine. VCaP and DuCaP cells were sub-cultured at 90% confluence and re-
seeded at around 50% confluence. DU145, PC3 and Hek293 cells were sub-
cultured at ~80% confluence and re-seeded at 10-30% confluence. 
 
 
2.4.1.1 Sub-culture of cells 
To passage cells, all growth medium was removed and a few ml (depending on 
size of culture vessel) of 1% trypsin-EDTA was added to the culture vessel. The 
cells were returned to the 37°C incubator for approx. 5 minutes. Cells were then 
recovered in fresh growth medium and added to new culture vessel(s).  
 
 
2.4.1.2 Cell counting 
All cell counting was performed using a haemocytometer.  
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2.4.1.3 Cryo-storage of cells 
For storage, cells were detached with trypsin as described above, recovered in 
fresh complete medium and pelleted by centrifugation before being re-
suspended in medium containing 10% DMSO and stored at -80°C.   
 
 
2.4.2 Transfection of Cell Lines. 
HEK-293 cells were transfected with Polyfect reagent (Qiagen) according to the 
manufacturer’s protocol. 
 
VCaP cells were transfected with both DNA and siRNA using Lipofectamine 2000 
(Life Technologies). At approx. 90% confluence the growth medium was removed 
and replaced with Opti-MEM (Invitrogen) 2-4 hours prior to transfection. This 
strips away any serum and antibiotics which may interfere with the transfection. 
The complex formation was carried out according to the manufacturer’s 
instructions. Once added, the cells were kept in Opti-MEM for another 4 hours. 
After this time the Opti-MEM was removed and normal growth medium was 
added.  
 
DU145 and PC3 cells were transfected with the Amaxa Nucleofection Kit L and V 
respectively (Lonza); according to the manufacturer’s instructions. Briefly, 1x106 
cells were counted and centrifuged at 10,000xg for 3 minutes. All medium was 
removed and the cells were re-suspended in 100ul of Nucleofection solution plus 
DNA. This cell suspension was placed in a cuvette and electroporated in the 
Amaxa machine on the appropriate setting. Cells were then recovered in 500ul 
of complete medium, and the cell suspension was placed in a new culture vessel 
containing more complete medium.  
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2.4.3 siRNA Mediated Gene Knockdown in VCaP Cells 
To achieve selective knockdown of the PDE4D subfamily or PDE4D7 specifically, 
double stranded RNA duplexes were designed to target regions of sequences 
unique to all PDE4D isoforms or the PDE4D7 N-terminus respectively. All 
oligonucleotide sequences were screened against the human expressed sequence 
tag (EST) library data base to ensure specificity of the siRNA. The duplexes were 
custom made by Thermo. siGENOME Non-Targeting siRNA#2 (Thermo) was used 
as a negative control.  
 
PDE4D7 siRNA: 
Sense strand:         5’ AUACCUGUGAUUUGCUUUC 3’  
Antisense strand:  5’ GAAAGCAAAUCACAGGUAU 3’  
 
panPDE4D siRNA: 
 
Sense strand:         5’ AAGAACUUGCCUUGAUGUACA 3’ 
Antisense strand:  5’ UGUACAUCAAGGCAAGUUCUU 3’ 
 
The cells were transfected with the siRNA using Lipofectamine 2000 (Life 
Technologies), according to the manufacturer’s instructions.  
 
 
2.4.3.1 Treatment of Cells 
2.4.3.1.1  5-aza-2’-deoxycytidine treatment of PC3 cells 
Cells were seeded in 10cm cell culture dishes in complete medium. 10nM 5-aza-
2’-deoxycytidine (5-aza-2-dC) was added in three pulses post seeding; at 24h, 
48h and 72h, in fresh complete medium. DMSO was added to the control cells. 
On day 4 cells were harvested as described below. 
2.4.3.1.2 Forskolin and KT5720 treatment of cells 
Cells were seeded in 10cm cell culture dishes or 6 well plates. Treatment was 
carried out 1 week post-seeding of VCaP and DuCaP cells, to allow for expression 
of endogenous PDE4D7. Cells were pre-treated with 4uM KT5720 (Enzo Life 
Sciences) for 20min prior to 100mM forskolin or DMSO treatment.  
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2.4.3.2 Protein Lysate Harvesting 
For IP and co-IP assays and western blot analysis, cells were harvested in 3T3-
lysis buffer (25mM HEPES, 10% w/v glycerol, 50mM NaCl, 1% w/v Triton x100, 
50mM NaF, 30mM NaPP, 5mM EDTA, pH7.4) containing Complete, EDTA-free 
Protease Inhibitor Cocktail Tablets (Roche). For phosphorylation studies, 
PhosStop Phosphatase Inhibitor Cocktail Tablets (Roche) were also added. For 
PDE assays, cells were harvested in KHEM buffer (50mM KCl, 50mM HEPES, 10mM 
EGTA, 1.92mM MgCl2, pH7.4), vortexed (due to lack of detergent) and snap 
frozen. Harvested lysate was centrifuged at 2000xg for 10 minutes to remove 
any insoluble material. The supernatant was transferred to a new Eppendorf 
tube and either used straight away or frozen at -80°C until required.  
 
 
2.4.4 xCelligence Measurement of Cell Proliferation and Migration 
The xCelligence system allows real time measurement of cell proliferation or 
migration on the bases that as cells grow over, or migrate through an electrode, 
they change the resistance of the current flowing through the metal. These 
changes in electrical impedance are recorded by the xCelligence machine (Acea) 
and interpreted by the proprietary software RTCA system (Acea). Changes in 
electrical impedance are represented by changes in cell index (CI); a 
dimensionless unit of measurement where CI=zero when cells are absent, and 
increases as cells proliferate or migrate (figure 2.2). 
 
The xCelligence system comprises a gold electrode-plated culture vessel and a 
docking unit for this vessel within a 37°C incubator (5% CO2, 95% air), which is 
connected to the impedance measurement unit outside the incubator. This is 
connected to a laptop PC on which proprietary RTCA software is run. This 
software collects the cell index data and generates growth or migration curves 
for the cells in the docked vessel. For proliferation assays the vessel used is an 
Eplate, while for migration assays a CIM plate is employed (figure 2.2). 
 
 
 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     138 
 
 
 
 
 
 
 
Figure 2.2. The xCelligence system for real time cell proliferation and migration 
measurement.  
Changes in electrical impedance are represented as changes in CI values, 
corresponding to increasing number of cells on the Eplate surface, or migrating 
through the electrode membrane of top chamber of the CIM plate. Z=electrical 
impedance.  
 
 
2.4.4.1 Cell proliferation assays 
A cell number titration for each of the cell lines used was initially carried out to 
find the optimum number of cells required to produce a good growth curve, 
dependant on adherence properties and doubling times. 30,000 VCaP cells, 
10,000 DU145 cells and 10,000 PC-3 cells were used in all experiments. This 
discrepancy is due to the vastly different adherence properties between the two 
cell lines as well as the significantly longer doubling time of the VCaP cell line. 
The volume of cell suspension required for 30,000 or 10,000 cells was subtracted 
from 200μl. The resulting figure was the volume of medium alone that was then 
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added to each well in the Eplate. With this medium the plate was inserted into 
the docking station and ‘blanked’, i.e. the impedance reading for medium alone 
was recorded. Following this, the cells were added to each well, to give a total 
of 200μl/well. The Eplate was returned to the docking station and the electrical 
impedance was measured every 10 minutes for ~4 hours and then every 15 
minutes for 4-5 days.  
 
siRNA transfection of VCaP cells was carried out the following day. 
 
DNA transfection of DU145 and PC3 cells was carried out prior to seeding of the 
cells.  
 
 
2.4.4.2 Cell Migration Assays 
A cell number titration was initially carried out, and 40,000 DU145 cells was 
found to be optimum for the migration curve. The CIM plate contains two 
compartments (figure 2.2). 165μl complete medium was added to the wells in 
the lower compartment; the serum acted as the chemoattractant. (Serum-free 
medium was added to 2-3 wells; these served as migration control wells). The 
volume of cell suspension required for 40,000 cells was subtracted from 200μl. 
The resulting figure was the volume of complete medium alone that was then 
added to all the wells in the top compartment. The CIM plate was then inserted 
into the docking station and ‘blanked’, i.e. the impedance reading for medium 
alone was recorded.  Cells were transfected as described above and 40,000 were 
added to each well in the top compartment, giving a total volume of 200ul.   The 
CIM plate was returned to the docking station and the electrical impedance was 
measured every 10 minutes for ~18 hours, prior to any proliferative events.  
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2.5 PLA Probe Staining and Confocal Microscopy 
The Duolink Proximity Ligation Assay (PLA) (Olink Bioscience) is designed 
primarily to look at co-localisation of interacting proteins in situ, when two 
different antibodies are used. In this case, the assay was used to detect PDE4D7 
alone, on the premise that signal amplification would allow detection of 
endogenous protein. Cells were seeded in multichamber slides (Nunc Lab-Tek II 
Chamber Slide System-Thermo). Cells were firstly rinsed in TBS and then fixed in 
4% paraformaldehyde at RT for 10min. Cells were then washed twice with TBS 
and permeabilised with 0.1% Triton-X100 in TBS at RT for 15 min. Blocking was 
then carried out using the Duolink blocking solution for 30 minutes. Following 
this cells were incubated with two primary antibodies at a dilution of 1:500 for 1 
hour 45 minutes-2 hours. The antibodies were from two different host animals.  
After this incubation, cells were washed with Duolink wash buffer A (0.01 M Tris, 
0.15 M NaCl and 0.05% Tween 20, pH 7.4). Cells were then incubated for 1 hour 
with PLA probes, which, like secondary antibodies, recognise the primary 
antibodies, but are conjugated to oligonucleotides. Following washing, a solution 
is added for 30 minutes to bring about hybridisation of the PLA probes. Again 
samples are washed, and a ligation reaction is carried out for 1 hour 40 minutes 
which brings about a rolling circle amplification (RCA) reaction. This amplifies 
the signal of the detected protein. All incubations were carried out in a humidity 
chamber, which was fabricated by placing a beaker of water into a 37oC 
incubator. Finally, the slides were mounted with coverslips using Duolink 
mounting medium and observed using a Zeiss Pascal laser-scanning confocal 
microscope (LSM) 510 Meta and an Axiovert 100 microscope (Carl Zeiss, UK) 
equipped with an oil immersion objective (63x/1.4 NA plan apochromat lens). 
Images were captured and processed on Zeiss LSM Image Examiner and analysed 
using the NIH Image J software (ImageJ, http://rsb.info.nih.gov/ij/).  The 
detected protein showed up as discrete red spots.  
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2.6 Statistical Analysis 
Statistical significances between groups were determined by the use of 
Student’s t-test or ANOVA, as indicated. Values were considered significant if p 
< 0.05. Where representative immunoblots or microscopy images were shown, 
similar data were obtained ≥ 3 times. Microsoft Excel was used to calculate the 
student’s t-test; Graphpad Prism (Graphpad software) was used for the ANOVA 
test.  
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3 PDE4D7 Signalling is Altered as Prostate Cancer 
Progresses 
3.1 Introduction 
 
The role of cAMP in PC progression has been well studied, as first noted by the 
differential expression of adenylyl cyclases in normal and tumour prostate tissue 
(Shima, Kawashima et al. 1976). Since then, a plethora of studies suggest that 
alterations in cAMP signalling cascades have an active role in PC progression. 
Increased expression of GPCRs (Nelson, Bagnato et al. 2003; Weng, Wang et al. 
2005) and promiscuous Gs signalling (Kasbohm, Guo et al. 2005) can lead to AR 
signalling in the absence of androgen, thereby driving the progression to AI PC. 
PKA isotype switching also promotes the AI phenotype (Kvissel, Ramberg et al. 
2007; Merkle and Hoffmann 2011). As discussed, cross talk of cAMP effector 
proteins with the AR is also an important factor in androgen-independent AR 
signalling and PC progression. However, given the importance of cAMP in this 
process, little is known on the role of cAMP PDEs in PC. 
 
As cAMP is a ubiquitous second messenger, specificity of action within the cAMP 
signalling system is maintained by compartmentalisation of proteins that act to 
produce, are affected by and degrade the cyclic nucleotide. As a consequence, 
the roles of individual PDEs are often directed by their differential tissue and 
cell expression. Uckert et al. determined the PDE profile in a zone-specific 
manner in the normal prostate, and found high PDE4 activity (Uckert, Kuthe et 
al. 2001). They later found PDE4 protein to be highly expressed in glandular and 
stromal cells, suggesting a role for this enzyme in proliferation (Uckert, Oelke et 
al. 2006; Waldkirch, Uckert et al. 2010). PDE4 has also been suggested to be 
involved in PC progression, although with varying observations (Rahrmann, 
Collier et al. 2009; Sarwar, Sandberg et al. 2013).  
 
Due to the high level of PDE4 expression noted by Uckert and colleagues and the 
suggested implication of PDE4 in PC, our group set out to determine the PDE4 
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expression profile in PC samples, with the aim of identifying a potential PDE PC-
specific biomarker (Byrne, Henderson et al. 2014). 
 
This aims of this chapter are to discuss firstly the earlier findings by our group on 
the changing PDE mRNA expression profile as PC progresses and to expand on 
these findings by investigating the levels of PDE4D7 protein within AS and AI cell 
lines. Secondly, to investigate the effect of PDE4D7-mediated cAMP hydrolysis on 
PC cell proliferation and migration. Thirdly, I present a hypothesis on why 
PDE4D7 expression changes as PC moves towards androgen insensitivity.  
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3.2 Results  
3.2.1 Phosphodiesterase 4D7 is downregulated as prostate 
cancer becomes androgen-insensitive  
3.2.1.1 PDE4 mRNA expression profiling  
 
PDE4 isoforms are differentially expressed in a tissue and cell-specific manner 
(Houslay 2010). To establish which, if any, PDE4 isoforms are associated with PC, 
our group carried out a PDE expression profile screen on 19 prostate cancer 
xenografts and cell lines representing both AS and AI cancer by means of qPCR 
(Henderson, Byrne, in review). The xenografts and cell lines used are shown in 
table 3.1. PDE4A, PDE4B and PDE4D enzymes were detected.  PDE4D was the 
most highly expressed subfamily and interestingly, showed a downregulation 
between the AS and AI samples. PDE4D7 was observed to be the most abundantly 
expressed isoform in the AS samples, and to show the most profound 
downregulation in all AI samples. We observed a 40-fold reduction in PDE4D7 
transcript expression in the AI samples, with no correlation between xenograft 
or cell line (figure 3.1). The samples used were derived from both primary and 
metastatic tumours, and the differential PDE4D7 expression was observed 
between all AS and AI samples, with no correlation to tumour origin.   
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Sample 
Description 
Cell 
Line 
Xenograft Origin Androgen 
Sensitivity 
AR Expression PSA Expression AR Sequence TMPRSS2: 
ERG Fusion 
VCaP X  Vertebra AS YES YES Wt YES 
DuCaP X  Dura Mater AS YES YES Wt YES 
LNCaP X  Lymph Node AS YES YES T877A ETV1 
PC346C x  Primary AS YES YES Wt NO 
PC346P  X Primary AS YES YES Wt NO 
PC346B  X Primary AS YES YES Wt NO 
PC82  X Primary AS YES YES Wt YES 
PC310  X Primary AS YES YES Wt YES 
PC295  X Lymph Node AS YES YES Wt YES 
PC-EW  X Lymph Node AS YES YES Wt YES 
PC346Flu2  X Primary AS YES YES T877A NO 
PC3 X  Bone AI NO NO N/A NO 
DU145 X  Brain AI NO NO N/A NO 
PC324 X  Primary AI NO NO N/A NO 
PC346DCC X  Primary AI Low Low K311R NO 
PC346Flu1 x  Primary AI YES YES Wt NO 
PC135  X Primary AI NO NO N/A NO 
PC374  X Skin AI NO NO N/A ETV1 
PC133  X Bone AI NO NO N/A ETV4 
 
 
Table 3.1. The 19 xenograft and cell line samples used in the PDE profiling of PC. 
The PC samples used represented both AS and AI carcinoma, and both primary and metastatic disease. The presence of AR and 
PSA, and the TEMPRSS2:ERG gene fusion are indicated. 
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Figure 3.1. Differential Expression of PDE4D isoforms in AS and AI PC.  
PDE4D7 is the most abundant isoform in AS samples, with significant downregulation into AI disease (Byrne, Henderson et al. 
2014).
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This screen provided a model of the changing PDE4D mRNA profile during disease 
progression. With the dramatic change in PDE4D7, we wished to further study 
this enzyme in the context of PC. Firstly, we wished to validate the protein 
levels of PDE4D7 in AS versus AI PC cell lines. As discussed, the transcript level 
of PDEs does not always match that of the protein, due to post-translational 
modifications (Rhodes, Yu et al. 2004; Richter, Jin et al. 2005; Rahrmann, Collier 
et al. 2009). Also, the presence of transcript does not given any indication of the 
presence of a functional enzyme.  
 
The cell lines used in this study to investigate the role of PDE4D7 in PC include; 
the AS VCaP and DuCaP cell lines, and the AI PC3 and DU145 cell lines.  
 
DuCaP and VCaP cells phenotypically represent clinical AS prostate carcinoma. 
They were isolated from metastatic sites in the dura mater and lumbar 
vertebrae, respectively, from patients with castrate resistant prostate cancer 
(CRPC) (as occurs following hormonal therapy, discussed later) post-mortem. 
The samples were xenografted into immune-deficient SCID mice from which 
immortalised cell lines were established. They express AS markers such as the 
AR and PSA (Korenchuk, Lehr et al. 2001; Lee, Korenchuk et al. 2001). 
 
The PC3 and DU145 cell lines are classical cell models of AI PC, and have been 
extensively used to study PC over the last few decades. They are derived from 
bone and brain metastases, respectively, and represent late stage PC with no 
expression of AR or PSA, and are not responsive to androgens (Stone, Mickey et 
al. 1978; Kaighn, Narayan et al. 1979).  
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3.2.2 Validation of PDE4D7 protein expression in AS and AI PC 
cell lines 
3.2.2.1 PLA probes confirm differential PDE4D7 protein expression between 
AS and AI PC 
 
For the most of this project, a specific PDE4D7 antibody that could detect 
endogenous levels of protein was unavailable. PDE4 isoform-specific antibodies 
are often difficult to raise due to the differential immunogenic properties of the 
various unique N-termini (unpublished observations in our laboratory). A specific 
antibody that could detect only overexpressed PDE4D7 was available, but was of 
no use for western blot analysis of endogenous protein. In order to study the 
level of endogenous PDE4D7, the Duolink PLA system (Olink) was employed 
(figure 3.2). The principle behind the Duolink system is that of a co-IP, in which 
antibodies against two proteins believed to interact are used for probing. These 
antibodies must be raised in different host animals. Following incubation with 
these primary antibodies, secondary antibodies conjugated to oligonucleotides 
(PLA probes) are added to the reaction. One probe must be minus, one plus; 
e.g., goat plus and rabbit minus. A ligation step is then performed using more 
oligonucleotides and ligase. The ligase catalyses binding of these 
oligonucleotides with the PLA probes which then join to form a closed circle if 
the proteins are in close enough proximity (<30-40nm), i.e. if they are 
interacting. Lastly an amplification reaction is carried out where more 
nucleotides and fluorescently labelled oligonucleotides are added to the 
reaction. The oligonucleotide arm of one PLA probe acts as a primer for a 
rolling-circle amplification (RCA) reaction using the ligated circle as template, 
thereby generating a concatemeric product. The fluorescently labelled 
oligonucleotides will hybridise to the RCA product which creates a signal that is 
detected by fluorescent microscopy. The signal is seen as distinct red spots and 
each spot represents one molecular interaction, but not all molecules are 
detected. It is essentially like PCR within the cell. Here, the PLA probes were 
used to detect PDE4D7, rather than an interacting pair. A panPDE4D antibody, 
which detects all PDE4D isoforms, was used with the aforementioned PDE4D7 
antibody that detects only overexpressed levels of protein in the hope that both 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     149 
 
would bind PDE4D7 and signal amplification would allow detection of 
endogenous protein in the VCaP cell line. 
 
 
 
 
 
 
 
 
Figure 3.2. Schematic representing the in situ PLA probe mechanism. 
 A; cells are incubated with specific primary antibodies from different hosts. The 
pair of PLA probes (plus and minus) which have oligonucleotides attached are 
added and they bind the respective antibody. B; ligase catalyses the binding of 
the PLA oligonucleotides to additional oligos and a circle is formed. C; additional 
fluorescently labelled oligonucleotides are added, and the oligonucleotides arm 
of one PLA probe acts as a primer for a rolling-circle amplification (RCA) 
reaction using the ligated circle as template, thereby generating a concatemeric 
product. D; the fluorescently labelled oligonucleotides hybridise to the RCA 
product which creates a signal that is detected by confocal fluorescent 
microscopy. 
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Employing confocal microscopy, spots were indeed detected in VCaP cells (figure 
3.3), which became abundant following overexpression of wtPDE4D7 (figure 3.3 
A&B), or a dominant-negative construct (figure 3.3 C), which displaces 
endogenous PDE4D7 protein (dnPDE4D7). Gratifyingly, control experiments gave 
no positive results as no spots were detected in VCaP cells when PDE4D7 and 
panPDE4B antibodies were used in combination (figure 3.3 F), nor with co-
detection of PDE4B2 and panPDE4D (figure 3.3 G). No spots were detected in the 
AI PC3 (figure 3.3 H) and DU145 cells (figure 3.3 I), confirming specific 
downregulation of the PDE4D7 enzyme into AI PC.   
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Figure 3.3. PLA probes verify PDE4D7 is differentially expressed in AS and AI PC cells at the 
protein level.  
PLA signal (red) is only visible where PDE4D7 is expressed. DAPI staining (blue) 
was used to mark nuclei. A&B; VCaP cells were probed with panPDE4D antibody 
and PDE4D7 antibody. C; VCaP cells overexpressing PDE4D7 were probed with 
panPDE4D antibody and PDE4D7 antibody. D; VCAP cells transfected with 
dnPDE4D7 were probed with panPDE4D antibody and PDE4D7 antibody. E; 
secondary antibody only, F; VCaP cells were probed with panPDE4B antibody and 
PDE4D7 antibody. G; VCaP cells were probed with panPDE4D antibody and 
PDE4B2 antibody. H; PC3 cells were probed with panPDE4D antibody and PDE4D7 
antibody. I; DU145 cells were probed with panPDE4D antibody and PDE4D7 
antibody. Images shown are representative of three separate experiments on 
different cell preparations.  
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3.2.2.2 Generation and Characterisation of a Novel PDE4D7-Specific 
Antibody: Confirmation of Differential PDE4D7 Protein Expression 
between AS and AI PC 
 
Due to the fact that the PDE4D7 antibody described above could only be used to 
detect over-expressed PDE4D7 or used in PLA studies, I decided to raise a new 
PDE4D7-specific antibody with the hope that it could be used to confirm our 
novel findings regarding PDE4D7 protein levels in the different stages of PC. To 
this end, specific anti-sera were generated against the complete PDE4D7 unique 
N-terminal region. This proved quite difficult due to the short N-terminus of this 
isoform, and in light of the fact that previous attempts using unique PDE4D7 N-
terminal peptides as antigens had failed. However, using a GST-fusion of the 
whole N-terminal region as an antigen proved successful due to the increased 
immunogenic nature of the fusion protein. The serum from the final bleed of the 
inoculated sheep was purified by affinity chromatography and the purified 
antibody was validated for specificity by means of peptide array technology and 
western blot analysis.  
 
Peptide array technology entails the production of immobilised peptide libraries 
of a full-length protein of interest. The protein is spotted onto the array in 
overlapping 25mer peptides which are conjugated to a nitrocellulose membrane 
using an amino-bond. Each peptide overlaps the next by 20 amino acids, so each 
is shifted along by 5 amino acids, until the full length protein is spotted. At any 
one time a batch of arrays is made. The peptide arrays can then be used to map 
residues of protein-protein interactions, by incubating with a purified protein of 
interest, or indeed to detect the epitope to which an antibody binds and 
validate its specificity. A PDE4D7 array was Coomassie blue stained to ensure all 
residues were indeed spotted (figure 3.4 A). Another PDE4D7 array from the 
same batch was probed with the novel antibody and signal was detected by 
chemiluminescence. Dark spots represent areas of cross-reactivity within the 
unique N-terminus (figure 3.4 B). As expected, the novel PDE4D7 antibody only 
recognised peptides within the unique N-terminal region, demonstrating the 
specificity of interaction. The PDE4D7 antibody was also tested for specificity 
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using protein standards of other long forms PDE4Ds, all of which migrate on SDS 
PAGE at ~100kDa (figure 3.4 C).  Again, only PDE4D7 was recognised. 
 
 
 
 
 
 
 
Figure 3.4. Peptide array technology verifies a novel PDE4D7 antibody.  
A; a full length PDE4D7 peptide array stained with Coomassie Brilliant Blue. The 
4D7 sequence is shown beside the array, with the unique N-terminal region 
highlighted in red. B; a full length PDE4D7 peptide array was probed with the 
novel PDE4D7 antibody. Control arrays with no primary antibody and pre-immune 
serum were also used, on which no spots were detected. C; PDE4D7, PDE4D5 and 
PDE4D3 protein standards were blotted with the novel PDE4D7 antibody. N=3. 
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Following the successful raising and characterisation of a highly-specific PDE4D7 
specific antibody, the protein expression of the isozyme could be verified in PC 
cell lines by means of western blot and immunoprecipitation (IP).  Using this 
novel antibody, it was again determined that PDE4D7 protein expression is 
downregulated as the cancer becomes androgen independent (figure 3.5 A), as 
PDE4D7 could only be detected in DuCaP and VCaP cell lines but not PC3 and 
DU145s. This result was confirmed using IP analysis, where endogenous PDE4D7 
was pulled down with the new antibody and detected with the pan-PDE4D 
antibody (figure 3.5 B). Overall, the protein expression studies carried out with 
the new antibody verified the PLA work (figure 3.3) and supported the findings 
from the PCR study (figure 3.1). 
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Figure 3.5. A novel PDE4D7-specific antibody validates PDE4D7 downregulation in AI PC 
cell lines.  
A; whole cell lysates of AS (DuCaP and VCaP) and AI (PC3 and DU145) PC cell 
lines were subjected to SDS-PAGE and western blot analysis, followed by probing 
with the novel PDE4D7-specific antibody. The predicted weight of PDE4D7 on SDS 
PAGE is ~100kDa, at which a band is detected in DuCaP and VCaP cells only. N=3. 
B; immunoprecipitation (IP) was carried out in AS (DuCaP and VCaP) and AI (PC3 
and DU145) cell lines using the novel PDE4D7 antibody. The western blot was 
probed with panPDE4D. Normal sheep IgG served as a negative control. Input is 
the whole cell lysate from which the IP was carried out. N=3. 
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3.2.3 PDE4D7 Mediates Prostate Cancer Cell Proliferation  
Immunocytochemistry and FRET analyses have shown that the majority of 
PDE4D7 localises to the sub-plasma membrane region where it plays a major role 
in regulating cAMP levels (Byrne, Henderson et al. 2014). Taken together with 
the qPCR screen data, these results suggest that PDE4D7 is the main cAMP 
hydrolysing PDE in AS PC cells and acts at the sub-plasma membrane region. 
Following validation of the downregulation of PDE4D7 as PC becomes AI, I wished 
to assign a function to this enzyme and to determine if this event was 
physiologically relevant. Uckert et al. suggested that PDE4 is involved in 
proliferation of normal prostate epithelium (Uckert, Oelke et al. 2006). With this 
in mind, proliferation assays were carried out to study the effect altering 
PDE4D7 levels may have on the phenotype of PC cells.  
 
 
3.2.3.1 xCelligence Measurement of Real Time Cell Proliferation and 
Migration 
 
The xCelligence method (Acea) of measuring cell growth relies on the detection 
of small changes in electrical impedance evoked by cells growing in specially 
modified culture plates. This technique avoids the use of invasive “end-point” 
techniques and labels. Additionally, monitoring can be done in real time, 
allowing kinetic analysis. Cells were seeded into an Eplate (proliferation assay) 
or a CIMplate (migration assay). Eplates are coated on the underside with 
embedded gold electrodes. CIM plates comprise two compartments, separated 
by a gold electrode-plated membrane. As cells grow over, or move through the 
electrodes, they cause a change in the electrical impedance, which is measured 
by the xCelligence machine and recorded as changes in cell index (CI). This is a 
dimensionless unit of measurement representing the measurement of zero 
impedance when cells are absent, and increasing impedance when cells begin 
adhering to the plate and proliferate, or move through the electrodes as they 
migrate. The advantage of using this system is that cell growth or migration is 
measured in real time, thus transient effects caused by any treatment can be 
measured, rather than just end-point analysis. 
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Firstly, a dominant-negative PDE4D7 approach was employed to investigate how 
displacement of endogenous PDE4D7 and accumulation of cAMP at the plasma 
membrane would affect AS cell proliferation. Our group was the first to use a 
novel dominant-negative approach to study the unique intracellular roles of 
sequestered PDEs (McCahill, McSorley et al. 2005). Dominant-negative (dn) 
constructs contain a single nucleotide substitution within the active site cAMP 
binding pocket, so as to render the enzyme catalytically inactive but without 
affecting its tertiary or quaternary structure. The dn construct is overexpressed 
in cells of interest, such that it causes displacement of the cognate endogenous 
wild-type (wt) protein from its functionally relevant intracellular location. This 
inhibits hydrolysis of cyclic nucleotide at this region, and renders any nearby 
PKA hyper-sensitive to activation. These constructs do not affect global cAMP 
gradients or total cellular PDE activity. The mutation in PDE4D7 that renders it 
catalytically inactive is D559A.  Transfection of both dn- and wt- PDE4D7 
constructs resulted in a measurable over-expression of both proteins compared 
with mock (empty vector) transfected cells (figure 3.6 C). Resulting 
displacement of PDE4D7 in VCaP cells following dnPDE4D7, over-expression led 
to a significant increase in the growth rate of the cells compared to control 
(p=0.02, students t-test), as determined by the slope of the log phase of the 
growth curve (figure 3.6 A,B). This increase was in contrast to a corresponding 
decrease caused by overexpression of wtPDE4D7. These results strongly 
implicate PDE4D7 in PC cells as having a role in growth control. 
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Figure 3.6. Dominant-negative displacement of PDE4D7 increases the proliferation of AS 
VCaP cells.  
A; the electrical impedance-based xCELLigence system was used to measure the 
proliferation of VCaP cells transfected with wild type (wt) PDE4D7 or the 
dominant negative, catalytically inactive mutant (dn) or a control construct 
(mock), as shown by a growth curve. B; the slope of the growth curve was 
calulcated by linear regression analysis using the cell indices (CI) from each 
proliferation assay. C; wt- and dn-PDE4D7 constructs were expressed at equal 
levels as assessed by western blot anlaysis using a PDE4D7 antibody. GAPDH was 
used as a protein loading control. N=6.  
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As displacement of PDE4D7 increased AS proliferation, I set out to see if 
knockdown of PDE4D7 by means of siRNA would also cause such an increase. 
siRNA takes advantage of the host cell’s immune response to double stranded 
RNA, such as when under viral attack. Once inside the cell, the siRNA forms a 
complex with the RNAi-induced silencing complex (RISC) which directs the siRNA 
to the target mRNA. The siRNA then brings about degradation of the target 
mRNA sequence by means of endo and exo-nucleases.  
 
siRNA targeted against the N-terminus of PDE4D7 (siPDE4D7) was compared to 
siRNA targeted to the common C-terminal region of all PDE4D isoforms 
(siPDE4D), along with a scrambled non-targeting control siRNA (siControl). As 
expected, both siPDE4D7 and siPDE4D evoked reductions of the protein levels of 
PDE4D (figure 3.7 C, D). It should be noted that a number of different PDE4D 
isoforms exhibit similar molecular weights and the increased silencing of the 
siPDE4D vs siPDE4D7 was expected. Knockdown of PDE4D7 led to a marked 
increase in VCaP proliferation (p=0.06, students t-test) compared to global 
PDE4D knockdown (figure 3.7 A, B), further indicating a specific role for this 
enzyme in cAMP regulation in PC.  
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Figure 3.7. siRNA mediated knockdown of PDE4D7 specifically increases the proliferation of 
AS VCaP cells.  
A; the electrical impedance-based xCELLigence system was used to measure the 
proliferation of VCaP cells transfected with siRNA targted againstst PDE4D7 
(si4D7) or total PDE4D (Pan4D) or a non-targeting control (siControl), as shown 
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by a growth curve. B; the slope of the growth curve was calulcated by linear 
regression analysis using the cell indices (CI) from each proliferation assay. C; 
expression of PDE4D7 and total PDE4D as a percentage of scrambled control, as 
calculated from western blot analyses of protein knockdown (D), which shows 
that siRNA knockdown decreased the abundance of endogenous PDE4D and 
PDE4D7 expression. N=5. 
 
 
 
With the observed increase in proliferation of AS cells when PDE4D7 is displaced 
or downregulated and the corresponding decrease when it is over-expressed, the 
logical next-step was to investigate whether ‘re-expression’ of the enzyme into 
PDE4D7-deficient AI cells would retard cell proliferation. Indeed, over-
expression of wtPDE4D7 (figure 3.8 C) led to a significant decrease in the 
proliferation of DU145 (p=0.002 students t-test) (figure 3.8 A and B), and PC3 
cells (p=0.00003, students t-test) (figure 3.9, A and B), suggesting that PDE4D7-
mediated cAMP hydrolysis causes a reduction in proliferative signalling events in 
PC cells.  
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Figure 3.8.  PDE4D7-mediated cAMP hydrolysis reduces the proliferation rate of DU145 
cells.  
A; the electrical impedance-based xCELLigence system was used to measure the 
proliferation of Du145 cells transfected with wild type (wt) PDE4D7 or a control 
construct (mock), as shown by a growth curve. B; the slope of the growth curve 
was calulcated by linear regression analysis using the cell indices (CI) from each 
proliferation assay. C; western blot analysis of transfection. N=3.  
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Figure 3.9. PDE4D7-mediated cAMP hydrolysis reduces the proliferation rate of PC3 cells.  
A; the electrical impedance-based xCELLigence system was used to measure the 
proliferation of PC3 cells transfected with wild type (wt) PDE4D7 or a control 
construct (mock), as shown by a growth curve. B; the slope of the growth curve 
was calulcated by linear regression analysis using the cell indices (CI) from each 
proliferation assay. C; western blot analysis of transfection. N=3.  
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3.2.4 PDE4D7 may Mediate Prostate Cancer Cell Migration.  
 
The role of cAMP in cancer cell migration is controversial, but it has long been 
known that PKA is involved in cell migration (Howe, Baldor et al. 2005; Howe 
2011). It has been suggested that cAMP can inhibit the migration of invasive 
breast cancer cells via both PKA and EPAC-dependent pathways involving 
downregulation of β3 integrin (Spina, Di Maiolo et al. 2012). It has also been 
suggested that cAMP/PKA signalling can  inhibit the migration of bladder cancer 
cells (Ou, Zheng et al. 2013) and pancreatic cancer cells (Zimmerman, Roy et al. 
2013). However, a lot of evidence suggests cAMP positively regulates cancer cell 
migration, for example in breast cancer (Chioni, Shao et al. 2010), and ovarian 
cancer (McKenzie, Campbell et al. 2011). In these cases, migration was mediated 
via PKA acting in the vicinity of the plasma membrane, and PKA was upregulated 
at the leading cell edge. Plasma membrane voltage-gated sodium channels 
(VGSCs) are often expressed on epithelial-derived cancer cells including breast 
and prostate cancer cells, and expression correlates with more aggressive 
metastatic cell lines (Diss, Archer et al. 2001). Here they do not serve a 
conductance function, but may act as cell adhesion molecules and mediate 
migration to potentiate the metastatic potential of cancer cells (Brackenbury, 
Djamgoz et al. 2008).VGSC activity stimulates PKA, which in turn, increases 
VGSC expression and externalisation (Chioni, Shao et al. 2010). Thus, the spatial 
dynamics of cAMP and the resulting differential activation of effector proteins 
may be an important factor in how the cAMP-signalling pathway regulates cancer 
cell migration. Indeed, the Zimmerman study showed that cell migration was 
retarded by increases in cAMP resulting from inhibition of total PDE3, and 
forskolin-induced increases in global cAMP. This suggests that the effect of cAMP 
increase seen by Zimmerman et al. is not specific, and specific effects may 
depend on local, region-specific increases in cAMP. 
 
Given the evidence that cAMP is involved in cancer cell migration and thus 
metastatic potential, the effect of PDE4D7-mediated cAMP hydrolysis on the 
migration of PC cells was investigated. If a loss of PDE4D7 is associated with an 
increase in proliferation, perhaps it also effects PC cell migration. The VCaP cell 
line which represents AS, non-aggressive cancer shows very low migratory 
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potential compared to the AI highly aggressive DU145 cell line (figure 3.10 A). 
Although these cell lines differ biochemically in many ways, such as AR 
expression, the effect of increasing cAMP hydrolysis at the plasma membrane in 
DU145 cells was investigated. When PDE4D7 was overexpressed (figure 3.10 D), 
DU145 cells showed a significantly lower migration rate (figure 3.10 B, C). Cells 
were assayed for 18 hours, prior to any proliferative events and the cell index is 
proportional to the number of cells that have migrated at a given time.    
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Figure 3.10. Increasing PDE4D7 cAMP hydrolysis reduces the migratory potential of DU145 
cells.  
A; the electrical impedance-based xCELLigence system was used to compare the 
migration rates of AS VCaP cells to AI DU145 cells. B; the system was used to 
measure the migration rate of DU145 cells transfected with wild type (wt) 
PDE4D7 or a control construct (mock), as shown by a migration curve. C; the 
migration of DU145 cells transfected with wt PDE4D7 or mock after 18 hours, as 
represented by cell index (CI).D; western blot analysis of transfection for B and 
C. N=3. 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     167 
 
3.2.5 Loss of PDE4D7 during the transition from AS to AI PC may 
be due to an Altered Epigenome   
 
The evidence presented here suggests that PDE4D7 expression is lost as PC 
progresses, and that this loss may contribute to increased cell proliferation and 
migratory potential due to aberrant cAMP signalling at the plasma membrane. I 
wanted to investigate why PDE4D7 undergoes differential transcriptional 
regulation as PC progresses. 
 
 It is known that a disrupted epigenome is associated with prostate 
carcinogenesis, with altered DNA methylation being the best characterised event 
(Jeronimo, Bastian et al. 2011). Hypomethylation acts to ‘loosen’ chromatin 
leading to increased gene transcription and commonly occurs with proto-
oncogenes, whereas hypermethylation ‘tightens’ the chromatin, repressing gene 
transcription and commonly occurs with tumour suppressor genes. DNA 
methylation is the addition of a methyl(-CH3) group to a cytosine residue 
adjacent to a guanine (CpG) in gene promoter regions (Dobosy, Roberts et al. 
2007). DNA methyltransferases (DMTs) carry out the reaction, using s-adenosyl-L-
methioine (SAM) as the methyl donor (Cheng 1995). DNA methylation occurs in 
stretches of DNA that are rich in CpGs, called CpG islands (Goldberg, Allis et al. 
2007). ~60% of mammalian genes contain CpG islands within their promoter 
regions. A number of PC-specific hypermethylated genes are known, and their 
detection in body fluids is showing promise as disease-specific biomarkers 
(Dobosy, Roberts et al. 2007). It has been found that noncoding RNA (ncRNA) 
found upstream of a promoter region can regulate DNA methylation by 
cooperating with histone-modifying machinery (Goldberg, Allis et al. 2007).  
 
There is little information on the epigenetics of PDEs. It has been shown that the 
PDE4D4 promoter contains a CpG island which becomes hypomethylated due to 
gestational exposure to environmental oestrogens and is associated with PC (Ho, 
Tang et al. 2006), although we observed a decrease in PDE4D4 in AI PC (Byrne, 
Henderson et al., in review). A CpG island is also predicted to be located 150bps 
upstream of the PDE4D7 5’ UTR (Henderson D., thesis 2011) and it overlaps with 
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a ncRNA called prostate androgen-regulated transcript 1 (PART1) (Gretarsdottir, 
Thorleifsson et al. 2003) (figure 3.11). PART1 is an androgen-regulated non-
coding transcript (Lin, White et al. 2000). The presence of the CpG island and 
the ncRNA suggest that PDE4D7 transcription may be regulated by DNA 
methylation, and I hypothesised that hypermethylation of this region is 
responsible for PDE4D7 downregulation into AI PC.  
 
 
 
 
 
Figure 3.11. A CpG island is predicted upstream of PDE4D7 (Henderson D., thesis 2011). 
 
 
 
5-aza-2’-deoxycytidine (5-aza-2-dC) is a cytosine analogue in which the 5 carbon 
atom is replaced by a nitrogen (Christman, Schneiderman et al. 1985) (figure 
3.12). It is used as an inhibitor of DNA methylation (Christman 2002; Garcia, Jain 
et al. 2010). 5-aza-2-dC is a prodrug that must be activated by phosphorylation 
to 5-aza-2’-deoxycytidine-triphosphate once inside the cell. Following this, it 
binds irreversibly to cytosine residues found within CpG islands. By tightly 
binding the cytosine, 5-aza-2-dC acts to inhibit its methylation by DMTs thereby 
allowing chromatin opening and gene transcription. It is a current treatment for 
myelodysplastic syndromes (MDS), a group of bone marrow neoplasms and blood 
disorders, and has been trialled for use in cancer therapy to allow re-
transcription of tumour suppressor genes (Christman 2002; Garcia, Jain et al. 
2010).  
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Figure 3.12. The structure of 5-aza-2’-deoxycytidine. 
 
 
 
 
5-aza-2-dC treatment of cells is commonly used to study gene repression. It is 
often followed by bisulphite sequencing to identify specific methylation sites.  
Bisulphite treatment deaminates unmethlyated cytosines which then convert to 
uracil, and 5-methylcytosines are unaffected. PCR and DNA sequencing then 
allow for detection and identification of any methylated cytosines in a given DNA 
sequence (Darst, Pardo et al. 2010). I hypothesised that the loss of PDE4D7 
expression as PC progresses may be due to hypermethylation of its upstream CpG 
island. In order to investigate this, PC3 cells were treated with 5-aza-2-dC over 3 
days, followed by quantitative real time PCR (qPCR) analysis to determine the 
total PDE4D, and PDE4D7 expression following treatment. The expression of 
PDE4D5 was also tested as a control.   
 
To analyse the qPCR, the Relative Quantification of Gene Expression approach 
was used as described by Livak and Schmittgen (Livak and Schmittgen 2001). This 
method compares the expression of the gene of interest (GOI) against an 
internal reference gene (RG), i.e. the expression of GOI relative to that of the 
RG.  It allows the quantification of differential expression of a GOI between 
different samples. The data produced is the fold change in the expression of a 
GOI. The expression of the internal RG should not vary between samples nor be 
affected by any experimental treatment. Housekeeping genes such as 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and actin are often used as 
reference genes, and despite controversy surrounding the use of  a single 
reference gene (Vandesompele, De Preter et al. 2002; Barber, Harmer et al. 
2005), the use of either has been shown to be reliable when studying PC samples 
(Mori, Wang et al. 2008).  
 
The data output gives Ct values for the GOI and GAPDH, which represents their 
expression level. For analysis, the comparative Ct approach was used which 
compares the Ct values of the GOI in the test sample to a control sample, and 
gives a ΔΔCt value.  
 
Firstly, the Ct values of the GOI in all samples are normalised to that of GAPDH;  
 
e.g.; test Ct-GAPDH Ct = ΔCt test 
 
Then; ΔCt test – ΔCt control = ΔΔCt.  
 
The Taqman® approach was used to determine the relative expression of 
PDE4D7, PDE4D5 and panPDE4D in the PC3 samples.  Taqman® probes provide 
high specificity which is required to detect and amplify the short unique N-
terminal sequences of specific PDE isoforms.  
 
Interestingly, there was a marked increase of almost 6 fold in PDE4D7 expression 
(figure 3.13 A), and this was almost identical to total PDE4D fold increase (figure 
3.13 B). As a control, expression of another PDE4 long form, PDE4D5, was also 
evaluated. In this case, there was a negligible increase in expression (figure 3.13 
C). This suggests that PDE4D7 may be specifically hypermethylated in late stage 
PC. However, due to time constraints this experiment was carried out only once, 
and verification is needed before steadfast conclusions can be made. Bisulphide 
treatment and DNA sequencing would also be necessary, to confirm specific 
PDE4D7 CpG island methylation.  
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Figure 3.13. Treatment of PC3 cells with the DNA methylation inhibitor 5-aza-2’-
deoxycytidine leads to an increase in PDE4D7 expression.  
PC3 cells were treated with 5-aza-2’-deoxycytidine (5-Aza-2dC) or vehicle 
control (DMSO) over 3 days. The fold changes in A) PDE4D7 expression, B) total 
PDE4D expression or C) PDE4D5 expression were determined by qPCR.  
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3.3 Discussion 
 
The original aim of the PDE expression profiling of PC samples was to identify a 
potential novel biomarker, and was done in collaboration with Philips Research 
and the Prostate Cancer and Molecular Medicine (PCMM) group, both in the 
Netherlands. As discussed, the current biomarker PSA is far from ideal. Although 
highly tissue specific, it is not disease-specific, and its use as a PC biomarker has 
led to much overdiagnosis and over treatment of otherwise non-life threatening 
cancers (Draisma, Etzioni et al. 2009). We were interested in the PDEs that 
modulate cAMP signalling because of the growing body of evidence showing that 
cAMP signalling is perturbed as PC progresses. Such studies have shown that the 
cAMP effector proteins PKA and EPAC are important in the androgen-
independent progression of PC (Sadar 1999; Misra and Pizzo 2013). PKA subunit 
switching also plays a role in PC progression (Kvissel, Ramberg et al. 2007; 
Merkle and Hoffmann 2011). Although the molecular mechanisms are ill 
understood, it is known that cAMP is necessary for NED, another important event 
in advanced PC (Bang, Pirnia et al. 1994; Pandit, Forman et al. 2009). Aberrant 
GPCR and G protein expression and signalling events are also implicated in 
advancing PC (Nelson, Bagnato et al. 2003; Kasbohm, Guo et al. 2005; Weng, 
Wang et al. 2005). Despite the vast evidence for the role of cAMP in PC 
progression into androgen-independence, little work has been done on the 
expression and roles of cAMP PDEs in PC. Uckert et al investigated PDE family 
expression within the various zones of the prostate (Uckert, Oelke et al. 2006), 
and other studies have looked more closely at  the PDE4 family in PC (Rahrmann, 
Collier et al. 2009; Sarwar, Sandberg et al. 2013), but no studies have really 
investigated the role of PDE4 splice variants in PC. The unique N-termini of PDE4 
isozymes confer highly specific roles and subcellular localisation to the enzymes, 
such that they are non-redundant. Isozyme-specific information needs to be 
gathered to better understand their role in PC. This is important as PDEs are the 
sole means of cAMP degradation and thus underpin compartmentalised cAMP 
signalling, with PDE4 isoforms being of particular pertinence in a disease context 
(Houslay 2010).  
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PDE4D7 certainly shows promise as a disease-specific biomarker. Our group 
previously showed that PDE4D7 mRNA is downregulated during the AS to AI PC 
transition, and whether the protein followed suit was unclear due to lack of 
competent anti-sera against PDE4D7. Here, using AS and AI PC cell lines I verify 
that PDE4D7 protein, and thus active enzyme, is also downregulated as PC 
progresses. PDE4D7 therefore may be a successful biomarker to determine 
disease stage, which would better allow the patient and clinician to decide if 
treatment is necessary at that time. Continual monitoring of PDE4D7 levels in a 
patient may help to identify if the cancer is progressing to an AI state. Our 
collaborators in the Netherlands have carried out clinical research and found 
that PDE4D7 mRNA is initially upregulated in AS cancer, and its expression 
successfully discriminates between non-tumour and tumour tissue. They also 
investigated the level of PDE4D7 mRNA in PC samples where 20 years 
longitudinal follow up was available, and found that primary tumours possessing 
a high relative expression level of PDE4D7 mRNA  positively correlated with 
patient outcome, and prostate cancer-specific survival (PCSS). These data are 
currently unpublished.  This suggests that PDE4D7 expression can predict disease 
outcome, thereby acting as a prognostic biomarker. Our collaborators in the 
Netherlands are currently testing the ease with which PDE4D7 can be used as a 
biomarker; ideally we want to be able to detect it in a urine sample, and such 
detection is showing promise. 
 
PDE4D7 showed the highest expression of all PDE4 isoforms in all AS PC samples 
screened. This suggests a possible protective role for this enzyme in early stage 
PC, where its expression correlates with slow growing, non-invasive PC cells, and 
its downregulation correlates with faster growing invasive cell types. The finding 
by our collaborators that PDE4D7 is upregulated in primary prostate tumours 
compared to normal tissue, may suggest a compensatory mechanism for an 
increase in cAMP signalling during tumourigenesis. Or, the increase may just be 
due to hyperplasia of PDE4D7-expressing tumour epithelia. Indeed PNT1 cells, 
isolated from normal prostate epithelium, also express high levels of PDE4D7 
(Henderson D. thesis 2011).  
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Indeed, the data from the proliferation and migration assays suggest that 
PDE4D7 mediates AS PC cell growth. The marked increase in cell proliferation 
upon displacement or reduction in PDE4D7 expression suggests that PDE4D7-
mediated cAMP hydrolysis maintains normal proliferation signalling. 
Downregulation of global PDE4D did not affect cell proliferation, suggesting a 
specific role for PDE4D7 in cAMP-mediated AS cell proliferation. The 
observations that ‘re-expressing’ PDE4D7 in AI cells leads to a marked reduction 
in proliferation rate and migratory potential strengthens this argument. Being 
the most abundantly expressed PDE4D isoform in AS PC, PDE4D7 must play a 
pivotal role in the cellular desensitisation system to cAMP in early stage PC. Its 
downregulation or loss as PC becomes AI would result in a large cAMP increase in 
the PDE4D7 locale; the sub-plasma membrane region, which may lead to 
promiscuous signalling and aberrant crosstalk with the AR via PKA and EPAC 
effector proteins. Several studies highlight the role of increased cAMP 
concentrations in non-genomic androgen signalling-mediated PC progression. 
Aberrant PKA phosphorylation of the AR is associated with the transition to AI PC 
(Nazareth and Weigel 1996; Gioeli, Ficarro et al. 2002), as is an increase in CBP 
expression (Comuzzi, Nemes et al. 2004). The evidence that GPCRs are over 
expressed in advancing PC (Nelson, Bagnato et al. 2003; Weng, Wang et al. 
2005), coupled with increasing cAMP levels due to loss of PDE4D7 is one way in 
which certain pro-proliferative pathways would become chronically stimulated. 
Loss of PDE4D7 therefore may play an important role in the switch from 
androgenic signalling to autocrine and paracrine signalling as PC moves into 
androgen insensitivity.  
 
Loss of PDE4D7-mediated cAMP hydrolysis may also play a role in the 
development of NED, which occurs in some AS PC models.  The molecular 
mechanisms underlying NED are not well understood, but an increase in cAMP is 
certainly involved (Merkle and Hoffmann 2011). Following androgen withdrawal, 
NED is accompanied by a huge increase in intracellular cAMP (Burchardt, 
Burchardt et al. 1999). NE cells secrete neuropeptides and cytokines that can 
bring about an increase in proliferation of neighbouring non-NE cells, and as PC 
progresses into androgen insensitivity the NE cell population increases (Gkonos, 
Krongrad et al. 1995; Jongsma, Oomen et al. 2000; Juarranz, Bolanos et al. 
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2001; Li, Chen et al. 2013). If PDE4D7 is one of the main regulators of cAMP in AS 
PC, then loss of its expression and thus activity could, over time, lead to NED.  
 
These results put into question the use of PDE4 inhibitors in the treatment of 
LUTS associated with BPH (Andersson, Uckert et al. 2007; Uckert and Oelke 
2011). It would be interesting to investigate the expression levels of PDE4D7 in 
BPH samples, to see if it is upregulated as was observed in primary prostate 
tumour tissue. If indeed it is, its inhibition could possibly potentiate PC 
development. However, most evidence suggest BPH is not a precursor of PC, and 
both originate from different prostatic zones (Lee and Peehl 2004). 
 
The Sleeping Beauty (SB) transposon study discussed earlier described PDE4D as 
a PC gene and found its expression to be upregulated in all stages of PC 
compared to BPH (Rahrmann, Collier et al. 2009). As discussed, our collaborators 
also found PDE4D to be upregulated in primary tumour tissue compared to 
normal prostate tissue, however we hypothesise that this may be a protective 
event, and we show PDE4D to be down regulated as PC progresses. Rahrmann 
and colleagues suggest that PDE4D is upregulated in both non-invasive and 
invasive PC, and that its expression is pro-proliferative and PDE4D inhibition is of 
therapeutic value. They found PDE4D5 to be the predominant isoform expressed, 
and that global PDE4D knockdown in AI DU145 and PC3 cells reduced their 
proliferation rate. Little is known about the transcriptional regulation of PDEs, 
however, PDE4D5 has been shown to be upregulated in response to cAMP due to 
a cAMP responsive promoter (Le Jeune, Shepherd et al. 2002). This is very 
interesting in light of the results presented here. A loss of PDE4D7 expression as 
PC moves into androgen insensitivity would lead to an increase in cAMP and thus 
aberrant signalling, possibly including an upregulation of PDE4D5 resulting in 
dysregulated cAMP hydrolysis at the PDE4D5 locale. This in turn would result in 
perturbed PDE4D5 signalling which could potentiate PC progression. Saying this, 
our group actually found a decrease in PDE4D5 expression between AS and AI PC 
samples (figure 3.1), however, it was not significant and also PDE4D5 showed 
higher expression than other isoforms in the AI samples.  
 
Since PDE4D7 was first described, little work has been done to investigate the 
signalling networks within which this isoform operates (Wang, Deng et al. 2003). 
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However, it has been linked to ischemic stroke. The PDE4D locus was found to be 
a stroke susceptibility gene, due to its role in arthrosclerosis. The stroke-
associated haplotype was found to extend over the PDE4D7 promoter region and 
5’ unique exon, and correlated with PDE4D7 mRNA, suggesting it perturbs 
transcription of this isoform (Gretarsdottir, Thorleifsson et al. 2003). 
Interestingly, this haplotype region includes the PDE4D7 overlapping region of 
PART1, a seemingly non-coding transcript which is highly expressed in cancers, 
including PC (Lin, White et al. 2000). Gretarsdottir et al. suggest the stroke 
haplotype results in a decrease in PDE4D7 expression, and therefore an increase 
in cAMP.  
 
The linkage study by Gretarsdottir and colleagues was carried out in an Icelandic 
cohort, and subsequent independent studies in other population cohorts have 
given conflicting results on the association of PDE4D and stroke (Staton, Sayer et 
al. 2006; Bevan, Dichgans et al. 2008; Munshi and Kaul 2008). It is likely that 
racial and ethnic differences may account for the discrepancies between 
studies. Saying that, a very recent study confirms the association in a Chinese 
cohort (Liu, Zhu et al. 2013). The most recent meta-analysis on data collected 
since the original study, which includes more studies than earlier meta-analyses, 
also confirms the linkage between PDE4D and stroke (Yoon, Park et al. 2011). 
 
The association of stroke and inflammation is well documented (Huang, 
Upadhyay et al. 2006; Chiba and Umegaki 2013), as is that of cAMP and 
inflammation (Moore and Willoughby 1995). It is therefore unsurprising that a 
cAMP PDE be implicated in stroke. There is also much evidence suggesting a role 
for inflammation in the development of both BPH and PC, such as a perturbed 
intra-prostatic immune system cytokine complement (Bouraoui, Ricote et al. 
2008; Drake 2010). PC often occurs with comorbidities, and mortality in PC 
patients with pre-existing stroke is higher than in those without (Jespersen, 
Norgaard et al. 2011) 
 
Finally, I wished to investigate if the downregulation/loss of PDE4D7 in AI PC was 
due to aberrant transcriptional regulation, namely hypermethylation. Aberrant 
DNA methylation is known to play a role in PC development (Jeronimo, Bastian 
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et al. 2011). A CpG island is predicted upstream of PDE4D7 (Henderson D. thesis 
2011), meaning that epigenetic regulation of this isoform is highly plausible. 
Interestingly, the 5’ exon of PDE4D7 which encodes part of its unique N-terminal 
region overlaps with the non-coding PART1 gene (Gretarsdottir, Thorleifsson et 
al. 2003). The two genes overlap in a cis-natural (cis-NAT) antisense manner 
(Henderson, thesis), meaning they are transcribed from opposite DNA strands. 
Natural antisense transcripts commonly include a protein coding gene with a 
non-coding antisense RNA partner, and the list of such pairs is growing and is 
suggested to comprise 15-25% of the mammalian genome (Werner and Berdal 
2005; Faghihi and Wahlestedt 2009). Cis-NATs are a type of regulatory RNA, in 
which the antisense partner can exert regulatory functions over the transcription 
of the coding gene, and antisense knockout studies result in aberrant expression 
of the sense partner (Werner and Berdal 2005). The role of such non-coding RNAs 
(ncRNAs) in the epigenetic regulation of coding genes is gaining much interest 
(Su, Xiong et al. 2010). Cis-NATs have been shown to both positively and 
negatively regulate the expression of genes (Faghihi and Wahlestedt 2009; 
Magistri, Faghihi et al. 2012), and the long term silencing of tumour suppressor 
genes is mediated by cis-NATs (Malecova and Morris 2010). Cis-NATS likely 
regulate transcription by recruiting histone-modifying enzymes to their sense 
strand partner to bring about chromatin remodelling (Magistri, Faghihi et al. 
2012). 
 
Although carried out only once, the upregulation of PDE4D7 following treatment 
with the DNA methylation inhibitor 5-aza-2dC suggests that hypermethylation 
may be responsible for the loss of expression in AI PC. Total PDE4D expression is 
also upregulated to same extent, suggesting total upregulation represents that 
of PDE4D7, and thus PDE4D7 is specifically hypermethylated. This is also 
suggested by the observation that PDE4D5 is not upregulated following 
treatment. I hypothesise that PART1 exerts transcriptional control over PDE4D7. 
PART1 is an androgen-regulated, non-coding transcript highly expressed in the 
prostate, placenta, thymus and salivary gland, and is upregulated in malignant 
compared to normal prostate samples (Lin, White et al. 2000; Sidiropoulos, 
Chang et al. 2001). The authors here do not describe whether  the malignant 
samples are AS or AI, but a later study describes the upregulation of PART1 in AS 
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LNCaP following DHT treatment, but not in DU145 or PC3 cells (Yu, Blackburn et 
al. 2003). Together, this suggests that PART1 may positively regulate PDE4D7 
expression in normal prostate tissue and early stage AS prostate carcinoma. As 
PC progresses, and signalling moves away from androgenic pathways, 
transcription of PART1 may be inhibited. This would then allow 
hypermethylation of the PDE4D7 promoter region and subsequent loss of 
expression. It must be noted that PDE4D7 does not appear to be under 
androgenic regulation (Henderson D. thesis 2011). This is an area that requires 
much further work; Firstly, the upregulation of PDE4D7 following DNA methyl-
transferase inhibition needs to be confirmed. If PDE4D7 is repeatedly specifically 
upregulated, it would be interesting to assay the proliferation and migration of 
AI PC cells following treatment, with the expectation that growth rate and 
migratory potential would be decreased. Also, bisulfite treatment and DNA 
sequencing would be necessary to confirm specific hypermethylation of the 
PDE4D7 CpG island.  
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3.4 Chapter Summary 
 
4) PDE4D7 is differentially expressed between AS and AI PC cell lines and is a 
potential diagnostic biomarker of disease stage. 
 
5) PDE4D7-mediated cAMP hydrolysis at the plasma membrane plays a role in 
the regulation of PC cell proliferation and migration. 
 
6) Loss of PDE4D7 expression in AI PC may be due to hypermethylation. 
 
7) I conclude that loss of PDE4D7-specific cAMP hydrolysis plays a role in the 
development of the AI phenotype (figure 3.15). 
 
 
 
 
 
Figure 3.14. cAMP signalling dysregulation plays an important role in PC progression and 
loss of PDE4D7 is likely a contributing factor.   
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4 Unique N-terminal Phosphorylation of PDE4D7  
4.1 Introduction 
 
PDEs are subject to a hierarchy of regulation. Primarily, regulation comes at the 
level of their tissue (Cole, Soutar et al. 2008) and cell-specific expression 
(Houslay 2010). Brain region-specific splice variant expression provides an 
elegant example of such a paradigm and underscores the non-redundant roles 
afforded to PDE isoforms (D'Sa, Eisch et al. 2005). Secondly, they are regulated 
by the possession of family specific domains such as GAFs, PAS’, Ca2+/ Cams, and 
UCRs which act to transduce regulatory signals from the signalling network 
within which a PDE is functioning (Bender and Beavo 2006; Omori and Kotera 
2007). PDEs are then further regulated by post-translational modifications 
(PTMs) such as phosphorylation, SUMOylation and ubiquitination (MacKenzie, 
Baillie et al. 2002; Li, Baillie et al. 2009; Li, Vadrevu et al. 2010). Over the past 
decade or so, PTMs of proteins have been recognised as an elegant way to 
manage protein regulation, and therefore fine-tune the functional outcome of 
signals within a cell. Aberrant PTMs are associated with cancer development and 
show potential both as disease biomarkers and targets for therapeutic 
intervention (Krueger and Srivastava 2006). 
 
All long form PDE4 isoforms are subject to phosphorylation by PKA within the 
conserved RRESF motif in their UCR1 region, and this underpins their activation 
(MacKenzie, Baillie et al. 2002). It is believed that in the inactive state, the 
UCR2 domain acts as an internal inhibitory unit by straddling the active site. It 
may be that the UCR1 and UCR2 domains interact via electrostatic interactions 
(Beard, Olsen et al. 2000). PKA phosphorylation of UCR1 causes a conformational 
change which relieves this inhibitory constraint by dissociation of UCR2 from the 
active site (Lim, Pahlke et al. 1999; Burgin, Magnusson et al. 2010) and possibly 
from UCR1 (figure 4.1).  
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Figure 4.1. A simplistic schematic representing the proposed model for the activation of 
long PDE4 isoforms.  
cAMP cannot access the active site due to hindrance by UCR2. Following an 
increase in active PKA, UCR1 is phosphorylated leading to a conformational 
change around the active site and activation of the PDE.  
 
 
Aside from UCR1 phosphorylation, the long isoform PDE4D3 undergoes PKA 
phosphorylation within its unique N-terminus, on serine13 (Sette and Conti 
1996). To date, this is the only known case of a long PDE isoform being 
phosphorylated by PKA other than within its UCR1 domain.  This Ser13 falls 
within a region involved in regulating a host of protein-protein interactions with 
the scaffolding proteins mAKAP, Nudel , Lis1, EPAC1, as well as members of the 
MAPK signalling pathway and protein phosphatase 2A (PP2A) (Carlisle Michel, 
Dodge et al. 2004; Dodge-Kafka, Soughayer et al. 2005; Dodge-Kafka and Kapiloff 
2006; Collins, Murdoch et al. 2008; Dodge-Kafka, Bauman et al. 2010; Murdoch, 
Vadrevu et al. 2011). Phosphorylation of ser13 increases the affinity of PDE4D3 
for mAKAP (Carlisle Michel, Dodge et al. 2004) while causing dissociation from 
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Ndel1 (Collins, Murdoch et al. 2008). This complex and dynamic signalosome acts 
to tightly and elegantly regulate cAMP signalling within the heart, and 
underscores the complexity and intricacy of the cAMP signalling axes.  
 
The aims of this chapter are to present evidence for the previously undiscovered 
PKA-mediated phosphorylation of PDE4D7 within its unique N-terminus (on serine 
42), to show that this event likely occurs in vivo, and that it acts to regulate 
PDE4D7 activity.  
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4.2 Results 
 
4.2.1 The Unique N-terminal Region of PDE4D7 Contains a PKA 
Consensus Site 
 
PDE4D7 was first described by Wang and colleagues. The unique N-terminal 
region is encoded by two exons, PDE4D7a and PDE4D7b, rather than a single 
exon, as in all other known PDE4D isoforms (Wang, Deng et al. 2003).  The 
unique N-terminal region of PDE4D7 is 90 amino acids long, encoded by 270 base 
pairs (figure 4.2).   
 
 
 
 
 
Figure 4.2. The unique N-terminal region of PDE4D7 (AF536976.1) comprises exon a and 
exon b.  
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Interestingly, within the PDE4D7 unique N-terminus there is a consensus PKA site 
of 37LVRRLSCR44 (figure 4.3). 
 
 
 
 
 
 
 
 
 
Figure 4.3. The unique N-terminus of PDE4D7 contains a PKA phosphorylation consensus 
site; RRLS. 
 
 
 
The consensus PKA phosphorylation motif is RxxS(h) or RRxS(h) where x is any amino 
acid, S is the target serine for the phospho moiety, and (h) represents a preferred 
hydrophobic residue. The residue in the (h) position of the PKA consensus motif 
within the N-terminus of PDE4D7 is a cysteine (C43). This is not a hydrophobic 
residue and so renders this a suboptimal PKA consensus site and this is the reason 
why it has not been investigated before now. However, I thought it quite plausible 
that this site, serine42 (Ser42) is indeed subject to PKA phosphorylation, and the 
following results confirm this.  
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4.2.2 PDE4D7-Ser42 is Phosphorylated by PKA in vitro  
4.2.2.1 Peptide Array Technology and a Novel Phospho-Specific Antibody 
Confirm that Serine 42 is a PKA Phospho-site. 
 
As described in Chapter 3, peptide array technology was used to create PDE4D7 
arrays. These arrays were used to investigate whether the N-terminus of PDE4D7 
can be phosphorylated by PKA. Peptide array technology is a relatively novel 
method of investigating the PTMs of proteins. It has been used by our group to 
successfully identify ubiquitination and SUMOylation sites on PDE4D5 (Li, Baillie 
et al. 2009; Li, Vadrevu et al. 2010), and PKA sites on PI3K and DNA-PK (Huston, 
Lynch et al. 2008; Perino, Ghigo et al. 2011).  
 
In order to investigate PDE4D7 N-terminal phosphorylation, PKA assays were 
carried out using PDE4D7 arrays. Firstly, an array was incubated with 100units of 
purified PKA catalytic subunit in a phospho-buffer containing Mg2+ and ATP. A 
control assay which did not contain active PKA was also carried out. Following 
this, the arrays were probed with a PKA-substrate antibody. This antibody 
detects the motif RXXpS, where X is any residue; i.e. this antibody detects any 
serine phosphorylated by PKA. Following incubation with HRP-conjugated 
secondary antibody and chemiluminescent detection, dark spots representing 
phosphorylated peptides were observed on the test array. The peptides 
phosphorylated were those encompassing the UCR1 region of PDE4D7, as 
expected, and also those containing the RRLS motif within the N-terminus 
(figure 4.4). 
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Figure 4.4. Peptide array technology confirms PDE4D7-Ser42 is phosphorylated by PKA. 
PDE4D7 peptide arrays were subjected to PKA assays; arrays were incubated in 
phospho-buffer with (+PKA) or without (-PKA) active PKA catalytic subunit. A 
PKA substrate antibody (RXXpS) detects phosphorylation (dark spots) of the UCR1 
PKA consensus site RRES, and the potential novel PKA substrate site, RRLS, on 
the test (+PKA) array. No spots were observed on the control array (-PKA). N=3. 
 
 
The spots representing the UCR1 region are much darker than those of the RRLS 
motif. This may be due to the lack of an optimal hydrophobic residue 
immediately after the target serine at position 42.   However, the detection of 
phosphorylation at Ser42 led me to investigate further this possible event. In 
order to determine if Ser42 is phosphorylated in vivo, a phospho-specific 
antibody was raised. This antibody, pSer42, would detect only PKA 
phosphorylated serine 42 of PDE4D7. The sequence CEPYLVRRL(p)SCRN was used 
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to create an antigen peptide that was injected into rabbits to raise the antibody. 
Following collection of serum, the antibody was purified. The purified pSer42 
antibody was then validated by means of peptide array. PKA assays were carried 
out on PDE4D7 arrays, including a control without active PKA. The arrays were 
then probed with the pSer42 antibody, or pre-immune serum from the host 
rabbit which acts as a negative control, to ensure detection is due to the 
antibody raised against the inoculated antigen and not some artefact e.g. non-
specific binding (figure 4.5).    
 
 
 
 
 
 
 
 
 
Figure 4.5. Peptide array technology verifies specificity of the novel phospho-Ser42 
antibody, and confirms that this site can be PKA phosphorylated.  
Again, PDE4D7 arrays were incubated in phospho-buffer, with (+PKA) or without 
(-PKA) active PKA catalytic subunit. The novel pSer42 antibody successfully and 
specifically detected phosphorylation (dark spots) of the RRLS motif in PDE4D7. 
The -PKA assay and pre-immune serum acted as negative controls. N=3. 
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The PDE4D7 peptide arrays served two purposes here; firstly they verified that 
the novel pSer42 antibody successfully detects PKA phosphorylation of this site, 
and does so specifically. Secondly, they validated the results from the first PKA 
assay experiment (figure 4.4), and gave credence to the idea that PDE4D7 is 
indeed phosphorylated within its N-terminal region.  
 
To further support the notion that a unique phosphorylation event can occur at 
Ser42, a phosphoresistant mutant was created. Site-directed mutagenesis (SDM) 
was carried out to change the Ser42 residue to a phospho-null/resistant alanine 
(S42A). The mutant protein (N-terminal only) was cloned and purified as a GST 
recombinant protein, as was the wild type (wt) protein (N-terminal only). Both 
proteins encompass the entire N-terminal region of PDE4D7 only. Henceforth 
they will be called S42A-Nt and wt-Nt respectively, to represent the mutation or 
wt.  
 
Firstly, expression and purification of the proteins were verified by SDS-PAGE 
and Coomassie staining (figure 4. 6). The N-terminal region of PDE4D7 weighs 
~10kDa, and with a GST tag weighs ~46kDa. Purified GST was also loaded on the 
gel as a control.  
 
 
 
 
Figure 4.6. Verification of protein purification by SDS PAGE and Coomassie staining.  
GST recombinant S42A-Nt (A) and Wt-Nt (B) purified proteins (along with 
purified GST) were detected by Coomassie staining. S42A-Nt and Wt-Nt run at 
~46kDa, GST runs at ~26kDa. Degradation can be seen, as is normal with purified 
proteins. TU = total uninduced protein, TI = total induced protein,    TS = total 
soluble protein, EP = eluted protein.  
A.M. Byrne  |  PhD Thesis 2014                                                                                                     189 
 
PKA assays were then carried out with the purified proteins. 2ug of each protein 
was incubated with or without 25 units of active catalytic PKA subunit in 
phospho-buffer containing Mg2+ and ATP. The proteins were then tested for 
phosphorylation by SDS-PAGE and western blot analysis. Probing of the blots with 
both the RXXpS and the pSer42 antibodies detected phosphorylation of only wt-
Nt following incubation with PKA (figure 4.7). These results again verify that 
PDE4D7 is phosphorylated on S42, and confirm specificity of the pS42 antibody. 
 
 
 
 
 
 
  
 
 
Figure 4.7. Purified wt and S42A proteins were assayed for phosphorylation by PKA.  
The GST fusion proteins were subjected to PKA assays. Incubation with PKA 
catalytic (cat) subunit brings about phosphorylation of the wt protein only 
(indicated by arrows), as detected by a PKA substrate antibody (RxxpS) (A) or 
the phospho-ser42 specific antibody (pS42) (B).  
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4.2.3 PDE4D7 Ser42 is Phosphorylated by PKA ex vivo-
Overexpression System 
 
The next step was to investigate if this phosphorylation event occurs in cells, in 
response to an increase in intracellular cAMP. This employed full length wild 
type PDE4D7 and mutant PDE4D7 VSV-tagged constructs.  A phosphoresistant 
alanine mutant (S42A), as described above, was cloned along with a 
phosphomimetic mutant (S42D). The phosphomimetic mutant has an aspartate 
substitution at the Ser42 position which bestows a negative charge to mimic the 
stoichiometry of PKA phosphorylation, ensuring the enzyme remains 
constitutively ‘active’ (Hoffmann, Wilkinson et al. 1998; MacKenzie, Baillie et al. 
2002). These VSV-tagged constructs were overexpressed in Hek293 cells, which 
were then treated with DMSO, forskolin or KT5720 (PKA inhibitor) and forskolin. 
Forskolin activates adenylyl cyclases and therefore raises cAMP levels. KT5720 is 
an ester derivative and a protein kinase inhibitor with specificity for PKA (Kase, 
Iwahashi et al. 1987). Cells were treated with 4uM of KT5720, 20 minutes prior 
to treatment with 100uM forskolin for 5 minutes. Cells treated with forskolin 
alone were also challenged with 100uM for 5 minutes. Forskolin and KT5720 were 
dissolved in DMSO, therefore this was used as a vehicle control.  
 
Interestingly, basal Ser42 phosphorylation was observed in the control, wt 
transfected cells. The band representing phosphorylated Ser42 (phospho band) is 
increased in intensity following forskolin treatment, and reduced to basal levels 
with pre-treatment of KT5720 (figure 4.8 A). This confirms that phosphorylation 
of PDE4D7-Ser42 is PKA-dependent. No such phosphorylation is observed with the 
S42A and S42D mutants, again confirming specificity of the phospho-ser42 
antibody. These results indicate that PDE4D7 is indeed phosphorylated within its 
N-terminal region at Ser42 in cells, and that this event is mediated by PKA.  A 
forskolin time course was carried out (figure 4.8 B) to investigate if PDE4D7-
Ser42 phosphorylation is maintained with a sustained increase in PKA levels. 
Phosphorylation remains above that of basal level for the duration of the 
timecourse (20 minutes), but is maximal at 5-10 minutes following forskolin 
challenge. A reduction in the phospho band is then observed, which stands to 
reason, as the UCR1 region becomes phosphorylated leading to an increase in 
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PDE activity and a corresponding decrease in active PKA in the vicinity of the 
enzyme. A forskolin timecourse was then carried out in cells expressing the 
dominant-negative PDE4D7 construct (figure 4.8 C). This construct is 
catalytically inactive while possessing an intact N-terminal region. This showed a 
marked and continual increase in Ser42 phosphorylation compared to wtPDE4D7. 
This finding suggests that phosphorylation at Ser42 is protected by the catalytic 
activity of the enzyme, possibly to prevent hyper-phosphorylation of this site. 
Forskolin-treated lysates were also probed with the PKA substrate antibody 
RXXpS, to ensure that forskolin challenge was indeed increasing PKA mediated 
phosphorylation of multiple unidentified substrates (figure 4.8 D). Hek293 cells 
transfected with a Control construct were also challenged with forskolin and 
compared to wtPDE4D7 transfected cells, to ensure the pSer42 antibody was not 
detecting any non-specific band in the lysate (figure 4.8 E); indeed our group 
have previously confirmed absence of PDE4D7 expression in Hek293 cells.  
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Figure 4.8. The unique N-terminus of PDE4D7 is phosphorylated by PKA ex vivo. 
A; Hek293 cells were transfected with VSV-tagged wild type PDE4D7 (wt) or the 
S42A or S42D mutants and treated with forskolin (Fsk) or forskolin after a pre-
treatment with the PKA inhibitor KT5720 (+KT). DMSO served as a vehicle control 
(D). Cellular lysates were blotted with serine 42 specific antibody or VSV 
antibody. N=3. B; Hek293 cells were transfected with VSV-tagged wild type 
PDE4D7 (wt) or the S42A or S42D mutants and treated with forskolin (Fsk) over 
20 minutes. Cellular lysates were blotted with serine 42 specific antibody or VSV 
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antibody. N=3. C; Hek293 cells were transfected with wt PDE4D7 or the 
dominant negative, catalytically inactive mutant (dn) and treated with forskolin 
(Fsk) over 20 minutes. Cellular lysates were blotted with a serine 42 specific 
antibody or VSV antibody. N=3. D; Hek293 cells were transfected with wt 
PDE4D7 or the S42A mutant and treated with forskolin (Fsk) over 20 minutes. 
Cellular lysates were blotted with a PKA-substrate antibody (RXXpS). N=3. E; 
Hek293 cells were transfected with wt PDE4D7 or a control construct (mock) and 
treated with forskolin (Fsk) over 20 minutes. Cellular lysates were blotted with a 
serine 42 specific antibody. N=1. 
 
 
 
4.2.4 PDE4D7 Ser42 Phosphorylation Negatively Regulates 
Enzyme Activity  
 
As discussed, all long form PDE4 isozymes are activated following PKA 
phosphorylation of their UCR1 domains (MacKenzie, Baillie et al. 2002). PDE4D3 
is also known to be phosphorylated by PKA within its N-terminus, but this has no 
effect on enzyme activity (Sette and Conti 1996). I wished to investigate if the 
phosphorylation of Ser42 had any effect on PDE4D7-mediated cAMP hydrolysis. 
To do this, a PDE activity assay was performed on lysates of Hek293 cells that 
had been transfected with wt, S42A or S42D PDE4D7 VSV-tagged constructs. The 
C terminal VSV tag allowed for specific detection of the expression of each 
enzyme, and has previously been used in such experiments without interfering 
with enzyme activity (Hoffmann, Wilkinson et al. 1998). The cells were left 
untreated (NT) or treated with 100uM forskolin for 5, 10, 15 or 20 minutes. Since 
maximal phosphorylation of Ser42 was found to occur after 5 minutes (figure 4.8 
B) the NT and 5 minute forskolin-treated cells were analysed for activity. Along 
with the PDE assay, the lysates were analysed for expression of each construct 
by means of western blot analysis and a VSV antibody. This was so densitometry 
could be used to calculate the expression of each construct, treated and 
untreated, compared to that of GAPDH. The expression of each was then taken 
as a percentage of NT wtPDE4D7, such that wtPDE4D7 basal activity equals 100%. 
The PDE assays values were then normalised against construct expression to give 
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an accurate activity reading. The picomoles of cAMP hydrolysed per minute per 
μg protein by the wt and mutant enzymes under basal and forskolin-challenged 
conditions are shown in figure 4.9 A. The activity of each enzyme is represented 
as a percentage of wtPDE4D7 NT in figure 4.9 B. Our group have previously 
determined that Hek293 cells exhibit negligible PDE4 activity (< 5% of 
transfected amounts), thus any activity measured is due to the overexpressed 
enzyme.  
 
Following forskolin treatment and thus a rise in cAMP and PKA activity, wt 
PDE4D7 showed ~2 fold (95%) increase in cAMP hydrolysis activity, as was 
expected due to UCR1 phosphorylation (Sette and Conti 1996). Interestingly, the 
phosphoresistant S42A mutant showed increased basal activity compared to 
wtPDE4D7 NT, of >170% (p=0.03, ANOVA); such that it was hyper-active and 
forskolin challenge did not further increase its activity. The phospho mimetic 
S42D mutant showed a small non significant increase in basal activity compared 
to wtPDE4D7 NT (36%), which was increased following forskolin challenge to a 
similar degree as wtPDE4D7 with forskolin (80%).  
 
The hyperactivity observed with the S42A mutant suggests that phosphorylation 
of this site provides a mode of negative regulation on PDE4D7, ablation of which 
leads to activation. The increase in basal activity observed with the S42D 
enzyme is not significant; suggesting the negative charge afforded by the 
aspartate residue confers activity similar to that of basal wtPDE4D7 activity.  
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Figure 4.9. Phospho-null mutation of the serine 42 -site renders PDE4D7 hyper-active. 
Hek293 cells were transfected with VSV-tagged wt PDE4D7 (wt) or the S42A or 
S42D mutants and treated with forskolin (Fsk) for 5 minutes, or left untreated 
(NT). The PDE activity of cellular lysates was determined (A) and expressed as a 
percentage of wild type control (wt NT) (B). ANOVA was used to determine 
significance of change. C; the cell lysates used for the activity assays were 
analysed for construct expression by means of western blots. N=3. 
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Since ablation of Ser42 phosphorylation led to a hyperactive enzyme, it was 
assumed that this mutation would result in a hyper-phosphorylated UCR1 region. 
To investigate this, the lysates prepared for the activity assays were analysed by 
SDS PAGE and western blotting, followed by immunoblotting for phospho-UCR1 
compared to phospho-Ser42 and VSV. Interestingly, the S42A mutation resulted 
in a marked reduction in phosho-UCR1, whereas the S42D mutation seemed to 
have no effect on UCR1 phosphorylation compared with wtPDE4D7 (figure 4.10 
A). These results again suggest that the phosphorylation of Ser42 acts to 
negatively regulate PDE4D7 activity; ablation of which leads to a hyper-active 
enzyme which so rapidly hydrolyses any available cAMP that little or no active 
PKA becomes available to phosphorylate the UCR1 domain. Indeed, the UCR1 
region is hyperphosphorylated in the dominant-negative (dn) construct, which is 
catalytically inactive (figure 4.10 B). 
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Figure 4.10. Ablation of phospho-serine42 in PDE4D7 inhibits UCR1 phosphorylation due to 
hyper-hydrolysis of cAMP.  
A; Hek293 cells were transfected with wt PDE4D7 or the S42A or S42D mutants 
and treated with forskolin (Fsk) over 20 minutes. Cellular lysates were blotted 
with a serine 42 phospho-specific antibody or a VSV antibody or a phospho-UCR1 
antibody.  B; Hek293 cells were transfected with wt PDE4D7 or the dominant 
negative, catalytically inactive mutant (dn) and treated with forskolin (Fsk) over 
20 minutes. Cellular lysates were blotted with a phospho-UCR1 antibody or a VSV 
antibody. N=3. 
 
 
 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     198 
 
4.2.5 PDE4D7 Ser42 is Phosphorylated by PKA ex vivo-
Endogenous Prostate Cancer Cell System.  
 
The next step was to investigate if endogenous PDE4D7 is phosphorylated on 
Ser42. The AS DuCaP and VCaP cell lines were treated with DMSO, forskolin or 
forskolin following pre-treatment with KT5720. In both cell lines, forskolin 
challenge resulted in an increase in pSer42 which was reduced when a KT5720 
pre-treatment was carried out (figure 4.11 A and B). Forskolin treatment 
timecourses show an increasing pSer42 band intensity over 20 minutes, 
compared with total PDE4D7 (figure 4.11 C and D). Interestingly, there is basal 
phosphorylation of PDE4D7 N-terminal in these endogenous systems also.  
 
 
 
 
 
 
 
 
Figure 4.11. Endogenous PDE4D7 Ser42 is phosphorylated by PKA.   
A; DuCaP cells were treated with forskolin (Fsk) or forskolin following a pre-
treatment with the PKA inhibitor KT5720 (+KT). DMSO served as a vehicle 
control. Cellular lysates were blotted with serine 42 phospho-specific antibody 
or PDE4D7 antibody. B; VCaP cells were treated with forskolin (Fsk) or forskolin 
following a pre-treatment with the PKA inhibitor KT5720 (+KT). DMSO served as a 
vehicle control. Cellular lysates were blotted with serine 42 phospho-specific 
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antibody or PDE4D7 antibody. C; DuCaP cells were treated with forskolin (Fsk) 
over 20 minutes. Cellular lysates were blotted with serine 42 phospho-specific 
antibody or PDE4D7 antibody or GAPDH antibody. D; VCaP cells were treated 
with forskolin (Fsk) over 20 minutes. Cellular lysates were blotted with serine 42 
phospho-specific antibody or PDE4D7 antibody or GAPDH antibody.    
 
 
These results suggest that PDE4D7 N-terminal PKA dependant phosphorylation 
occurs in endogenously expressed proteins within cultured cells. An interesting 
observation is that endogenous Ser42 shows basal phosphorylation.  Taken 
together with the results of the PDE activity assay, these data suggest that 
phosphorylation of Ser42 negatively regulates PDE4D7 activity, and may allow for 
basal cAMP signalling. It could be that PDE4D7 is constitutively phosphorylated 
on Ser42 under such conditions, or certainly a sub-population of PDE4D7. Usually 
phospho-sites are subject to rapid dephosphorylation by phosphatases, but Ser42 
may be resistant to such dephosphorylation, particularly when cAMP is at basal 
levels.  
 
 
4.2.6 Mutation of PDE4D7 N-terminal Phospho-site Confirms Loss 
of PDE4D7-mediated cAMP Hydrolysis is Important for the 
AI Phenotype. 
 
In chapter 3, I presented evidence that PDE4D7-mediated cAMP hydrolysis 
reduced the proliferation rate of AI PC cells. If an abundance of cAMP at the 
plasma membrane is an important factor in the aberrant proliferation of AI PC, 
then it would be expected that overexpression of the hyperactive S42A mutant 
would substantially reduce the growth rate of such cells. Indeed, DU145 cells 
transfected with this mutant or wtPDE4D7 displayed significantly reduced 
proliferation (figure 4.12 A and B). Both proteins brought about such a 
reduction, as previously reported for wtPDE4D7, but S42A retarded growth by a 
further 65% (figure 4.12 C). The expression of the mutant construct was 15% that 
of wtPDE4D7 (figure 4.12 D), and so cell index and slope values were corrected 
for this by multiplying the values by 15%. The decrease in proliferation rate 
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caused by the hyperactive mutant supports the hypothesis that loss of PDE4D7-
mediated cAMP hydrolysis is an important factor in the development of the AI 
phenotype. 
 
 
 
 
 
 
 
 
Figure 4.12. The S42A-PDE4D7 mutant significantly reduces AI cell growth compared to 
wtPDE4D7.  
A; the electrical impedance-based xCELLigence system was used to measure the 
proliferation of DU145 cells transfected with VSV-tagged wild type PDE4D7 (wt) 
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or the S42A mutant or a control construct (mock), as shown by a growth curve. 
B; the slope of the growth curve was calulcated by linear regression analysis 
using the cell indices (CI) from each proliferation assay. C; the slope of DU145 
cells transfected with S42A-PDE4D7 as a % of wtPDE4D7. D; western blot analysis 
of transfection, S42A construct expressed at 15% that of wt, the cell indeces and 
slope values were adjusted for this.  
 
 
4.3 Discussion 
 
PDE splice variants are subject to various levels of regulation; differential tissue 
expression, subcellular localisation and protein-protein interactions, with further 
regulation achieved through PTMs that regulate their enzymatic activity and 
association with binding partners (Bender and Beavo 2006; Omori and Kotera 
2007). Tight control of these regulatory mechanisms is paramount to maintaining 
compartmentalised cyclic nucleotide signalling and thus cellular homeostasis 
(Houslay 2010).  
 
In the last decade or so, PTMs have gained much interest as markers of disease 
and as potential therapeutic targets (Krueger and Srivastava 2006). As discussed, 
hyperphosphorylation is an important event in diseases such as AD (Cole, Soutar 
et al. 2008). Inappropriate PTMs of signalling pathway intermediates is also an 
important factor in the repression or activation of anti- and pro-oncogenic 
pathways. Among them, aberrant phosphorylation is a key event in 
carcinogenesis and occurs with the tumour suppressor PTEN and members of the 
MAPK signalling cascade (Krueger and Srivastava 2006). The tumour suppressors 
Rb and p53, are also both hyperphosphorylated during tumourigenesis, due to 
inhibition of phosphatase activity (Yatsunami, Komori et al. 1993). In breast 
cancer, the Akt substrate of 160kDa (AS160), is hyperphosphorylated on a single 
site; T642, compared to normal breast tissue (Jiang, Sun et al. 2010). The 
phosphoproteome of a tumour may predict the efficacy of a given anti-cancer 
drug, and its elucidation is becoming easier thanks to the ever increasing 
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number of phospho-specific antibodies being designed (Krueger and Srivastava 
2006). 
 
Phosphorylation plays an important role in the regulation of PDE4 isoforms. PKA 
phosphorylation on the UCR1 region of long form PDE4s is fundamental to their 
activation, enabling hydrolysis of local cAMP (Sette and Conti 1996; MacKenzie, 
Baillie et al. 2002). It is believed that a conformational change involving the 
active site and UCR2 underpins the mechanism of long form PDE4 activation. 
PDE4D3 was rendered constitutively active following cleavage of its UCR2 
domain (Lim, Pahlke et al. 1999), and the crystal structure of the PDE4 UCR2 
domain showed that it exhibited good shape complementarity with the active 
site, its affinity for which was increased by PDE4 inhibitors (Burgin, Magnusson et 
al. 2010). It has also been proposed that the UCR1 and UCR2 domains interact, 
via electrostatic interactions in the inactive conformation, and PKA 
phosphorylation of UCR1 disrupts this interaction (Beard, Olsen et al. 2000). 
Perhaps UCR2 is bound to both UCR1 and the active site and dissociation of both 
interactions occurs following PKA phosphorylation of UCR1, as depicted in figure 
4.1.   
 
While PKA activates long PDE4 isoforms, ERK phosphorylation acts to inhibit their 
activity (Hoffmann, Baillie et al. 1999). All PDE4 isoforms possess two ERK 
docking sites around the catalytic region; FQF and KIM, which are C and N-
terminal to the target serine respectively (MacKenzie, Baillie et al. 2000). ERK 
phosphorylation at this site inhibits long and super short PDE4 isoforms, but 
activates short PDE4 isoforms (Baillie, MacKenzie et al. 2000; MacKenzie, Baillie 
et al. 2000). The PDE profile within a given cell will therefore determine the 
result of ERK signalling within that cell. ERK inhibition of long PDE4 isozymes 
allows a transient increase in local cAMP and PKA activity, which permits 
downstream signalling cascades. PKA then phosphorylates the PDE, overriding 
ERK inhibition and bringing about cAMP hydrolysis and cessation of signal via 
feedback control. 
 
Phosphorylation of PDE4 isoforms may not only act to regulate enzyme activity, 
but may be important for protein-protein interactions. Indeed, the long PDE4D3 
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isoform is phosphorylated by PKA within its unique N-terminus on Ser13, an 
event distinct from UCR1 phosphorylation (Sette and Conti 1996). 
Phosphorylation on Ser13 mediates interactions with scaffolding proteins such as 
MAKAP, as well as PKA, MAPKs and PP2A (Carlisle Michel, Dodge et al. 2004; 
Dodge-Kafka, Soughayer et al. 2005; Dodge-Kafka and Kapiloff 2006; Collins, 
Murdoch et al. 2008; Dodge-Kafka, Bauman et al. 2010; Murdoch, Vadrevu et al. 
2011). This phosphorylation event acts to sequester PDE4D3 in the vicinity of 
local cAMP, and enables a dynamic ‘swapping’ of binding partners mechanism, 
thereby spatially and temporally sculpting the signalling cascade in which the 
aforementioned scaffolds and enzymes are involved.  
 
PDE4D3 is the only known case to date where such N-terminal phosphorylation 
occurs within a PDE4 isoform. However, here I present evidence for similar PKA 
mediated phosphorylation of PDE4D7 within its unique N-terminal region. The 
use of peptide array technology and purified GST recombinant proteins verified 
that Ser42 is a PKA substrate. This was further validated with the successful 
cloning of phospho-site mutants and the use of a novel phospho-site specific 
antibody. The successful raising of this antibody was pivotal to the success of 
these experiments, and necessary for any ex vivo endogenous, and potential 
future in vivo studies.   
 
It must be noted there is a concern with PKA assays carried out using purified 
PKA catalytic subunit, as they can produce artifactual results. It is known that 
phospho-proteins can be phosphorylated by a greater number of kinases in vitro 
compared to in vivo because isolated catalytic units of kinases used in vitro are 
promiscuous with regard to substrates, possibly due to lack of regulation such as 
that conferred by the regulatory domains of PKA (Ge Wu 2010, Assay 
Development: Fundamentals and Practices). However, I show that the 
phosphorylation of Ser42 occurs ex vivo; both in overexpressing Hek293 cells, 
and in the DuCaP and VCaP endogenous systems. The latter results especially 
give much credence to the notion that this event occurs in vivo.  
 
What is interesting from the results presented here is the level of basal Ser42 
phosphorylation, as opposed to UCR1 phosphorylation, which occurs only after 
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forskolin challenge. Basal (pertaining to cells which have not been stimulated) 
phosphorylation of PKA substrate proteins has been previously reported 
(Steinberg and Kiss 1985). Steinberg and colleagues found that many PKA 
substrates show basal phosphorylation which is dependent on active PKA 
catalytic subunits and the extent of phosphorylation is mediated by basal AC 
activity. They suggest that PKA can be partially activated under basal cAMP 
conditions. Interestingly, they reported that such basal phosphorylation was not 
transient, but stable and prolonged. Steinberg and colleagues also looked at 
vimentin which has two cAMP regulated phospho sites, but they could not detect 
dual-phosphorylated vimentin even under activating PKA conditions, suggesting 
that cAMP can bring about both phosphorylation and dephosphorylation by 
independent mechanisms, or phosphorylation of one site may inhibit that of 
another. Basal phosphorylation of hormone sensitive lipase (HPL), involved in 
adipose tissue lipolysis, has also been reported (Garton, Campbell et al. 1989; 
Garton and Yeaman 1990). Here, under basal conditions, phosphorylation of site 
2 (termed the basal site) inhibits subsequent phosphorylation of site 1. 
Stimulation of the adipocytes causes a net increase in phosphorylation of site 1 
resulting in activation of HPL. Such mutually exclusive phosphorylation of two 
sites also occurs on acetyl-CoA carboxylase (Munday, Carling et al. 1988). These 
data suggest that enzyme activity can be subject to a complex balancing act of 
other protein kinases and phosphatases, and that such basal phosphorylation 
events are likely important for cellular homeostasis.  
 
The observations by Steinberg and colleagues are very interesting in light of the 
results presented here. Phosphorylation of PDE4D7 on Ser42 under basal 
conditions may retain the enzyme in an inactive state to allow basal cAMP 
signalling, thus acting in a positive feedback loop. Following ligand stimulation 
of the Gs–coupled GPCR associated with PDE4D7 signalling, the rise in cAMP and 
thus PKA activity may lead to phosphorylation of UCR1 in concurrence with 
dephosphorylation of pSer42, such as suggested by Steinberg and colleagues in 
their system. Alternatively, phosphorylation of UCR1 may simply override the 
effect of pSer42, while both sites remain phosphorylated. The latter hypothesis 
seems more plausible, as Ser42 remains phosphorylated alongside UCR1 
phosphorylation following forskolin challenge (figure 4.10 A).  
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However, PKA phosphorylation of UCR1 is sufficient to activate PDE4D7, and loss 
of this phosphorylation following a drop in intracellular cAMP is sufficient to 
inactivate PDE4D7 again. So why then have this phosphorylation event within the 
N-terminus? It could be that basal cAMP signals in cells expressing PDE4D7 are 
important for cellular homeostasis and a reduction in the intrinsic activity of the 
PDE4 complement is required to allow these signals to propagate. Nevertheless, 
it certainly seems necessary, as inhibition of this event leads to hyperactivity as 
observed with the PDE4 activity assays, and results in a significantly higher rate 
of cAMP hydrolysis as suggested by the proliferation assays. I hypothesise that 
PDE4D7 N-terminal phosphorylation may be involved in keeping PDE4D7 in an 
inactive conformation. The UCR1 and UCR2 domains are suggested to form an 
interacting module via non-covalent interactions in the inactive state, which is 
disrupted upon UCR1 phosphorylation (Beard, Olsen et al. 2000). Perhaps in the 
inactive state the phosphorylated N-terminal region of PDE4D7 interacts with the 
UCR domains in a similar manner, possibly acting to stabilise the UCR1-UCR2 
module/catalytic site interaction. Following stimulation of the cell and a rise in 
cAMP, UCR1 becomes phosphorylated which overrides the effect of N-terminal 
phosphorylation and allows the enzyme to take on a looser conformation via 
release of the UCR1/UCR2/catalytic domain association. Such a mechanism 
would prevent enzyme activity under basal levels of cAMP, thereby allowing 
basal signalling to occur. ERK phosphorylation and/or UCR1 dephosphorylation 
may then result in reformation of the tighter inactive enzyme conformation 
(figure 4.13).  
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Figure 4.13. Possible mechanism of Ser42 phosphorylation regulation.  
Under basal conditions, the enzyme is in a tight inactive conformation where 
Ser42 is phosphorylated by PKA and is associated with UCR1/UCR2 via 
electrostatic interactions. A rise in cAMP and PKA brings about UCR1 
phosphorylation leading to dissociation of the N-terminal/UCR1/UCR2/active site 
conformation. Enzyme inhibition due to ERK phosphorylation and/or 
dephosphorylation of UCR1 causes the enzyme to adopt the tight inactive 
conformation again.  
 
 
It may be that the N-terminal region of PDE4D7 is intrinsically disordered, which 
would allow transient association with the UCR1/UCR2 module in a kinetically 
favourable manner. Disordered protein domains have gained much interest in 
recent years. Modular proteins such as PDEs often posses both structured and 
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disorded domains (Dyson and Wright 2005), the latter being linker regions 
between the UCR domains of PDE4 isoforms, and possibly the N-termini. 
Eukaryotes posses the highest degree of protein disorder, as disorder permitted 
rapid evolution to quickly become multi-cellular organisms (Mittag, Kay et al. 
2010). Alternatively spliced exons have been found to commonly code for regions 
of intrinsic disorder in the resultant protein product, which prevents any 
structural damage to rest of the protein (Romero, Zaidi et al. 2006). Intrinsic 
disorder has also been shown to be strongly associated with protein regulation 
and signalling, with disordered regions often possessing phosphorylation sites, 
and being involved in auto-inhibition of enzyme function (Romero, Zaidi et al. 
2006). Charged residues within a disordered protein region also give rise to the 
‘polyelectrostatic’ effect, where multiple charges influence its binding affinity 
for other proteins via long-range electrostatic interactions, which give rise to a 
net charge (Borg, Mittag et al. 2007). The charges are often given by 
phosphorylation of multiple sites; however, in the case of PDE4D7, Ser42 
phosphorylation may confer an electrostatic effect that increases the affinity of 
the N-terminus for the UCR2/UCR1 module. The change in net charge upon UCR1 
phosphorylation may bring about the conformational change necessary for 
activation. Given that the UCR1/UCR2 electrostatic interaction is ablated by 
UCR1 phosphorylation or mutation of the target serine to aspartate  (Beard, 
Olsen et al. 2000), it seems likely that the change in net charge conferred by the 
negatively charged phosphate group on UCR1 induces conformational change. 
Perhaps phosphorylation of UCR1 causes a conformational change of the whole 
UCR1/UCR2/N-terminal module, resulting in a more linear enzyme in which 
cAMP can access the active site. Conversely, phosphorylation of Ser42 alone 
provides PDE4D7 with a net charge that supports a UCR1/UCR2/N-terminal 
module, which associates with the catalytic domain to ensure enzyme inactivity. 
Indeed, when Ser42 is mutated to aspartate, enzyme activity is negligibly 
altered (figure 4.9), giving credence to the idea that the phosphorylation of 
Ser42 provides a negative charge necessary for the inactive conformation. Such 
electrostatic interactions are known to play important roles in stabilising protein 
structures and phosphate groups provide enhanced electrostatic interactions not 
available to unmodified amino acids (Johnson and Barford 1994).  
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Another advantage of disorder is that such proteins or protein domains can bind 
other proteins in ways difficult for ordered proteins by wrapping around their 
binding partner, and thus increasing the specificity of the interaction by surface 
area (Mittag, Kay et al. 2010). Perhaps the PDE4D7 N-terminus wraps around the 
UCR1/UCR2/catalytic site module. Intrinsic disorder also allows proteins to 
interact with high specificity, but low affinity. This is desirable where such 
interactions need to be quickly ‘turned on and off’ (Mittag, Kay et al. 2010). Yet 
another advantage of disorder is that it allows proteins to bind various partners 
while retaining specificity (Wright and Dyson 1999), this may be the case with 
the PDE4D3 N-terminal domain, where phosphorylation of Ser13 is important for 
association with many other proteins, and indeed may also be the case for 
PDE4D7 Ser42. It is plausible to suggest that PDE4D7 may act in such a 
signalosome at the sub-plasma membrane region of PC cells. Like PDE4D3, it may 
associate with an AKAP and other proteins. The search for the PDE4D7 
interactome is discussed in Chapter 5. 
 
As discussed, PDE4 isoforms are said to exist in either the high affinity rolipram 
binding site (HARBS) or the low affinity rolipram binding site (LARBS) depending 
on tissue/cell expression, as different affinities for rolipram have been observed 
with the same isoform in different tissues and cellular fractions. (Souness and 
Rao 1997). Perhaps PDE4D7 N-terminal phosphorylation influences the ‘choice’ 
of conformer.  
 
Phosphorylation can also bring about a change in protein localisation, such as 
with the AR (Gioeli, Ficarro et al. 2002). It would be interesting to investigate if 
this occurred with PDE4D7 following a rise in cAMP. Due to time constraints the 
phospho-Ser42 specific antibody was not optimised for immunocytochemistry, 
but this is something we wish to pursue. Our collaborators in the Netherlands 
possess tissue slices from prostate cancer patients with varying stages of 
disease. It would be very interesting to use this antibody to investigate if there 
is a change in the population of N-terminally phosphorylated PDE4D7 as PC 
progresses from AS towards AI, until PDE4D7 expression is eventually lost. 
Perhaps the phospho-status of PDE4D7 would give an indication of disease stage.  
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As discussed, aberrant phosphorylation is often associated with disease, 
including cancer. Hyperphosphorylation of tumour suppressor proteins is a 
common occurrence in various cancers (Yatsunami, Komori et al. 1993; Krueger 
and Srivastava 2006; Jiang, Sun et al. 2010). It is quite conceivable to suggest 
that PDE4D7 becomes hyperphosphorylated on Ser42 during prostate 
carcinogenesis. A shift in the equilibrium towards a larger population of Ser42 
phosphorylated PDE4D7 enzymes would result in inappropriate levels of cAMP 
and thus PKA at the plasma membrane. This in turn would perpetuate the 
situation, increasing PDE4D7 N-terminal hyperphosphorylation. A large 
population of inactive PDE4D7 would lead to the abundance of cAMP at the 
plasma membrane we see in AI PC (Chapter 3). It is known that PKA isotype 
switching occurs during PC progression (Merkle and Hoffmann 2011), perhaps this 
would lead to aberrant PDE4D7 N-terminal phosphorylation.  However, PDE4D7 
expression is lost in AI PC, it is not just inactivated. Perhaps, as cAMP is ever 
increasing, inappropriate and promiscuous downstream signalling may be 
important in the shift away from androgenic signalling, which, as hypothesised in 
Chapter 3, would result in transcriptional repression of PART1 and consequently 
PDE4D7.  
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4.4 Chapter Summary  
1) PDE4D7 is phosphorylated by PKA within its N-terminal region. 
 
2) PDE4D7 N-terminal phosphorylation likely occurs in endogenously 
expressed proteins from cultured cells. 
 
3) PDE4D7 N-terminal phosphorylation acts to negatively regulate enzyme 
activity. 
 
4) Expression of the hyper-active S42A PDE4D7 mutant decreased AI PC cell 
growth, backing up the notion that increased cAMP within the PDE4D7 
locale is a contributing factor to the AI PC phenotype. 
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5  The Search for the PDE4D7 Interactome 
5.1 Introduction 
 
The end of the last century saw science move from the genomic era into the 
proteomic era, with protein interaction networks, or interactomes, becoming a 
main area of research in the cell biology field (De Las Rivas and Fontanillo 2010). 
Proteins rarely work alone, in fact >80% are said to work in complexes (Berggard, 
Linse et al. 2007), thus protein-protein interactions (PPIs) are important for any 
given protein to exert its biological functions. PPIs can be binary (direct) or 
functional (indirect), they may be defined as specific contacts between proteins 
that occur by selective molecular docking in a particular biological context (De 
Las Rivas and Fontanillo 2010), and are usually part of a larger subcellular PPI 
network, or signalling hub (Berggard, Linse et al. 2007). Elucidating how the 
proteome of a given cell is organised into these higher-order networks can be 
achieved by the daunting task of mapping all constitutive and transient PPIs, and 
large scale high-throughput proteomics experiments are ever increasing our 
knowledge of PPIs, with many online repositories now available (Drewes and 
Bouwmeester 2003; De Las Rivas and Fontanillo 2010). However, the hunt for 
PPIs is far more difficult than DNA sequencing, as these interactions are 
dynamic, ‘moving targets’, which often depend on cell type, cell cycle stage, 
PTMs, environmental factors and the presence of other interactors; and despite 
the vast amount of research and the technological advances in the methods used 
for such investigations, our knowledge of the complex protein networks within 
cells is still developing (Berggard, Linse et al. 2007; Blow 2009; De Las Rivas and 
Fontanillo 2010; Ngounou Wetie, Sokolowska et al. 2013). Expounding PPIs gives 
us insight in the workings of cell signalling pathways and thus the 
pathophysiology of disease. Knowledge of PPIs is essential, especially when a 
protein is considered as a promising therapeutic target. In such a case, any 
up/downstream proteins or events that would be affected by intervention should 
be identified.   
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A good deal is known about PDE4 interactions, particularly with scaffolds such as 
AKAPs and β-arrestins. As discussed, the long isoform PDE4D3 interacts with 
various proteins in different signalling cascades depending on subcellular 
localisation, such as with AKAP79 to mediate relaxin signalling (Halls and Cooper 
2010), and MAKAP to regulate local cAMP in the heart (Carlisle Michel, Dodge et 
al. 2004). PDE4D3 functions in a highly complex signalosome within the heart, 
where its phosphorylation status mediates its interactions with binding partners 
in a dynamic manner (Collins, Murdoch et al. 2008). PDE4D3 is also a member of 
the cardiac ryanodine receptor (RyR2)/ calcium-release-channel macromolecular 
complex which plays a role in excitation coupling in the heart (Lehnart, Wehrens 
et al. 2005). Thus, this isoform interacts with a range of other proteins to tightly 
control cAMP gradients within the heart. Interestingly, PDE4D3 can also act as a 
scaffold where it interacts with LIS1 to regulate neuronal cell migration 
(Murdoch, Vadrevu et al. 2011).  
 
Dynamic PPIs also play an important role in PDE4D5-mediated cAMP regulation at 
the β2-AR in cardiac cells, where it interacts with RACK1 or β-arrestin (Bolger, 
Baillie et al. 2006). Indeed, PDE4D5 is also suggested to function as a scaffold in 
the heart by sequestering EPAC1 (Berthouze-Duquesnes, Lucas et al. 2013).  
 
Recognition of certain protein domains is also important for PDE4 PPIs. PDE4A5 
and PDE4D4 interact with other proteins via SH3 domains, and such interactions 
regulate their subcellular localisation (Beard, O’Connell et al. 1999; McPhee, 
Yarwood et al. 1999; Beard, Huston et al. 2002).  
 
I have described how PDE4D7 protein expression is absent in AI PC cells and that 
PDE4D7-mediated cAMP signalling regulates AS PC cell proliferation. I have also 
presented evidence to suggest PDE4D7 is N-terminally phosphorylated by PKA, 
which may indeed mediate PPIs and this may be perturbed as PC progresses.  
However, no PDE4D7 interacting partners are known, and so I sought to identify 
such protein(s) in order to gain information on the signalling pathway(s) in which 
PDE4D7 is involved. If a pathway could be identified, the expression and/or 
activity of other signalling intermediates within that pathway could be compared 
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between AS and AI PC cells, perhaps providing a further point for potential 
therapeutic intervention.  
 
The aims of this chapter are to present the three proteomics approaches 
employed to investigate the PDE4D7 interactome; IP coupled with mass 
spectrometry (IP/MS); a yeast-two-hybrid (Y2H) screen; and ProtoArray 
technology. 
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5.2 Results  
5.2.1 Immunoprecipitation Coupled with Mass Spectrometry  
 
Immunoprecipitation coupled with mass spectrometry (IP/MS) is akin to affinity 
purification/MS, a common biochemical method for investigating PPIs (Ngounou 
Wetie, Sokolowska et al. 2013). The protein of interest, or bait, is overexpressed 
as a tagged fusion protein in cell system. Following an appropriate expression 
time, lysis of the cells and immunoprecipitation of the bait protein is carried out 
using an antibody against the tag, which increases specificity of the IP. This is a 
co-complex approach, so that any interacting partners, either direct or 
functional, are pulled down with the bait. Gel bands representing these 
interacting proteins are excised, digested and analysed by MS to determine their 
identity.  
 
Mass spectrometry (MS) is an analytical tool that has been used for decades to 
measure the molecular mass of organic compounds such as proteins/peptides, 
lipids, carbohydrates, nucelosides and environmental compounds (Biemann 
1963). Technological advances in MS over the last 20 years or so have made the 
identification of PPIs a relatively simple task, even allowing for the purification 
and analysis of large macromolecular complexes (Berggard, Linse et al. 2007). 
MS can determine the peptide and protein composition of very pure to more 
crude starting samples, and there are now a number of different instruments 
and types of analyses to give the desired information based on the sample used. 
There are two methods commonly used for protein analyses; Electrospray 
Ionisation (ESI) and Matrix Assisted Laser Desorption Ionisation (MALDI) (Trauger, 
Webb et al. 2002). ESI is a popular choice for identification of large proteins 
within a complex sample, particularly when coupled to nano-scale liquid 
chromatography and  tandem MS (nLC-ESI-MS/MS) (Yang, Zhang et al. 2007). 
Firstly, proteins in the sample are digested into smaller fragments by 
proteolysis, usually by trypsin. The fragments are then separated and purified by 
nano-capillary HPLC, analysing each peptide mass as they elute from the HPLC 
column.  The peptide fragments are then fed into the mass spectrometer via an 
inlet and ionisation, such as ESI, is carried out to allow separation based on mass 
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to charge (M/Z) ratio. If ESI is being used, charged droplets are produced when 
the solubilised sample is passed through a high voltage needle at atmospheric 
pressure (Wysocki, Resing et al. 2005).  A high vacuum then allows the ions to 
easily travel from one end of the instrument to the other (An Introduction to 
Mass Spectrometry, Scott E. Van Bramer, 1998). 
 
Tandem MS (MS/MS) instruments allow the detection of specific ions in a given 
sample. Ions are then fragmented and the m/z of the fragment ions is 
evaluated. (Wysocki, Resing et al. 2005).  Tandem MS usually comprises two 
mass spectrometers connected by a chamber, in which ions are selected in the 
first spectrometer according to weight, activated by collision with argon in the 
chamber, and the ion fragments are then analysed by a mass analyser in the 
second spectrometer. Analysis can be performed by a choice of mass analysers, 
which resolve the m/z by different methods, to give data output of a mass 
spectrum; a graph showing each specific molecule/amino acid by mass and how 
much of each molecule/amino acid is present in the sample. From analysis, the 
protein composition of the original sample can be determined by comparing 
sequence information to the databases, as the masses of all 20 amino acids are 
known.  
 
To identify PDE4D7 PPIs, VSV-tagged PDE4D7 was overexpressed in Hek293 cells. 
This was because at the time of this experiment, the new highly specific PDE4D7 
antibody had not yet been raised. The cells were lysed and immunoprecipitation 
undertaken with agarose beads conjugated to a VSV antibody. An IP was also 
carried out with mock transfected lysates. Following SDS-PAGE, the gel was 
Coomassie stained to identify any bands co-purifying with the PDE4D7-VSV. Any 
bands observed to repeatedly pull down (n=3), were excised from the gel, along 
with the corresponding gel band in the control lane. These bands were then 
subjected to nLC-ESI-MS/MS using quadrupole time of flight (Q-TOF). Q-TOF 
employs an electric field to accelerate the ions and the time it takes them to 
reach a detector at a known distance is measured. The velocity of an ion 
depends on its m/z, and heavier ions travel more slowly. The use of nLC-ESI-
MS/MS coupled with Q-TOF is commonly used due to enhanced sensitivity and 
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thus improved identification of amino acids (Lacorte and Fernandez-Alba 2006). 
Figure 5.1 illustrates the IP/MS workflow. 
 
 
 
 
 
Figure 5.1. nLC-ESI-MS/MS with Q-TOF workflow. 
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The bands excised for MS analysis are shown in figure 5.2. These bands could 
only be seen in the PDE4D7 VSV IP lane, and not in any other lane. Bands present 
in all lanes, or solely in any control lane were not excised. Since they could only 
be seen with the naked eye on the actual gel and did not scan well, the bands 
excised are indicted by red lines. Bands 5 and 7 represent two bands that were 
too close to excise individually, and so were analysed together. The 
corresponding areas in the mock-transfected VSV IP lane were also excised and 
analysed. IPs were also carried out using agarose beads conjugated to a FLAG 
antibody as a negative control. Along with the test bands, the band representing 
PDE4D7 was analysed to confirm identification.  
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Figure 5.2. A PDE4D7 pull down assay produces a number of possibly interacting proteins. 
Hek293 cells were transfected with VSV-tagged PDE4D7 or a control construct 
(mock) and cellular lysates were immunoprecipitated (IP) with agarose beads 
conjugated to VSV antibody or FLAG antibody. The samples were analysed by 
SDS-PAGE and Coomassie Blue staining. Inputs are the whole cell lysates from 
which the IPs were carried out. Red bands represent samples 1-7 that were 
excised for MS analysis, along with the corresponding region in the mock VSV IP 
lane. N=3.
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5.2.1.1 IP/MS Identified 5 potential PDE4D7 Interacting Partners 
 
IP/MS identified 20 proteins in the samples, 5 of which were in the PDE4D7 
samples only (table 5.1), along with identification of PDE4D7. The putative 
function of the interactors was obtained using Uniprot 
(http://www.uniprot.org/uniprot). 
 
 
 
 
Identified 
Protein 
Accession 
Number 
Putative Function 
 
Heat shock 
cognate 71 kDa 
protein (HSPA8) 
 
gi|123647  
 
Repressor of transcriptional activation. Chaperone. 
Involved in the spliceosome and activating pre-
mRNA splicing. 
PREDICTED: 
similar to heat 
shock protein 70 
[Equus caballus] 
 
gi|149732056  
 
Unknown. 
Octamer-binding 
protein (NONO) 
 
gi|1083440  
 
Binds DNA and RNA. Pre-mRNA splicing. Defective 
RNA retention. DNA repair. Necessary for cAMP 
dependant activation of CREB target genes. . It has 
also been shown to act as a transcriptional 
coactivator of the AR activation function 1 (AF-1) 
domain, and conflictingly, to repress AR 
transactivation.  It is activated in response to stress. 
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ATP-dependent RNA 
helicase A (DHX9). 
 
gi|100913206  
 
A member of the DEAH/DEAD box containing 
family of RNA helicases. It catalyses ATP-
dependant unwinding of dsRNA and DNA-RNA 
complexes. It shuttles between nucleus and 
cytosol and functions as a transcriptional 
regulator. 
PREDICTED: protein 
phosphatase 1 
regulatory subunit 
12A isoform 4  
 
gi|109097899  
 
Regulates myosin phosphatase activity in the 
cytoplasm. 
 
Table 5.1. MS analysis identified 5 potential PDE4D7 interacting proteins.  
Those in bold were chosen for PPI verification, based on association with cAMP 
signalling and cancer, as found in the literature. Verification analysis by 
secondary co-immunoprecipitation is reported below in figure 5.12. 
 
 
5.2.2 Yeast Two-Hybrid (Y2H) Screen 
 
The Y2H method was first described in the late 1980’s (Fields and Song 1989) 
and has become the method of choice when looking for novel interactions. It 
takes advantage of eukaryotic transcription factors which have discrete and 
separable DNA binding and Activation Domains (DBD/AD) (Causier and Davies 
2002). It takes place in genetically-modified yeast strains, into which the protein 
of interest and potential binding partners are co-transformed as fusion vectors, 
attached to the DNA DBD and AD of a transcription factor respectively, usually 
Gal4. The protein of interest is called the ‘bait’, and any interaction with ‘prey’ 
proteins brings about the reconstitution of the functional transcription factor, 
recruitment of RNA polymerase and transcription of a reporter gene that allows 
the yeast to grow on selective media, or cause a colour change. The reporter 
gene may code for an essential amino acid, such that only cells containing a 
bait-prey interacting pair may grow in broth deficient in amino acids. E.coli are 
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often employed to amplify the plasmids quickly, prior to a second yeast cell 
selection. The amplified plasmids are co-transformed back into yeast and 
positive clones are selected for by means of a β galactosidase assay. Yeast cells 
are grown on agar containing the lactose analog X-gal, which is broken down by 
β galactosidase to produce a blue colour. This colour represents colonies positive 
for a bait-prey interaction. A schematic representing the Y2H method is shown in 
figure 5.3. Y2H screens can be high-throughput to study protein interactions on a 
large scale, and many PPIs in the literature have been identified by this method 
(Bruckner, Polge et al. 2009).  
 
Commonly, a cDNA-library Y2H screen is carried out (Bruckner, Polge et al. 
2009). This investigates pair-wise interactions between a bait and a defined set 
of preys present in a given cDNA library. Libraries may contain DNA fragments or 
full length ORFs to cover a whole transcriptome. This method involves colony 
PCR analysis and sequencing to identify interacting partners.   
 
Y2H screens are generally preferred over IP/MS, mainly due to accessibility, as 
MS requires expensive instrumentation. Y2H is also an in vivo approach, whereas 
IP/MS employs ex vivo and in vitro techniques. Another advantage of Y2H 
concerns its binary nature, as this can give information about the dynamics of a 
PPI, such as dissociation rates (Blow 2009). Y2H also has the ability to detect 
weak PPIs (Causier and Davies 2002). However, a Y2H screen cannot detect 
interactions if they are dependent on a PTM (Bruckner, Polge et al. 2009). Since 
its introduction by Fields and Song, the Y2H has been modified to improve its use 
for identifying PPIs, and also interactions between proteins and nucleic acids 
(Causier and Davies 2002).  
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Figure 5.3. A yeast two hybrid screen.  
Plasmids engineered to express genes encoding fusion bait and prey proteins are 
transformed into yeast cells which are grown in selective medium, allowing only 
transformed cells to grow. M=marker gene, such as an essential amino acid. 
Colonies are then selected on amino acid deficient agar followed by isolation of 
the plasmids which are co-transformed into E.coli for amplification. Plasmids are 
again isolated, and co-transformed into yeast for confirmation of interactions 
and selection of cells expressing a bait-prey interacting pair by a β galactosidase 
assay. These positive plasmids are then sequenced for identification of the 
bait/prey pair.  
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5.2.2.1 A Yeast Two-Hybrid Screen Identified 13 Potential PDE4D7 
Interacting Partners 
 
The PDE4D7 Y2H screen was carried out by Mr. Bangze Jin of Shanghai Genomics 
Inc. PDE4D7-VSV (pcDNA3.1-PDE4D7) was used as template for the bait fusion 
vector; pGB-PDE4D7. Following cloning into yeast Y190 strains, and sequencing 
of pGB-PDE4D7, a self-activation test was performed which is imperative to 
ensure the bait-DBD fusion does not autonomously activate transcription of the 
reporter gene in the absence of the prey. The prey library available to us was a 
human foetal brain cDNA library. The Y2H screen involved 4 phases; 
 
Phase I: Subcloning; PDE4D7 was cloned into the pGB vector, and the construct 
was verified by DNA gel electrophoresis and sequencing (figure 5.4 A), followed 
by purification of the bait plasmid. 
 
Phase II: Toxicity and self activation test; yeast were transformed with the bait 
plasmid and auto-activation was tested for by a β galactosidase assay. pGB-
PDE4D7 did not induce toxicity in yeast, or self activation (figure 5.4 B-D).  
 
 
 
 
 
Figure 5.4. pGB-PDE4D7 was successfully cloned and did not induce self-activation in 
yeast.  
A; verification of the cloning of PDE4D7 into the pGB vector. B; a negative β 
galactosidase control test shows brown colonies. C; a positive β galactosidase 
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control test shows blue colonies. D; a β galactosidase assay for the bait plasmid, 
pGB-PDE4D7. Brown colonies confirm lack of self activation.  
 
 
Phase III and IV: Y2H screening of cDNA libraries and phenotypic validation 
(colour change). Yeast cells were co-transformed with bait plasmid and prey 
library. Cells were firstly transformed with the bait plasmid, cultured, and then 
transformed with prey plasmids from the library. 69 colonies grew on the amino 
acid-deficient agar plates and so were validated by a β galactosidase assay. Of 
these, 45 proved positive for β galactosidase (figure 5.5 A), the plasmids from 
which were isolated and transformed into E.coli for amplification. The amplified 
plasmids were then isolated and co-transformed into yeast for further validation 
by β galactosidase assays. From this, 15 positive colonies grew (figure 5.5 B). 
Sequencing of the 15 clones verified 13 potential PDE4D7 interactors (table 5.2). 
The putative function of the interactors was obtained using UniProt 
(http://www.uniprot.org/uniprot). 
 
 
 
 
 
 
Figure 5.5. Results of the yeast the hybrid screen.  
A; yeast cells were co-transformed with the bait plasmid (pGB-PDE4D7) and prey 
library. 45 of the yeast colonies that successfully grew on selective agar plates 
gave a positive result (blue colour) for the β galactosidase assay. B; these 45 
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positive plasmids were isolated and amplified in bacteria before being 
transformed back into yeast cells, and 15 colonies produced positive results 
(blue colour) for the β galactosidase assay. Varying degrees of blue colour 
change can be seen, representing different binding affinities of the bait-prey 
pairs. 
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Identified Protein Accession Number Putative Function 
(Uniprot) 
Microspherule Protein 1/ MSP58 
(MCRS1) 
NM_006337.3 
 
Putative regulatory component of the chromatin remodelling INO80 
complex which is involved in transcriptional regulation, DNA replication 
and probably DNA repair. 
SNAP-associated protein (SNAPIN) NM_012437.4 
 
a component of the SNARE complex of proteins that is required for 
synaptic vesicle docking and fusion. 
ENKURIN/ 
C10ORF63 
NM_145010.2 
 
Adapter that functions to localize a calcium-sensitive signal transduction 
machinery in sperm to a calcium-permeable ion channel. 
Protein phosphatase 3 catalytic 
subunit beta isozyme (PPP3CB) 
NM_021132.2 
 
Calcium-dependent, calmodulin-stimulated protein phosphatase. 
Retinoid X receptor beta (RXRB) NM_021976.3 
 
a member of the retinoid X receptor (RXR) family of nuclear receptors 
which are involved in mediating the effects of retinoic acid (RA). 
PHD finger protein 19 (PHF19) NM_001009936.1 
 
Transcriptional repressor. 
BTB (POZ) Domain Containing 2 
(BTBD2) 
NM_017797.3 
 
Involved in several cellular processes including proliferation, apoptosis and 
transcription regulation. 
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UPF3 Regulator Of Nonsense 
Transcripts Homolog  (UPF3B) 
NM_080632.2 
 
Involved in nonsense-mediated decay (NMD) of mRNAs containing 
premature stop codons. 
Zinc finger protein 302 (ZNF302) NM_001012320.1 
 
May be involved in transcriptional regulation 
Ribosomal protein L12 (RPL12) NM_000976.3 
 
Ribosomal protein that is a component of the 60S subunit. 
General Transcription Factor IIIA 
(GTF3A) 
 
NM_002097 
 
Functions as an RNA polymerase III transcription factor to induce 
transcription of the 5S rRNA genes. 
 
Glyoxylate Reductase 1 Homolog 
(GLYR1)  
 
NM_032569.3  
 
Regulates p38 MAP kinase activity by mediating stress activation of 
p38alpha/MAPK14 and specifically regulating MAPK14 signalling.  
 
PDE4A NM_001111307.1  
 
Phosphodiesterase 4A family 
Table 5.2. A Y2H screen identified 13 potential PDE4D7 interacting proteins. Those in bold were chosen for PPI verification, based on 
association with cAMP signalling and cancer as found in the literature. Verification analysis by co-immunoprecipitation is reported 
below in figure 5.12. 
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5.2.3 ProtoArray Technology 
 
For years the yeast two hybrid screen was the only available genome-wide 
method for studying protein interactions and it is associated with a number of 
limitations; false positives, particularly from proteins that function as 
transcriptional activators, incorrect protein folding, inappropriate PTMs, and 
difficulty controlling environmental conditions (MacBeath and Schreiber 2000). 
The subsequent advent and advancement of protein microarrays has allowed 
rapid and robust screening of interactions in a high-throughput, miniaturised and 
parallel manner. Protein-protein, protein-nucleic acid, protein-small molecule, 
protein-lipid, and enzyme-substrate interactions can be identified, as well as 
antibody specificity and autoantibody characterisation (Schweitzer, Predki et al. 
2003; Predki 2004). Protein microarrays have been successfully used to identify 
differentially expressed proteins in ovarian cancer (Hudson, Pozdnyakova et al. 
2007), and to identify novel intermediates of the NFκB signalling pathway 
(Fenner, Scannell et al. 2010). The commercial introduction of functional 
protein microarrays has led to huge potential for the discovery of novel protein 
interactions and drug development (Predki 2004). 
 
The ProtoArray human protein microarray-based platform (Invitrogen) was 
employed to investigate PDE4D7 PPIs. These microarrays contain >9,500 
proteins, highly purified from Sf9 insect cells as N-terminal GST fusion proteins 
which are immobilised at spatially addressable positions on nitro-cellulose-
coated glass slides. Expression in insect cells allows for correct mammalian 
protein folding and PTMs (Bouvier, Menard et al. 1998). A bait protein that is 
overlaid on the array may interact with the immobilised proteins, which are 
spotted in duplicate and extend from the array surface via the epitope tags, 
allowing them to be spatially accessible to the purified bait. Each ProtoArray has 
a barcode that can be used to download the Protein Content List for that array. 
The arrays also contain a number of control proteins which allow for correct 
orientation of the array and verification of probing and detection methods, some 
of which are listed in table 5.3. Following probing of the array with bait and 
antibody detection, the array is scanned using a suitable microarray scanner and 
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images of the array are analysed for any interactions (figure 5.6). Binding of the 
protein of interest to any protein on the array manifests as a fluorescent spot, 
and both duplicate protein spots on the array must be bound before a positive 
result is recorded (see figure 5.7). Any spots other than the positive controls 
represent a possible interaction. The scanned images of the arrays are analysed 
by a software programme that gives the spots a confidence score and a flag 
value of A-E, where A indicates strongest fluorescence/binding, and the 
duplicate pair must both score A or B to be considered interactors of the bait 
protein. The test array scores are cross-referenced with those from control 
arrays, and any hits with a score of A/B on the test array only, are considered 
for further investigation. The protein identities (Ids) can then be used to identify 
any interactor in the Protein Content List.  
 
Protein Function 
Alexa Fluor® Antibody(Rabbit anti-mouse 
IgG Antibody labelled with Alexa Fluor® 
647, Alexa Fluor® 555, and Alexa 
Fluor® 488). 
Serves as a positive control for fluorescence 
scanning and for orientation of the 
microarray image.  
Bovine Serum Albumin (BSA) A negative control for non-specific protein 
interactions. 
GST Protein Gradient Serves as a negative control and signals are 
used by ProtoArray® Prospector software 
for background and statistical significance  
calculations 
Alignment Control Kinase (PKCeta)  Kinases autophosphorylate and produce 
signals which are used for orientation of 
the microarray image; also serves as a 
positive control for the radiolabel and assay 
conditions. 
BioEase™ V5 Control Protein (biotinylated, 
V5-tagged control protein) 
A positive control for detection with the 
Anti-V5-Alexa Fluor® 647 Antibody, used 
with the ProtoArray Control Protein 
Microarray (described below). 
Anti-biotin Antibody (mouse anti-biotin 
antibody)  
Detects biotin labeled protein probes and 
serves as a control for anti-mouse antibody 
detection reagent. 
Yeast calmodulin (Cmd1p) or human 
calmodulin (CALM2)  
A positive control for protein-protein 
interaction application and interacts with 
the Array Control Protein. 
 
Table 5.3. ProtoArray slides contain a number of control proteins for background, 
orientation of the array, and verification of detection conditions.  
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Figure 5.6.  The ProtoArray experimental workflow 
 
 
5.2.3.1 Optimisation of ProtoArray Conditions  
 
Due to the expense of the ProtoArray slides, the experimental conditions were 
optimised prior to the PPI experiment, using a ProtoArray Control Protein 
Microarray with an Array Control Protein (Invitrogen). The control ProtoArray 
chips contain only controls (table 5.3) which allow validation of probing and 
scanning procedures. The control protein is a recombinant BioEase™-V5-tagged 
yeast calmodulin kinase (Cmk1p) and probing with an anti-V5 antibody verified 
the experimental procedure and conditions as seen by detection of the Alexa 
Fluor™ and biotin antibodies, the  BioEase™V5 control protein and calmodulin 
(figure 5.7).  
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Figure 5.7. A ProtoArray Control Protein Microarray verifies experimental conditions. 
A ProtoArray Control Protein Microarray was incubated with Array Control 
Protein. The array was then probed with anti-V5 primary antibody and Alexa 
Fluor® secondary antibody, and scanned. The bound Array Control Protein (spots 
7), biotin (spots 6) and calmodulin (spots 8,) were detected on the ProtoArray 
Control Protein Microarray; validating the experimental procedure and 
conditions such as wash times, buffers etc. Spots 1-5 are Alexa Fluor® antibodies 
immobilised on the ProtoArray Control Protein Microarray which serve as positive 
controls for fluorescent scanning and allow correct orientation of the array. N=1. 
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5.2.3.2 Validation of Purified PDE4D7 
 
A full length recombinant GST-fusion of PDE4D7, purified from a baculovirus SF9 
expression system, was purchased. Prior to carrying out the ProtoArray, the 
protein and the ability of a PDE4D7 antibody to detect the protein were verified 
by means of a spot blot and western blot analysis. The PDE4D7 specific antibody 
discussed in Chapter 3 that detects only overexpressed protein was used, as the 
novel highly specific antibody was not available at the time of this experiment. 
The PDE4D7-GST fusion protein was successfully detected using a GST antibody 
(figure 5.8 A) and the PDE4D7 antibody (figure 5.8 B); verifying both the protein 
and the antibody.  Spot blot analysis was also carried out to verify that the 
PDE4D7 antibody could detect the native protein (figure 5.8 C). 
 
 
 
 
 
 
 
 
Figure 5.8. Validation of PDE4D7-GST for ProtoArray.  
The GST-PDE4D7 fusion protein was validated by blotting with A) GST antibody 
and B) PDE4D7 antibody. C; spot blot analysis confirms the PDE4D7 antibody can 
detect native PDE4D7-GST.  N=1. 
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5.2.3.3 ProtoArray Technology Identifies 22 Potential PDE4D7 Interactors 
 
Following the positive control experiment, a PDE4D7 ProtoArray along with two 
negative control ProtoArrays was investigated. Since the ProtoArray proteins and 
PDE4D7 were GST fusions, one negative control employed incubation with 
purified GST, the second was an antibody-only control. All three ProtoArrays 
contained the same protein library. Scanning the ProtoArrays detected positive 
control spots such as the Alexa Fluor® antibodies, again verifying the 
probing/detection/scanning protocols and allowing for orientation of the arrays. 
Both control arrays displayed minimal spots other than the controls, whereas 
there were a number of fluorescent sots on the PDE4D7 array (figure 5.9). 
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Figure 5.9. ProtoArray technology detects a number of potential PDE4D7 interactors, 
compared to control arrays.  
ProtoArray Human Protein Microarrays containing identical protein libraries were 
incubated with purified GST-PDE4D7 fusion protein (PDE4D7) or purified GST or 
secondary antibody only. The arrays were then probed with PDE4D7 primary 
antibody followed by Alexa Fluor secondary antibody, and a number of potential 
protein interactors were detected on the GST-PDE4D7 array only. N=1. 
 
 
 
Following scanning of the arrays and acquisition of the images (figure 5.9), 
BlueFuse (BlueGenome) microarray processing software was used to analyse and 
interpret the results. BlueFuse gave an excel output listing the IDs of all the 
proteins on each array. The IDs were then used to find the corresponding protein 
accession numbers in the Protein Content List, which were entered into the 
excel files (figure 5.10). The scores for all proteins from the PDE4D7 array were 
cross referenced with those of the negative controls. Any high scoring proteins 
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that scored A-C in the controls were disregarded, until a shortlist of proteins 
with a flag score of A/B for PDE4D7, but D/E for the controls, was obtained. The 
shortlist of hits was then checked against the scanned image of the PDE4D7 
ProtoArray, to ensure the corresponding pair of fluorescent spots were 
prominent, and thus not a false positive, in which case it would be disregarded. 
The final list of potential PDE4D7 interactors is shown in table 5.4. The putative 
function of the interactors was obtained using UniProt 
(http://www.uniprot.org/uniprot). 
 
 
 
 
 Figure 5.10. An example of the BlueFuse results for PDE4D7 PPIs.  
A; an Alexa Fluor® positive control pair scores a high confidence and Flag score. 
B; a BSA negative control pair scores a low confidence and Flag score. C and D; 
potential PDE4D7 interactors score high confidence and flag scores.  
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Identified Protein Accession Number Putative Function 
AMPK-related protein kinase 5 NM_014840 Involved in tolerance to glucose starvation. 
Activating transcription factor 3 (ATF3) NM_001674.1 Member of the mammalian 
(CREB) protein family of transcription factors. 
Regulatory factor X, 5 (RFX5) NM_000449.2 Influences HLA class II expression. 
Atlastin GTPase 3 (ATL3) NM_015459.3 Involved in endoplasmic reticulum tubular network biogenesis. 
Mitogen-activated protein kinase kinase kinase 9 
(MAP3K9/MLK1) 
NM_033141.2 Phosphorylates a number of transcription factors in response to activation 
by environmental stress and pro-inflammatory cytokines. 
Chemokine (C-X-C motif) ligand 5 (CXCL5) NM_002994.2 Proposed to bind the G-protein coupled receptor chemokine (C-X-C motif) 
receptor 2 to recruit neutrophils, to promote angiogenesis and to remodel 
connective tissues. Thought to play a role in cancer cell proliferation, 
migration, and invasion. 
Ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase) (UCHL1) 
NM_004181.2 specifically expressed in the neurons and in cells of the diffuse 
neuroendocrine system. Mutations in this gene may be associated with 
Parkinson disease. 
 
Phosphatidic acid phosphatase type 2B (PPAP2B) NM_003713.3 Hydrolyses extracellular lysophosphatidic 
acid and short-chain phosphatidic acid. 
Leukocyte specific transcript 1 (LST1 NM_205840.1 
 
Possible role in modulating immune responses; a membrane protein that 
can inhibit the proliferation of lymphocytes 
CHK2 checkpoint homolog (CHEK2) NM_001005735 A cell cycle checkpoint regulator and putative tumour suppressor. 
Lipolysis stimulated lipoprotein receptor (LSR), 
transcript variant 2 
NM_205834.2 Unknown 
Peroxisomal biogenesis factor 16 (PEX16), transcript 
 
NM_004813.1 Peroxisome rganiSation and biogenesis. 
Mal, T-cell differentiation protein-like (MALL), NM_005434.3   Raft-mediated trafficking in endothelial cells 
Cancer/testis antigen family 45, member A3, BC028711.2   Unknown. Expressed in cancer cell lines. 
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V-raf murine sarcoma 3611 viral oncogene homolog 
(A-RAF) 
 
NM_001654.1 This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein 
kinase family, and maybe involved in cell growth and development. 
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) NM_001261409.1 
 
Component of intracellular signal transduction that causes estrogen-
independent proliferation in human breast cancer cells.  
Interleukin-1 receptor-associated kinase 4 (IRAK4) 
 
NM_016123 
 
Activates NF-kappaB in both the Toll-like receptor (TLR) and T-cell receptor 
(TCR) signalling pathways 
Nemo-like kinase (NLK), 
 
NM_016231.2 MAPK and Wnt signalling. Inhibits NFκB. 
Casein kinase 1, epsilon (CSNK1E). 
 
NM_001894 
 
 Implicated in the control of cytoplasmic and nuclear processes, including 
DNA replication and repair. Component of the circadian clock. 
ERBB receptor feedback inhibitor 1 (ERRFI1/MIG6) 
NM_018948.2 
 
Negatively regulates EGFR signalling.  
Homo sapiens NUAK family, SNF1-like kinase, 
(NUAK1). 
 
NM_014840 Serine/threonine-protein kinase involved in various processes such as cell 
adhesion, regulation of cell ploidy and senescence, cell proliferation and 
tumour progression.  
 
NFKB inhibitor interacting Ras-like 2 (NKIRAS2) 
 
NM_017595.2 
 
A potent regulator of NFκB activity by preventing the degradation of NF-
kappa-B inhibitor beta (NFKBIB). 
 
 
Table 5.4. ProtoArray hits of potential PDE4D7 interactors.  
Those in bold were chosen for PPI verification, based on association with cAMP signalling and cancer as found in the literature. 
Verification analysis by secondary co-immunoprecipitation is reported below in figure 5.12. 
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5.2.4 Verification of Potential PDE4D7 Interactors  
 
From the three proteomics approaches employed, the following 23 proteins were 
chosen for verification of PDE4D7 PPIs. The reasons behind the prioritisation of 
these candidates are discussed below: 
 
 
1) Activating transcription factor 3 (ATF3) is a member of the ATF/CREB family 
of transcription factors and is involved in responses to various stress signals 
(Thompson, Xu et al. 2009). It is implicated in various cancers and a number of 
studies suggest it regulates PC cell growth (Liu, Gao et al. 2013; Wang and Yang 
2013). Interestingly, ATF3 is androgen-regulated (Pelzer, Bektic et al. 2006) and 
can bind the AR, inhibiting AR-mediated transcription (Wang, Jiang et al. 2012). 
 
2) Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) is a ubiquitously expressed 
protein involved in breast cancer cell proliferation and overexpression confers 
resistance to anti-oestrogens (van Agthoven, van Agthoven et al. 1998). 
 
3) Casein kinase 1, epsilon (CSNK1 ε) regulates circadian rhythm and is suggested 
to be involved in cancer by phosphorylating p53, and may be a potential target 
for cancer therapy (Knippschild, Milne et al. 1997; Yang and Stockwell 2008). 
More recently CSNK1 ε has been implicated in beta-catenin active cancers (Kim, 
Dunn et al. 2010), and beta-catenin signalling is often dysregulated in PC (Lee, 
Madar et al. 2013).  
 
4) Nemo-like kinase (NLK) is a MAPK-like kinase involved in wnt signalling, it has 
been shown to be downregulated in metastatic prostate tumours compared to 
primary tumours and normal tissue, and to inhibit AR-mediated transcription 
thereby inducing apoptosis (Emami, Brown et al. 2009).  
 
5) Glyoxylate Reductase 1 Homolog (GLYR1) regulates stress induced MAPK/p38 
signalling (Fu, Yang et al. 2006). It has been shown to be a highly mutated driver 
gene in colorectal cancer (CRC), with loss of function in a subset of tumours 
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(Alhopuro, Sammalkorpi et al. 2012), and the fusion protein GLYR1-SLC9A8 
which also results in GLYR1loss of function has recently been implicated in PC 
progression (Wang, Liu et al. 2014). CRC has been shown to predispose younger 
men to PC, and there may be common genetic factors (Moot, Polglase et al. 
2003). 
 
6) Octamer-binding protein NONO/p54nrb mediates cAMP-regulated transcription 
by tethering transducers of regulated CREB (TORCs) to RNA polymerase II at CRE 
loci and has been found to regulate AR transcriptional activity (Ishitani, Yoshida 
et al. 2003; Amelio, Miraglia et al. 2007; Dong, Sweet et al. 2007). 
 
7) ENKURIN is an adaptor protein that can bind SH3 domains, with high affinity 
for the p85 regulatory subunit of PI3K (Sutton, Jungnickel et al. 2004) which 
mediates breast cancer tumour activity (Folgiero, Di Carlo et al. 2012), and AS 
PC cell growth upon PKA phosphorylation (Feola, Cimini et al. 2013). 
 
8) Cancer/testis antigen family 45, member A3 is member of the cancer/testis 
(C/T) gene family that is normally expressed exclusively in the testes but is 
expressed elsewhere in a wide variety of malignant tumours (Costa, Le Blanc et 
al. 2007). CT45 is a recently identified isoform, expression of which is correlated 
to cancer progression and poor prognosis (Koop, Sellami et al. 2013). 
 
9) Protein phosphatase 3 catalytic subunit beta isozyme (PPP3CB) is upregulated 
in response to cAMP signalling (Consales, Volpicelli et al. 2007). Long non-coding 
RNA (lncRNA) within the PPP3CB locus has been associated with cancer (Tahira, 
Kubrusly et al. 2011).   
 
10) General Transcription Factor IIIA (GTF3A) is involved in cAMP signalling by 
interacting with cAMP-responsive element modulator (CREM) (De Cesare, Fimia 
et al. 2003). 
 
11) Interleukin-1 receptor-associated kinase 4 (IRAK4) is a critical component of 
the Toll-like receptor (TLR) signalling pathway and SNPs in this gene may be 
associated with PC (Sun, Wiklund et al. 2006; Rogers, Jones et al. 2013). 
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 12) ERBB receptor feedback inhibitor 1 (ERRFI1) is a negative regulator or EGFR 
signalling, which is associated with many cancers including PC (Siu, Virtanen et 
al. 2011).  
 
13) NFKB inhibitor interacting Ras-like 2 (NKIRAS2) is an NFκB inhibitor   (Huxford 
and Ghosh 2006). NFκB has been shown to work with CREB to induce tumour cell 
migration and invasion during hypoxia, and PKA/ NFκB signalling mediates AI PC 
cell growth (Vinall, Mahaffey et al. 2011; Nakayama 2013). 
 
14) ATP-dependent RNA helicase A (DHX9) has been shown to be necessary for 
human embryonic stem cell (hESC) renewal and cancer cell proliferation (Narva, 
Rahkonen et al. 2012). It has also been implicated in multi-drug resistance in 
cancer (Zhong and Safa 2004), and interestingly maps to a major PC 
susceptibility locus (Lee, Eki et al. 1999). 
 
15) Homo sapiens NUAK family, SNF1-like kinase, (NUAK1) is a member of the 
stress-activated AMP protein kinase (AMPK) family which has been found to 
mediate tumourgeneisis, particularly invasion and angiogenesis (Kusakai, Suzuki 
et al. 2004; Chen, Li et al. 2013). 
 
16) Mitogen-activated protein kinase kinase kinase 9 (MAP3K9) is a 
serine/threonine kinase within the ERK/MAPK signal transduction cascade and is 
associated with melanoma, lung cancer and CRC (Slattery, Lundgreen et al. 
2012; Stark, Woods et al. 2012; Fawdar, Trotter et al. 2013).  
 
17) Chemokine (C-X-C motif) ligand 5 (CXCL5) is part of the intraprostatic 
immune system and has been associated with PC progression by mediating 
proliferation, migration, metastasis, angiogenesis and epithelial to mesenchymal 
transition (EMT) (Begley, Kasina et al. 2008; Begley, Kasina et al. 2008; Eyman, 
Damodarasamy et al. 2009; Kuo, Chen et al. 2011; Karagiannis, Saraon et al. 
2013).  
 
18) Retinoid X receptor beta (RXRB) is a steroid hormone receptor involved in 
transcriptional regulation of target genes, loss of which is implicated in some 
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cancers (Cheung, Yan et al. 2003). Conversely, RXRB mRNA has been shown to 
correlate negatively with breast cancer associated patient survival (Liu, Graham 
et al. 2012). 
 
19) SNAP-associated protein (SNAPIN) has been shown to be phosphorylated by 
PKA (Chheda, Ashery et al. 2001), and it has been shown to be associated with 
hepatocellular carcinoma (HCC) (Inagaki, Yasui et al. 2008) and PC (Quintero, 
Herrala et al. 2013). 
 
20) Microspherule Protein 1 (MCRS1) has recently has been assigned oncogenic 
status (Okumura, Zhao et al. 2005) and is associated with colorectal cancer 
(CRC) (Shi, Chen et al. 2009). 
 
21) Heat shock cognate 71 kDa protein (HSPA8) is a member of the HSP70 family 
of heat shock chaperones which is expressed in various tumours and may 
mediate cell proliferation and survival (Rohde, Daugaard et al. 2005; Jose-
Eneriz, Roman-Gomez et al. 2008).  
 
22) Zinc finger protein 302 (ZNF302) is located on chromosome 19q13, SNPs in 
which are associated with PC (Schaid, Stanford et al. 2007; Hsu, Sun et al. 
2009).  
 
23) PDE4A; the phosphodiesterase 4A subfamily; it would be very interesting to 
find an interaction between two different PDE4 isoforms.  
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Antibodies against the above  proteins were used to investigate PPIs by means of 
co-IPs, which is a commonly used method to verify PPIs that have been 
identified using the approaches described here (Berggard, Linse et al. 2007). 
Initially, VCaP and Hek293 cells were transfected with VSV-tagged or FLAG 
tagged PDE4D7, followed by a VSV/FLAG IP and immunoblotting for a number of 
the PPI hits.  Detection was carried out using HRP-conjugated secondary 
antibody and chemiluminescence. PDE4D7 was successfully immunoprecipitated; 
however, none of the above PPIs could be verified (figure 5.11).  
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Figure 5.11. Initial verification of a number of PDE4D7 PPIs by co-immunoprecipitation of 
overexpressed PDE4D7-VSV and immunoblotting for PPI hits. A; HeK293 cells were 
transfected with FLAG tagged PDE4D7, or were untransfected. Cellular lysates 
were immunoprecipitated (IP) with agarose beads conjugated to FLAG antibody. 
Lysate=untransfected lysate from which a FLAG IP was carried out (Neg). 
Input=transfected lysate from which a FLAG IP (IP) was carried out. N=3. B; VCaP 
cells were transfected with VSV tagged PDE4D7, or were untransfected. Cellular 
lysates were immunoprecipitated (IP) with agarose beads conjugated to VSV 
antibody. Lysate=untransfected lysate from which a VSV IP was carried out 
(Neg). Input=transfected lysate from which a VSV IP (IP) was carried out. The 
approximate weight at which the proteins should run is specified under each 
western blot, and denoted by red asterisks. N=3. 
 
 
 
PDE4D7 was successfully immunoprecipitated in both Hek293 (figure 5.11 A, top 
left blot) and VCaP (figure 5.11 B, top left blot) cells, thus, any interactors 
present would have been co-purified. The proteins HSPA8, NONO, DHX9, CSNK1ε 
and IRAK4 are present in the cell lysates, suggesting these proteins indeed do 
not interact with PDE4D7. CT45A3 and NUAK1 do not seem to be present in 
Hek293 lysate, as bands observed are not at their respective predicted weights; 
thus these are non-specific bands. For this reason it cannot be concluded that 
they are not PDE4D7 interactors. BCAR3 and NIKRAS2 are not present in VCaP 
cell lysate, but VCaP cells endogenously express PDE4D7, and so this may suggest 
that indeed these proteins do not interact with PDE4D7, at least not in early 
stage PC.  
 
Although VCaP cells express PDE4D7 endogenously and therefore any 
physiological PDE4D7 interactors, the overexpression of PDE4D7 to enable 
immunoprecipitation would have resulted in non-physiological levels of this 
enzyme, and which can inhibit interaction complex formation (Berggard, Linse et 
al. 2007). Following the generation of the novel highly specific PDE4D7 antibody, 
antibodies against the rest of the chosen PPI hits were purchased and all 23 were 
investigated using endogenously expressed proteins. It was also at this stage in 
the project that the DuCaP cell line became available. IPs of endogenous PDE4D7 
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were accordingly carried out using VCaP (figure 5.12 A) and DuCaP cells (figure 
5.12 B), followed by probing for all 23 possible interacting partners. IPs of 
endogenous PDE4D7 has the advantage of physiologically-relevant interacting 
partners being pulled down. Here, detection was carried out using the Odyssey 
(LiCor) imaging system, which is more sensitive than chemiluminescence. 
PDE4D7 was successfully immunoprecipitated; however still none of the PPIs 
could be verified.   
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Figure 5.12 A 
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Figure 5.12. Verification of PDE4D7 PPIs by co-immunoprecipitation of endogenous PDE4D7 
and immunoblotting for PPI hits.  
A; endogenous PDE4D7 was immunoprecipitated from VCaP cells using the novel 
PDE4D7 antibody. Cellular lysates were blotted with antibodies targeted against 
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the potential interacting proteins. Input=lysate from which the control (IgG) and 
PDE4D7 IPs (IP) were carried out. N=3. B; endogenous PDE4D7 was 
immunoprecipitated from DuCaP cells using the novel PDE4D7 antibody. Cellular 
lysates were blotted with antibodies targeted against the potential interacting 
proteins. Input=lysate from which the control (IgG) and PDE4D7 IPs (IP) were 
carried out. The approximate weight at which the proteins should run is 
specified under each western blot, and denoted by white asterisks. N=3.  
 
 
PDE4D7 was successfully immunoprecipitated in both VCaP (figure 5.10 A top left 
blot) and DuCaP (figure 5.10 B top left blot) cell lines, thus any interacting 
partners would have been pulled down. None of the possible 23 interactors were 
pulled down in the IP lane alone, suggesting these proteins do not interact with 
PDE4D7 in a cellular context. However, aside from the panPDE4A antibody which 
has been well characterised in our laboratory, the antibodies were not verified 
for affinity and specificity prior to the Co-IPs. A number of the proteins are not 
detected in the inputs suggesting they are not expressed in PC cells, or perhaps 
the antibodies failed to detect a low level of those proteins.  ATF3, NLK, GLYR1, 
ENKURIN, CT45A3, NUAK1, MAP3K9, RXR and SNAPIN are not present in the VCaP 
input lanes, or certainly not at the predicted weights. It seems the antibodies 
against these proteins are detecting some non-specific bands, as is quite 
common.  PPP3CB and GTF3A may be expressed in VCaP cells, but are running 
slightly different to their predicted weights. BCAR3 which weighs 38kDa seems 
to be expressed in VCaP cells but this weight is obscured by the light chains of 
the antibodies in the IgG and IP lanes, and so it is difficult to determine whether 
or not a band is co-purifying. ATF3, GTF3A, MCRS1 and ZNF302 appear not to be 
expressed in DuCaP cells.  
 
Lack of an interaction with a PDE4A isoform was not unexpected as we 
previously determined very low PDE4A mRNA expression in these cell lines 
(Henderson D. thesis 2011). For the other proteins investigated, the use of 
positive controls such as purified protein or standards from overexpressing cell 
lysates would confirm their specificity, and if these proteins are indeed not part 
of the PDE4D7 interactome. However, to employ such controls would require 
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much cloning and a great deal of time, and would not be reasonable for a first 
verification experiment. 
 
 
5.3 Discussion 
 
Intracellular signalling systems depend on direct and functional PPIs to tightly 
regulate signal transduction. Spatial and temporal regulation of cAMP signalling 
is paramount to cell homeostasis, and is mediated by the sequestration of 
specific PDE isoforms within the vicinity of the cAMP pool in order to shape 
appropriate cAMP gradients. Targeting of the PDE to this pool is arbitrated by 
protein-protein interactions, such as the anchoring of PDE4D3 by MAKAP to the 
nuclear membrane in cardiomyocytes (Dodge, Khouangsathiene et al. 2001) or 
sequestration of PDE4D5 by β-arrestin (Bolger, McCahill et al. 2003) or RACK1 
(Yarwood, Steele et al. 1999). These specific interactions act to maintain 
appropriate cAMP signalling cascades. PPIs are often dynamic and may be 
influenced by PTMS; an elegant example of both is the PDE4D3 ‘switching of 
partners’ which is induced by phosphorylation within its N-terminus, thereby 
modulating the affinity of PDE4D3 for different interactors (Carlisle Michel, 
Dodge et al. 2004; Collins, Murdoch et al. 2008).  
 
The function of a novel protein is often elucidated by determining its 
interactome, as function can be inferred from identifying annotated binding 
partners; the ‘guilt by association’ model. By identifying such binding partners, 
biologists can gain insight into the hierarchical organisation of the proteome of a 
given tissue (Drewes and Bouwmeester 2003).  A number of methods have been 
developed to investigate PPIs, three of which were employed in the search for 
the PDE4D7 interactome. It has been demonstrated that different approaches 
used to identify PPIs often produce very little overlap, and so analysis of PPIs by 
more than one method is important (von Mering, Krause et al. 2002; Ngounou 
Wetie, Sokolowska et al. 2013). The three approaches reported here, have a 
unique set of advantages and drawbacks. 
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IP/ MS is a desirable  method of detecting PPIs  because it involves the ex vivo 
analysis of protein complexes made up of direct and functional (non-direct) 
interactions that have occurred in mammalian cells, and not in vitro (Drewes 
and Bouwmeester 2003). This allows the overexpressed bait protein to undergo 
PTMs, which may be necessary for increased affinity towards a binding partner 
(Berggard, Linse et al. 2007). IP/ MS has been successfully used to identify many 
PPIs, and technological advances have allowed the ultra-sensitive detection of 
peptides in the fentimolar range (Drewes and Bouwmeester 2003), enabling 
determination of whole macromolecular complexes (Ho, Gruhler et al. 2002) and 
the mapping of whole signalling networks (Bouwmeester, Bauch et al. 2004).  
 
 However this approach has a number of limitations. The IP favours proteins of 
high abundance and PPIs with high affinity, as transient or weak interactions 
may dissociate upon cell lysis (Berggard, Linse et al. 2007). Transient 
overexpression of the bait protein can often lead to a high bait:prey ratio, 
limiting the detection of less abundant interactors, and leading to the isolation 
of chaperones and HSPs that are likely interacting with misfolded overexpressed 
protein. Also, the epitope recognised by the antibody used for affinity 
purification may be within a protein-binding domain and thus inhibit any PPIs 
(Gingras, Aebersold et al. 2005). Although a major part of its appeal, the high 
sensitivity of MS can result in the identification of large numbers of contaminant 
proteins, thus producing false-positives (Berggard, Linse et al. 2007). MS is also 
quite inaccessible and very costly, being usually carried out only is specialised 
laboratories. 
 
None of the MS hits were verified as PDE4D7 interactors. This could be the result 
of a variety of confounding factors. Overexpression of the tagged-PDE4D7 was 
carried out in Hek293 cells. On retrospective reflection, this may not have been 
a good choice as our group has found this cell line to express little PDE4D7. 
Thus, these cells may not express PDE4D7 interacting proteins, nor the scaffolds 
required for correct subcellular localisation. VCaP cells which express PDE4D7 
and thus any interacting partners would have been a better expression system 
for this experiment; however, these cells are incredibly difficult to transfect and 
due to time constraints Hek293 cells were employed. Now that a PDE4D7-
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specific antibody capable of detecting endogenous protein is available, this 
experiment could be repeated, with a greater chance of isolating valid PDE4D7 
interactors. Immunoprecipitation of endogenous PDE4D7 would eliminate the 
problems associated with overexpressed bait, such as misfolding and thus 
isolation of chaperones, as is what likely occurred here, with the identification 
of HSPA8.  
 
The Y2H technique is one of the most widely used for the detection of PPIs, and 
has been instrumental in the mapping of the human proteome and interactome, 
essential for identifying  protein networks responsible for disease  (Gandhi, 
Zhong et al. 2006; Berggard, Linse et al. 2007). It is relatively cheap, simple to 
set up and the PPIs under investigation occur in vivo. The Y2H system allows for 
the detection of weak interactions due to significant signal amplification by the 
genetic reporter system. It also enables discrimination between weakly and 
strongly interacting pairs due to differential activation of reporter genes, 
leading to weak or strong penetrance of the interacting phenotype, i.e. the 
colour change  (Estojak, Brent et al. 1995).  
 
However, this method also possesses a number of shortcomings. Interactions are 
not always detected in both orientations, some have been identified when one 
partner is bait and the other prey, but not when the reciprocal screen is 
performed (Estojak, Brent et al. 1995). Unlike IP/ MS, the Y2H method can only 
detect binary or direct physical interactions (De Las Rivas and Fontanillo 2010). 
Y2H screens also give many false positives, a big problem when these are listed 
in the PPI databases and repositories. Such discrepancies can be seen with the 
well studied Saccharomyces cerevisiae (S. cerevisiae), where mapping its 
interactome by four independent high throughput Y2H screens produced very 
little overlap (Deane, Salwinski et al. 2002; De Las Rivas and Fontanillo 2010). 
Such problems may arise from the use of different yeast strains, vectors, 
experimental design, and whether the proteins are C- or N-terminally fused to 
the transcription factor domains (Caufield, Sakhawalkar et al. 2012). Another 
problem that may occur during a Y2H screen is the incorrect folding and post-
translational modification of mammalian proteins, upon which an interaction 
may rely. However, the development of mammalian two-hybrid systems, which 
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employ the same method of bait and prey fusion proteins bringing about 
transcription of a reporter gene, has helped to alleviate this problem (He and Li 
2008).  
The above limitations may be why a bona fide PDE4D7 PPI was not identified 
using the Y2H system. The unique N-terminal region of PDE4D7 should be 
responsible for specific PPIs, and incorrect folding within yeast cells may inhibit 
accessibility of the region to any interactors. If N-terminal phosphorylation is 
necessary to bring about an interaction, or vice versa, then this too would be 
thwarted. Although PDE4D7 is expressed in brain (Wang, Deng et al. 2003), the 
use of a foetal brain library may not allow for the detection of interactions 
occurring in prostate cells, or indeed PC cells. However, this prey library was all 
that was available at the time of this experiment.  
 
DNA microarrays have been hugely successful in gene expression profiling, but, 
as discussed, protein levels are not always correlated with mRNA abundance, 
and so the development of protein microarrays was the next logical step in the 
endeavour to understand complex cellular molecular networks (Zhu and Qian 
2012). Protein microarrays allow the immobilisation of all annotated proteins of 
a given organism onto a chip, thereby comprising a whole proteome. The largest 
proteome chip to date was recently developed, containing >17,000 human 
proteins (Jeong, Jiang et al. 2012). This en masse analyses of PPIs and the 
miniaturised size of the microarrays means very low quantities of purified bait 
proteins and antibodies are required. Protein microarrays have successfully 
identified PPIs as well as a host of interactions between proteins and other 
biomolecules (Schweitzer, Predki et al. 2003; Predki 2004; Zhu and Qian 2012). 
Unlike the Y2H system, the proteins on the ProtoArray chips are expressed in 
insect cells which allows correct folding and PTMs to occur (Bouvier, Menard et 
al. 1998). They have been used to successfully identify proteins involved in 
ovarian cancer progression and to elucidate many new components of the NFκB 
signalling network (Hudson, Pozdnyakova et al. 2007; Fenner, Scannell et al. 
2010).   
 
Although much progress has been made with protein microarrays, the 
expression, purification and immobilisation of such large numbers of 
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biochemically diverse proteins in a functional state remains costly and labour 
intensive (Braun 2012). Therefore, ProtoArray chips are expensive and not 
accessible to many laboratories. Also, this approach identifies only binary 
interactions and it is likely to produce a large number of false positives due to 
the detection of proteins that can physically interact, but under physiological 
conditions may never be in close enough proximity, or expressed at the same 
cell cycle stage (Berrade, Garcia et al. 2011). The detection of weak or transient 
interactions may also be inhibited due to the rigorous washing steps involved in 
the procedure.  
 
The conditions of the ProtoArray are not physiological, which may the reason 
why no real PDE4D7 PPIs were identified using this approach. Another issue may 
lie with the GST tag, which is fused to the N-terminus of PDE4D7. Although 
commonly used in the study of PPIs, it has been demonstrated that GST tags can 
induce misfolding of the tagged protein domain (Wissmueller, Font et al. 2011). 
Perhaps this large tag disrupted the folding of the N-terminal domain, which of 
course is crucial for PDE4D7 specific interactions. Such misfolding may inhibit 
bona fide interactions, and promote false positives. Saying that, the PDE4D7 
specific antibody which is targeted against the N-terminus, successfully detected 
the fusion protein in both native and denatured states. Additionally, PDE4D7 
PTMs, such as N-terminal phosphorylation, may be essential for PPIs in vivo.  
 
Unfortunately, no light has been shed on the PDE4D7 interactome. The three 
approaches used to identify interacting partners have been well validated and 
successful in determining PPIs, as seen in the wealth of literature, but they all 
present a number of limitations, and are far removed from a physiological 
setting. However, the negative findings for the putative PDE4D7 PPIs reported 
here cannot be accepted with confidence just yet, and a number of further steps 
should be taken. In order to verify that the Co-IP results are not false negatives, 
positive controls for the antibodies that did not detect protein in the cell inputs 
should be used to ensure that indeed they are not expressed in the AS PC cells 
used.  Also, reciprocal Co-IPs should be carried out; where each of the potential 
interactors is immunoprecipitated followed by immunoblotting for PDE4D7, as 
interactions can sometime occur in one direction only (Elion 2007). Co-IP is the 
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commonest method to verify PPIs identified by the three approaches reported 
here, and has the advantage of retaining all proteins in their native states and 
concentrations when examining endogenously expressed proteins (Berggard, 
Linse et al. 2007; Dwane and Kiely 2011). However, it also presents some 
limitations, notably it may not allow detection of weak or transient interactions 
due to the number of washing steps involved and the time taken to carry out the 
experiment, respectively (Lee, Ryu et al. 2013). Thus, a number of other 
approaches could be employed, particularly if the antibodies fail to detect 
positive controls. Peptide array technology could be used to create full length 
arrays of each of the 23 potential interactors, which could then be overlaid with 
purified PDE4D7 protein. If PDE4D7 were to interact with any of the proteins, 
this method would also identify the epitope to which it binds. The reciprocal 
experiment could then also be carried out. Another technique used to verify 
molecular interactions identified by a previous approach is surface plasmon 
resonance (SPR) (Berggard, Linse et al. 2007). SPR involves the immobilisation of 
the bait protein on a chip via an affinity tag, such as a GST tag. Prey proteins 
are then added to the chip in solution. SPR biosensors measure the change in 
refractive index of the solvent near the surface that occurs following complex 
association and disassociation, thereby not only confirming the PPI, but giving 
quantitative information on the kinetic and thermodynamic parameters of the 
interaction in a label-free manner (Lalonde, Ehrhardt et al. 2008). Of course, 
this would require a large number of purified proteins. Should a bona fide 
PDE4D7 PPI be validated, a number of subsequent experiments could be carried 
out; for example the Duolink PLA probe system discussed in Chapter 3 would 
further verify any interaction via co-localisation. The novel phospho-specific 
antibody described in Chapter 4 could be employed to investigate the effect of 
N-terminal phosphorylation on the PDE4D7 PPI. In any case, using the novel 
PDE4D7 antibody now available to us, IP/MS with PC cell lines may be 
considered, and would undoubtedly yield more likely PDE4D7 interactors.  
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6 Final Discussion 
 
6.1 PDE4D7 is a Promising Novel Biomarker for Prostate 
Cancer  
 
In collaboration with Philips Research and the PCMM, we set out to identify a 
novel PC biomarker. This is currently a major endeavour in PC research, as the 
current biomarker, PSA, is not disease-specific and thus often leads to over 
diagnosis and over treatment of non-life threatening indolent cancers, or BPH 
(Draisma, Etzioni et al. 2009). Due to the wealth of literature implicating cAMP 
signalling in this disease (Bang, Pirnia et al. 1994; Sadar 1999; Nelson, Bagnato 
et al. 2003; Kasbohm, Guo et al. 2005; Weng, Wang et al. 2005; Kvissel, 
Ramberg et al. 2007; Merkle and Hoffmann 2011; Misra and Pizzo 2013; Sarwar, 
Sandberg et al. 2013), we chose to investigate the expression of cAMP PDEs as 
PC progresses, in the hope that changes in cAMP signalling would translate into 
potential novel biomarkers. Indeed, we identified differential expression of 
PDE4D isoforms at the mRNA level between AS and AI PC cell lines and 
xenografts (Byrne, Henderson et al., under review), with PDE4D7 showing the 
most acute change such that its expression successfully discriminates between 
tumour and non-tumour tissue, and correlates with prostate cancer-specific 
survival (PCSS) (unpublished data, PCMM).  By means of urine detection, our 
collaborators have also found, in an initial study using a small sample size, that 
PDE4D7 downregulation correlates with diagnosed metastasis of PC, thus PDE4D7 
may be indicative of not only PC progression, but also of metastatic potential.  
Although PDEs are intracellular and not excreted, urinary sediments contain 
dislodged prostatic cells from which PDE4D7 mRNA abundance was measured. 
This is an exciting discovery, as a novel biomarker we can non-invasively detect 
in urine, with both diagnostic and prognostic value, and disease-specificity could 
be a huge asset in the fight against the disease. The correlation of PDE4D7 with 
disease stage suggests that this is indeed a very promising biomarker, which 
would allow clinicians and patients to make more informed decisions about 
whether or not to undergo cancer treatment. Furthermore, PDE4D7 is not under 
androgenic regulation (Byrne, Henderson et al., under review); therefore 
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measurement of its expression level would not merely reflect that of other AS PC 
biomarkers.    
 
Despite the growing body of literature on the role of cAMP in PC, this was the 
first investigation of the expression of an individual cAMP PDE isoform in PC 
samples. Uckert and colleagues described the expression of PDE isoforms in the 
different prostatic zones, but not within the different cell types (Uckert, Oelke 
et al. 2006). Other studies have looked at the PDE4 family in relation to PC, with 
a downregulation of the PDE4B subfamily in AI PC being reported (Kashiwagi, 
Shiota et al. 2012; Sarwar, Sandberg et al. 2013), but with no investigation into 
the expression of splice variants. The PDE4 family is of particular relevance to 
disease, and is the main cAMP hydrolysing family (Houslay 2010).  PDE4 splice 
variants have highly-specific, non-redundant roles due to their unique N-termini, 
hence Isozyme-specific knowledge is crucial to understanding their roles in 
diseases such as PC.  
 
 
6.2 A Novel PDE4D7 Specific Antibody may be of Clinical 
Value 
 
Studying the expression of PDE splice variant proteins is not easy as raising 
highly specific antibodies is made difficult due to the disparity in 
immunogenicity of their unique N-termini. During my PhD experimental work, I 
managed to successfully generate a highly specific PDE4D7 antibody by fusing 
GST to the unique N-terminal region to create a highly-immunogenic antigen. 
This antibody, along with PLA probe detection, verified that PDE4D7 protein is 
downregulated in AI PC cell lines, thus reducing PDE4 activity at a discrete 
intracellular location. Our group have determined that the major population of 
PDE4D7 localises to the sub-plasma membrane region (Byrne, Henderson et al. 
2014), therefore its downregulation/loss as PC transitions from an AS to AI 
disease would result in perturbed cAMP signalling at this locale. The availability 
of this antibody is also exciting with regards to PDE4D7 detection in urine 
samples. Protein analysis by means of western blot or ELISA is far simpler and 
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less technically challenging than mRNA analysis, which can be subject to much 
loss and contamination during the handling process. It has recently been 
reported that measuring urinary protein levels may be superior to measuring 
mRNA levels in the detection of disease, though the measurement of both is best 
(Hricik, Nickerson et al. 2013). Thus, if this novel PDE4D7 antibody can detect 
protein in urine sediments from PC patients, which our collaborators will 
investigate, it may be a very useful tool in the clinic. Indeed, this year Mohan 
and colleagues reported the detection of prostate specific membrane antigen 
(PSMA) in urine using a bioaffinity matrix (Mohan, Donavan et al. 2013), which 
they reported in the media as a potential home ‘pregnancy’ test for prostate 
cancer. In short, a ‘pee-on-a-stick’ device which would allow men to purchase a 
home testing kit from the pharmacy. However, PSMA is also present in urothelial 
and bladder carcinomas (Ristau, O'Keefe et al. 2013), which may lead to non-
specific results when using a urine test. What’s more, PSMA expression has been 
found to be dependent on the TMPRSS2:ERG gene fusion event (Yin, Rao et al. 
2011), which is present in 70% of primary prostate adenocarcinomas (Mehra, 
Tomlins et al. 2007), meaning the PSMA test may not work for some subsets of 
PC cases. On the other hand, our group found the differential expression of 
PDE4D7 to be consistent between AS and AI cells lines and xenografts, with and 
without the TMPRSS2:ERG fusion, and with no correlation to tumour origin. The 
device fabricated by Mohan and colleagues employed bacteirophages; however, 
an even simpler test would be akin to a pregnancy test, which contains 
immobilised anti-hCG antibodies, and if present in the urine, bound hGC brings 
about a colour change. With the availability of the high affinity and highly 
specific PDE4D7 antibody, it is a plausible to suggest that such a device could be 
fabricated to detect the presence of PDE4D7 protein in urine samples. Such a 
test could help determine if the primary tumour has become androgen-
insensitive/castration-resistant following ADT. On the other hand, if PDE4D7 is 
indeed upregulated from normal tissue to early stage AS tissue, as observed by 
our collaborators, then such a device would allow for the detection of early 
stage PC, for which there is currently no biomarker (Cernei, Heger et al. 2013). 
Such early stage detection would of course require normal PDE4D7 levels to be 
known, and a threshold for PC detection set. It is also becoming clear that the 
use of a single biomarker for PC detection is not sufficient (Laxman, Morris et al. 
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2008), and so perhaps such a device that can measure more than one biomarker 
in this way, such as PDE4D7 along with PSMA, and perhaps together with PSA 
testing, would be of greatest clinical value.  
 
 
6.3 PDE4D7 Mediates Androgen-Sensitive Prostate 
Cancer Cell Proliferation 
 
The observation that PDE4D7 showed the highest relative expression of all PDE4 
isoforms in AS PC cell lines and xenografts, strongly suggests that this isoform 
plays a pivotal role in cAMP signalling in early stage PC. But what is the 
physiological relevance of the dramatic downregulation of this enzyme into 
androgen insensitivity? Given that Uckert et al. had previously suggested a role 
for PDE4 in the proliferation of normal prostate epithelium (Uckert, Oelke et al. 
2006), it seemed prudent to investigate the role of PDE4D7 in this respect. 
Indeed, evidence presented here suggests that PDE4D7-specific-mediated cAMP 
hydrolysis at the sub-plasma membrane region acts to maintain normal 
proliferative signalling in AS PC cells. Loss of PDE4D7, via displacement of active 
enzyme or gene knockdown, resulted in a marked increase in AS PC cell 
proliferation. This increase was not observed following knockdown of global 
PDE4D, which convincingly suggests a specific role for PDE4D7 in cAMP mediated 
AS cell growth. The marked decrease in proliferation and migration rate 
following the re-expression of PDE4D7 in AI cell lines backs up this hypothesis. 
This is further substantiated by the observed decrease in AI cell proliferation 
following over-expression of the hyper-active PDE4D7 mutant. The importance of 
increasing cAMP in the progression of PC is well reported, particularly in the 
shift away from androgenic signalling. Cross talk between the cAMP and AR 
signalling networks plays an important role in such steroid independent PC 
progression (Merkle and Hoffmann 2011), including aberrant PKA phosphorylation 
of the AR (Nazareth and Weigel 1996; Gioeli, Ficarro et al. 2002) and  over 
expression of GPCRs (Nelson, Bagnato et al. 2003; Weng, Wang et al. 2005). An 
increase in the number of ligand-bound GPCRs would lead to aberrant synthesis 
of cAMP, which, when coupled with loss of PDE4 isoforms such as PDE4D7, would 
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potentiate PC progression into androgen-insensitivity. Increasing levels of cAMP 
also results in NED, another pivotal event in the progression of PC (Burchardt, 
Burchardt et al. 1999; Merkle and Hoffmann 2011). If PDE4D7 is the main 
“gatekeeper” of cAMP signalling in early stage AS PC, then loss of this isoform 
may be a major contributing factor in the shift towards non-genomic androgen 
signalling and in the development of NED, and thus loss of PDE4D7 expression 
may play a role in the development of the AI phenotype, and PC progression.  
 
The results presented here conflict with the study by Rahrmann et al. who 
suggest that PDE4D is pro-tumourigenic, and its inhibition would be of 
therapeutic value for the treatment of PC (Rahrmann, Collier et al. 2009). They 
found that knockdown of global PDE4D reduced the proliferation rate and 
migratory potential of PC cells. Interestingly, the cells used were the AI DU145 
and PC3 lines, which our group found to express very little PDE4D. They studied 
the proliferation of these cells using end point assays, whereas, here, I 
performed real time proliferation and migration assays, which provide constant 
quality control for the cells under investigation. Given the non-redundant roles 
of PDE isoforms, it is naive to suggest inhibiting all PDE4D splice variants in the 
treatment of PC, or any disease, and doing so may well be detrimental to PC 
patients. However, Rahrmann and colleagues do pinpoint the majority of PDE4D 
expression in PC to that of PDE4D5. Our group also found PDE4D5 to have the 
highest relative expression in the AI samples, and this part of their findings may 
be in agreement with the results presented here. PDE4D5 transcription is cAMP-
responsive (Le Jeune, Shepherd et al. 2002), so as PDE4D7 is downregulated 
during the AS to AI transition, the resulting increase in cAMP may bring about 
aberrant PDE4D5 expression, which in turn could potentiate PC progression due 
to inappropriate cAMP hydrolysis at the PDE4D5 locale. This hypothesis, along 
with my observation that global PDE4D knockdown has little effect on AS cell 
growth, suggests that the effect of cAMP on PC progression is varied, and 
depends on the subcellular localisation of the cAMP pool and the PDEs involved.   
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6.4 Perturbed Transcriptional Regulation of PDE4D7 
 
The transcriptional regulation of PDE4D7 is not currently understood, however it 
does not appear to be under the control of androgens (Byrne, Henderson et al., 
under review).  The reason for PDE4D7 downregulation as PC becomes AI is 
unknown, but as presented here, it is plausible to suggest DNA hypermethylation 
is involved, as a perturbed epigenome has been shown to play a role in the 
development of PC (Jeronimo, Bastian et al. 2011). The predicted CpG island 
upstream of PDE4D7 (Henderson D. thesis 2011), and the specific upregulation of 
PDE4D7 following inhibition of DNA methylation backs up hypothesis. This is 
further supported by the cis-NAT genetic structure of PDE4D7, with the non-
coding transcript PART1. NcRNAs can both positively and negatively regulate the 
transcription of their coding partner by recruiting chromatin remodelling 
machinery (Faghihi and Wahlestedt 2009; Su, Xiong et al. 2010; Magistri, Faghihi 
et al. 2012). PART1 is androgen-regulated (Lin, White et al. 2000), and in 
response to DHT can be upregulated in AS cells, but not in AI PC cells (Yu, 
Blackburn et al. 2003). Perhaps PART1 positively regulates PDE4D7 transcription 
in normal prostate cells and AS PC. As PC progresses and signalling moves 
towards non-steroidal pathways, PART1 expression would be inhibited, resulting 
in the loss of positive PDE4D7 transcriptional regulation, and thus loss of 
expression. The loss of PDE4D7-mediated cAMP hydrolysis might then potentiate 
the inhibition of PART1 transcription, and thus PDE4D7 expression; a ‘vicious 
circle’ of feedback. However, this area requires further work before any firm 
conclusions can be drawn.  
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6.5 A Novel Mode of PDE4D7 Regulation  
 
Most proteins are subject to PTMS that alter their activity, subcellular 
localisation or molecular interactions, and such modifications are a main area of 
cancer research (Krueger and Srivastava 2006). Protein phosphorylation is 
perhaps the commonest and certainly the best studied PTM. Reversible protein 
phosphorylation is paramount to a host of cell signalling events, with >2% of the 
genome encoding kinases and phosphatases (Hunter and Pawson 2012). To date, 
PDE4D3 is the only PDE4 isoform known to undergo unique N-terminal 
phosphorylation (Sette and Conti 1996). Here, I presented evidence to suggest 
that PDE4D7 is also subject to PKA-dependent phosphorylation within its unique 
N-terminus (on serine 42), that this event occurs under basal conditions, and 
that it provides a novel, isoform-specific mode of regulation.  
 
The hyper-activity imparted on PDE4D7 following ablation of this phospho-site, 
coupled with inhibition of UCR1 phosphorylation, suggest that Ser42 
phosphorylation retains the enzyme in an inactive state to allow basal cAMP 
signalling. Stimulation of the PDE4D7-associated Gs –coupled GPCR would elicit 
the rise in cAMP and active PKA necessary to bring about UCR1 phosphorylation 
and relieve this constraint. I hypothesise that the conformation of PDE4D7, 
whilst in the inactive state, comprises a tightly folding UCR1/UCR2/catalytic site 
module, enveloped and stabilised by a disordered phosphorylated N-terminal 
region. Disorder of the N-terminus would allow for dynamic interaction with this 
module. Indeed, modular proteins such as PDE4 isoforms often possess 
disordered regions (Dyson and Wright 2005).  The notion of a disordered PDE4D7 
N-terminus is further supported by the fact that alternatively spliced exons 
often encode disorded protein domains to prevent structural impairment to the 
rest of the protein (Romero, Zaidi et al. 2006). It is then likely that all PDE4 long 
isoform unique N-terminal regions are disordered, which would enable a 
common C-terminal domain to be fused to a number of different N-termini. 
Furthermore, disordered regions are often subject to phosphorylation, the 
charge conferred by which influences associations with other proteins via 
electrostatic interactions (Romero, Zaidi et al. 2006; Borg, Mittag et al. 2007). 
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Phosphorylation on Ser42 may increase the affinity of the N-terminal region for 
the UCR1/UCR2/catalytic site module, which would be ablated by the change in 
net charge following UCR1 phosphorylation, leading to a looser, active enzyme 
conformation which is accessible to cAMP. Indeed, it has been shown that UCR1 
and UCR2 interact via electrostatic interactions, and dissociate upon UCR1 
phosphorylation or mutation of the target serine to aspartate (Beard, Olsen et 
al. 2000), suggesting that it is the net charge responsible for dissociation of the 
module and conformational change to the active state. Also, as presented here, 
mutation of PDE4D7-Ser42 to aspartate had negligible effect on enzyme activity, 
giving credence to the idea that the negative charge bestowed on this site by 
phosphorylation acts to retain PDE4D7 in an inactive conformation via 
electrostatic interactions.  
 
The increasing and sustained phosphorylation of endogenous PDE4D7-Ser42 in the 
AS cell lines, following activation of PKA, strongly suggests that PDE4D7-Ser42 is 
phosphorylated in vivo.  Perhaps, at any one time a proportion of the PDE4D7 
protein population is phosphorylated on Ser42 to allow for basal cAMP signalling, 
which may be necessary for cellular homeostasis. Indeed, stable and prolonged 
basal phosphorylation has previously been described for a number of PKA 
substrates (Steinberg and Kiss 1985), suggesting such basal phosphorylation 
events are likely important for cellular homeostasis. But what is the implication 
of this event in PC? Hyperphosphorylation of tumour suppressor genes is an 
important event in carcinogenesis (Yatsunami, Komori et al. 1993; Krueger and 
Srivastava 2006; Jiang, Sun et al. 2010). The evidence presented in Chapter 3 
ardently suggests that loss of PDE4D7 expression and activity is pro-
tumourigenic. Perhaps, aberrant Ser42 phosphorylation plays a role in the 
downregulation of PDE4D7. The normal population of PDE4D7 proteins would 
likely comprise both Ser42 phosphorylated and unphosphorylated pools, as the 
stoichiometry of any phospho-substrate population ranges from completely 
unphosphorylated to completely phosphorylated molecular states (Prabakaran, 
Lippens et al. 2012). As PC progresses, this stoichiometry may be perturbed, 
with a shift in the equilibrium towards the phospho-PDE4D7.  A larger proportion 
of the PDE4D7 population phosphorylated on Ser42 would result in the increase 
of cAMP levels at the sub-plasma membrane region. This inappropriate level of 
A.M. Byrne  |  PhD Thesis 2014                                                                                                     263 
 
cAMP could play a role in the shift away from androgenic signalling, which as 
hypothesised, may lead to transcriptional inhibition of PART1 and PDE4D7, thus 
self-perpetuating inhibition. If indeed PDE4D7 is initially upregulated in early 
stage PC, cAMP at the PDE4D7 locale would be subject to inappropriate 
hydrolysis, and hyperphosphorylation may provide molecular protection against 
the increase in expression of active enzyme.   
 
In light of the results presented here, it is interesting to think of PDE4D7 as a 
tumour suppressor as its expression correlates with slow growing AS PC cells, 
which show no/little migration. This is in contrast to a loss of PDE4D7 
expression, which is correlated with fast growing, advanced AI PC cells with 
developed migratory potential.  Intriguingly, a tumour suppressor gene has been 
proposed to reside on the long arm of chromosome 5, with linkage to PC 
between 5q11 and 5q12 (Ozen, Navone et al. 1998; Xu, Dimitrov et al. 2005), 
and PDE4D maps to 5q12.1 (Szpirer, Szpirer et al. 1995).  
 
 
6.6 A Novel PDE4D7 Phospho-Specific Antibody may be 
of Clinical Value 
 
Since a changing phospho-proteome is implicated in many cancers, the study of 
phosphorylation-based signalling pathways in crucial to understanding cancer 
biology and to the diagnosis and treatment of this disease (Krueger and 
Srivastava 2006). Labelling with radioactive phosphate is a widely used method 
to identify phospho-substrates, but it gives no spatio-temporal  information on 
these proteins (Teraishi and Miura 2009). The advent of phospho-site specific 
antibodies has allowed for such investigations. These antibodies are invaluable 
tools in uncovering the phospho-proteome in health and disease and are often 
used in the detection of disease biomarkers (Teraishi and Miura 2009; Lothrop, 
Torres et al. 2013). A major advance in the study of the phospho-proteome is 
phosphoflow cytometry (Rogne and Tasken 2013). This is a combination of flow 
cytometry with phospho-specific antibodies against various signal phospho-
proteins to analyse intracellular signalling networks ex vivo, and it is also being 
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used to investigate the phospho-signalling events in a number of diseases, such 
as cancer. However, this assay is limited by the availability of phospho-
antibodies, and the raising of antibodies that recognise biologically and 
pathologically important PTMs is now a growing area of research (Lothrop, 
Torres et al. 2013). If indeed PDE4D7 N-terminal hyperphosphorylation occurs as 
PC progresses, the novel phospho-site specific antibody reported here may be of 
clinical value. PDE4D7 hyperphosphorylation would be a result of aberrant PKA 
signalling, due to a increase in cAMP as discussed early, and/or due to changes in 
the expression of PKA regulatory subunits, which occurs during PC progression 
(Cho, Lee et al. 2000). If the latter is the case, and the antibody could detect 
PDE4D7-pSer42 in patient samples (for example by means of phosphoflow 
cytometry), it would indicate inappropriate PKA activity which may then be 
targeted. Indeed, targeted inhibition of RIα has been shown to inhibit prostate 
tumour growth in vivo (Cho, Kim et al. 2002). If PDE4D7 N-terminal 
hyperphosphorylation does indeed occur, and if it is an early event in PC, then it 
would be another potential biomarker for the detection of early stage PC, for 
which none currently exist (Cernei, Heger et al. 2013). However, a great deal 
more work must be done in this area, not least investigating the specificity of 
the pSer42 antibody in immunocytochemistry/immunohistochemistry. If the 
antibody proves successful in these applications, it could be used to investigate 
the PDE4D7 N-terminal phospho-status as PC progresses, using patient tissue 
samples of various stages of disease. 
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6.7 Conclusions 
 
The findings presented within this thesis:  
 
1) Support both the previous findings of the qPCR PDE screen to show that 
PDE4D7 is significantly downregulated as PC progresses into androgen-
insensitivity, and, the notion that PDE4D7 is a promising novel biomarker 
for PC and disease stage.   
 
2) Suggest that the novel PDE4D7 antibody shows promise as a valuable 
diagnostic tool for the detection of early stage PC, or to determine 
disease stage. 
 
3) Suggest that loss of PDE4D7-mediated cAMP hydrolysis is pro-
proliferative and pro-migratory, and plays a role in the development of 
the AI PC cell phenotype.  
 
4) Suggest that PDE4D7 N-terminal PKA mediated phosphorylation 
provides a novel molecular mode of regulation on enzyme activity. 
 
5) Suggest that the novel phospho-specific antibody may also be a 
valuable diagnostic tool in the detection of PC, should we find that the N-
terminal phospho-status of PDE4D7 changes as PC progresses. Perhaps 
employing both of the novel antibodies may provide a dual diagnosis tool 
by detecting concurrent decreasing levels of PDE4D7 with increasing 
levels of phospho-PDE4D7. 
 
6) Call for further research on both PDE4D7 epigenetic regulation and N-
terminal phosphorylation, as both may provide novel points for the 
therapeutic manipulation of PC. 
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